{"f76d1232bed4d35c275586cae342338b4cb5d9d6": [["INTRODUCTIONBiologic tissues are among the many clinical options available to orthopedic surgeons, with over 1 million annual implants of human allografts alone.", [["INTRODUCTIONBiologic tissues", "ANATOMY", 0, 28], ["allografts", "ANATOMY", 144, 154], ["INTRODUCTIONBiologic tissues", "TISSUE", 0, 28], ["human", "ORGANISM", 138, 143], ["allografts", "TISSUE", 144, 154], ["human", "SPECIES", 138, 143], ["human", "SPECIES", 138, 143], ["1 million annual implants of human allografts", "TREATMENT", 109, 154], ["human allografts", "OBSERVATION", 138, 154]]], ["1 Such biologic tissues may be considered structural, for example, tendons or cortical bone struts, or nonstructural, such as ground demineralized bone matrices (DBMs) or amniotic membranes.", [["tissues", "ANATOMY", 16, 23], ["tendons", "ANATOMY", 67, 74], ["cortical bone struts", "ANATOMY", 78, 98], ["bone", "ANATOMY", 147, 151], ["DBMs", "ANATOMY", 162, 166], ["amniotic membranes", "ANATOMY", 171, 189], ["tissues", "TISSUE", 16, 23], ["tendons", "TISSUE", 67, 74], ["cortical bone", "MULTI-TISSUE_STRUCTURE", 78, 91], ["bone", "TISSUE", 147, 151], ["amniotic membranes", "MULTI-TISSUE_STRUCTURE", 171, 189], ["tendons or cortical bone struts", "PROBLEM", 67, 98], ["nonstructural, such as ground demineralized bone matrices", "PROBLEM", 103, 160], ["amniotic membranes", "PROBLEM", 171, 189], ["may be considered", "UNCERTAINTY", 24, 41], ["tendons", "ANATOMY", 67, 74], ["cortical", "ANATOMY_MODIFIER", 78, 86], ["bone", "ANATOMY", 87, 91], ["struts", "OBSERVATION", 92, 98], ["bone", "ANATOMY", 147, 151], ["amniotic membranes", "ANATOMY", 171, 189]]], ["Their intended use may mimic their original anatomical function, such as using a patellar ligament for anterior cruciate ligament (ACL) reconstruction or a cortical bone segment to repair a long-bone fracture.", [["patellar ligament", "ANATOMY", 81, 98], ["anterior cruciate ligament", "ANATOMY", 103, 129], ["ACL", "ANATOMY", 131, 134], ["cortical bone", "ANATOMY", 156, 169], ["bone", "ANATOMY", 195, 199], ["fracture", "DISEASE", 200, 208], ["patellar ligament", "TISSUE", 81, 98], ["anterior cruciate ligament", "TISSUE", 103, 129], ["ACL", "MULTI-TISSUE_STRUCTURE", 131, 134], ["cortical bone", "MULTI-TISSUE_STRUCTURE", 156, 169], ["bone", "TISSUE", 195, 199], ["a patellar ligament for anterior cruciate ligament (ACL) reconstruction", "TREATMENT", 79, 150], ["a cortical bone segment", "TREATMENT", 154, 177], ["repair", "TREATMENT", 181, 187], ["a long-bone fracture", "PROBLEM", 188, 208], ["patellar ligament", "ANATOMY", 81, 98], ["anterior", "ANATOMY_MODIFIER", 103, 111], ["cruciate ligament", "ANATOMY", 112, 129], ["ACL", "ANATOMY", 131, 134], ["cortical", "ANATOMY_MODIFIER", 156, 164], ["bone", "ANATOMY", 165, 169], ["segment", "ANATOMY_MODIFIER", 170, 177], ["long", "OBSERVATION_MODIFIER", 190, 194], ["bone", "ANATOMY", 195, 199], ["fracture", "OBSERVATION", 200, 208]]], ["In other circumstances, their use may differ from original anatomy, such as using a dermal layer for rotator cuff repair or a ground amniotic membrane combined with demineralized cortical bone for a spine fusion procedure.", [["dermal layer", "ANATOMY", 84, 96], ["rotator", "ANATOMY", 101, 108], ["amniotic membrane", "ANATOMY", 133, 150], ["cortical bone", "ANATOMY", 179, 192], ["spine", "ANATOMY", 199, 204], ["dermal layer", "TISSUE", 84, 96], ["rotator cuff", "TISSUE", 101, 113], ["amniotic membrane", "MULTI-TISSUE_STRUCTURE", 133, 150], ["cortical bone", "MULTI-TISSUE_STRUCTURE", 179, 192], ["a dermal layer", "TREATMENT", 82, 96], ["rotator cuff repair", "TREATMENT", 101, 120], ["a ground amniotic membrane", "TREATMENT", 124, 150], ["demineralized cortical bone", "TREATMENT", 165, 192], ["a spine fusion procedure", "TREATMENT", 197, 221], ["rotator cuff repair", "OBSERVATION", 101, 120], ["ground amniotic membrane", "OBSERVATION", 126, 150], ["cortical", "ANATOMY_MODIFIER", 179, 187], ["bone", "ANATOMY", 188, 192], ["spine", "ANATOMY", 199, 204], ["fusion", "OBSERVATION", 205, 211]]], ["This chapter focuses on the intent and science of various means of processing human allograft tissues to ensure safety and clinical use.INTRODUCTIONAlthough xenografts, derived from nonhuman sources, have found clinical use in a variety of surgical disciplines, including the use of porcine heart valves for heart valve replacement surgery 2 and ground bovine bone for dental procedures, 3, 4 their use in orthopedic surgery has met with more limited use and success.", [["allograft tissues", "ANATOMY", 84, 101], ["xenografts", "ANATOMY", 157, 167], ["heart", "ANATOMY", 291, 296], ["heart valve", "ANATOMY", 308, 319], ["bone", "ANATOMY", 360, 364], ["human", "ORGANISM", 78, 83], ["allograft tissues", "TISSUE", 84, 101], ["xenografts", "CANCER", 157, 167], ["porcine", "ORGANISM", 283, 290], ["heart valves", "MULTI-TISSUE_STRUCTURE", 291, 303], ["heart", "ORGAN", 308, 313], ["bovine", "ORGANISM", 353, 359], ["bone", "TISSUE", 360, 364], ["human", "SPECIES", 78, 83], ["bovine", "SPECIES", 353, 359], ["human", "SPECIES", 78, 83], ["processing human allograft tissues", "TREATMENT", 67, 101], ["surgical disciplines", "TREATMENT", 240, 260], ["porcine heart valves", "TREATMENT", 283, 303], ["heart valve replacement surgery", "TREATMENT", 308, 339], ["ground bovine bone", "TREATMENT", 346, 364], ["dental procedures", "TREATMENT", 369, 386], ["orthopedic surgery", "TREATMENT", 406, 424], ["heart valves", "ANATOMY", 291, 303], ["heart valve", "ANATOMY", 308, 319], ["replacement", "OBSERVATION", 320, 331], ["bone", "ANATOMY", 360, 364]]], ["In particular, porcine-derived small intestinal submucosa did not perform well as a tissue augmentation material, 5, 6 and bovine tendons are not commonly used 7 ; thus, xenografts will not be discussed in this chapter.INTRODUCTIONAlthough autografts, taken directly from the patient, are widely used 8, 9 for procedures such as ACL reconstruction or spinal implant of an iliac crest segment, these grafts are not subject to any significant processing other than some cleaning, shaping, or suture attachment before intrasurgery transplantation and therefore are also not covered in this chapter.", [["small intestinal submucosa", "ANATOMY", 31, 57], ["tissue", "ANATOMY", 84, 90], ["tendons", "ANATOMY", 130, 137], ["xenografts", "ANATOMY", 170, 180], ["ACL", "ANATOMY", 329, 332], ["spinal", "ANATOMY", 351, 357], ["iliac crest", "ANATOMY", 372, 383], ["grafts", "ANATOMY", 399, 405], ["porcine", "ORGANISM", 15, 22], ["intestinal submucosa", "ORGAN", 37, 57], ["tissue", "TISSUE", 84, 90], ["bovine", "ORGANISM", 123, 129], ["tendons", "ORGAN", 130, 137], ["xenografts", "CANCER", 170, 180], ["autografts", "TISSUE", 240, 250], ["patient", "ORGANISM", 276, 283], ["ACL", "MULTI-TISSUE_STRUCTURE", 329, 332], ["iliac crest", "MULTI-TISSUE_STRUCTURE", 372, 383], ["grafts", "TISSUE", 399, 405], ["porcine", "SPECIES", 15, 22], ["bovine", "SPECIES", 123, 129], ["patient", "SPECIES", 276, 283], ["bovine", "SPECIES", 123, 129], ["porcine-derived small intestinal submucosa", "PROBLEM", 15, 57], ["a tissue augmentation material", "TEST", 82, 112], ["xenografts", "TREATMENT", 170, 180], ["autografts", "TREATMENT", 240, 250], ["procedures", "TREATMENT", 310, 320], ["ACL reconstruction", "TREATMENT", 329, 347], ["spinal implant of an iliac crest segment", "TREATMENT", 351, 391], ["these grafts", "TREATMENT", 393, 405], ["any significant processing", "PROBLEM", 425, 451], ["suture attachment before intrasurgery transplantation", "TREATMENT", 490, 543], ["porcine", "OBSERVATION", 15, 22], ["small", "OBSERVATION_MODIFIER", 31, 36], ["intestinal submucosa", "ANATOMY", 37, 57], ["tendons", "ANATOMY", 130, 137], ["spinal", "ANATOMY", 351, 357], ["implant", "OBSERVATION", 358, 365], ["iliac", "ANATOMY", 372, 377], ["crest", "ANATOMY_MODIFIER", 378, 383], ["segment", "ANATOMY_MODIFIER", 384, 391], ["grafts", "OBSERVATION", 399, 405], ["cleaning", "OBSERVATION", 468, 476]]], ["Other autograft materials, such as those used for autologous cartilage implantation 10 or blood-derived preparations such as platelet-rich plasma, 11, 12 are described elsewhere in this book.INTRODUCTIONBefore being used by the orthopedic surgeon, allografts are commonly processed through physical, chemical, or biochemical means.", [["cartilage", "ANATOMY", 61, 70], ["blood", "ANATOMY", 90, 95], ["platelet-rich plasma", "ANATOMY", 125, 145], ["allografts", "ANATOMY", 248, 258], ["cartilage", "TISSUE", 61, 70], ["blood", "ORGANISM_SUBSTANCE", 90, 95], ["platelet", "CELL", 125, 133], ["plasma", "ORGANISM_SUBSTANCE", 139, 145], ["allografts", "TISSUE", 248, 258], ["platelet", "CELL_TYPE", 125, 133], ["Other autograft materials", "TREATMENT", 0, 25], ["autologous cartilage implantation", "TREATMENT", 50, 83], ["blood-derived preparations", "TREATMENT", 90, 116], ["platelet-rich plasma", "TEST", 125, 145], ["allografts", "TREATMENT", 248, 258], ["autograft materials", "OBSERVATION", 6, 25], ["allografts", "OBSERVATION", 248, 258]]], ["Such processing steps are typically performed to accomplish one or more objectives such as:INTRODUCTION\u2022 to reduce risk of disease transmission (e.g., through various disinfection or sterilization steps); \u2022 to reduce immunogenic response (e.g., through decellularization); \u2022 to reduce barriers to optimal physiological activity (e.g., by demineralizing cortical bone to enhance bioavailability of growth factors); \u2022 to physically convert grafts into more usable forms (e.g., shaping a bone graft for placement as an intervertebral body spacer); \u2022 to combine grafts with synthetics to enhance ease of use (e.g., by combining ground demineralized bone with a carrier to produce a putty-like material); \u2022 to preserve tissue to increase shelf life or simplify storage (e.g., lyophilization of ground bone that enables retention at ambient temperatures).INTRODUCTIONWith the focus here on human allografts, a brief historical and regulatory perspective is provided as background, followed by sections on reduction of disease transmission, enhancing fusion potential of bone void fillers, lowering immunogenic response by decellularization, preservation methods, and future directions.BACKGROUNDHuman allografts have been used in orthopedic surgery for many decades.", [["cortical bone", "ANATOMY", 353, 366], ["grafts", "ANATOMY", 438, 444], ["bone", "ANATOMY", 485, 489], ["intervertebral body", "ANATOMY", 516, 535], ["grafts", "ANATOMY", 558, 564], ["bone", "ANATOMY", 645, 649], ["tissue", "ANATOMY", 714, 720], ["bone", "ANATOMY", 796, 800], ["allografts", "ANATOMY", 890, 900], ["sections", "ANATOMY", 987, 995], ["bone", "ANATOMY", 1064, 1068], ["allografts", "ANATOMY", 1195, 1205], ["cortical bone", "TISSUE", 353, 366], ["grafts", "TISSUE", 438, 444], ["bone", "TISSUE", 485, 489], ["graft", "TISSUE", 490, 495], ["grafts", "TISSUE", 558, 564], ["bone", "TISSUE", 645, 649], ["tissue", "TISSUE", 714, 720], ["bone", "TISSUE", 796, 800], ["human", "ORGANISM", 884, 889], ["allografts", "TISSUE", 890, 900], ["bone", "TISSUE", 1064, 1068], ["BACKGROUNDHuman allografts", "TISSUE", 1179, 1205], ["growth factors", "PROTEIN", 397, 411], ["human", "SPECIES", 884, 889], ["human", "SPECIES", 884, 889], ["Such processing steps", "PROBLEM", 0, 21], ["disease transmission", "PROBLEM", 123, 143], ["various disinfection", "TREATMENT", 159, 179], ["sterilization steps", "TREATMENT", 183, 202], ["immunogenic response", "PROBLEM", 217, 237], ["demineralizing cortical bone", "PROBLEM", 338, 366], ["grafts", "TREATMENT", 438, 444], ["a bone graft", "TREATMENT", 483, 495], ["placement", "TREATMENT", 500, 509], ["an intervertebral body spacer", "TREATMENT", 513, 542], ["combine grafts", "TREATMENT", 550, 564], ["synthetics", "TREATMENT", 570, 580], ["combining ground demineralized bone", "PROBLEM", 614, 649], ["a putty-like material", "PROBLEM", 676, 697], ["lyophilization of ground bone", "TREATMENT", 771, 800], ["human allografts", "TREATMENT", 884, 900], ["disease transmission", "TREATMENT", 1012, 1032], ["enhancing fusion", "TREATMENT", 1034, 1050], ["bone void fillers", "PROBLEM", 1064, 1081], ["BACKGROUNDHuman allografts", "TREATMENT", 1179, 1205], ["orthopedic surgery", "TREATMENT", 1224, 1242], ["disease", "OBSERVATION", 123, 130], ["bone", "ANATOMY", 362, 366], ["grafts", "OBSERVATION", 438, 444], ["bone", "ANATOMY", 485, 489], ["graft", "OBSERVATION", 490, 495], ["intervertebral", "ANATOMY", 516, 530], ["grafts", "OBSERVATION", 558, 564], ["bone", "ANATOMY", 645, 649], ["bone", "ANATOMY", 796, 800], ["bone", "ANATOMY", 1064, 1068], ["void fillers", "OBSERVATION", 1069, 1081], ["allografts", "OBSERVATION", 1195, 1205]]], ["In the 19th century William Macewen 13 described the successful use of allogeneic cortical bone fragments to graft a replacement for a missing humeral mid-shaft.", [["cortical bone fragments", "ANATOMY", 82, 105], ["humeral mid-shaft", "ANATOMY", 143, 160], ["cortical bone", "MULTI-TISSUE_STRUCTURE", 82, 95], ["graft", "TISSUE", 109, 114], ["humeral mid-shaft", "CANCER", 143, 160], ["allogeneic cortical bone fragments", "TREATMENT", 71, 105], ["graft a replacement", "TREATMENT", 109, 128], ["a missing humeral mid-shaft", "TREATMENT", 133, 160], ["allogeneic cortical", "OBSERVATION", 71, 90], ["bone", "ANATOMY", 91, 95], ["fragments", "OBSERVATION", 96, 105], ["graft", "OBSERVATION", 109, 114], ["replacement", "OBSERVATION", 117, 128], ["humeral", "ANATOMY", 143, 150], ["mid-shaft", "ANATOMY_MODIFIER", 151, 160]]], ["Over 100 years ago, Fred Albee published a long list of surgical uses of bone allografts including applications and stated, \"[I have] been able during the past 2 years to avoid entirely the use of metal \u2026 for internal bone fixation purposes \u2026 made possible, largely, by utilizing the best of well known mechanical devices hitherto rarely, if at all, used in surgery, such as bone inlays, wedges, dowels, tongue and groove joints, mortised and dovetailed joints.\" 14 Through the 20th century bone grafts continued to be used, and tendon allografts started gaining widespread acceptance by the 1980s.", [["bone allografts", "ANATOMY", 73, 88], ["bone", "ANATOMY", 218, 222], ["bone", "ANATOMY", 375, 379], ["tongue", "ANATOMY", 404, 410], ["joints", "ANATOMY", 422, 428], ["joints", "ANATOMY", 454, 460], ["bone grafts", "ANATOMY", 491, 502], ["tendon allografts", "ANATOMY", 529, 546], ["bone", "TISSUE", 73, 77], ["allografts", "TISSUE", 78, 88], ["bone", "TISSUE", 218, 222], ["bone", "TISSUE", 375, 379], ["tongue", "ORGANISM_SUBDIVISION", 404, 410], ["joints", "MULTI-TISSUE_STRUCTURE", 422, 428], ["joints", "MULTI-TISSUE_STRUCTURE", 454, 460], ["bone grafts", "MULTI-TISSUE_STRUCTURE", 491, 502], ["tendon allografts", "TISSUE", 529, 546], ["bone allografts", "TREATMENT", 73, 88], ["metal \u2026", "TREATMENT", 197, 204], ["internal bone fixation purposes", "TREATMENT", 209, 240], ["surgery", "TREATMENT", 358, 365], ["bone inlays, wedges, dowels, tongue and groove joints", "TREATMENT", 375, 428], ["the 20th century bone grafts", "TREATMENT", 474, 502], ["tendon allografts", "TREATMENT", 529, 546], ["bone", "ANATOMY", 73, 77], ["allografts", "OBSERVATION", 78, 88], ["bone", "ANATOMY", 218, 222], ["fixation", "OBSERVATION", 223, 231], ["bone", "ANATOMY", 375, 379], ["tongue", "ANATOMY", 404, 410], ["groove joints", "ANATOMY", 415, 428], ["joints", "ANATOMY", 454, 460], ["bone", "ANATOMY", 491, 495], ["grafts", "OBSERVATION", 496, 502], ["tendon", "ANATOMY", 529, 535], ["allografts", "OBSERVATION", 536, 546]]], ["15 the mid-to late-20th century, most \"bone banks\" for allografts were hospital-based with tissue derived from deceased or amputated patients.", [["bone", "ANATOMY", 39, 43], ["allografts", "ANATOMY", 55, 65], ["tissue", "ANATOMY", 91, 97], ["bone", "TISSUE", 39, 43], ["allografts", "TISSUE", 55, 65], ["tissue", "TISSUE", 91, 97], ["patients", "ORGANISM", 133, 141], ["patients", "SPECIES", 133, 141], ["allografts", "TREATMENT", 55, 65]]], ["18 These tissues often underwent only minimal chemical processing, such as antibiotic or disinfectant soaks.", [["tissues", "ANATOMY", 9, 16], ["tissues", "TISSUE", 9, 16], ["minimal chemical processing", "TREATMENT", 38, 65], ["antibiotic", "TREATMENT", 75, 85], ["disinfectant soaks", "TREATMENT", 89, 107], ["minimal", "OBSERVATION_MODIFIER", 38, 45]]], ["In addition, any physical alteration of these tissues was typically performed by the surgical team at the time of implantation and included bone shaping or grinding or tendon trimming or suturing.", [["tissues", "ANATOMY", 46, 53], ["bone", "ANATOMY", 140, 144], ["tendon", "ANATOMY", 168, 174], ["tissues", "TISSUE", 46, 53], ["bone", "TISSUE", 140, 144], ["tendon", "ORGANISM_SUBDIVISION", 168, 174], ["any physical alteration of these tissues", "PROBLEM", 13, 53], ["implantation", "TREATMENT", 114, 126], ["bone shaping", "PROBLEM", 140, 152], ["grinding or tendon trimming", "PROBLEM", 156, 183], ["suturing", "TREATMENT", 187, 195], ["bone", "ANATOMY", 140, 144], ["tendon", "ANATOMY", 168, 174], ["suturing", "OBSERVATION", 187, 195]]], ["In answer to the need for better defined methods for ensuring graft safety and consistency, as well as appropriate respect for the tissue donors and their families, more formal systems began to be established by the Navy Tissue Bank in Bethesda, MD.", [["graft", "ANATOMY", 62, 67], ["tissue", "ANATOMY", 131, 137], ["graft", "TISSUE", 62, 67], ["tissue donors", "CELL", 131, 144], ["ensuring graft safety", "TREATMENT", 53, 74], ["the tissue donors", "TREATMENT", 127, 144], ["graft", "OBSERVATION", 62, 67]]], ["[17] [18] [19] Tissue Bank Standards and RegulationBACKGROUNDIn the latter half of the 20th century, the methodologies and practices developed by the Navy Tissue Bank were increasingly adopted by other organizations.", [["Tissue Bank Standards", "TEST", 15, 36]]], ["In 1976 the American Association of Tissue Banks (AATB) was formed, and in 1984 it issued the first set of tissueprocessing standards, which established guidelines such as acceptable time from death to recovery, storage conditions for tissues, microbial testing requirements, definitions of demineralization, freeze-drying, and so forth.", [["Tissue", "ANATOMY", 36, 42], ["tissues", "ANATOMY", 235, 242], ["death", "DISEASE", 193, 198], ["Tissue", "TISSUE", 36, 42], ["tissues", "TISSUE", 235, 242], ["microbial testing requirements", "TEST", 244, 274], ["demineralization", "PROBLEM", 291, 307], ["demineralization", "OBSERVATION", 291, 307]]], ["A certification program was also established to assure the surgical community that qualified tissue banks met AATB standards.BACKGROUNDSimilarly, around the turn of the 21st century, the US Food and Drug Administration (FDA) developed the classification of Human Cell and Tissue Products (HCT/Ps) as a separate regulatory classification into which most human tissue transplants fell.", [["tissue", "ANATOMY", 93, 99], ["Cell", "ANATOMY", 263, 267], ["Tissue", "ANATOMY", 272, 278], ["tissue", "ANATOMY", 359, 365], ["tissue", "TISSUE", 93, 99], ["Human", "ORGANISM", 257, 262], ["Cell", "CELL", 263, 267], ["Tissue", "TISSUE", 272, 278], ["human", "ORGANISM", 353, 358], ["tissue", "TISSUE", 359, 365], ["Human", "SPECIES", 257, 262], ["human", "SPECIES", 353, 358], ["Human", "SPECIES", 257, 262], ["human", "SPECIES", 353, 358], ["A certification program", "TEST", 0, 23], ["Human Cell and Tissue Products", "TREATMENT", 257, 287], ["HCT/Ps", "TREATMENT", 289, 295], ["most human tissue transplants", "TREATMENT", 348, 377], ["Human Cell", "OBSERVATION", 257, 267]]], ["This classification applies to most human tissue transplants.", [["tissue", "ANATOMY", 42, 48], ["human", "ORGANISM", 36, 41], ["tissue", "TISSUE", 42, 48], ["human", "SPECIES", 36, 41], ["human", "SPECIES", 36, 41], ["most human tissue transplants", "TREATMENT", 31, 60], ["most human tissue", "OBSERVATION_MODIFIER", 31, 48], ["transplants", "OBSERVATION", 49, 60]]], ["It differs from a medical device classification, in which, to qualify as an HCT/P, the tissue needs to meet standards of not exceeding \"minimal manipulation\" such that the \"original relevant characteristics\" are not altered, and also \"homologous use\" meaning the tissue is used clinically in a similar manner to that intended in the body of origin.", [["tissue", "ANATOMY", 87, 93], ["tissue", "ANATOMY", 263, 269], ["body", "ANATOMY", 333, 337], ["tissue", "TISSUE", 87, 93], ["tissue", "TISSUE", 263, 269], ["body", "ORGANISM_SUBDIVISION", 333, 337], ["a medical device classification", "TREATMENT", 16, 47], ["an HCT", "TEST", 73, 79], ["origin", "ANATOMY_MODIFIER", 341, 347]]], ["20,21 A clear example of a tissue meeting these requirements would be a hamstring tendon that is recovered intact, disinfected, sterilized, and then used for tendon replacement.", [["tissue", "ANATOMY", 27, 33], ["hamstring tendon", "ANATOMY", 72, 88], ["tendon", "ANATOMY", 158, 164], ["tissue", "TISSUE", 27, 33], ["hamstring tendon", "TISSUE", 72, 88], ["tendon", "TISSUE", 158, 164], ["tendon replacement", "TREATMENT", 158, 176], ["clear", "OBSERVATION", 8, 13], ["hamstring tendon", "ANATOMY", 72, 88], ["tendon", "ANATOMY", 158, 164], ["replacement", "OBSERVATION", 165, 176]]], ["Conversely, although bone void filler putty containing DBM would be considered for homologous use, it may be considered more than minimally manipulated because of the addition of a synthetic carrier and thus be classified as a medical device requiring FDA clearance before distribution.", [["bone", "ANATOMY", 21, 25], ["bone", "TISSUE", 21, 25], ["bone void filler putty containing DBM", "TREATMENT", 21, 58], ["a synthetic carrier", "TREATMENT", 179, 198], ["a medical device", "TREATMENT", 225, 241], ["FDA clearance", "TREATMENT", 252, 265], ["bone", "ANATOMY", 21, 25], ["filler putty", "OBSERVATION", 31, 43]]], ["In further example, a disinfected and freeze-dried cortical bone segment used as an intervertebral body spacer is considered both minimally manipulated and intended for homologous use.", [["cortical bone", "ANATOMY", 51, 64], ["intervertebral body", "ANATOMY", 84, 103], ["cortical bone", "MULTI-TISSUE_STRUCTURE", 51, 64], ["intervertebral body", "MULTI-TISSUE_STRUCTURE", 84, 103], ["a disinfected and freeze-dried cortical bone segment", "TREATMENT", 20, 72], ["an intervertebral body spacer", "TREATMENT", 81, 110], ["disinfected", "OBSERVATION", 22, 33], ["cortical", "ANATOMY_MODIFIER", 51, 59], ["bone", "ANATOMY", 60, 64], ["segment", "ANATOMY_MODIFIER", 65, 72], ["intervertebral", "ANATOMY", 84, 98], ["body spacer", "OBSERVATION", 99, 110]]], ["As processors continue to become more innovative in the use and treatment of human tissues, these definitions will undoubtedly be tested and clarified.BACKGROUNDIn adding further regulatory safeguards especially with respect to the risk of disease transmission, FDA issued the \"Interim Rule\" in 1993 to \"require certain infectious disease testing, donor screening, and recordkeeping facilities to help prevent the transmission of AIDS and hepatitis through human tissue used in transplantation.\" 22 In general, methods to reduce risk of disease transmission, such as antibiotic soaks, peroxide disinfection, and sterilization using radiation methods, are considered to be no more than minimal manipulation.", [["tissues", "ANATOMY", 83, 90], ["tissue", "ANATOMY", 463, 469], ["infectious disease", "DISEASE", 320, 338], ["AIDS", "DISEASE", 430, 434], ["hepatitis", "DISEASE", 439, 448], ["peroxide", "CHEMICAL", 585, 593], ["peroxide", "CHEMICAL", 585, 593], ["human", "ORGANISM", 77, 82], ["tissues", "TISSUE", 83, 90], ["human", "ORGANISM", 457, 462], ["tissue", "TISSUE", 463, 469], ["peroxide", "SIMPLE_CHEMICAL", 585, 593], ["human", "SPECIES", 77, 82], ["human", "SPECIES", 457, 462], ["human", "SPECIES", 77, 82], ["human", "SPECIES", 457, 462], ["treatment of human tissues", "TREATMENT", 64, 90], ["further regulatory safeguards", "TREATMENT", 171, 200], ["disease transmission", "PROBLEM", 240, 260], ["infectious disease testing", "TEST", 320, 346], ["donor screening", "TEST", 348, 363], ["AIDS", "PROBLEM", 430, 434], ["hepatitis through human tissue", "TREATMENT", 439, 469], ["transplantation", "TREATMENT", 478, 493], ["methods", "TREATMENT", 511, 518], ["disease transmission", "PROBLEM", 537, 557], ["antibiotic soaks", "TREATMENT", 567, 583], ["peroxide disinfection", "TREATMENT", 585, 606], ["sterilization", "TREATMENT", 612, 625], ["radiation methods", "TREATMENT", 632, 649], ["human tissues", "ANATOMY", 77, 90], ["disease", "OBSERVATION", 240, 247]]], ["Further on the regulatory front, in 2005, FDA established, 20, 21 in conjunction with tissue bank input, a standard of good tissue practices to \"create a unified registration and listing system for establishments that manufacture HCT/Ps and to establish donor eligibility, current good tissue practice, and other procedures to prevent the introduction, transmission, and spread of communicable disease.\"BACKGROUNDIn summary, the US system of AATB Standards and FDA regulations and inspections provide many safeguards for the provision of effective transplantable allograft tissues.REDUCING RISK OF DISEASE TRANSMISSION IN TRANSPLANTED ALLOGRAFTSHuman tissue carries an inherent, yet minimal, risk of disease transmission, which has been made essentially negligible through advancements in cleaning and processing methodologies.", [["tissue", "ANATOMY", 86, 92], ["tissue", "ANATOMY", 124, 130], ["tissue", "ANATOMY", 286, 292], ["transplantable allograft tissues", "ANATOMY", 548, 580], ["tissue", "ANATOMY", 651, 657], ["communicable disease", "DISEASE", 381, 401], ["tissue", "TISSUE", 86, 92], ["tissue", "TISSUE", 124, 130], ["tissue", "TISSUE", 286, 292], ["transplantable allograft tissues", "TISSUE", 548, 580], ["tissue", "TISSUE", 651, 657], ["HCT/Ps", "TREATMENT", 230, 236], ["other procedures", "TREATMENT", 307, 323], ["communicable disease", "PROBLEM", 381, 401], ["AATB Standards", "TREATMENT", 442, 456], ["FDA regulations", "TREATMENT", 461, 476], ["inspections", "TREATMENT", 481, 492], ["many safeguards", "TREATMENT", 501, 516], ["effective transplantable allograft tissues", "TREATMENT", 538, 580], ["DISEASE TRANSMISSION", "PROBLEM", 598, 618], ["TRANSPLANTED ALLOGRAFTSHuman tissue", "TREATMENT", 622, 657], ["disease transmission", "PROBLEM", 700, 720], ["transplantable allograft tissues", "OBSERVATION", 548, 580], ["DISEASE", "OBSERVATION", 598, 605], ["ALLOGRAFTSHuman tissue", "OBSERVATION", 635, 657], ["minimal", "OBSERVATION_MODIFIER", 683, 690], ["disease", "OBSERVATION", 700, 707]]], ["A 2005 survey from AATB estimated an overall allograft-associated infection rate of 0.014%.", [["allograft", "ANATOMY", 45, 54], ["infection", "DISEASE", 66, 75], ["allograft", "TISSUE", 45, 54], ["an overall allograft", "PROBLEM", 34, 54], ["infection rate", "TEST", 66, 80], ["overall", "OBSERVATION_MODIFIER", 37, 44], ["allograft", "OBSERVATION", 45, 54], ["infection", "OBSERVATION", 66, 75]]], ["23 It is important to note that this survey preceded widespread implementation of more advanced methods aimed at reducing the risk of disease transmission, including FDA-mandated and sensitive nucleic acid testing (NAT) for certain viruses as well as routine terminal sterilization.", [["nucleic acid", "CHEMICAL", 193, 205], ["disease transmission", "PROBLEM", 134, 154], ["FDA", "TEST", 166, 169], ["nucleic acid testing", "TEST", 193, 213], ["certain viruses", "PROBLEM", 224, 239], ["routine terminal sterilization", "TREATMENT", 251, 281], ["terminal", "OBSERVATION_MODIFIER", 259, 267], ["sterilization", "OBSERVATION", 268, 281]]], ["Although well-documented cases of disease transmission have occurred, 24-26 modern tissue bank practices and processes have successfully diminished incidences over the last few decades.", [["tissue", "ANATOMY", 83, 89], ["tissue", "TISSUE", 83, 89], ["disease transmission", "PROBLEM", 34, 54], ["successfully diminished incidences", "PROBLEM", 124, 158], ["diminished", "OBSERVATION_MODIFIER", 137, 147]]], ["In a case beginning in 1985, four organs and 54 allograft tissues were distributed from an HIV-infected donor who had a favorable screening history and negative serology test.", [["organs", "ANATOMY", 34, 40], ["allograft tissues", "ANATOMY", 48, 65], ["HIV-infected", "DISEASE", 91, 103], ["organs", "ORGAN", 34, 40], ["allograft tissues", "TISSUE", 48, 65], ["HIV", "ORGANISM", 91, 94], ["HIV", "SPECIES", 91, 94], ["54 allograft tissues", "PROBLEM", 45, 65], ["serology test", "TEST", 161, 174], ["allograft tissues", "OBSERVATION", 48, 65]]], ["25 All four organ recipients and the three recipients who received fresh frozen bone tissue tested positive for HIV.", [["organ", "ANATOMY", 12, 17], ["bone tissue", "ANATOMY", 80, 91], ["organ", "ORGAN", 12, 17], ["recipients", "ORGANISM", 43, 53], ["bone tissue", "TISSUE", 80, 91], ["HIV", "ORGANISM", 112, 115], ["HIV", "SPECIES", 112, 115], ["HIV", "SPECIES", 112, 115], ["fresh frozen bone tissue", "TEST", 67, 91], ["HIV", "PROBLEM", 112, 115], ["organ", "ANATOMY", 12, 17], ["recipients", "OBSERVATION", 18, 28]]], ["Investigators suspected that the transmissions occurred because the seronegative donor had very recently become infected and, being in the \"window\" period, had not yet developed an HIV-1 antibody detectable by the tests in use at the time.", [["HIV-1", "ORGANISM", 181, 186], ["HIV-1 antibody", "PROTEIN", 181, 195], ["HIV-1", "SPECIES", 181, 186], ["HIV-1", "SPECIES", 181, 186], ["the seronegative donor", "PROBLEM", 64, 86], ["an HIV-1 antibody", "PROBLEM", 178, 195], ["the tests", "TEST", 210, 219], ["infected", "OBSERVATION", 112, 120]]], ["In 2002 another case surfaced where 40 recipients received organs and tissues from a donor infected with hepatitis C virus (HCV), and 8 consequently developed HCV infections.", [["organs", "ANATOMY", 59, 65], ["tissues", "ANATOMY", 70, 77], ["hepatitis C", "DISEASE", 105, 116], ["HCV infections", "DISEASE", 159, 173], ["recipients", "ORGANISM", 39, 49], ["organs", "ORGAN", 59, 65], ["tissues", "TISSUE", 70, 77], ["hepatitis C virus", "ORGANISM", 105, 122], ["HCV", "ORGANISM", 124, 127], ["HCV", "ORGANISM", 159, 162], ["hepatitis C virus", "SPECIES", 105, 122], ["hepatitis C virus", "SPECIES", 105, 122], ["HCV", "SPECIES", 124, 127], ["HCV", "SPECIES", 159, 162], ["organs and tissues", "PROBLEM", 59, 77], ["a donor", "TREATMENT", 83, 90], ["hepatitis C virus", "PROBLEM", 105, 122], ["HCV", "PROBLEM", 124, 127], ["HCV infections", "PROBLEM", 159, 173], ["HCV", "OBSERVATION_MODIFIER", 159, 162], ["infections", "OBSERVATION", 163, 173]]], ["26 As with the earlier HIV transmission case, the donor was seronegative for HCV, and NAT had not been performed.", [["HCV", "ORGANISM", 77, 80], ["HIV", "SPECIES", 23, 26], ["HCV", "SPECIES", 77, 80], ["the donor", "TREATMENT", 46, 55], ["HCV", "PROBLEM", 77, 80], ["NAT", "TEST", 86, 89]]], ["Subsequent NAT of stored serum from the donor detected the virus, which highlighted the importance of using more sensitive testing before releasing donor tissue.", [["serum", "ANATOMY", 25, 30], ["tissue", "ANATOMY", 154, 160], ["serum", "ORGANISM_SUBSTANCE", 25, 30], ["tissue", "TISSUE", 154, 160], ["the virus", "PROBLEM", 55, 64], ["virus", "OBSERVATION", 59, 64], ["donor tissue", "OBSERVATION", 148, 160]]], ["NAT for HIV and HCV is now required by FDA after being added as a requirement by AATB in 2005.", [["HIV and HCV", "DISEASE", 8, 19], ["HIV", "ORGANISM", 8, 11], ["HCV", "ORGANISM", 16, 19], ["HIV", "SPECIES", 8, 11], ["HIV", "SPECIES", 8, 11], ["HCV", "SPECIES", 16, 19], ["HIV", "PROBLEM", 8, 11], ["HCV", "PROBLEM", 16, 19], ["HCV", "OBSERVATION", 16, 19]]], ["27 There have also been reported cases of transmission of tuberculosis, various Clostridium species, Group A Streptococci, and rabies.", [["tuberculosis", "DISEASE", 58, 70], ["Clostridium species", "DISEASE", 80, 99], ["rabies", "DISEASE", 127, 133], ["Clostridium species", "ORGANISM", 80, 99], ["Group A Streptococci", "ORGANISM", 101, 121], ["rabies", "SPECIES", 127, 133], ["tuberculosis", "PROBLEM", 58, 70], ["various Clostridium species", "PROBLEM", 72, 99], ["Group A Streptococci", "PROBLEM", 101, 121], ["rabies", "PROBLEM", 127, 133], ["tuberculosis", "OBSERVATION", 58, 70], ["Clostridium species", "OBSERVATION", 80, 99]]], ["28 Overall, the relative risk of disease transmission is small considering the millions of allografts transplanted; however, the possibility of transmission makes avoidance, control, and reduction of microbial and viral bioburden integral to tissue-processing practices.Reducing Risk of Disease Transmission: ApproachAllograft tissue providers reduce risk of disease transmission by three primary means: 1. minimizing occurrence of processing donor tissue with unacceptable bioburden; 2. controlling environment and tissue-handling practices to avoid contamination; and 3. reducing any remaining bioburden through disinfection and sterilization techniques.Reducing Risk of Disease Transmission: ApproachIn the first category, the occurrence of recovering or processing tissue that is contaminated can be minimized through stringent bioburden tests, including anaerobic and aerobic culture tests for bacteria and fungi, as well as serological testing and NAT to detect specific viruses.", [["allografts", "ANATOMY", 91, 101], ["tissue", "ANATOMY", 242, 248], ["tissue", "ANATOMY", 327, 333], ["tissue", "ANATOMY", 449, 455], ["tissue", "ANATOMY", 516, 522], ["tissue", "ANATOMY", 769, 775], ["allografts", "TISSUE", 91, 101], ["tissue", "TISSUE", 242, 248], ["tissue", "TISSUE", 449, 455], ["tissue", "TISSUE", 516, 522], ["tissue", "TISSUE", 769, 775], ["disease transmission", "PROBLEM", 33, 53], ["allografts transplanted", "TREATMENT", 91, 114], ["microbial and viral bioburden integral", "TREATMENT", 200, 238], ["ApproachAllograft tissue providers", "TREATMENT", 309, 343], ["disease transmission", "PROBLEM", 359, 379], ["processing donor tissue", "PROBLEM", 432, 455], ["unacceptable bioburden", "PROBLEM", 461, 483], ["contamination", "PROBLEM", 551, 564], ["sterilization techniques", "TREATMENT", 631, 655], ["processing tissue", "PROBLEM", 758, 775], ["stringent bioburden tests", "TEST", 822, 847], ["anaerobic and aerobic culture tests", "TEST", 859, 894], ["bacteria", "PROBLEM", 899, 907], ["fungi", "PROBLEM", 912, 917], ["serological testing", "TEST", 930, 949], ["NAT", "TEST", 954, 957], ["specific viruses", "PROBLEM", 968, 984], ["disease", "OBSERVATION", 33, 40], ["small", "OBSERVATION_MODIFIER", 57, 62], ["allografts", "OBSERVATION", 91, 101], ["viral bioburden", "OBSERVATION", 214, 229], ["Disease", "OBSERVATION", 287, 294], ["disease", "OBSERVATION", 359, 366], ["donor tissue", "OBSERVATION", 443, 455], ["unacceptable", "OBSERVATION_MODIFIER", 461, 473], ["bioburden", "OBSERVATION", 474, 483], ["remaining", "OBSERVATION_MODIFIER", 586, 595], ["bioburden", "OBSERVATION", 596, 605], ["disinfection", "OBSERVATION", 614, 626], ["Disease", "OBSERVATION", 673, 680]]], ["Specific tests are required by FDA and also to meet AATB standards.", [["Specific tests", "TEST", 0, 14]]], ["Note that proper infectious disease tests must be validated for use specifically with cadaveric specimens.", [["specimens", "ANATOMY", 96, 105], ["infectious disease", "DISEASE", 17, 35], ["proper infectious disease tests", "PROBLEM", 10, 41], ["cadaveric specimens", "TEST", 86, 105], ["infectious", "OBSERVATION", 17, 27]]], ["21 A detailed donor-screening process is also critical for minimizing bioburden; medical records and social history, such as travel, tattoos, high-risk sexual behavior, illicit drug use, and incarceration, as well as physical examination, help assess donor eligibility.", [["high-risk sexual behavior", "DISEASE", 142, 167], ["A detailed donor-screening process", "TREATMENT", 3, 37], ["minimizing bioburden", "PROBLEM", 59, 79], ["tattoos", "PROBLEM", 133, 140], ["incarceration", "PROBLEM", 191, 204], ["physical examination", "TEST", 217, 237], ["incarceration", "OBSERVATION", 191, 204]]], ["28 In the second category, bioburden loads can be controlled by using aseptic handling techniques during recovery and processing to prevent contamination of the tissue by pathogens.", [["tissue", "ANATOMY", 161, 167], ["tissue", "TISSUE", 161, 167], ["bioburden loads", "TREATMENT", 27, 42], ["aseptic handling techniques", "TREATMENT", 70, 97], ["contamination of the tissue", "PROBLEM", 140, 167], ["pathogens", "PROBLEM", 171, 180], ["bioburden loads", "OBSERVATION", 27, 42]]], ["However, it is important to note that using aseptic conditions by themselves can only prevent additional contamination but will not reduce or eliminate any existing bioburden.", [["aseptic conditions", "TREATMENT", 44, 62], ["additional contamination", "PROBLEM", 94, 118], ["any existing bioburden", "PROBLEM", 152, 174], ["bioburden", "OBSERVATION", 165, 174]]], ["For the third risk-reduction category, processing methods designed to reduce any remaining bioburden are addressed in the following sections.Bioburden Reduction MethodsBioburden loads can be reduced by cleaning and disinfecting the tissue.", [["sections", "ANATOMY", 132, 140], ["tissue", "ANATOMY", 232, 238], ["tissue", "TISSUE", 232, 238], ["processing methods", "TREATMENT", 39, 57], ["any remaining bioburden", "PROBLEM", 77, 100], ["Bioburden Reduction MethodsBioburden loads", "TREATMENT", 141, 183], ["bioburden", "OBSERVATION", 91, 100], ["reduced", "OBSERVATION_MODIFIER", 191, 198]]], ["These steps vary by tissue type and may include: \u2022 debridement; \u2022 low doses of preirradiation (irradiation before other chemical processing steps); \u2022 physical methods such as lavage, pulsatile fluid flow, centrifuge, fluid bath rotation, and sonication; \u2022 enzymatic digestion of cellular material;Bioburden Reduction Methods\u2022 penetrating agents such as supercritical CO 2 in combination with chemical activators; \u2022 milder chemicals including alcohol, detergents, and antibiotics; \u2022 more aggressive chemicals such as NaOH, acetone, and peroxide.", [["tissue", "ANATOMY", 20, 26], ["fluid", "ANATOMY", 193, 198], ["cellular", "ANATOMY", 279, 287], ["alcohol", "CHEMICAL", 442, 449], ["NaOH, acetone, and peroxide", "CHEMICAL", 516, 543], ["CO 2", "CHEMICAL", 367, 371], ["alcohol", "CHEMICAL", 442, 449], ["NaOH", "CHEMICAL", 516, 520], ["acetone", "CHEMICAL", 522, 529], ["peroxide", "CHEMICAL", 535, 543], ["tissue", "TISSUE", 20, 26], ["cellular", "CELL", 279, 287], ["supercritical CO 2", "SIMPLE_CHEMICAL", 353, 371], ["alcohol", "SIMPLE_CHEMICAL", 442, 449], ["NaOH", "SIMPLE_CHEMICAL", 516, 520], ["acetone", "SIMPLE_CHEMICAL", 522, 529], ["peroxide", "SIMPLE_CHEMICAL", 535, 543], ["debridement", "TREATMENT", 51, 62], ["preirradiation (irradiation", "TREATMENT", 79, 106], ["chemical processing steps", "TREATMENT", 120, 145], ["lavage", "TREATMENT", 175, 181], ["pulsatile fluid flow", "TREATMENT", 183, 203], ["fluid bath rotation", "TREATMENT", 217, 236], ["sonication", "TREATMENT", 242, 252], ["cellular material", "TREATMENT", 279, 296], ["Bioburden Reduction Methods", "TREATMENT", 297, 324], ["penetrating agents", "TREATMENT", 326, 344], ["supercritical CO 2", "TREATMENT", 353, 371], ["chemical activators", "TREATMENT", 392, 411], ["detergents", "TREATMENT", 451, 461], ["antibiotics", "TREATMENT", 467, 478], ["aggressive chemicals", "TREATMENT", 487, 507], ["NaOH", "TREATMENT", 516, 520], ["acetone", "TREATMENT", 522, 529], ["peroxide", "TREATMENT", 535, 543], ["debridement", "OBSERVATION", 51, 62], ["low doses", "OBSERVATION_MODIFIER", 66, 75], ["cellular material", "OBSERVATION", 279, 296]]], ["Cleaning processes can remove bone marrow elements, lipids, and low-molecular-weight proteins, thus reducing any graft immunogenic potential as well as bacterial, viral, and fungal contamination.", [["bone marrow", "ANATOMY", 30, 41], ["graft", "ANATOMY", 113, 118], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 30, 41], ["lipids", "SIMPLE_CHEMICAL", 52, 58], ["graft", "TISSUE", 113, 118], ["low-molecular-weight proteins", "PROTEIN", 64, 93], ["bone marrow elements", "TEST", 30, 50], ["lipids", "TEST", 52, 58], ["any graft immunogenic potential", "PROBLEM", 109, 140], ["bacterial, viral, and fungal contamination", "PROBLEM", 152, 194], ["viral", "OBSERVATION", 163, 168], ["fungal contamination", "OBSERVATION", 174, 194]]], ["29 More aggressive agents that may be commonly used to disinfect bone, such as hydrogen peroxide, are not typically used for soft tissue grafts.", [["bone", "ANATOMY", 65, 69], ["soft tissue grafts", "ANATOMY", 125, 143], ["hydrogen peroxide", "CHEMICAL", 79, 96], ["hydrogen peroxide", "CHEMICAL", 79, 96], ["bone", "TISSUE", 65, 69], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 79, 96], ["soft tissue grafts", "TISSUE", 125, 143], ["aggressive agents", "TREATMENT", 8, 25], ["hydrogen peroxide", "TREATMENT", 79, 96], ["soft tissue grafts", "TREATMENT", 125, 143], ["soft tissue", "ANATOMY", 125, 136], ["grafts", "OBSERVATION", 137, 143]]], ["At least one process that includes the use of hydrogen peroxide on tendons was correlated with a significant increase in risk for revision ACL repair.", [["tendons", "ANATOMY", 67, 74], ["ACL", "ANATOMY", 139, 142], ["hydrogen peroxide", "CHEMICAL", 46, 63], ["hydrogen peroxide", "CHEMICAL", 46, 63], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 46, 63], ["tendons", "ORGAN", 67, 74], ["ACL", "PATHOLOGICAL_FORMATION", 139, 142], ["hydrogen peroxide on tendons", "TREATMENT", 46, 74], ["revision ACL repair", "TREATMENT", 130, 149], ["one", "OBSERVATION_MODIFIER", 9, 12], ["process", "OBSERVATION", 13, 20], ["tendons", "ANATOMY", 67, 74], ["significant", "OBSERVATION_MODIFIER", 97, 108], ["increase", "OBSERVATION_MODIFIER", 109, 117], ["risk for", "UNCERTAINTY", 121, 129], ["revision ACL repair", "OBSERVATION", 130, 149]]], ["30 In this case, however, the contribution of the hydrogen peroxide to apparent graft weakening is unclear because the process also includes pulsatile fluid flow.", [["graft", "ANATOMY", 80, 85], ["fluid", "ANATOMY", 151, 156], ["hydrogen peroxide", "CHEMICAL", 50, 67], ["hydrogen peroxide", "CHEMICAL", 50, 67], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 50, 67], ["graft", "TISSUE", 80, 85], ["fluid", "ORGANISM_SUBSTANCE", 151, 156], ["the hydrogen peroxide", "TREATMENT", 46, 67], ["graft weakening", "PROBLEM", 80, 95], ["pulsatile fluid flow", "PROBLEM", 141, 161], ["graft weakening", "OBSERVATION", 80, 95], ["pulsatile", "OBSERVATION_MODIFIER", 141, 150], ["fluid flow", "OBSERVATION", 151, 161]]], ["Cellular remnants and, presumably, associated infectious agents may also be removed through tissue decellularization methods, which will also be discussed in a later section.", [["tissue", "ANATOMY", 92, 98], ["tissue", "TISSUE", 92, 98], ["Cellular remnants", "PROBLEM", 0, 17], ["tissue decellularization methods", "TREATMENT", 92, 124], ["remnants", "OBSERVATION", 9, 17], ["infectious", "OBSERVATION", 46, 56], ["decellularization", "OBSERVATION", 99, 116]]], ["These methods include the use of chemicals such as nondenaturing anionic detergent, recombinant endonuclease, sodium dodecyl sulfate, sodium hydroxide, sodium peroxide, sodium chloride, and antibiotics.", [["sodium dodecyl sulfate", "CHEMICAL", 110, 132], ["sodium hydroxide", "CHEMICAL", 134, 150], ["sodium peroxide", "CHEMICAL", 152, 167], ["sodium chloride", "CHEMICAL", 169, 184], ["sodium dodecyl sulfate", "CHEMICAL", 110, 132], ["sodium hydroxide", "CHEMICAL", 134, 150], ["sodium peroxide", "CHEMICAL", 152, 167], ["sodium chloride", "CHEMICAL", 169, 184], ["sodium dodecyl sulfate", "SIMPLE_CHEMICAL", 110, 132], ["sodium hydroxide", "SIMPLE_CHEMICAL", 134, 150], ["sodium peroxide", "SIMPLE_CHEMICAL", 152, 167], ["sodium chloride", "SIMPLE_CHEMICAL", 169, 184], ["recombinant endonuclease", "PROTEIN", 84, 108], ["chemicals", "TREATMENT", 33, 42], ["nondenaturing anionic detergent", "TREATMENT", 51, 82], ["recombinant endonuclease", "TREATMENT", 84, 108], ["sodium dodecyl sulfate", "TREATMENT", 110, 132], ["sodium hydroxide", "TREATMENT", 134, 150], ["sodium peroxide", "TREATMENT", 152, 167], ["sodium chloride", "TREATMENT", 169, 184], ["antibiotics", "TREATMENT", 190, 201]]], ["[31] [32] [33] [34] Assurance of Tissue Sterility After processing to reduce or eliminate bioburden, the tissue is typically either tested for sterility or subjected to a terminal sterilization step.", [["tissue", "ANATOMY", 105, 111], ["Tissue", "TISSUE", 33, 39], ["tissue", "TISSUE", 105, 111], ["Tissue Sterility", "TREATMENT", 33, 49], ["bioburden", "PROBLEM", 90, 99], ["sterility", "PROBLEM", 143, 152], ["a terminal sterilization step", "TREATMENT", 169, 198]]], ["Testing for sterility usually involves sampling a portion of the tissue or processing solutions according to United States Pharmacopeia <71> sterility test guidelines before packaging.", [["tissue", "ANATOMY", 65, 71], ["tissue", "TISSUE", 65, 71], ["sterility", "PROBLEM", 12, 21], ["processing solutions", "TREATMENT", 75, 95]]], ["It is important to note that the United States Pharmacopeia <71> label does not necessarily indicate that the tissue product is sterile but rather that a sample of the product batch was culture negative thus passing the test for sterility.", [["tissue", "ANATOMY", 110, 116], ["tissue", "TISSUE", 110, 116], ["the tissue product", "PROBLEM", 106, 124], ["the product batch", "TEST", 164, 181], ["culture", "TEST", 186, 193], ["sterility", "PROBLEM", 229, 238], ["tissue", "OBSERVATION", 110, 116]]], ["35, 36 As an alternative to testing for sterility, the tissue may be processed, packaged, and then subjected to sterilization after placement in its final package thus at the terminus of the process.", [["tissue", "ANATOMY", 55, 61], ["tissue", "TISSUE", 55, 61], ["testing", "TEST", 28, 35], ["sterility", "PROBLEM", 40, 49], ["sterilization", "TREATMENT", 112, 125], ["placement", "TREATMENT", 132, 141], ["its final package", "TREATMENT", 145, 162]]], ["In this case of terminal sterilization the chosen method must effectively penetrate the packaging; such options will be discussed in subsequent sections.Bioburden Reduction MethodsIn terms of measuring sterility, an absolute assurance of sterility is not probabilistically feasible, but there is a measure known as sterility assurance level, commonly referred to as SAL.", [["sections", "ANATOMY", 144, 152], ["SAL", "CHEMICAL", 366, 369], ["terminal sterilization", "TREATMENT", 16, 38], ["the packaging", "TREATMENT", 84, 97], ["Bioburden Reduction Methods", "TREATMENT", 153, 180], ["measuring sterility", "PROBLEM", 192, 211], ["terminal", "OBSERVATION_MODIFIER", 16, 24], ["sterilization", "OBSERVATION", 25, 38], ["measuring sterility", "OBSERVATION", 192, 211]]], ["This designation indicates the degree, or level, of assurance of sterility achieved through a validated sterilization process.", [["sterility", "PROBLEM", 65, 74], ["a validated sterilization process", "TREATMENT", 92, 125], ["degree", "OBSERVATION_MODIFIER", 31, 37]]], ["The two most common SALs for allografts are 10 -3 and 10 -6 .", [["allografts", "ANATOMY", 29, 39], ["SALs", "CANCER", 20, 24], ["allografts", "TISSUE", 29, 39], ["allografts", "TEST", 29, 39], ["allografts", "OBSERVATION", 29, 39]]], ["A product labeled with an SAL of 10 -3 indicates that there is a 1 in 1,000 chance of a single viable microbe present in the tissue, whereas an SAL of 10 -6 indicates a greater degree of sterility with a 1 in 1,000,000 chance of the same.", [["tissue", "ANATOMY", 125, 131], ["tissue", "TISSUE", 125, 131], ["microbe", "OBSERVATION", 102, 109], ["tissue", "ANATOMY", 125, 131], ["greater degree", "OBSERVATION_MODIFIER", 169, 183], ["sterility", "OBSERVATION", 187, 196]]], ["An SAL of 10 -6 is the required level of sterilization by the Center for Disease Control and Prevention for medical instruments that breach the skin 37 and is thus often referred to as a medical device level of sterility.", [["skin", "ANATOMY", 144, 148], ["skin", "ORGAN", 144, 148], ["sterilization", "TREATMENT", 41, 54], ["Disease Control", "TREATMENT", 73, 88], ["medical instruments", "TREATMENT", 108, 127], ["skin", "ANATOMY", 144, 148]]], ["This level of sterility can only be achieved through terminal sterilization, though some terminally sterilized tissue products still retain an SAL of only 10 -3 .", [["tissue", "ANATOMY", 111, 117], ["tissue", "TISSUE", 111, 117], ["terminal sterilization", "TREATMENT", 53, 75], ["some terminally sterilized tissue products", "PROBLEM", 84, 126], ["terminal", "OBSERVATION_MODIFIER", 53, 61], ["sterilization", "OBSERVATION", 62, 75], ["SAL", "OBSERVATION_MODIFIER", 143, 146]]], ["38 Note that SAL is only a measure of microbial sterility and is unrelated to viruses, although the methods used to achieve an acceptable SAL may be effective at lowering viral risk.", [["SAL", "CHEMICAL", 138, 141], ["SAL", "SIMPLE_CHEMICAL", 138, 141], ["microbial sterility", "PROBLEM", 38, 57], ["viruses", "PROBLEM", 78, 85], ["the methods", "TREATMENT", 96, 107], ["microbial sterility", "OBSERVATION", 38, 57], ["unrelated to", "UNCERTAINTY", 65, 77], ["viruses", "OBSERVATION", 78, 85]]], ["As mentioned previously, tissue processors use strict donor-screening and viral test methods to prevent viral transmission.", [["tissue", "ANATOMY", 25, 31], ["tissue", "TISSUE", 25, 31], ["tissue processors", "TREATMENT", 25, 42], ["strict donor-screening", "TREATMENT", 47, 69], ["viral test methods", "TEST", 74, 92], ["viral transmission", "PROBLEM", 104, 122]]], ["Furthermore, several processing methods have been demonstrated to result in significant viral inactivation.", [["significant viral inactivation", "PROBLEM", 76, 106], ["significant", "OBSERVATION_MODIFIER", 76, 87], ["viral inactivation", "OBSERVATION", 88, 106]]], ["For example, low-dose gamma irradiation was demonstrated to inactivate a broad spectrum of viruses, including HIV and enveloped, nonenveloped, DNA, and RNA viruses.", [["HIV", "ORGANISM", 110, 113], ["DNA", "CELLULAR_COMPONENT", 143, 146], ["HIV", "SPECIES", 110, 113], ["HIV", "SPECIES", 110, 113], ["low-dose gamma irradiation", "TREATMENT", 13, 39], ["a broad spectrum of viruses", "PROBLEM", 71, 98], ["HIV", "PROBLEM", 110, 113], ["DNA", "PROBLEM", 143, 146], ["RNA viruses", "PROBLEM", 152, 163], ["viruses", "OBSERVATION", 91, 98], ["RNA viruses", "OBSERVATION", 152, 163]]], ["39 Another processing method uses vacuum and oscillating pressure combined with chemical agents to inactivate pathogens.", [["Another processing method", "TREATMENT", 3, 28], ["vacuum", "TREATMENT", 34, 40], ["oscillating pressure", "TREATMENT", 45, 65], ["chemical agents", "TREATMENT", 80, 95], ["pathogens", "PROBLEM", 110, 119]]], ["40 The use of a terminal sterilization process with the ability to inactivate a wide range of virus types is particularly advantageous as new viruses (e.g., Zika, severe acute respiratory syndrome, and so forth) emerge for which validated blood tests may not yet exist.Terminal SterilizationReported methods to terminally sterilize allografts in their final packaging include plasma H 2 O 2 , ethylene oxide (EO), supercritical CO 2 , electron beam irradiation, and gamma irradiation, all with benefits and risks.", [["blood", "ANATOMY", 239, 244], ["allografts", "ANATOMY", 332, 342], ["plasma", "ANATOMY", 376, 382], ["acute respiratory syndrome", "DISEASE", 170, 196], ["H 2 O 2 , ethylene oxide", "CHEMICAL", 383, 407], ["EO", "CHEMICAL", 409, 411], ["H 2 O 2", "CHEMICAL", 383, 390], ["ethylene oxide", "CHEMICAL", 393, 407], ["CO 2", "CHEMICAL", 428, 432], ["blood", "ORGANISM_SUBSTANCE", 239, 244], ["allografts", "TISSUE", 332, 342], ["plasma", "ORGANISM_SUBSTANCE", 376, 382], ["H 2 O 2", "SIMPLE_CHEMICAL", 383, 390], ["ethylene oxide", "SIMPLE_CHEMICAL", 393, 407], ["EO", "SIMPLE_CHEMICAL", 409, 411], ["supercritical CO 2", "SIMPLE_CHEMICAL", 414, 432], ["a terminal sterilization process", "TREATMENT", 14, 46], ["a wide range of virus types", "PROBLEM", 78, 105], ["new viruses", "PROBLEM", 138, 149], ["Zika", "PROBLEM", 157, 161], ["severe acute respiratory syndrome", "PROBLEM", 163, 196], ["blood tests", "TEST", 239, 250], ["Terminal SterilizationReported methods", "TREATMENT", 269, 307], ["terminally sterilize allografts", "TREATMENT", 311, 342], ["plasma H", "TREATMENT", 376, 384], ["ethylene oxide (EO", "TREATMENT", 393, 411], ["supercritical CO", "TREATMENT", 414, 430], ["electron beam irradiation", "TREATMENT", 435, 460], ["gamma irradiation", "TREATMENT", 466, 483], ["virus", "OBSERVATION", 94, 99], ["new", "OBSERVATION_MODIFIER", 138, 141], ["viruses", "OBSERVATION", 142, 149], ["severe", "OBSERVATION_MODIFIER", 163, 169], ["acute", "OBSERVATION_MODIFIER", 170, 175], ["respiratory syndrome", "OBSERVATION", 176, 196]]], ["Plasma H 2 O 2 has the disadvantage of removing osteoinductive potential from DBM 41 and may damage soft tissues.", [["soft tissues", "ANATOMY", 100, 112], ["H 2 O", "CHEMICAL", 7, 12], ["H 2 O 2", "CHEMICAL", 7, 14], ["Plasma", "ORGANISM_SUBSTANCE", 0, 6], ["H 2 O 2", "GENE_OR_GENE_PRODUCT", 7, 14], ["soft tissues", "TISSUE", 100, 112], ["osteoinductive potential from DBM", "TREATMENT", 48, 81], ["damage soft tissues", "PROBLEM", 93, 112], ["soft tissues", "ANATOMY", 100, 112]]], ["Although EO is commonly used to sterilize medical instruments, it has been reported to cause persistent synovial effusions and inflammatory responses in EO-treated allografts.", [["synovial", "ANATOMY", 104, 112], ["allografts", "ANATOMY", 164, 174], ["EO", "CHEMICAL", 9, 11], ["effusions", "DISEASE", 113, 122], ["EO", "CHEMICAL", 153, 155], ["EO", "SIMPLE_CHEMICAL", 9, 11], ["synovial effusions", "PATHOLOGICAL_FORMATION", 104, 122], ["EO", "SIMPLE_CHEMICAL", 153, 155], ["allografts", "TISSUE", 164, 174], ["persistent synovial effusions", "PROBLEM", 93, 122], ["inflammatory responses in EO", "PROBLEM", 127, 155], ["allografts", "TREATMENT", 164, 174], ["persistent", "OBSERVATION_MODIFIER", 93, 103], ["synovial", "ANATOMY", 104, 112], ["effusions", "OBSERVATION", 113, 122], ["inflammatory", "OBSERVATION_MODIFIER", 127, 139], ["allografts", "OBSERVATION", 164, 174]]], ["42 Both supercritical CO 2 and electron beam irradiation have been reported capable of safely providing terminal sterilization without significantly damaging tissue.", [["tissue", "ANATOMY", 158, 164], ["CO 2", "CHEMICAL", 22, 26], ["tissue", "TISSUE", 158, 164], ["electron beam irradiation", "TREATMENT", 31, 56], ["terminal sterilization", "TREATMENT", 104, 126], ["significantly damaging tissue", "PROBLEM", 135, 164], ["sterilization", "OBSERVATION", 113, 126]]], ["43, 44 However, these processes are relatively unproven clinically and account for a small percentage of sterilized tissue.", [["tissue", "ANATOMY", 116, 122], ["tissue", "TISSUE", 116, 122], ["a small percentage of sterilized tissue", "PROBLEM", 83, 122], ["small", "OBSERVATION_MODIFIER", 85, 90], ["percentage", "OBSERVATION_MODIFIER", 91, 101], ["sterilized tissue", "OBSERVATION", 105, 122]]], ["The most frequently used method of terminal sterilization is gamma irradiation.", [["method of terminal sterilization", "TREATMENT", 25, 57], ["gamma irradiation", "TREATMENT", 61, 78], ["gamma irradiation", "OBSERVATION", 61, 78]]], ["45Gamma IrradiationGamma irradiation is the most common sterilization treatment method used on allografts and is also used in a majority of processed tendons whether for terminal sterilization or as an intermediate step.", [["allografts", "ANATOMY", 95, 105], ["tendons", "ANATOMY", 150, 157], ["allografts", "TISSUE", 95, 105], ["tendons", "ORGAN", 150, 157], ["Gamma IrradiationGamma irradiation", "TREATMENT", 2, 36], ["the most common sterilization treatment method", "TREATMENT", 40, 86], ["allografts", "TREATMENT", 95, 105], ["terminal sterilization", "TREATMENT", 170, 192], ["Gamma irradiation", "OBSERVATION", 19, 36], ["most common", "OBSERVATION_MODIFIER", 44, 55], ["tendons", "ANATOMY", 150, 157]]], ["45 Although there have been reports of negative outcomes with gamma-irradiated allografts, 46,47 the tissues studied were either first treated with harsh chemical pretreatments or by applying irradiation at higher, less desirable temperatures.", [["allografts", "ANATOMY", 79, 89], ["tissues", "ANATOMY", 101, 108], ["allografts", "TISSUE", 79, 89], ["tissues", "TISSUE", 101, 108], ["gamma-irradiated allografts", "TREATMENT", 62, 89], ["harsh chemical pretreatments", "TREATMENT", 148, 176], ["irradiation", "TREATMENT", 192, 203], ["gamma-irradiated allografts", "OBSERVATION", 62, 89]]], ["[46] [47] [48] Other studies have demonstrated that the use of irradiated grafts did not negatively affect clinical efficacy.", [["grafts", "ANATOMY", 74, 80], ["grafts", "TISSUE", 74, 80], ["Other studies", "TEST", 15, 28], ["irradiated grafts", "TREATMENT", 63, 80], ["grafts", "OBSERVATION", 74, 80]]], ["30, [49] [50] [51] In interpreting these inconsistent results, it is important to note four key variables that allow a reader to more accurately evaluate the method used for applying gamma irradiation and the potential impact on clinical outcomes.", [["gamma irradiation", "TREATMENT", 183, 200]]], ["These four key variables 48 include: \u2022 target dose \u2022 dose range. \u2022 temperature at irradiation \u2022 tissue treatment before irradiation Target dose refers to the intended dose delivered to the tissue, although tissues actually receive a range of dosages due to the nature of irradiation.", [["tissue", "ANATOMY", 96, 102], ["tissue", "ANATOMY", 189, 195], ["tissues", "ANATOMY", 206, 213], ["tissue", "TISSUE", 96, 102], ["tissue", "TISSUE", 189, 195], ["tissues", "TISSUE", 206, 213], ["temperature at irradiation \u2022 tissue treatment", "TREATMENT", 67, 112], ["irradiation", "TREATMENT", 120, 131], ["a range of dosages", "TREATMENT", 231, 249], ["irradiation", "OBSERVATION", 271, 282]]], ["A dose range is a more precise description because it conveys both the minimum and maximum amount of radiation exposure a graft has received.", [["graft", "TISSUE", 122, 127], ["radiation exposure a graft", "TREATMENT", 101, 127], ["maximum", "OBSERVATION_MODIFIER", 83, 90], ["amount", "OBSERVATION_MODIFIER", 91, 97], ["radiation exposure", "OBSERVATION", 101, 119], ["graft", "OBSERVATION", 122, 127]]], ["A narrow dose range indicates a higher degree of control.", [["narrow", "OBSERVATION_MODIFIER", 2, 8], ["higher degree", "OBSERVATION_MODIFIER", 32, 45]]], ["Bone allografts irradiated with approximately 25 kGy (or 2.5 Mrad) have shown similar clinical results to nonirradiated bone, but irradiation dosages greater than this may negatively impact biomechanical properties, 52,53 although the clinical significance is unclear.", [["Bone allografts", "ANATOMY", 0, 15], ["bone", "ANATOMY", 120, 124], ["Bone allografts", "TISSUE", 0, 15], ["bone", "TISSUE", 120, 124], ["Bone allografts", "TREATMENT", 0, 15], ["irradiation dosages", "TREATMENT", 130, 149], ["allografts", "OBSERVATION", 5, 15], ["bone", "ANATOMY", 120, 124], ["biomechanical properties", "OBSERVATION_MODIFIER", 190, 214]]], ["Soft tissue allografts are reported to perform well when treated at <20 kGy (2.0 Mrad).", [["Soft tissue allografts", "ANATOMY", 0, 22], ["Soft tissue allografts", "TISSUE", 0, 22], ["Soft tissue allografts", "TREATMENT", 0, 22], ["tissue", "ANATOMY", 5, 11], ["allografts", "OBSERVATION", 12, 22]]], ["30, 54 The irradiation of allografts at low temperatures, e.g., on dry ice, has also been shown to effectively mitigate potential damage to the graft by minimizing the generation of free radicals.", [["allografts", "ANATOMY", 26, 36], ["graft", "ANATOMY", 144, 149], ["allografts", "TISSUE", 26, 36], ["graft", "TISSUE", 144, 149], ["free radicals", "SIMPLE_CHEMICAL", 182, 195], ["The irradiation of allografts", "TREATMENT", 7, 36], ["low temperatures", "PROBLEM", 40, 56], ["dry ice", "TREATMENT", 67, 74], ["the graft", "TREATMENT", 140, 149], ["the generation of free radicals", "TREATMENT", 164, 195], ["irradiation", "OBSERVATION_MODIFIER", 11, 22], ["allografts", "OBSERVATION", 26, 36], ["low temperatures", "OBSERVATION_MODIFIER", 40, 56], ["graft", "OBSERVATION", 144, 149], ["free radicals", "OBSERVATION", 182, 195]]], ["55, 56 If the temperature of irradiation is not provided in a study, it may indicate that the grafts were irradiated at ambient temperature and more prone to damage.", [["grafts", "ANATOMY", 94, 100], ["grafts", "TISSUE", 94, 100], ["irradiation", "TREATMENT", 29, 40], ["a study", "TEST", 60, 67], ["the grafts", "TREATMENT", 90, 100], ["grafts", "OBSERVATION", 94, 100]]], ["Thus, the temperature of irradiation should always be taken into account when analyzing the results of a study.", [["the temperature of irradiation", "TREATMENT", 6, 36], ["a study", "TEST", 103, 110]]], ["Some studies 47 report results that come from grafts irradiated at ambient temperature; it is important to note that these outcomes cannot be accurately applied to grafts more carefully irradiated at ultralow temperatures.", [["grafts", "ANATOMY", 46, 52], ["grafts", "ANATOMY", 164, 170], ["grafts", "TISSUE", 46, 52], ["grafts", "TISSUE", 164, 170], ["Some studies", "TEST", 0, 12], ["grafts", "TREATMENT", 46, 52], ["grafts", "TREATMENT", 164, 170]]], ["In support, after reviewing 5968 cases of ACL repair, Tejwani et al. 30 did not find an increased risk of revision surgery with the use of two proprietary process that use low-dose (<1.8 Mrad) gamma irradiation applied at a low temperature.", [["ACL", "ANATOMY", 42, 45], ["ACL", "PATHOLOGICAL_FORMATION", 42, 45], ["ACL repair", "TREATMENT", 42, 52], ["revision surgery", "TREATMENT", 106, 122], ["two proprietary process", "TREATMENT", 139, 162], ["gamma irradiation", "TREATMENT", 193, 210], ["a low temperature", "PROBLEM", 222, 239], ["ACL repair", "OBSERVATION", 42, 52], ["revision", "OBSERVATION", 106, 114], ["low temperature", "OBSERVATION_MODIFIER", 224, 239]]], ["This outcome, along with the findings of other studies, 50,51,57 support the clinical efficacy of low-temperature irradiated sterile tendons.Gamma IrradiationIn summary, advanced tissue recovery and processing methods include steps to ensure bioburden prevention, control, and reduction.", [["tendons", "ANATOMY", 133, 140], ["tissue", "ANATOMY", 179, 185], ["tendons", "ORGANISM_SUBDIVISION", 133, 140], ["tissue", "TISSUE", 179, 185], ["other studies", "TEST", 41, 54], ["low-temperature irradiated sterile tendons", "PROBLEM", 98, 140], ["advanced tissue recovery", "TREATMENT", 170, 194], ["processing methods", "TREATMENT", 199, 217], ["bioburden prevention", "TREATMENT", 242, 262], ["tendons", "ANATOMY", 133, 140]]], ["However, methods used by tissue processors vary at each step resulting in differences among available allografts.", [["tissue", "ANATOMY", 25, 31], ["allografts", "ANATOMY", 102, 112], ["tissue", "TISSUE", 25, 31], ["allografts", "TISSUE", 102, 112], ["tissue processors", "TREATMENT", 25, 42]]], ["Tissue may either be offered aseptically or with a terminal sterilization step to reach an SAL of 10 -3 or 10 -6 .", [["Tissue", "ANATOMY", 0, 6], ["Tissue", "TISSUE", 0, 6], ["a terminal sterilization step", "TREATMENT", 49, 78]]], ["The type of terminal sterilization used also differs and can impact the clinical performance of the allograft tissue.", [["allograft tissue", "ANATOMY", 100, 116], ["allograft tissue", "TISSUE", 100, 116], ["terminal sterilization", "TREATMENT", 12, 34], ["the allograft tissue", "TREATMENT", 96, 116], ["terminal", "OBSERVATION_MODIFIER", 12, 20], ["sterilization", "OBSERVATION", 21, 34], ["allograft tissue", "OBSERVATION", 100, 116]]], ["Low-dose gamma irradiation at a low temperature is still the most common method with well-documented success, 50,51,57 but bench-top studies have shown encouraging early results for supercritical CO 2 and electron beam irradiation.", [["CO 2", "CHEMICAL", 196, 200], ["Low-dose gamma irradiation", "TREATMENT", 0, 26], ["a low temperature", "PROBLEM", 30, 47], ["bench-top studies", "TEST", 123, 140], ["supercritical CO", "TREATMENT", 182, 198], ["electron beam irradiation", "TREATMENT", 205, 230]]], ["43, 44, 58, 59 ENHANCING FUSION POTENTIAL OF ALLOGRAFT BONE VOID FILLERS Bone allografts have long been used to provide structural support and to fill voids.", [["Bone allografts", "ANATOMY", 73, 88], ["Bone allografts", "MULTI-TISSUE_STRUCTURE", 73, 88], ["ALLOGRAFT BONE VOID FILLERS", "PROBLEM", 45, 72], ["Bone allografts", "TREATMENT", 73, 88], ["structural support", "TREATMENT", 120, 138], ["ALLOGRAFT BONE", "OBSERVATION", 45, 59], ["VOID FILLERS", "OBSERVATION", 60, 72], ["allografts", "OBSERVATION", 78, 88]]], ["Traditionally, these grafts have been processed as previously described to reduce risk of disease transmission and also to meet specific surgical dimensional needs through cutting, machining, and grinding.", [["grafts", "ANATOMY", 21, 27], ["grafts", "TISSUE", 21, 27], ["these grafts", "TREATMENT", 15, 27], ["disease transmission", "PROBLEM", 90, 110], ["grafts", "OBSERVATION", 21, 27], ["disease", "OBSERVATION", 90, 97]]], ["Traditional allografts, such as cortical struts, ground cortical bone, cancellous cubes, femoral heads, and shaped interbody spacers, have played, and continue to play, a prominent role in orthopedic surgery.", [["allografts", "ANATOMY", 12, 22], ["cortical struts", "ANATOMY", 32, 47], ["cortical bone", "ANATOMY", 56, 69], ["cubes", "ANATOMY", 82, 87], ["femoral heads", "ANATOMY", 89, 102], ["allografts", "TISSUE", 12, 22], ["cortical struts", "MULTI-TISSUE_STRUCTURE", 32, 47], ["cortical bone", "MULTI-TISSUE_STRUCTURE", 56, 69], ["cancellous cubes", "MULTI-TISSUE_STRUCTURE", 71, 87], ["femoral heads", "MULTI-TISSUE_STRUCTURE", 89, 102], ["Traditional allografts", "TREATMENT", 0, 22], ["cortical struts, ground cortical bone, cancellous cubes, femoral heads", "PROBLEM", 32, 102], ["shaped interbody spacers", "TREATMENT", 108, 132], ["orthopedic surgery", "TREATMENT", 189, 207], ["allografts", "OBSERVATION", 12, 22], ["cortical struts", "OBSERVATION", 32, 47], ["ground", "OBSERVATION", 49, 55], ["cortical", "ANATOMY_MODIFIER", 56, 64], ["bone", "ANATOMY", 65, 69], ["cancellous cubes", "OBSERVATION", 71, 87], ["femoral heads", "ANATOMY", 89, 102], ["shaped", "OBSERVATION_MODIFIER", 108, 114], ["interbody spacers", "OBSERVATION", 115, 132]]], ["In addition, as reviewed in this chapter, when accelerated fusion is an objective, the orthopedic surgeon now also has a wide array of more advanced options to facilitate new bone growth.Gamma IrradiationThe breakthrough in this field came with the discovery that certain extractable bone elements could promote bone growth [60] [61] [62] [63] [64] and, subsequently, when Marshall Urist and colleagues isolated the proteinaceous factors that were found to stimulate or induce new bone formation.", [["bone", "ANATOMY", 175, 179], ["bone", "ANATOMY", 284, 288], ["bone", "ANATOMY", 312, 316], ["bone", "ANATOMY", 481, 485], ["bone", "TISSUE", 175, 179], ["bone", "TISSUE", 284, 288], ["bone", "TISSUE", 312, 316], ["bone", "TISSUE", 481, 485], ["extractable bone elements", "DNA", 272, 297], ["proteinaceous factors", "PROTEIN", 416, 437], ["accelerated fusion", "TREATMENT", 47, 65], ["more advanced options", "TREATMENT", 135, 156], ["new bone growth", "PROBLEM", 171, 186], ["Gamma Irradiation", "TREATMENT", 187, 204], ["The breakthrough", "PROBLEM", 204, 220], ["certain extractable bone elements", "PROBLEM", 264, 297], ["bone growth", "TEST", 312, 323], ["the proteinaceous factors", "PROBLEM", 412, 437], ["new bone formation", "PROBLEM", 477, 495], ["fusion", "OBSERVATION", 59, 65], ["Irradiation", "OBSERVATION", 193, 204], ["breakthrough", "OBSERVATION_MODIFIER", 208, 220], ["new", "OBSERVATION_MODIFIER", 477, 480], ["bone", "ANATOMY", 481, 485]]], ["[65] [66] [67] This family of osteoinductive proteins was named bone morphogenic proteins (BMPs).Gamma IrradiationWe now recognize that three key properties are required for new bone formation and growth: (1) osteoconductivity (scaffolding), (2) osteoinductivity (signals such as BMPs), and (3) osteogenicity (cells).", [["bone", "ANATOMY", 64, 68], ["bone", "ANATOMY", 178, 182], ["cells", "ANATOMY", 310, 315], ["bone morphogenic proteins", "GENE_OR_GENE_PRODUCT", 64, 89], ["bone", "TISSUE", 178, 182], ["cells", "CELL", 310, 315], ["osteoinductive proteins", "PROTEIN", 30, 53], ["bone morphogenic proteins", "PROTEIN", 64, 89], ["BMPs", "PROTEIN", 91, 95], ["BMPs", "PROTEIN", 280, 284], ["osteoinductive proteins", "PROBLEM", 30, 53], ["new bone formation", "PROBLEM", 174, 192], ["osteoconductivity (scaffolding), (2) osteoinductivity (signals such as BMPs), and (3) osteogenicity (cells", "PROBLEM", 209, 315], ["bone", "ANATOMY", 178, 182]]], ["In order, new bone must have a scaffold to grow, referred to as an osteoconductive matrix.", [["bone", "ANATOMY", 14, 18], ["bone", "TISSUE", 14, 18], ["matrix", "CELLULAR_COMPONENT", 83, 89], ["bone", "ANATOMY", 14, 18], ["osteoconductive matrix", "OBSERVATION", 67, 89]]], ["Then cytokine signals are required to induce precursor cells to either differentiate toward the osteoblastic lineage or for cells to further express the osteoblastic phenotype of bone formation; these factors are thus considered osteoinductive.", [["precursor cells", "ANATOMY", 45, 60], ["osteoblastic lineage", "ANATOMY", 96, 116], ["cells", "ANATOMY", 124, 129], ["bone", "ANATOMY", 179, 183], ["precursor cells", "CELL", 45, 60], ["osteoblastic lineage", "CELL", 96, 116], ["cells", "CELL", 124, 129], ["bone", "TISSUE", 179, 183], ["cytokine", "PROTEIN", 5, 13], ["precursor cells", "CELL_TYPE", 45, 60], ["osteoblastic lineage", "CELL_TYPE", 96, 116], ["cytokine signals", "TEST", 5, 21], ["precursor cells", "PROBLEM", 45, 60], ["the osteoblastic phenotype of bone formation", "PROBLEM", 149, 193], ["osteoblastic lineage", "OBSERVATION", 96, 116], ["osteoblastic", "ANATOMY", 153, 165], ["bone", "ANATOMY", 179, 183]]], ["Finally, new bone growth requires the presence of bone-forming cells such as osteoblasts or precursors to produce an extracellular, mineralizing matrix, and this cellular component is referred to as osteogenic.", [["bone", "ANATOMY", 13, 17], ["bone", "ANATOMY", 50, 54], ["cells", "ANATOMY", 63, 68], ["osteoblasts", "ANATOMY", 77, 88], ["extracellular", "ANATOMY", 117, 130], ["matrix", "ANATOMY", 145, 151], ["cellular", "ANATOMY", 162, 170], ["bone", "TISSUE", 13, 17], ["bone", "TISSUE", 50, 54], ["cells", "CELL", 63, 68], ["osteoblasts", "CELL", 77, 88], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 117, 130], ["mineralizing matrix", "CELLULAR_COMPONENT", 132, 151], ["cellular", "CELL", 162, 170], ["bone-forming cells", "CELL_TYPE", 50, 68], ["osteoblasts", "CELL_TYPE", 77, 88], ["new bone growth", "PROBLEM", 9, 24], ["bone-forming cells", "PROBLEM", 50, 68], ["osteoblasts", "PROBLEM", 77, 88], ["precursors", "PROBLEM", 92, 102], ["an extracellular, mineralizing matrix", "PROBLEM", 114, 151], ["this cellular component", "PROBLEM", 157, 180], ["new", "OBSERVATION_MODIFIER", 9, 12], ["bone", "ANATOMY", 13, 17], ["growth", "OBSERVATION_MODIFIER", 18, 24], ["bone", "ANATOMY", 50, 54], ["forming cells", "OBSERVATION", 55, 68], ["osteoblasts", "OBSERVATION", 77, 88], ["extracellular", "OBSERVATION_MODIFIER", 117, 130], ["mineralizing matrix", "OBSERVATION", 132, 151], ["osteogenic", "OBSERVATION", 199, 209]]], ["Different bone-grafting options may provide one, two, or all three of these properties.", [["bone", "ANATOMY", 10, 14], ["bone", "TISSUE", 10, 14], ["Different bone-grafting options", "TREATMENT", 0, 31], ["bone", "ANATOMY", 10, 14], ["grafting", "OBSERVATION", 15, 23]]], ["For example, a processed cancellous cube is still considered an osteoconductive scaffold capable of supporting new bone growth by interacting with host bone and signals despite potentially having neither significant osteoinductive capacity, being low in native growth factors, nor any osteogenic potential, being devitalized.", [["bone", "ANATOMY", 115, 119], ["bone", "ANATOMY", 152, 156], ["bone", "TISSUE", 115, 119], ["bone", "TISSUE", 152, 156], ["native growth factors", "PROTEIN", 254, 275], ["a processed cancellous cube", "PROBLEM", 13, 40], ["new bone growth", "PROBLEM", 111, 126], ["significant osteoinductive capacity", "PROBLEM", 204, 239], ["cancellous cube", "OBSERVATION", 25, 40], ["still considered", "UNCERTAINTY", 44, 60], ["osteoconductive scaffold", "OBSERVATION", 64, 88], ["new", "OBSERVATION_MODIFIER", 111, 114], ["bone", "ANATOMY", 115, 119], ["growth", "OBSERVATION_MODIFIER", 120, 126], ["significant", "OBSERVATION_MODIFIER", 204, 215], ["osteoinductive capacity", "OBSERVATION", 216, 239], ["low", "OBSERVATION_MODIFIER", 247, 250]]], ["In another example, a recombinant form of one commercially available specific human growth factor, BMP-2, would be considered as an osteoinductive signal 68 but would require the additional presence of osteogenic and osteoconductive components to drive bone formation.", [["bone", "ANATOMY", 253, 257], ["human", "ORGANISM", 78, 83], ["BMP-2", "GENE_OR_GENE_PRODUCT", 99, 104], ["osteogenic", "CELL", 202, 212], ["bone", "TISSUE", 253, 257], ["human growth factor", "PROTEIN", 78, 97], ["BMP", "PROTEIN", 99, 102], ["human", "SPECIES", 78, 83], ["human", "SPECIES", 78, 83], ["BMP", "TEST", 99, 102], ["an osteoinductive signal", "TEST", 129, 153], ["osteogenic and osteoconductive components", "PROBLEM", 202, 243], ["bone formation", "PROBLEM", 253, 267], ["osteogenic", "OBSERVATION", 202, 212], ["osteoconductive components", "OBSERVATION", 217, 243]]], ["Furthermore, an autograft bone and marrow mixture derived from the patient may theoretically provide all three components necessary for new bone formation, but the quantity and quality of grafting material may depend on the surgical site, health, and age of the patient.", [["bone", "ANATOMY", 26, 30], ["marrow", "ANATOMY", 35, 41], ["bone", "ANATOMY", 140, 144], ["bone", "TISSUE", 26, 30], ["marrow", "TISSUE", 35, 41], ["patient", "ORGANISM", 67, 74], ["bone", "TISSUE", 140, 144], ["patient", "ORGANISM", 262, 269], ["patient", "SPECIES", 67, 74], ["patient", "SPECIES", 262, 269], ["an autograft bone and marrow mixture", "TEST", 13, 49], ["new bone formation", "PROBLEM", 136, 154], ["grafting material", "TREATMENT", 188, 205], ["autograft", "OBSERVATION", 16, 25], ["bone", "ANATOMY", 26, 30], ["marrow", "ANATOMY", 35, 41], ["new", "OBSERVATION_MODIFIER", 136, 139], ["bone", "ANATOMY", 140, 144], ["grafting", "OBSERVATION", 188, 196]]], ["As an alternative, viable cellular allografts can theoretically provide all three components, and these will be described further in the following sections.Gamma IrradiationBeyond simply filling bone voids, allografts can also be processed in different manners to enhance fusion potential.", [["cellular allografts", "ANATOMY", 26, 45], ["sections", "ANATOMY", 147, 155], ["bone", "ANATOMY", 195, 199], ["allografts", "ANATOMY", 207, 217], ["cellular allografts", "TISSUE", 26, 45], ["bone", "TISSUE", 195, 199], ["allografts", "TISSUE", 207, 217], ["viable cellular allografts", "TREATMENT", 19, 45], ["Gamma Irradiation", "TREATMENT", 156, 173], ["simply filling bone voids", "PROBLEM", 180, 205], ["allografts", "TREATMENT", 207, 217], ["cellular allografts", "OBSERVATION", 26, 45], ["Irradiation", "OBSERVATION", 162, 173], ["filling bone voids", "OBSERVATION", 187, 205], ["allografts", "OBSERVATION", 207, 217]]], ["The most prevalent processing method involves taking advantage of the pervasiveness of native BMPs found in cortical bone.", [["cortical bone", "ANATOMY", 108, 121], ["BMPs", "GENE_OR_GENE_PRODUCT", 94, 98], ["cortical bone", "MULTI-TISSUE_STRUCTURE", 108, 121], ["native BMPs", "PROTEIN", 87, 98], ["native BMPs", "PROBLEM", 87, 98], ["most prevalent", "OBSERVATION_MODIFIER", 4, 18], ["BMPs", "OBSERVATION", 94, 98], ["cortical", "ANATOMY_MODIFIER", 108, 116], ["bone", "ANATOMY", 117, 121]]], ["Through careful demineralization, these factors can become bioavailable in the resultant DBM.", [["careful demineralization", "PROBLEM", 8, 32], ["the resultant DBM", "PROBLEM", 75, 92], ["demineralization", "OBSERVATION", 16, 32], ["resultant DBM", "OBSERVATION", 79, 92]]], ["Typically, a dilute hydrochloric acid solution is used to dissolve some of the bone's mineral phase (apatitic calcium phosphate), thus exposing these growth factors.", [["bone", "ANATOMY", 79, 83], ["hydrochloric acid", "CHEMICAL", 20, 37], ["calcium phosphate", "CHEMICAL", 110, 127], ["hydrochloric acid", "CHEMICAL", 20, 37], ["calcium phosphate", "CHEMICAL", 110, 127], ["hydrochloric acid", "SIMPLE_CHEMICAL", 20, 37], ["bone", "TISSUE", 79, 83], ["apatitic calcium phosphate", "SIMPLE_CHEMICAL", 101, 127], ["growth factors", "PROTEIN", 150, 164], ["a dilute hydrochloric acid solution", "TREATMENT", 11, 46], ["the bone's mineral phase", "TEST", 75, 99], ["apatitic calcium phosphate", "TREATMENT", 101, 127], ["bone", "ANATOMY", 79, 83]]], ["In fact, this process mimics the natural action of osteoclasts in bone remodeling as they create a localized acidic environment which similarly dissolves the mineral phase, releasing BMPs to signal cells to lay down new bone.", [["osteoclasts", "ANATOMY", 51, 62], ["bone", "ANATOMY", 66, 70], ["cells", "ANATOMY", 198, 203], ["bone", "ANATOMY", 220, 224], ["osteoclasts", "CELL", 51, 62], ["bone", "TISSUE", 66, 70], ["BMPs", "GENE_OR_GENE_PRODUCT", 183, 187], ["cells", "CELL", 198, 203], ["bone", "TISSUE", 220, 224], ["osteoclasts", "CELL_TYPE", 51, 62], ["BMPs", "PROTEIN", 183, 187], ["signal cells", "CELL_TYPE", 191, 203], ["osteoclasts in bone remodeling", "PROBLEM", 51, 81], ["a localized acidic environment", "PROBLEM", 97, 127], ["osteoclasts", "OBSERVATION", 51, 62], ["bone", "ANATOMY", 66, 70], ["localized", "OBSERVATION_MODIFIER", 99, 108], ["acidic environment", "OBSERVATION", 109, 127], ["mineral phase", "OBSERVATION_MODIFIER", 158, 171], ["new", "OBSERVATION_MODIFIER", 216, 219], ["bone", "ANATOMY", 220, 224]]], ["[69] [70] [71] [72] If undertreated, hypodemineralization would result in osteoinductive factors still being trapped in the bone matrix and unavailable for rapid signaling, whereas hyperdemineralization may lead to those factors either being eluted out of the matrix during demineralization or overly acid-exposed and denatured, thus yielding a nonosteoinductive material.Gamma IrradiationAt least one study demonstrates this relationship by correlation of the residual calcium levels, as a measure of demineralization, to new bone formation using a rodent bone growth model.", [["bone matrix", "ANATOMY", 124, 135], ["matrix", "ANATOMY", 260, 266], ["bone", "ANATOMY", 527, 531], ["bone", "ANATOMY", 557, 561], ["hypodemineralization", "DISEASE", 37, 57], ["hyperdemineralization", "DISEASE", 181, 202], ["calcium", "CHEMICAL", 470, 477], ["calcium", "CHEMICAL", 470, 477], ["[69] [70] [71] [72]", "SIMPLE_CHEMICAL", 0, 19], ["bone", "TISSUE", 124, 128], ["matrix", "CELLULAR_COMPONENT", 260, 266], ["calcium", "SIMPLE_CHEMICAL", 470, 477], ["bone", "TISSUE", 527, 531], ["bone", "TISSUE", 557, 561], ["osteoinductive factors", "PROTEIN", 74, 96], ["hypodemineralization", "PROBLEM", 37, 57], ["osteoinductive factors", "PROBLEM", 74, 96], ["rapid signaling", "PROBLEM", 156, 171], ["hyperdemineralization", "PROBLEM", 181, 202], ["those factors", "PROBLEM", 215, 228], ["demineralization", "PROBLEM", 274, 290], ["a nonosteoinductive material", "PROBLEM", 343, 371], ["Gamma Irradiation", "TREATMENT", 372, 389], ["one study", "TEST", 398, 407], ["the residual calcium levels", "TEST", 457, 484], ["demineralization", "PROBLEM", 502, 518], ["new bone formation", "PROBLEM", 523, 541], ["a rodent bone growth model", "TREATMENT", 548, 574], ["bone", "ANATOMY", 124, 128], ["demineralization", "OBSERVATION", 274, 290], ["Irradiation", "OBSERVATION", 378, 389], ["residual", "OBSERVATION_MODIFIER", 461, 469], ["calcium levels", "OBSERVATION", 470, 484], ["demineralization", "OBSERVATION", 502, 518], ["new", "OBSERVATION_MODIFIER", 523, 526], ["bone", "ANATOMY", 527, 531]]], ["73 The authors support the premise that overdemineralization or underdemineralization lowers the osteoinductive potential of DBMs, indicating that there is an optimal range in the middle.", [["overdemineralization", "DISEASE", 40, 60], ["DBMs", "PATHOLOGICAL_FORMATION", 125, 129], ["overdemineralization", "PROBLEM", 40, 60], ["underdemineralization", "PROBLEM", 64, 85], ["middle", "ANATOMY_MODIFIER", 180, 186]]], ["Thus given the presence of bioavailable growth factors within a human bony matrix, properly demineralized DBMs are considered both osteoinductive and osteoconductive, still relying on the patient's own cells for the osteogenic component.", [["bony matrix", "ANATOMY", 70, 81], ["DBMs", "ANATOMY", 106, 110], ["cells", "ANATOMY", 202, 207], ["human", "ORGANISM", 64, 69], ["bony matrix", "CELLULAR_COMPONENT", 70, 81], ["DBMs", "SIMPLE_CHEMICAL", 106, 110], ["patient", "ORGANISM", 188, 195], ["cells", "CELL", 202, 207], ["bioavailable growth factors", "PROTEIN", 27, 54], ["human", "SPECIES", 64, 69], ["patient", "SPECIES", 188, 195], ["human", "SPECIES", 64, 69], ["bioavailable growth factors", "PROBLEM", 27, 54], ["a human bony matrix", "TREATMENT", 62, 81], ["properly demineralized DBMs", "PROBLEM", 83, 110], ["osteoinductive and osteoconductive", "PROBLEM", 131, 165], ["the osteogenic component", "PROBLEM", 212, 236], ["demineralized", "OBSERVATION", 92, 105], ["osteoinductive", "OBSERVATION_MODIFIER", 131, 145], ["osteoconductive", "OBSERVATION", 150, 165], ["osteogenic component", "OBSERVATION", 216, 236]]], ["To improve handling, many DBM formulations also use a carrier such as glycerol, hyaluronic acid, starch, and so forth.", [["glycerol", "CHEMICAL", 70, 78], ["hyaluronic acid", "CHEMICAL", 80, 95], ["glycerol", "CHEMICAL", 70, 78], ["glycerol", "SIMPLE_CHEMICAL", 70, 78], ["hyaluronic acid", "SIMPLE_CHEMICAL", 80, 95], ["starch", "SIMPLE_CHEMICAL", 97, 103], ["many DBM formulations", "TREATMENT", 21, 42], ["a carrier", "TREATMENT", 52, 61], ["glycerol, hyaluronic acid, starch", "TREATMENT", 70, 103]]], ["An extensive study of the impact of these carriers on long-term clinical outcomes is generally lacking, although clinical evidence supports glycerol and hyaluronic acid as DBM carriers.", [["glycerol", "CHEMICAL", 140, 148], ["hyaluronic acid", "CHEMICAL", 153, 168], ["glycerol", "CHEMICAL", 140, 148], ["glycerol", "SIMPLE_CHEMICAL", 140, 148], ["hyaluronic acid", "SIMPLE_CHEMICAL", 153, 168], ["An extensive study", "TEST", 0, 18], ["glycerol and hyaluronic acid", "TREATMENT", 140, 168]]], ["[74] [75] [76] More recently, cellular bone allografts have emerged as a new option.", [["cellular bone allografts", "ANATOMY", 30, 54], ["cellular", "CELL", 30, 38], ["bone allografts", "MULTI-TISSUE_STRUCTURE", 39, 54], ["cellular bone allografts", "TREATMENT", 30, 54], ["bone", "ANATOMY", 39, 43], ["allografts", "OBSERVATION", 44, 54]]], ["77 These grafts are formulated to provide all three elements of bone formation.", [["grafts", "ANATOMY", 9, 15], ["bone", "ANATOMY", 64, 68], ["grafts", "TISSUE", 9, 15], ["bone", "TISSUE", 64, 68], ["These grafts", "TREATMENT", 3, 15], ["grafts", "OBSERVATION", 9, 15], ["bone", "ANATOMY", 64, 68]]], ["The osteoconductive component is bone in the form of chips, fibers, or particulates.", [["bone", "ANATOMY", 33, 37], ["fibers", "ANATOMY", 60, 66], ["bone", "TISSUE", 33, 37], ["fibers", "CELLULAR_COMPONENT", 60, 66], ["The osteoconductive component", "PROBLEM", 0, 29], ["osteoconductive", "OBSERVATION_MODIFIER", 4, 19], ["component", "OBSERVATION_MODIFIER", 20, 29], ["bone", "ANATOMY", 33, 37], ["chips", "OBSERVATION", 53, 58], ["particulates", "OBSERVATION_MODIFIER", 71, 83]]], ["The osteogenic component is comprised of cells either adhering to the bone component or added from another source, for example, adipose-derived cells or amniotic tissue.", [["cells", "ANATOMY", 41, 46], ["bone", "ANATOMY", 70, 74], ["adipose-derived cells", "ANATOMY", 128, 149], ["amniotic tissue", "ANATOMY", 153, 168], ["cells", "CELL", 41, 46], ["bone", "TISSUE", 70, 74], ["adipose-derived cells", "CELL", 128, 149], ["amniotic tissue", "TISSUE", 153, 168], ["adipose-derived cells", "CELL_TYPE", 128, 149], ["The osteogenic component", "PROBLEM", 0, 24], ["cells", "PROBLEM", 41, 46], ["the bone component", "PROBLEM", 66, 84], ["amniotic tissue", "PROBLEM", 153, 168], ["osteogenic", "OBSERVATION_MODIFIER", 4, 14], ["component", "OBSERVATION_MODIFIER", 15, 24], ["bone", "ANATOMY", 70, 74], ["amniotic tissue", "OBSERVATION", 153, 168]]], ["The osteoinductive component may be DBM derived from the same donor or may rely on endogenous trophic factors inherent to the cellular component.", [["cellular", "ANATOMY", 126, 134], ["cellular", "CELL", 126, 134], ["endogenous trophic factors", "PROTEIN", 83, 109], ["The osteoinductive component", "PROBLEM", 0, 28], ["DBM", "PROBLEM", 36, 39], ["endogenous trophic factors", "PROBLEM", 83, 109], ["osteoinductive", "OBSERVATION", 4, 18], ["may be", "UNCERTAINTY", 29, 35], ["DBM", "OBSERVATION", 36, 39], ["cellular", "OBSERVATION_MODIFIER", 126, 134], ["component", "OBSERVATION_MODIFIER", 135, 144]]], ["Most current cellular bone void filler approaches rely on inclusion of mesenchymal stem cells, assuming that they will produce factors conducive to the healing process and that they will differentiate down the osteoblastic lineage to initiate bone formation.", [["cellular", "ANATOMY", 13, 21], ["bone", "ANATOMY", 22, 26], ["mesenchymal stem cells", "ANATOMY", 71, 93], ["osteoblastic lineage", "ANATOMY", 210, 230], ["bone", "ANATOMY", 243, 247], ["cellular", "CELL", 13, 21], ["mesenchymal stem cells", "CELL", 71, 93], ["osteoblastic lineage", "CELL", 210, 230], ["bone", "TISSUE", 243, 247], ["mesenchymal stem cells", "CELL_TYPE", 71, 93], ["osteoblastic lineage", "CELL_TYPE", 210, 230], ["cellular bone void filler", "TREATMENT", 13, 38], ["mesenchymal stem cells", "TREATMENT", 71, 93], ["the healing process", "PROBLEM", 148, 167], ["bone formation", "PROBLEM", 243, 257], ["bone", "ANATOMY", 22, 26], ["void filler", "OBSERVATION", 27, 38], ["mesenchymal stem cells", "OBSERVATION", 71, 93], ["osteoblastic", "ANATOMY", 210, 222], ["bone", "ANATOMY", 243, 247]]], ["The impact of the patient's local environment on the differentiation pathway and timing is not well understood.", [["patient", "ORGANISM", 18, 25], ["patient", "SPECIES", 18, 25]]], ["This question becomes increasingly complex when the cell component derives from a nonbone source such as placenta or adipose tissue.", [["cell", "ANATOMY", 52, 56], ["nonbone", "ANATOMY", 82, 89], ["placenta", "ANATOMY", 105, 113], ["adipose tissue", "ANATOMY", 117, 131], ["cell", "CELL", 52, 56], ["placenta", "TISSUE", 105, 113], ["adipose tissue", "TISSUE", 117, 131], ["a nonbone source", "PROBLEM", 80, 96], ["placenta or adipose tissue", "PROBLEM", 105, 131], ["increasingly", "OBSERVATION_MODIFIER", 22, 34], ["complex", "OBSERVATION_MODIFIER", 35, 42], ["adipose tissue", "OBSERVATION", 117, 131]]], ["Alternatively, cellular bone void fillers can include living cells that are integral to the donor bone and thus, being \"bone cells,\" are already committed to the osteoblastic lineage.", [["cellular bone", "ANATOMY", 15, 28], ["cells", "ANATOMY", 61, 66], ["bone", "ANATOMY", 98, 102], ["bone cells", "ANATOMY", 120, 130], ["osteoblastic lineage", "ANATOMY", 162, 182], ["cellular", "CELL", 15, 23], ["bone", "TISSUE", 24, 28], ["cells", "CELL", 61, 66], ["bone", "TISSUE", 98, 102], ["bone cells", "CELL", 120, 130], ["osteoblastic lineage", "CELL", 162, 182], ["bone cells", "CELL_TYPE", 120, 130], ["osteoblastic lineage", "CELL_TYPE", 162, 182], ["cellular bone void fillers", "PROBLEM", 15, 41], ["living cells", "PROBLEM", 54, 66], ["\"bone cells", "PROBLEM", 119, 130], ["cellular bone", "OBSERVATION", 15, 28], ["void fillers", "OBSERVATION", 29, 41], ["living cells", "OBSERVATION", 54, 66], ["donor", "ANATOMY_MODIFIER", 92, 97], ["bone", "ANATOMY", 98, 102], ["bone", "ANATOMY", 120, 124], ["osteoblastic lineage", "OBSERVATION", 162, 182]]], ["Longer term, controlled clinical data would be beneficial in helping support providing the orthopedist with a single grafting material with all three components of bone formation.LOWERING ALLOGRAFT IMMUNOGENIC POTENTIAL: DECELLULARIZATIONMost allografts are generally considered nonimmunogenic either due to the nature of human tissue being transplanted into humans, as a consequence of cleaning processes that remove cellular material such as bone marrow elements, 29 or through preservation processes, including freezing and freeze-drying.", [["bone", "ANATOMY", 164, 168], ["allografts", "ANATOMY", 243, 253], ["tissue", "ANATOMY", 328, 334], ["cellular", "ANATOMY", 418, 426], ["bone marrow", "ANATOMY", 444, 455], ["bone", "TISSUE", 164, 168], ["allografts", "TISSUE", 243, 253], ["human", "ORGANISM", 322, 327], ["tissue", "TISSUE", 328, 334], ["humans", "ORGANISM", 359, 365], ["cellular material", "TISSUE", 418, 435], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 444, 455], ["human", "SPECIES", 322, 327], ["humans", "SPECIES", 359, 365], ["human", "SPECIES", 322, 327], ["humans", "SPECIES", 359, 365], ["a single grafting material", "TREATMENT", 108, 134], ["bone formation", "PROBLEM", 164, 178], ["DECELLULARIZATIONMost allografts", "TREATMENT", 221, 253], ["nonimmunogenic", "PROBLEM", 279, 293], ["human tissue", "PROBLEM", 322, 334], ["cleaning processes", "PROBLEM", 387, 405], ["cellular material", "PROBLEM", 418, 435], ["bone marrow elements", "PROBLEM", 444, 464], ["grafting", "OBSERVATION", 117, 125], ["bone", "ANATOMY", 164, 168], ["ALLOGRAFT", "OBSERVATION", 188, 197], ["DECELLULARIZATIONMost allografts", "OBSERVATION", 221, 253], ["bone", "ANATOMY", 444, 448], ["marrow elements", "OBSERVATION", 449, 464]]], ["78 However, depending on the tissue type and intended clinical application, unprocessed allograft tissue can pose issues with immunogenicity, 18,78 which need to be minimized for an allograft to be optimally biocompatible upon implantation.", [["tissue", "ANATOMY", 29, 35], ["allograft tissue", "ANATOMY", 88, 104], ["tissue", "TISSUE", 29, 35], ["allograft tissue", "TISSUE", 88, 104], ["allograft", "TISSUE", 182, 191], ["unprocessed allograft tissue", "PROBLEM", 76, 104], ["immunogenicity", "TEST", 126, 140], ["an allograft", "TREATMENT", 179, 191], ["implantation", "TREATMENT", 227, 239], ["allograft tissue", "OBSERVATION", 88, 104], ["allograft", "OBSERVATION", 182, 191], ["implantation", "OBSERVATION", 227, 239]]], ["79 Furthermore, different types of tissue exhibit varying degrees of immunogenicity, as measured by antigenicity.", [["tissue", "ANATOMY", 35, 41], ["tissue", "TISSUE", 35, 41], ["varying degrees of immunogenicity", "PROBLEM", 50, 83], ["different types", "OBSERVATION_MODIFIER", 16, 31], ["tissue exhibit", "OBSERVATION_MODIFIER", 35, 49], ["varying degrees", "OBSERVATION_MODIFIER", 50, 65], ["immunogenicity", "OBSERVATION", 69, 83]]], ["Skin is generally more immunogenic 80 than bone and tendon tissues, which exhibit lower immunogenicity 81 that can generally be resolved through the typical allograft-cleaning processes.", [["Skin", "ANATOMY", 0, 4], ["bone", "ANATOMY", 43, 47], ["tendon tissues", "ANATOMY", 52, 66], ["allograft", "ANATOMY", 157, 166], ["Skin", "ORGAN", 0, 4], ["bone", "TISSUE", 43, 47], ["tendon tissues", "TISSUE", 52, 66], ["lower immunogenicity", "PROBLEM", 82, 102], ["the typical allograft", "TREATMENT", 145, 166], ["generally", "OBSERVATION_MODIFIER", 8, 17], ["more", "OBSERVATION_MODIFIER", 18, 22], ["immunogenic", "OBSERVATION", 23, 34], ["bone", "ANATOMY", 43, 47], ["tendon tissues", "ANATOMY", 52, 66], ["lower", "OBSERVATION_MODIFIER", 82, 87], ["immunogenicity", "OBSERVATION", 88, 102], ["typical", "OBSERVATION_MODIFIER", 149, 156], ["allograft", "OBSERVATION", 157, 166]]], ["More immunogenic tissues may need alternative processes to lower antigenicity.", [["tissues", "ANATOMY", 17, 24], ["tissues", "TISSUE", 17, 24], ["More immunogenic tissues", "PROBLEM", 0, 24], ["alternative processes", "TREATMENT", 34, 55], ["immunogenic tissues", "OBSERVATION", 5, 24], ["lower antigenicity", "OBSERVATION_MODIFIER", 59, 77]]], ["One method treats tissue with glutaraldehyde, an aldehyde fixative, to greatly reduce immunogenicity by cross-linking antigens.", [["tissue", "ANATOMY", 18, 24], ["glutaraldehyde", "CHEMICAL", 30, 44], ["aldehyde", "CHEMICAL", 49, 57], ["glutaraldehyde", "CHEMICAL", 30, 44], ["aldehyde", "CHEMICAL", 49, 57], ["tissue", "TISSUE", 18, 24], ["glutaraldehyde", "SIMPLE_CHEMICAL", 30, 44], ["aldehyde", "SIMPLE_CHEMICAL", 49, 57], ["glutaraldehyde", "TREATMENT", 30, 44], ["an aldehyde fixative", "TREATMENT", 46, 66]]], ["82 However, glutaraldehyde has been associated with allergic reactions and may have contributed to the extremely high ACL failure rates reported in one study.", [["glutaraldehyde", "CHEMICAL", 12, 26], ["allergic reactions", "DISEASE", 52, 70], ["ACL failure", "DISEASE", 118, 129], ["glutaraldehyde", "CHEMICAL", 12, 26], ["glutaraldehyde", "SIMPLE_CHEMICAL", 12, 26], ["ACL", "PATHOLOGICAL_FORMATION", 118, 121], ["glutaraldehyde", "TREATMENT", 12, 26], ["allergic reactions", "PROBLEM", 52, 70], ["the extremely high ACL failure rates", "PROBLEM", 99, 135], ["one study", "TEST", 148, 157], ["associated with", "UNCERTAINTY", 36, 51], ["allergic", "OBSERVATION", 52, 60], ["high", "OBSERVATION_MODIFIER", 113, 117], ["ACL failure", "OBSERVATION", 118, 129]]], ["83 Another method, frequently applied to dermal tissue, uses decellularization to reduce potential immunogenicity and is intended to yield a biocompatible scaffold as a favorable environment for host recellularization and remodeling.", [["dermal tissue", "ANATOMY", 41, 54], ["dermal tissue", "TISSUE", 41, 54], ["Another method", "TREATMENT", 3, 17], ["decellularization", "TREATMENT", 61, 78], ["potential immunogenicity", "PROBLEM", 89, 113], ["a biocompatible scaffold", "TREATMENT", 139, 163], ["host recellularization", "TREATMENT", 195, 217], ["dermal tissue", "ANATOMY", 41, 54]]], ["84 Although there are several different decellularization methods in use, the common goal is to eliminate cellular remnants that could cause an immune response while preserving the tissue architecture and maintaining the mechanical properties of the scaffold.", [["cellular", "ANATOMY", 106, 114], ["tissue", "ANATOMY", 181, 187], ["cellular", "CELL", 106, 114], ["tissue", "TISSUE", 181, 187], ["several different decellularization methods", "TREATMENT", 22, 65], ["cellular remnants", "PROBLEM", 106, 123], ["an immune response", "PROBLEM", 141, 159], ["several", "OBSERVATION_MODIFIER", 22, 29], ["different", "OBSERVATION_MODIFIER", 30, 39], ["decellularization", "OBSERVATION", 40, 57], ["remnants", "OBSERVATION", 115, 123], ["immune response", "OBSERVATION", 144, 159], ["tissue architecture", "OBSERVATION", 181, 200], ["mechanical properties", "OBSERVATION", 221, 242], ["scaffold", "OBSERVATION", 250, 258]]], ["85, 86 Once the dermal tissue is decellularized, this scaffold can be used in orthopedic procedures, such as superior capsule shoulder reconstruction, Achilles tendon repair, and others.", [["dermal tissue", "ANATOMY", 16, 29], ["capsule shoulder", "ANATOMY", 118, 134], ["tendon", "ANATOMY", 160, 166], ["dermal tissue", "TISSUE", 16, 29], ["Achilles tendon", "TISSUE", 151, 166], ["this scaffold", "TREATMENT", 49, 62], ["orthopedic procedures", "TREATMENT", 78, 99], ["superior capsule shoulder reconstruction", "TREATMENT", 109, 149], ["Achilles tendon repair", "TREATMENT", 151, 173], ["dermal tissue", "ANATOMY", 16, 29], ["decellularized", "OBSERVATION", 33, 47], ["superior", "ANATOMY_MODIFIER", 109, 117], ["capsule shoulder", "ANATOMY", 118, 134], ["Achilles tendon", "ANATOMY", 151, 166], ["repair", "OBSERVATION", 167, 173]]], ["[87] [88] [89] [90] [91] As noted previously, decellularization processes can include both chemical and mechanical extraction methods.", [["[87] [88] [89] [90] [91] As", "CHEMICAL", 0, 27], ["[87] [88] [89] [90] [91", "SIMPLE_CHEMICAL", 0, 23], ["decellularization processes", "PROBLEM", 46, 73], ["mechanical extraction methods", "TREATMENT", 104, 133], ["mechanical extraction", "OBSERVATION", 104, 125]]], ["92 More specifically, decellularization techniques are reported to use anionic agents (e.g., sodium dodecyl sulfate, sodium chloride), alkali compounds (e.g., sodium hydroxide), and oxidizing agents (e.g., hydrogen peroxide) to solubilize cellular remnants before removal.", [["cellular", "ANATOMY", 239, 247], ["sodium dodecyl sulfate", "CHEMICAL", 93, 115], ["sodium chloride", "CHEMICAL", 117, 132], ["sodium hydroxide", "CHEMICAL", 159, 175], ["hydrogen peroxide", "CHEMICAL", 206, 223], ["sodium dodecyl sulfate", "CHEMICAL", 93, 115], ["sodium chloride", "CHEMICAL", 117, 132], ["sodium hydroxide", "CHEMICAL", 159, 175], ["hydrogen peroxide", "CHEMICAL", 206, 223], ["anionic agents", "SIMPLE_CHEMICAL", 71, 85], ["sodium dodecyl sulfate", "SIMPLE_CHEMICAL", 93, 115], ["sodium chloride", "SIMPLE_CHEMICAL", 117, 132], ["alkali compounds", "SIMPLE_CHEMICAL", 135, 151], ["sodium hydroxide", "SIMPLE_CHEMICAL", 159, 175], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 206, 223], ["cellular", "CELL", 239, 247], ["anionic agents", "TREATMENT", 71, 85], ["sodium dodecyl sulfate", "TREATMENT", 93, 115], ["sodium chloride", "TREATMENT", 117, 132], ["alkali compounds", "TREATMENT", 135, 151], ["sodium hydroxide", "TREATMENT", 159, 175], ["oxidizing agents", "TREATMENT", 182, 198], ["hydrogen peroxide)", "TREATMENT", 206, 224], ["removal", "TREATMENT", 264, 271]]], ["[31] [32] [33] [34] However, the type of chemicals used and the duration of the decellularization process can affect the strength of the graft by removing collagen and glycosaminoglycans in addition to the immunogenic components, 33 making the differences among decellularization processes worthy of consideration.LOWERING ALLOGRAFT IMMUNOGENIC POTENTIAL: DECELLULARIZATIONThe amount of cellular remnants remaining after decellularization may be indicated using residual DNA content; a lower DNA content would theoretically indicate a cleaner matrix and more favorable host response.", [["graft", "ANATOMY", 137, 142], ["cellular", "ANATOMY", 387, 395], ["[31] [32] [33] [34]", "SIMPLE_CHEMICAL", 0, 19], ["graft", "TISSUE", 137, 142], ["collagen", "GENE_OR_GENE_PRODUCT", 155, 163], ["glycosaminoglycans", "SIMPLE_CHEMICAL", 168, 186], ["cellular", "CELL", 387, 395], ["DNA", "CELLULAR_COMPONENT", 471, 474], ["DNA", "CELLULAR_COMPONENT", 492, 495], ["matrix", "CELLULAR_COMPONENT", 543, 549], ["collagen", "PROTEIN", 155, 163], ["the decellularization process", "TREATMENT", 76, 105], ["the graft", "TREATMENT", 133, 142], ["collagen and glycosaminoglycans", "TREATMENT", 155, 186], ["the immunogenic components", "PROBLEM", 202, 228], ["cellular remnants", "PROBLEM", 387, 404], ["decellularization", "TREATMENT", 421, 438], ["residual DNA content", "PROBLEM", 462, 482], ["a lower DNA content", "PROBLEM", 484, 503], ["a cleaner matrix", "PROBLEM", 533, 549], ["decellularization", "OBSERVATION", 80, 97], ["graft", "OBSERVATION", 137, 142], ["ALLOGRAFT", "OBSERVATION", 323, 332], ["amount", "OBSERVATION_MODIFIER", 377, 383], ["cellular remnants", "OBSERVATION", 387, 404], ["lower DNA", "OBSERVATION_MODIFIER", 486, 495], ["more favorable", "OBSERVATION_MODIFIER", 554, 568], ["host response", "OBSERVATION", 569, 582]]], ["33 The residual DNA content of grafts varies widely.", [["grafts", "ANATOMY", 31, 37], ["DNA", "CELLULAR_COMPONENT", 16, 19], ["grafts", "TISSUE", 31, 37], ["The residual DNA content of grafts", "TREATMENT", 3, 37], ["residual", "OBSERVATION_MODIFIER", 7, 15], ["DNA content", "OBSERVATION", 16, 27], ["grafts", "OBSERVATION", 31, 37], ["varies", "OBSERVATION_MODIFIER", 38, 44], ["widely", "OBSERVATION_MODIFIER", 45, 51]]], ["Published reports include ranges from less than 25 to greater than 250-ng DNA/mg dry weight for acellular dermal matrix (ADM) tissues.", [["acellular dermal matrix", "ANATOMY", 96, 119], ["ADM) tissues", "ANATOMY", 121, 133], ["DNA", "CELLULAR_COMPONENT", 74, 77], ["acellular dermal matrix", "TISSUE", 96, 119], ["ADM) tissues", "TISSUE", 121, 133], ["acellular dermal matrix (ADM) tissues", "TREATMENT", 96, 133], ["dermal matrix", "ANATOMY", 106, 119]]], ["32, 93, 94 As residual DNA levels may correlate with host response, it is not surprising that different ADMs incorporate at different rates, 33 as specifically noted when an ADM with lower residual DNA content was found to more rapidly integrate and recellularize in a comparative animal model.", [["DNA", "CELLULAR_COMPONENT", 23, 26], ["ADM", "GENE_OR_GENE_PRODUCT", 174, 177], ["DNA", "CELLULAR_COMPONENT", 198, 201], ["residual DNA levels", "PROBLEM", 14, 33], ["an ADM", "PROBLEM", 171, 177], ["lower residual DNA content", "PROBLEM", 183, 209], ["DNA content", "OBSERVATION", 198, 209]]], ["32, 95, 96 Recellularization Once an ADM has been implanted, host cells may begin repopulating the scaffold and initiating incorporation of the graft.", [["cells", "ANATOMY", 66, 71], ["graft", "ANATOMY", 144, 149], ["ADM", "CHEMICAL", 37, 40], ["host cells", "CELL", 61, 71], ["graft", "TISSUE", 144, 149], ["host cells", "CELL_TYPE", 61, 71], ["an ADM", "PROBLEM", 34, 40], ["host cells", "PROBLEM", 61, 71], ["repopulating the scaffold", "TREATMENT", 82, 107], ["incorporation of the graft", "TREATMENT", 123, 149], ["graft", "OBSERVATION", 144, 149]]], ["This process starts with the migration of inflammatory host cells, followed by matrix remodeling, and then finally revascularization, leading to recellularization.", [["cells", "ANATOMY", 60, 65], ["matrix", "ANATOMY", 79, 85], ["inflammatory host cells", "CELL", 42, 65], ["matrix", "CELLULAR_COMPONENT", 79, 85], ["inflammatory host cells", "CELL_TYPE", 42, 65], ["inflammatory host cells", "PROBLEM", 42, 65], ["revascularization", "TREATMENT", 115, 132], ["migration", "OBSERVATION_MODIFIER", 29, 38], ["inflammatory host cells", "OBSERVATION", 42, 65]]], ["The initial inflammatory host response is mediated by macrophages and monocytes, which must achieve a careful balance between wound healing and tissue destruction.", [["macrophages", "ANATOMY", 54, 65], ["monocytes", "ANATOMY", 70, 79], ["wound", "ANATOMY", 126, 131], ["tissue", "ANATOMY", 144, 150], ["macrophages", "CELL", 54, 65], ["monocytes", "CELL", 70, 79], ["wound", "PATHOLOGICAL_FORMATION", 126, 131], ["tissue", "TISSUE", 144, 150], ["macrophages", "CELL_TYPE", 54, 65], ["monocytes", "CELL_TYPE", 70, 79], ["monocytes", "TEST", 70, 79], ["wound healing", "PROBLEM", 126, 139], ["tissue destruction", "PROBLEM", 144, 162], ["inflammatory host response", "OBSERVATION", 12, 38], ["macrophages", "OBSERVATION", 54, 65], ["wound", "ANATOMY", 126, 131], ["healing", "OBSERVATION", 132, 139], ["tissue", "ANATOMY", 144, 150], ["destruction", "OBSERVATION", 151, 162]]], ["97 Macrophages regulate the expression of interleukin-1b, 98 a cytokine which contributes to the wound-healing process by controlling fibroblast activation.", [["Macrophages", "ANATOMY", 3, 14], ["wound", "ANATOMY", 97, 102], ["fibroblast", "ANATOMY", 134, 144], ["Macrophages", "CELL", 3, 14], ["interleukin-1b", "GENE_OR_GENE_PRODUCT", 42, 56], ["98", "GENE_OR_GENE_PRODUCT", 58, 60], ["wound", "PATHOLOGICAL_FORMATION", 97, 102], ["fibroblast", "CELL", 134, 144], ["interleukin-1b", "PROTEIN", 42, 56], ["cytokine", "PROTEIN", 63, 71], ["interleukin", "TEST", 42, 53], ["a cytokine", "PROBLEM", 61, 71], ["the wound", "PROBLEM", 93, 102], ["healing process", "PROBLEM", 103, 118], ["Macrophages", "OBSERVATION", 3, 14], ["wound", "ANATOMY", 97, 102], ["healing", "OBSERVATION", 103, 110], ["fibroblast activation", "OBSERVATION", 134, 155]]], ["97 The M1 macrophage phenotype is more associated with an inflammatory response, whereas the M2 macrophage phenotype is associated with tissue repair and constructive tissue remodeling.", [["M1 macrophage", "ANATOMY", 7, 20], ["macrophage", "ANATOMY", 96, 106], ["tissue", "ANATOMY", 136, 142], ["tissue", "ANATOMY", 167, 173], ["M1 macrophage", "CELL", 7, 20], ["M2 macrophage", "CELL", 93, 106], ["tissue", "TISSUE", 136, 142], ["tissue", "TISSUE", 167, 173], ["an inflammatory response", "PROBLEM", 55, 79], ["the M2 macrophage phenotype", "PROBLEM", 89, 116], ["tissue repair", "TREATMENT", 136, 149], ["constructive tissue remodeling", "PROBLEM", 154, 184], ["M1", "OBSERVATION_MODIFIER", 7, 9], ["macrophage phenotype", "OBSERVATION", 10, 30], ["more associated with", "UNCERTAINTY", 34, 54], ["inflammatory", "OBSERVATION", 58, 70], ["M2", "OBSERVATION_MODIFIER", 93, 95], ["macrophage phenotype", "OBSERVATION", 96, 116], ["associated with", "UNCERTAINTY", 120, 135], ["tissue repair", "OBSERVATION", 136, 149], ["constructive tissue remodeling", "OBSERVATION", 154, 184]]], ["99,100 Agrawal et al. 95 investigated the mechanism of incorporation by examining the effect of macrophage phenotype expression on matrix remodeling using three different human ADMs and one synthetic/bovine ADM.", [["macrophage", "ANATOMY", 96, 106], ["matrix", "ANATOMY", 131, 137], ["ADMs", "ANATOMY", 177, 181], ["ADM", "CHEMICAL", 207, 210], ["macrophage", "CELL", 96, 106], ["matrix", "CELLULAR_COMPONENT", 131, 137], ["human", "ORGANISM", 171, 176], ["ADMs", "CANCER", 177, 181], ["bovine", "ORGANISM", 200, 206], ["ADM", "CANCER", 207, 210], ["human", "SPECIES", 171, 176], ["bovine", "SPECIES", 200, 206], ["human", "SPECIES", 171, 176], ["macrophage phenotype expression", "PROBLEM", 96, 127], ["matrix remodeling", "TREATMENT", 131, 148], ["three different human ADMs", "TREATMENT", 155, 181], ["one synthetic/bovine ADM", "TREATMENT", 186, 210], ["macrophage phenotype", "OBSERVATION", 96, 116]]], ["The ADM products displayed differing patterns and timing of macrophage infiltration, leading the authors to conclude that this variability was due to the distinct decellularization processes used for each of the ADM products.", [["macrophage", "ANATOMY", 60, 70], ["macrophage", "CELL", 60, 70], ["The ADM products", "TREATMENT", 0, 16], ["macrophage infiltration", "PROBLEM", 60, 83], ["the distinct decellularization processes", "PROBLEM", 150, 190], ["the ADM products", "TREATMENT", 208, 224], ["macrophage infiltration", "OBSERVATION", 60, 83], ["distinct", "OBSERVATION_MODIFIER", 154, 162], ["decellularization", "OBSERVATION", 163, 180]]], ["Capito et al. 96 also concluded that different decellularization processes may have accounted for the varying degrees of cellular and vascular ingrowth shown by the four different materials in this study.LOWERING ALLOGRAFT IMMUNOGENIC POTENTIAL: DECELLULARIZATIONAs discussed in this chapter, decellularization can be beneficial for further reducing immunogenicity of certain tissue types.", [["cellular", "ANATOMY", 121, 129], ["vascular", "ANATOMY", 134, 142], ["tissue", "ANATOMY", 376, 382], ["cellular", "CELL", 121, 129], ["vascular", "MULTI-TISSUE_STRUCTURE", 134, 142], ["tissue", "TISSUE", 376, 382], ["different decellularization processes", "PROBLEM", 37, 74], ["cellular and vascular ingrowth", "PROBLEM", 121, 151], ["this study", "TEST", 193, 203], ["decellularization", "TREATMENT", 293, 310], ["decellularization", "OBSERVATION", 47, 64], ["may have accounted for", "UNCERTAINTY", 75, 97], ["varying degrees", "OBSERVATION_MODIFIER", 102, 117], ["cellular", "OBSERVATION_MODIFIER", 121, 129], ["vascular", "ANATOMY", 134, 142], ["ingrowth", "OBSERVATION", 143, 151], ["four", "OBSERVATION_MODIFIER", 165, 169], ["different", "OBSERVATION_MODIFIER", 170, 179], ["materials", "OBSERVATION", 180, 189], ["ALLOGRAFT", "OBSERVATION", 213, 222], ["certain tissue", "OBSERVATION_MODIFIER", 368, 382]]], ["Different methods can result in different rates of recellularization, which may impact incorporation rates and ultimate tissue remodeling.ALLOGRAFT PRESERVATION AND STORAGE METHODSUnlike organs and composite tissue allotransplants, which are typically transplanted within hours after the donor's death, allografts may be stored from weeks to years before use.", [["tissue", "ANATOMY", 120, 126], ["organs", "ANATOMY", 187, 193], ["tissue", "ANATOMY", 208, 214], ["death", "DISEASE", 296, 301], ["tissue", "TISSUE", 120, 126], ["organs", "ORGAN", 187, 193], ["tissue", "TISSUE", 208, 214], ["allografts", "TISSUE", 303, 313], ["Different methods", "TREATMENT", 0, 17], ["recellularization", "TREATMENT", 51, 68], ["ultimate tissue remodeling", "PROBLEM", 111, 137], ["ALLOGRAFT PRESERVATION", "TREATMENT", 138, 160], ["STORAGE METHODSUnlike organs", "PROBLEM", 165, 193], ["composite tissue allotransplants", "PROBLEM", 198, 230], ["the donor's death", "PROBLEM", 284, 301], ["allografts", "TREATMENT", 303, 313], ["ultimate tissue remodeling", "OBSERVATION", 111, 137], ["composite tissue allotransplants", "OBSERVATION", 198, 230]]], ["Consequently, these grafts must be processed in ways that maintain their safety and clinical efficacy for an extended period of time.", [["grafts", "ANATOMY", 20, 26], ["grafts", "TISSUE", 20, 26], ["these grafts", "TREATMENT", 14, 26], ["grafts", "OBSERVATION", 20, 26]]], ["In addition to the processing and sterilization methods described previously, another factor which can impact the use and clinical effectiveness of allografts is the manner in which they are preserved, stored, and handled before use.", [["allografts", "ANATOMY", 148, 158], ["allografts", "TISSUE", 148, 158], ["sterilization methods", "TREATMENT", 34, 55], ["allografts", "TREATMENT", 148, 158]]], ["Currently, allograft preservation typically includes using storage media, cryopreservation, or freeze-drying to store grafts in ambient, refrigerated, or frozen states.", [["allograft", "ANATOMY", 11, 20], ["grafts", "ANATOMY", 118, 124], ["allograft", "TISSUE", 11, 20], ["grafts", "TISSUE", 118, 124], ["allograft preservation", "TREATMENT", 11, 33], ["storage media", "TREATMENT", 59, 72], ["cryopreservation", "TREATMENT", 74, 90], ["store grafts", "TREATMENT", 112, 124], ["allograft", "OBSERVATION", 11, 20], ["grafts", "OBSERVATION", 118, 124]]], ["The storage temperature determines requirements for shipping, on-site storage, and presurgery preparation.", [["The storage temperature", "PROBLEM", 0, 23], ["presurgery preparation", "TREATMENT", 83, 105]]], ["There are several main considerations concerning the preservation and storage of allograft tissues: (1) cell viability if applicable, (2) maintaining the structural integrity and native properties of the bone or extracellular matrix, and (3) convenient storage and use.", [["allograft tissues", "ANATOMY", 81, 98], ["cell", "ANATOMY", 104, 108], ["bone", "ANATOMY", 204, 208], ["extracellular matrix", "ANATOMY", 212, 232], ["allograft tissues", "TISSUE", 81, 98], ["cell", "CELL", 104, 108], ["bone", "TISSUE", 204, 208], ["extracellular matrix", "CELLULAR_COMPONENT", 212, 232], ["allograft tissues", "PROBLEM", 81, 98], ["cell viability", "TEST", 104, 118], ["several", "OBSERVATION_MODIFIER", 10, 17], ["main", "OBSERVATION_MODIFIER", 18, 22], ["allograft tissues", "OBSERVATION", 81, 98], ["bone", "ANATOMY", 204, 208], ["extracellular matrix", "ANATOMY", 212, 232]]], ["This section reviews the main types of preservation and storage, as well as their advantages and disadvantages.", [["main", "OBSERVATION_MODIFIER", 25, 29], ["preservation", "OBSERVATION", 39, 51]]], ["The methods are also summarized in Table 5 .1.RefrigerationThe simplest type of preservation is to store aseptically recovered tissues by refrigeration; however, the simplicity of the preservation belies the complex logistics involved when using so-called \"fresh\" tissues.", [["tissues", "ANATOMY", 127, 134], ["tissues", "ANATOMY", 264, 271], ["tissues", "TISSUE", 127, 134], ["tissues", "TISSUE", 264, 271], ["Refrigeration", "TREATMENT", 46, 59], ["simplest type", "OBSERVATION_MODIFIER", 63, 76], ["complex", "OBSERVATION_MODIFIER", 208, 215]]], ["Currently, fresh grafts have a very limited shelf life between release and expiration in which they can be implanted.", [["grafts", "ANATOMY", 17, 23], ["grafts", "TISSUE", 17, 23], ["fresh grafts", "TREATMENT", 11, 23], ["expiration", "TREATMENT", 75, 85], ["fresh grafts", "OBSERVATION", 11, 23], ["implanted", "OBSERVATION", 107, 116]]], ["The most commonly used fresh tissues in orthopedic surgery are osteochondral allografts used for cartilage restoration in the knee, shoulder, and talus.", [["tissues", "ANATOMY", 29, 36], ["osteochondral allografts", "ANATOMY", 63, 87], ["cartilage", "ANATOMY", 97, 106], ["knee", "ANATOMY", 126, 130], ["shoulder", "ANATOMY", 132, 140], ["talus", "ANATOMY", 146, 151], ["tissues", "TISSUE", 29, 36], ["osteochondral allografts", "TISSUE", 63, 87], ["cartilage", "TISSUE", 97, 106], ["knee", "ORGANISM_SUBDIVISION", 126, 130], ["shoulder", "ORGANISM_SUBDIVISION", 132, 140], ["talus", "PATHOLOGICAL_FORMATION", 146, 151], ["orthopedic surgery", "TREATMENT", 40, 58], ["osteochondral allografts", "TREATMENT", 63, 87], ["cartilage restoration in the knee, shoulder, and talus", "PROBLEM", 97, 151], ["fresh tissues", "OBSERVATION", 23, 36], ["orthopedic", "ANATOMY", 40, 50], ["osteochondral allografts", "OBSERVATION", 63, 87], ["knee", "ANATOMY", 126, 130], ["shoulder", "ANATOMY", 132, 140], ["talus", "ANATOMY", 146, 151]]], ["[101] [102] [103] [104] The advantage of this preservation type is that it can maintain viable cells.", [["cells", "ANATOMY", 95, 100], ["cells", "CELL", 95, 100]]], ["In the case of osteochondral grafts, this includes viable chondrocytes that may help restore the recipient's articular surfaces.", [["osteochondral grafts", "ANATOMY", 15, 35], ["chondrocytes", "ANATOMY", 58, 70], ["articular surfaces", "ANATOMY", 109, 127], ["osteochondral grafts", "TISSUE", 15, 35], ["chondrocytes", "CELL", 58, 70], ["articular surfaces", "TISSUE", 109, 127], ["osteochondral grafts", "TREATMENT", 15, 35], ["viable chondrocytes", "PROBLEM", 51, 70], ["osteochondral", "ANATOMY", 15, 28], ["grafts", "OBSERVATION", 29, 35], ["chondrocytes", "OBSERVATION", 58, 70], ["articular", "ANATOMY", 109, 118], ["surfaces", "ANATOMY_MODIFIER", 119, 127]]], ["These living cells are immunoprivileged and do not require immunosuppressants, making this graft type advantageous because the donor cells can contribute to generating collagenous extracellular matrix.", [["cells", "ANATOMY", 13, 18], ["cells", "ANATOMY", 133, 138], ["extracellular matrix", "ANATOMY", 180, 200], ["cells", "CELL", 13, 18], ["graft", "TISSUE", 91, 96], ["donor cells", "CELL", 127, 138], ["collagenous", "CELLULAR_COMPONENT", 168, 179], ["extracellular matrix", "CELLULAR_COMPONENT", 180, 200], ["donor cells", "CELL_TYPE", 127, 138], ["immunosuppressants", "TREATMENT", 59, 77], ["this graft type", "TREATMENT", 86, 101], ["the donor cells", "TREATMENT", 123, 138], ["generating collagenous extracellular matrix", "PROBLEM", 157, 200], ["donor cells", "OBSERVATION", 127, 138], ["collagenous", "OBSERVATION_MODIFIER", 168, 179], ["extracellular matrix", "OBSERVATION", 180, 200]]], ["105 To maintain viable cells, the tissue processor will aseptically recover the tissue, take cultures, debride and disinfect, size, and treat with antibiotics.", [["cells", "ANATOMY", 23, 28], ["tissue", "ANATOMY", 34, 40], ["tissue", "ANATOMY", 80, 86], ["cells", "CELL", 23, 28], ["tissue", "TISSUE", 34, 40], ["tissue", "TISSUE", 80, 86], ["the tissue processor", "TREATMENT", 30, 50], ["cultures", "TEST", 93, 101], ["debride", "TREATMENT", 103, 110], ["disinfect", "TREATMENT", 115, 124], ["antibiotics", "TREATMENT", 147, 158], ["viable cells", "OBSERVATION", 16, 28], ["size", "OBSERVATION_MODIFIER", 126, 130]]], ["The tissue processor will avoid using methods which remove cellular material either deliberately, as those used in decellularization processes previously discussed, or incidentally, as a result of some type of chemical or physical cleaning processes.", [["tissue", "ANATOMY", 4, 10], ["cellular", "ANATOMY", 59, 67], ["tissue", "TISSUE", 4, 10], ["cellular material", "TISSUE", 59, 76], ["The tissue processor", "TREATMENT", 0, 20], ["methods", "TREATMENT", 38, 45]]], ["105 Once processed, the allograft is packaged and stored at 1-10\u00b0C in quarantine until the bacterial, fungal, and viral tests results are obtained.", [["allograft", "ANATOMY", 24, 33], ["allograft", "TISSUE", 24, 33], ["C", "GENE_OR_GENE_PRODUCT", 65, 66], ["the allograft", "TREATMENT", 20, 33], ["the bacterial, fungal, and viral tests", "TEST", 87, 125], ["allograft", "OBSERVATION", 24, 33]]], ["Storage time is a critical factor for these grafts as studies have shown that cell viability decreases with time.", [["grafts", "ANATOMY", 44, 50], ["cell", "ANATOMY", 78, 82], ["grafts", "TISSUE", 44, 50], ["cell", "CELL", 78, 82], ["these grafts", "TREATMENT", 38, 50], ["cell viability", "PROBLEM", 78, 92], ["grafts", "OBSERVATION", 44, 50], ["cell viability", "OBSERVATION", 78, 92], ["decreases", "OBSERVATION_MODIFIER", 93, 102]]], ["104 Storage media can also impact cell viability, and this is an area of ongoing research and development.", [["cell", "ANATOMY", 34, 38], ["cell", "CELL", 34, 38], ["cell viability", "OBSERVATION", 34, 48]]], ["[106] [107] [108] [109] If the graft is cleared for distribution, the current graft expiration times are generally fewer than 60 days, including the quarantine period.", [["graft", "TISSUE", 31, 36], ["graft", "TISSUE", 78, 83], ["the graft", "TREATMENT", 27, 36], ["graft", "OBSERVATION", 31, 36], ["cleared", "OBSERVATION", 40, 47], ["graft", "OBSERVATION", 78, 83]]], ["Because surgery cannot be reasonably scheduled until a suitable match is found, this short window of availability contributes to the logistical complexity involved with using fresh allografts.", [["allografts", "ANATOMY", 181, 191], ["allografts", "TISSUE", 181, 191], ["surgery", "TREATMENT", 8, 15], ["fresh allografts", "TREATMENT", 175, 191]]], ["Despite these challenges, fresh osteochondral allografts are becoming more popular.", [["osteochondral allografts", "ANATOMY", 32, 56], ["osteochondral allografts", "MULTI-TISSUE_STRUCTURE", 32, 56], ["fresh osteochondral allografts", "TREATMENT", 26, 56], ["osteochondral allografts", "OBSERVATION", 32, 56]]], ["101 Although fresh tissues have advantages in some particular circumstances, current time constraints can make their use challenging for surgeons, patients, hospitals, and tissue processors alike.Frozen and Cryopreserved AllograftsUnlike fresh, refrigerated tissues, some frozen allografts may be stored for years before implantation.", [["tissues", "ANATOMY", 19, 26], ["tissue", "ANATOMY", 172, 178], ["tissues", "ANATOMY", 258, 265], ["allografts", "ANATOMY", 279, 289], ["tissues", "TISSUE", 19, 26], ["patients", "ORGANISM", 147, 155], ["tissue", "TISSUE", 172, 178], ["tissues", "TISSUE", 258, 265], ["allografts", "TISSUE", 279, 289], ["patients", "SPECIES", 147, 155], ["fresh tissues", "PROBLEM", 13, 26], ["Frozen and Cryopreserved Allografts", "TREATMENT", 196, 231], ["fresh, refrigerated tissues", "PROBLEM", 238, 265], ["some frozen allografts", "TREATMENT", 267, 289], ["implantation", "TREATMENT", 321, 333], ["fresh tissues", "OBSERVATION_MODIFIER", 13, 26], ["Cryopreserved Allografts", "OBSERVATION", 207, 231], ["fresh", "OBSERVATION_MODIFIER", 238, 243], ["refrigerated tissues", "OBSERVATION_MODIFIER", 245, 265], ["frozen allografts", "OBSERVATION", 272, 289]]], ["Freezing, without using special cryopreservation methods and solutions, can cause the formation of ice crystals within the cells or extracellular matrix, resulting in lysis.", [["cells", "ANATOMY", 123, 128], ["extracellular matrix", "ANATOMY", 132, 152], ["cells", "CELL", 123, 128], ["extracellular matrix", "CELLULAR_COMPONENT", 132, 152], ["special cryopreservation methods", "TREATMENT", 24, 56], ["solutions", "TREATMENT", 61, 70], ["ice crystals", "PROBLEM", 99, 111], ["lysis", "PROBLEM", 167, 172], ["extracellular matrix", "ANATOMY", 132, 152], ["lysis", "OBSERVATION", 167, 172]]], ["Therefore, this type of preservation is used for allografts in which maintenance of viability is not an objective, such as in structural bone allografts, tendons, and acellular dermis.", [["allografts", "ANATOMY", 49, 59], ["bone allografts", "ANATOMY", 137, 152], ["tendons", "ANATOMY", 154, 161], ["acellular dermis", "ANATOMY", 167, 183], ["allografts", "TISSUE", 49, 59], ["bone allografts", "MULTI-TISSUE_STRUCTURE", 137, 152], ["tendons", "TISSUE", 154, 161], ["acellular dermis", "TISSUE", 167, 183], ["allografts", "TREATMENT", 49, 59], ["tendons, and acellular dermis", "PROBLEM", 154, 183], ["bone", "ANATOMY", 137, 141], ["allografts", "OBSERVATION", 142, 152], ["tendons", "ANATOMY", 154, 161], ["acellular", "ANATOMY_MODIFIER", 167, 176], ["dermis", "ANATOMY", 177, 183]]], ["For frozen grafts not processed with cryopreservants, the process generally includes pathogen testing, debridement, cleaning, and disinfecting to remove remnant cells, marrow, lipids, and bioburden before being frozen and stored.", [["grafts", "ANATOMY", 11, 17], ["remnant cells", "ANATOMY", 153, 166], ["marrow", "ANATOMY", 168, 174], ["grafts", "TISSUE", 11, 17], ["remnant cells", "CELL", 153, 166], ["marrow", "TISSUE", 168, 174], ["lipids", "SIMPLE_CHEMICAL", 176, 182], ["remnant cells", "CELL_TYPE", 153, 166], ["frozen grafts", "TREATMENT", 4, 17], ["cryopreservants", "TREATMENT", 37, 52], ["pathogen testing", "TEST", 85, 101], ["debridement", "TREATMENT", 103, 114], ["cleaning", "TREATMENT", 116, 124], ["remnant cells", "PROBLEM", 153, 166], ["lipids", "TREATMENT", 176, 182], ["bioburden", "TREATMENT", 188, 197], ["grafts", "OBSERVATION", 11, 17], ["debridement", "OBSERVATION", 103, 114], ["marrow", "ANATOMY", 168, 174]]], ["For tissues that do contain living cells, for example, cellular bone void fillers or osteochondral grafts, cryopreservation solutions are used.", [["tissues", "ANATOMY", 4, 11], ["cells", "ANATOMY", 35, 40], ["cellular bone", "ANATOMY", 55, 68], ["osteochondral grafts", "ANATOMY", 85, 105], ["tissues", "TISSUE", 4, 11], ["cells", "CELL", 35, 40], ["cellular", "CELL", 55, 63], ["bone", "TISSUE", 64, 68], ["osteochondral grafts", "TISSUE", 85, 105], ["living cells", "TREATMENT", 28, 40], ["cellular bone void fillers", "TREATMENT", 55, 81], ["osteochondral grafts", "TREATMENT", 85, 105], ["cryopreservation solutions", "TREATMENT", 107, 133], ["living cells", "OBSERVATION", 28, 40], ["bone", "ANATOMY", 64, 68], ["void fillers", "OBSERVATION", 69, 81], ["osteochondral grafts", "OBSERVATION", 85, 105]]], ["Cryopreservation can extend the storage time for tissues that require viable cells, avoiding the logistical, timesensitive issues noted for fresh refrigerated allografts.Frozen and Cryopreserved AllograftsCryopreservation methods include controlling the rate of the freezing process and reducing the formation of ice crystals by removing water from the cells and replacing it with a cryopreservant.", [["tissues", "ANATOMY", 49, 56], ["cells", "ANATOMY", 77, 82], ["allografts", "ANATOMY", 159, 169], ["cells", "ANATOMY", 353, 358], ["tissues", "TISSUE", 49, 56], ["cells", "CELL", 77, 82], ["allografts", "TISSUE", 159, 169], ["cells", "CELL", 353, 358], ["Cryopreservation", "TREATMENT", 0, 16], ["viable cells", "PROBLEM", 70, 82], ["the logistical, timesensitive issues", "PROBLEM", 93, 129], ["fresh refrigerated allografts", "TREATMENT", 140, 169], ["Frozen and Cryopreserved AllograftsCryopreservation methods", "TREATMENT", 170, 229], ["the freezing process", "PROBLEM", 262, 282], ["ice crystals", "TREATMENT", 313, 325], ["a cryopreservant", "TREATMENT", 381, 397], ["allografts", "OBSERVATION", 159, 169], ["Cryopreserved Allografts", "OBSERVATION", 181, 205]]], ["Common cryopreservants include glycerol and dimethyl sulfoxide.", [["glycerol", "CHEMICAL", 31, 39], ["dimethyl sulfoxide", "CHEMICAL", 44, 62], ["glycerol", "CHEMICAL", 31, 39], ["dimethyl sulfoxide", "CHEMICAL", 44, 62], ["glycerol", "SIMPLE_CHEMICAL", 31, 39], ["dimethyl sulfoxide", "SIMPLE_CHEMICAL", 44, 62], ["Common cryopreservants", "TREATMENT", 0, 22], ["glycerol", "TREATMENT", 31, 39], ["dimethyl sulfoxide", "TREATMENT", 44, 62]]], ["110 Tissues are processed, treated with cryopreservant, and slowly cooled to cryogenic temperatures.", [["Tissues", "ANATOMY", 4, 11], ["Tissues", "CANCER", 4, 11], ["cryopreservant", "TREATMENT", 40, 54]]], ["111 Cryopreserved allografts are then either stored in ultralow-temperature freezers or using liquid nitrogen to maintain temperature below the transition phase of ice to an amorphous glass, which will prevent the reformation of ice crystals and can maintain the state of tissues for several years.", [["allografts", "ANATOMY", 18, 28], ["tissues", "ANATOMY", 272, 279], ["nitrogen", "CHEMICAL", 101, 109], ["allografts", "TISSUE", 18, 28], ["tissues", "TISSUE", 272, 279], ["Cryopreserved allografts", "TREATMENT", 4, 28], ["liquid nitrogen", "TREATMENT", 94, 109], ["an amorphous glass", "TREATMENT", 171, 189], ["ice crystals", "TREATMENT", 229, 241], ["allografts", "OBSERVATION", 18, 28]]], ["112 This preservation method allows for longer storage time for allografts which require viable cells, such as cellular bone void fillers and osteochondral grafts, avoiding the complex timing logistics seen with fresh allografts.", [["allografts", "ANATOMY", 64, 74], ["cells", "ANATOMY", 96, 101], ["cellular bone", "ANATOMY", 111, 124], ["osteochondral grafts", "ANATOMY", 142, 162], ["allografts", "ANATOMY", 218, 228], ["allografts", "TISSUE", 64, 74], ["cells", "CELL", 96, 101], ["cellular", "CELL", 111, 119], ["bone", "TISSUE", 120, 124], ["osteochondral grafts", "TISSUE", 142, 162], ["allografts", "TISSUE", 218, 228], ["This preservation method", "TREATMENT", 4, 28], ["allografts", "TREATMENT", 64, 74], ["viable cells", "TREATMENT", 89, 101], ["cellular bone void fillers", "TREATMENT", 111, 137], ["osteochondral grafts", "TREATMENT", 142, 162], ["the complex timing logistics", "TREATMENT", 173, 201], ["fresh allografts", "TREATMENT", 212, 228], ["bone", "ANATOMY", 120, 124], ["void fillers", "OBSERVATION", 125, 137], ["osteochondral grafts", "OBSERVATION", 142, 162], ["fresh allografts", "OBSERVATION", 212, 228]]], ["However, the tissues must remain frozen until use and therefore require special shipping conditions, as well as on-site storage in a validated freezer that is monitored 24/7 for temperature.", [["tissues", "ANATOMY", 13, 20], ["tissues", "TISSUE", 13, 20], ["special shipping conditions", "TREATMENT", 72, 99], ["tissues", "ANATOMY", 13, 20]]], ["113 Frozen tissue may also require a lengthy thawing time depending on the tissue type, and once the allograft has been thawed, the allograft must be used or discarded.", [["Frozen tissue", "ANATOMY", 4, 17], ["tissue", "ANATOMY", 75, 81], ["allograft", "ANATOMY", 101, 110], ["allograft", "ANATOMY", 132, 141], ["Frozen tissue", "TISSUE", 4, 17], ["tissue", "TISSUE", 75, 81], ["allograft", "TISSUE", 101, 110], ["allograft", "TISSUE", 132, 141], ["the allograft", "TREATMENT", 97, 110], ["the allograft", "TREATMENT", 128, 141], ["allograft", "OBSERVATION", 101, 110], ["allograft", "OBSERVATION", 132, 141]]], ["Although freezing is an effective form of allograft preservation, its specialized shipping and storage requirements have motivated the development of alternate methods.Freeze-driedTo avoid the shipping and storage limitations associated with frozen tissues, another preservation option is freeze-drying, also known as lyophilization, which can be used for ligaments, bone, and dermis.", [["allograft", "ANATOMY", 42, 51], ["tissues", "ANATOMY", 249, 256], ["ligaments", "ANATOMY", 356, 365], ["bone", "ANATOMY", 367, 371], ["dermis", "ANATOMY", 377, 383], ["allograft", "TISSUE", 42, 51], ["tissues", "TISSUE", 249, 256], ["ligaments", "TISSUE", 356, 365], ["bone", "TISSUE", 367, 371], ["dermis", "TISSUE", 377, 383], ["allograft preservation", "TREATMENT", 42, 64], ["alternate methods", "TREATMENT", 150, 167], ["storage limitations", "PROBLEM", 206, 225], ["frozen tissues", "PROBLEM", 242, 256], ["lyophilization", "TREATMENT", 318, 332], ["ligaments, bone, and dermis", "PROBLEM", 356, 383], ["effective", "OBSERVATION_MODIFIER", 24, 33], ["allograft", "OBSERVATION", 42, 51], ["frozen tissues", "OBSERVATION_MODIFIER", 242, 256], ["bone", "ANATOMY", 367, 371], ["dermis", "ANATOMY", 377, 383]]], ["After the tissue has been cleaned and processed, freeze-drying is achieved by using specialized equipment to reduce the residual moisture to a level that maintains tissue quality, which may vary depending on the tissue type.", [["tissue", "ANATOMY", 10, 16], ["tissue", "ANATOMY", 164, 170], ["tissue", "ANATOMY", 212, 218], ["tissue", "TISSUE", 10, 16], ["tissue", "TISSUE", 164, 170], ["tissue", "TISSUE", 212, 218], ["freeze-drying", "TREATMENT", 49, 62], ["specialized equipment", "TREATMENT", 84, 105], ["the residual moisture", "PROBLEM", 116, 137], ["cleaned", "OBSERVATION", 26, 33], ["residual moisture", "OBSERVATION", 120, 137]]], ["The lyophilization process must be validated and monitored, and the storage conditions must maintain the appropriate moisture level.", [["The lyophilization process", "TREATMENT", 0, 26], ["the storage conditions", "PROBLEM", 64, 86], ["lyophilization", "OBSERVATION", 4, 18]]], ["114 An advantage of freezedrying is that the allograft can typically be stored for years at ambient temperature and then rehydrated when needed.", [["allograft", "ANATOMY", 45, 54], ["allograft", "TISSUE", 45, 54], ["the allograft", "TREATMENT", 41, 54], ["allograft", "OBSERVATION", 45, 54]]], ["With ambient temperature storage, there is no need for a special freezer or specialized shipping conditions.", [["ambient temperature storage", "TREATMENT", 5, 32], ["a special freezer", "TREATMENT", 55, 72], ["no", "UNCERTAINTY", 43, 45]]], ["However, the rehydration time can be lengthy, and some grafts may never fully rehydrate.", [["grafts", "ANATOMY", 55, 61], ["grafts", "TISSUE", 55, 61], ["some grafts", "TREATMENT", 50, 61], ["grafts", "OBSERVATION", 55, 61]]], ["Even full hydration may not be able to restore the tissue's native properties and may leave tissues in a fragile state, making them susceptible to damage during implantation.", [["tissue", "ANATOMY", 51, 57], ["tissues", "ANATOMY", 92, 99], ["tissue", "TISSUE", 51, 57], ["tissues", "TISSUE", 92, 99], ["damage during implantation", "TREATMENT", 147, 173]]], ["For example, some studies have found that freeze-dried bone may exhibit brittleness and weakness compared with frozen or glycerol-preserved bone, which could be especially problematic for a weight-bearing graft.", [["bone", "ANATOMY", 55, 59], ["bone", "ANATOMY", 140, 144], ["weakness", "DISEASE", 88, 96], ["glycerol", "CHEMICAL", 121, 129], ["glycerol", "CHEMICAL", 121, 129], ["bone", "TISSUE", 55, 59], ["glycerol", "SIMPLE_CHEMICAL", 121, 129], ["bone", "TISSUE", 140, 144], ["graft", "TISSUE", 205, 210], ["some studies", "TEST", 13, 25], ["dried bone", "PROBLEM", 49, 59], ["brittleness", "PROBLEM", 72, 83], ["weakness", "PROBLEM", 88, 96], ["frozen or glycerol-preserved bone", "PROBLEM", 111, 144], ["a weight-bearing graft", "TREATMENT", 188, 210], ["bone", "ANATOMY", 55, 59], ["weakness", "OBSERVATION", 88, 96], ["bone", "ANATOMY", 140, 144], ["graft", "OBSERVATION", 205, 210]]], ["[115] [116] [117] In addition, preclinical and clinical reports [118] [119] [120] have raised concerns about immunologic response to freeze-dried bone and tendons.", [["bone", "ANATOMY", 146, 150], ["tendons", "ANATOMY", 155, 162], ["bone", "TISSUE", 146, 150], ["tendons", "TISSUE", 155, 162], ["immunologic response", "TEST", 109, 129], ["dried bone and tendons", "PROBLEM", 140, 162], ["bone", "ANATOMY", 146, 150], ["tendons", "ANATOMY", 155, 162]]], ["In spite of these potential limitations, freeze-dried allografts, especially ground bone void fillers, are widely used and clinically successful.", [["bone", "ANATOMY", 84, 88], ["allografts", "TISSUE", 54, 64], ["bone", "TISSUE", 84, 88], ["freeze-dried allografts", "TREATMENT", 41, 64], ["ground bone void fillers", "TREATMENT", 77, 101], ["dried allografts", "OBSERVATION", 48, 64]]], ["[121] [122] [123] [124] Media-derived preservationFreeze-driedTo provide the convenience of ambient storage while avoiding potential tissue alterations inherent with freeze-drying, some tissue processors have developed solution-based methods of ambient preservation.", [["tissue", "ANATOMY", 133, 139], ["tissue", "ANATOMY", 186, 192], ["[121] [122] [123] [124] Media-", "CHEMICAL", 0, 30], ["[121] [122] [123] [124] Media-", "SIMPLE_CHEMICAL", 0, 30], ["tissue", "TISSUE", 133, 139], ["tissue", "TISSUE", 186, 192], ["Media-derived preservationFreeze", "TREATMENT", 24, 56], ["ambient storage", "TREATMENT", 92, 107], ["potential tissue alterations", "PROBLEM", 123, 151], ["freeze-drying", "TREATMENT", 166, 179], ["some tissue processors", "TREATMENT", 181, 203], ["ambient preservation", "TREATMENT", 245, 265]]], ["Currently, there are two main preservants used for allografts, namely solutions containing ethanol or glycerol, although saline solution is used for some bone grafts.", [["allografts", "ANATOMY", 51, 61], ["bone grafts", "ANATOMY", 154, 165], ["ethanol", "CHEMICAL", 91, 98], ["glycerol", "CHEMICAL", 102, 110], ["ethanol", "CHEMICAL", 91, 98], ["glycerol", "CHEMICAL", 102, 110], ["allografts", "TISSUE", 51, 61], ["ethanol", "SIMPLE_CHEMICAL", 91, 98], ["glycerol", "SIMPLE_CHEMICAL", 102, 110], ["saline", "SIMPLE_CHEMICAL", 121, 127], ["bone grafts", "MULTI-TISSUE_STRUCTURE", 154, 165], ["allografts", "TREATMENT", 51, 61], ["ethanol", "TREATMENT", 91, 98], ["glycerol", "TREATMENT", 102, 110], ["saline solution", "TREATMENT", 121, 136], ["some bone grafts", "TREATMENT", 149, 165], ["two", "OBSERVATION_MODIFIER", 21, 24], ["main", "OBSERVATION_MODIFIER", 25, 29], ["allografts", "OBSERVATION", 51, 61], ["bone", "ANATOMY", 154, 158], ["grafts", "OBSERVATION", 159, 165]]], ["Ethanol storage is a traditional and economical method used to preserve tissues.", [["tissues", "ANATOMY", 72, 79], ["Ethanol", "CHEMICAL", 0, 7], ["Ethanol", "CHEMICAL", 0, 7], ["Ethanol", "SIMPLE_CHEMICAL", 0, 7], ["tissues", "TISSUE", 72, 79], ["Ethanol storage", "TREATMENT", 0, 15], ["a traditional and economical method", "TREATMENT", 19, 54]]], ["Ecologists and natural history museums have been using this method to preserve intact specimens for many decades.", [["specimens", "ANATOMY", 86, 95], ["this method", "TREATMENT", 55, 66]]], ["It is also used in forensic science to preserve DNA samples.", [["samples", "ANATOMY", 52, 59], ["DNA", "CELLULAR_COMPONENT", 48, 51]]], ["Ethanol preserves tissue by driving water out of tissue and cells, essentially dehydrating the tissue.", [["tissue", "ANATOMY", 18, 24], ["tissue", "ANATOMY", 49, 55], ["cells", "ANATOMY", 60, 65], ["tissue", "ANATOMY", 95, 101], ["Ethanol", "CHEMICAL", 0, 7], ["Ethanol", "CHEMICAL", 0, 7], ["Ethanol", "SIMPLE_CHEMICAL", 0, 7], ["tissue", "TISSUE", 18, 24], ["tissue", "TISSUE", 49, 55], ["cells", "CELL", 60, 65], ["tissue", "TISSUE", 95, 101]]], ["125 The other most common ambient temperature storage method is to treat the tissue with glycerol, which acts as a humectant to protect the tissues, keeping them fully hydrated.", [["tissue", "ANATOMY", 77, 83], ["tissues", "ANATOMY", 140, 147], ["glycerol", "CHEMICAL", 89, 97], ["glycerol", "CHEMICAL", 89, 97], ["tissue", "TISSUE", 77, 83], ["glycerol", "SIMPLE_CHEMICAL", 89, 97], ["tissues", "TISSUE", 140, 147], ["ambient temperature storage method", "TREATMENT", 26, 60], ["glycerol", "TREATMENT", 89, 97], ["a humectant", "TREATMENT", 113, 124], ["tissues", "ANATOMY", 140, 147]]], ["Glycerol is a nontoxic, biodegradable liquid that the FDA classifies as \"generally recognized as safe.\" 126 It is a common ingredient in over 1500 food, cosmetic, and pharmaceutical products 127 and has been widely used in DBM allografts for spinal applications since 1991.", [["spinal", "ANATOMY", 242, 248], ["Glycerol", "CHEMICAL", 0, 8], ["Glycerol", "CHEMICAL", 0, 8], ["Glycerol", "SIMPLE_CHEMICAL", 0, 8], ["DBM allografts", "TISSUE", 223, 237], ["DBM", "SPECIES", 223, 226], ["Glycerol", "TREATMENT", 0, 8], ["a nontoxic, biodegradable liquid", "TREATMENT", 12, 44], ["pharmaceutical products", "TREATMENT", 167, 190], ["DBM allografts", "TREATMENT", 223, 237], ["spinal applications", "TREATMENT", 242, 261], ["nontoxic", "OBSERVATION_MODIFIER", 14, 22], ["spinal", "ANATOMY", 242, 248]]], ["By holding in moisture, glycerol allows allografts to be stored at ambient temperature without drying out.", [["glycerol", "CHEMICAL", 24, 32], ["glycerol", "CHEMICAL", 24, 32], ["glycerol", "SIMPLE_CHEMICAL", 24, 32], ["allografts", "TISSUE", 40, 50], ["glycerol allows allografts", "TREATMENT", 24, 50]]], ["Ethanol storage is most commonly used on ADM allografts, whereas glycerol storage can be effectively used for bone as well as ADMs.", [["bone", "ANATOMY", 110, 114], ["Ethanol", "CHEMICAL", 0, 7], ["glycerol", "CHEMICAL", 65, 73], ["Ethanol", "CHEMICAL", 0, 7], ["glycerol", "CHEMICAL", 65, 73], ["Ethanol", "SIMPLE_CHEMICAL", 0, 7], ["ADM allografts", "TISSUE", 41, 55], ["glycerol", "SIMPLE_CHEMICAL", 65, 73], ["bone", "TISSUE", 110, 114], ["Ethanol storage", "TREATMENT", 0, 15], ["ADM allografts", "TREATMENT", 41, 55], ["glycerol storage", "TREATMENT", 65, 81]]], ["In clinical studies comparing glycerol-preserved bone to either freeze-dried or frozen bone, the authors found that glycerol-preserved bone performed as well as freezedried and frozen bone while having a shorter preparation time.", [["bone", "ANATOMY", 49, 53], ["bone", "ANATOMY", 87, 91], ["bone", "ANATOMY", 135, 139], ["bone", "ANATOMY", 184, 188], ["glycerol", "CHEMICAL", 30, 38], ["glycerol", "CHEMICAL", 116, 124], ["glycerol", "CHEMICAL", 30, 38], ["glycerol", "CHEMICAL", 116, 124], ["glycerol", "SIMPLE_CHEMICAL", 30, 38], ["bone", "TISSUE", 49, 53], ["bone", "TISSUE", 87, 91], ["glycerol", "SIMPLE_CHEMICAL", 116, 124], ["bone", "TISSUE", 135, 139], ["bone", "TISSUE", 184, 188], ["clinical studies", "TEST", 3, 19], ["glycerol", "TEST", 30, 38], ["dried or frozen bone", "PROBLEM", 71, 91], ["glycerol", "TREATMENT", 116, 124], ["frozen bone", "PROBLEM", 177, 188], ["bone", "ANATOMY", 49, 53], ["bone", "ANATOMY", 87, 91], ["bone", "ANATOMY", 135, 139], ["bone", "ANATOMY", 184, 188]]], ["117, 128 Both glycerol and alcohol preservation methods endow tissues with desirable storage characteristics, eliminating the need for the lengthy thawing and rehydration times that accompany frozen or freezedried allografts.", [["tissues", "ANATOMY", 62, 69], ["allografts", "ANATOMY", 214, 224], ["glycerol", "CHEMICAL", 14, 22], ["alcohol", "CHEMICAL", 27, 34], ["glycerol", "CHEMICAL", 14, 22], ["alcohol", "CHEMICAL", 27, 34], ["glycerol", "SIMPLE_CHEMICAL", 14, 22], ["alcohol", "SIMPLE_CHEMICAL", 27, 34], ["tissues", "TISSUE", 62, 69], ["allografts", "TISSUE", 214, 224], ["Both glycerol", "TREATMENT", 9, 22], ["alcohol preservation", "TREATMENT", 27, 47], ["the lengthy thawing", "TREATMENT", 135, 154], ["rehydration", "TREATMENT", 159, 170], ["frozen or freezedried allografts", "TREATMENT", 192, 224], ["allografts", "OBSERVATION", 214, 224]]], ["The advantages include ease of shipping and storage, as well as increased flexibility for the operating room staff.", [["shipping", "OBSERVATION", 31, 39]]], ["Unlike frozen tissues that may need thawing to begin well in advance of a scheduled surgery, a surgeon can decide whether or not to use a glycerol-or alcohol-preserved allograft once surgery has already begun, allowing the surgeon the option to make real-time decisions based on the state of the patient.", [["tissues", "ANATOMY", 14, 21], ["glycerol", "CHEMICAL", 138, 146], ["alcohol", "CHEMICAL", 150, 157], ["glycerol", "CHEMICAL", 138, 146], ["alcohol", "CHEMICAL", 150, 157], ["tissues", "TISSUE", 14, 21], ["glycerol", "SIMPLE_CHEMICAL", 138, 146], ["alcohol", "SIMPLE_CHEMICAL", 150, 157], ["allograft", "TISSUE", 168, 177], ["patient", "ORGANISM", 296, 303], ["patient", "SPECIES", 296, 303], ["frozen tissues", "PROBLEM", 7, 21], ["a scheduled surgery", "TREATMENT", 72, 91], ["a glycerol", "TREATMENT", 136, 146], ["surgery", "TREATMENT", 183, 190], ["frozen tissues", "OBSERVATION", 7, 21], ["allograft", "OBSERVATION", 168, 177]]], ["Given the proven clinical effectiveness and convenience of ambient-stored allografts, it is likely that tissue banks will seek to develop and improve these storage methods for a wider variety of tissues.FUTURE DIRECTIONSHuman allograft tissues have played an increasing role in orthopedic practice, and their use is likely to continue and increase.", [["tissue", "ANATOMY", 104, 110], ["tissues", "ANATOMY", 195, 202], ["allograft tissues", "ANATOMY", 226, 243], ["allografts", "TISSUE", 74, 84], ["tissue", "TISSUE", 104, 110], ["tissues", "TISSUE", 195, 202], ["allograft tissues", "TISSUE", 226, 243], ["ambient-stored allografts", "TREATMENT", 59, 84], ["tissue banks", "PROBLEM", 104, 116], ["these storage methods", "TREATMENT", 150, 171], ["FUTURE DIRECTIONSHuman allograft tissues", "TREATMENT", 203, 243], ["allografts", "OBSERVATION", 74, 84], ["allograft", "OBSERVATION", 226, 235], ["increasing", "OBSERVATION_MODIFIER", 259, 269]]], ["Although future development of more human-like synthetics and xenografts may lead to a decline in the use of some traditional human tissues, the natural matrix structure and human cellular content available with allografts is hard to replicate.", [["xenografts", "ANATOMY", 62, 72], ["tissues", "ANATOMY", 132, 139], ["matrix", "ANATOMY", 153, 159], ["cellular", "ANATOMY", 180, 188], ["allografts", "ANATOMY", 212, 222], ["human", "ORGANISM", 36, 41], ["xenografts", "CANCER", 62, 72], ["human", "ORGANISM", 126, 131], ["tissues", "TISSUE", 132, 139], ["matrix", "CELLULAR_COMPONENT", 153, 159], ["human", "ORGANISM", 174, 179], ["cellular", "CELL", 180, 188], ["allografts", "TISSUE", 212, 222], ["human", "SPECIES", 36, 41], ["human", "SPECIES", 126, 131], ["human", "SPECIES", 174, 179], ["human", "SPECIES", 36, 41], ["human", "SPECIES", 126, 131], ["human", "SPECIES", 174, 179], ["more human-like synthetics and xenografts", "PROBLEM", 31, 72], ["a decline", "PROBLEM", 85, 94], ["some traditional human tissues", "TREATMENT", 109, 139], ["allografts", "TREATMENT", 212, 222], ["human tissues", "ANATOMY", 126, 139], ["cellular content", "OBSERVATION", 180, 196]]], ["Limitations and considerations noted previously point to areas of improvement and are subjects of active research within industry and academia, which include:FUTURE DIRECTIONS\u2022 increased cell viability and viability time in osteochondral grafts; \u2022 increasing type of tissues preserved for ambient temperature storage; \u2022 development of more time-efficient and less aggressive disinfection and sterilization technologies; \u2022 rapid test methods to detect microbes and viruses before donor tissue is even recovered; \u2022 use of late clinical stage antibiotics and antiviral agents to further assure allograft safety; \u2022 preconditioning of implanted cells or genetic transfection of transplanted cells to overexpress key factors such as BMPs or insulin-like growth factor; \u2022 nontoxic, slowly degradable cross-linking methods to allow tissues to have favorable initial biomechanical properties and low immunogenicity but also to eventually remodel; \u2022 modifications of allografts to promote recruitment of key cell types based on the clinical application; \u2022 seeding autologous cells in situ on allogeneic scaffolds; \u2022 isolating key proteins from allografts as a chemotactic coating in combination with synthetic implants; \u2022 modifications to allow injection and deployment of structural and nonstructural grafts in minimally invasive procedures; \u2022 use of human-derived cells, perhaps genetically altered, for direct injection at clinical site or provided systemically; \u2022 use of allograft-sourced induced pluripotent stem cells as a source of personalized medicine treat-ments (e.g., induce cells along a lineage specific to treat a patient's unique condition); \u2022 expandable allografts for geometrically challenging bone void filling applications.", [["cell", "ANATOMY", 187, 191], ["osteochondral grafts", "ANATOMY", 224, 244], ["tissues", "ANATOMY", 267, 274], ["tissue", "ANATOMY", 485, 491], ["allograft", "ANATOMY", 591, 600], ["cells", "ANATOMY", 640, 645], ["cells", "ANATOMY", 686, 691], ["tissues", "ANATOMY", 824, 831], ["allografts", "ANATOMY", 957, 967], ["cell", "ANATOMY", 998, 1002], ["cells", "ANATOMY", 1065, 1070], ["situ", "ANATOMY", 1074, 1078], ["allografts", "ANATOMY", 1134, 1144], ["grafts", "ANATOMY", 1292, 1298], ["cells", "ANATOMY", 1356, 1361], ["allograft", "ANATOMY", 1465, 1474], ["pluripotent stem cells", "ANATOMY", 1491, 1513], ["cells", "ANATOMY", 1577, 1582], ["allografts", "ANATOMY", 1661, 1671], ["bone", "ANATOMY", 1702, 1706], ["cell", "CELL", 187, 191], ["osteochondral grafts", "TISSUE", 224, 244], ["tissues", "TISSUE", 267, 274], ["tissue", "TISSUE", 485, 491], ["allograft", "TISSUE", 591, 600], ["cells", "CELL", 640, 645], ["cells", "CELL", 686, 691], ["BMPs", "GENE_OR_GENE_PRODUCT", 727, 731], ["insulin-like growth factor", "GENE_OR_GENE_PRODUCT", 735, 761], ["tissues", "TISSUE", 824, 831], ["allografts", "TISSUE", 957, 967], ["cell", "CELL", 998, 1002], ["cells", "CELL", 1065, 1070], ["allografts", "TISSUE", 1134, 1144], ["grafts", "TISSUE", 1292, 1298], ["human", "ORGANISM", 1342, 1347], ["cells", "CELL", 1356, 1361], ["pluripotent stem cells", "CELL", 1491, 1513], ["cells", "CELL", 1577, 1582], ["patient", "ORGANISM", 1619, 1626], ["allografts", "TISSUE", 1661, 1671], ["bone", "TISSUE", 1702, 1706], ["implanted cells", "CELL_TYPE", 630, 645], ["transplanted cells", "CELL_TYPE", 673, 691], ["BMPs", "PROTEIN", 727, 731], ["insulin", "PROTEIN", 735, 742], ["autologous cells", "CELL_TYPE", 1054, 1070], ["human-derived cells", "CELL_TYPE", 1342, 1361], ["allograft-sourced induced pluripotent stem cells", "CELL_LINE", 1465, 1513], ["human", "SPECIES", 1342, 1347], ["patient", "SPECIES", 1619, 1626], ["human", "SPECIES", 1342, 1347], ["increased cell viability", "PROBLEM", 177, 201], ["osteochondral grafts", "TREATMENT", 224, 244], ["increasing type of tissues", "PROBLEM", 248, 274], ["ambient temperature storage", "TREATMENT", 289, 316], ["aggressive disinfection", "TREATMENT", 364, 387], ["sterilization technologies", "TREATMENT", 392, 418], ["rapid test methods", "TEST", 422, 440], ["microbes", "PROBLEM", 451, 459], ["viruses", "PROBLEM", 464, 471], ["donor tissue", "PROBLEM", 479, 491], ["late clinical stage antibiotics", "TREATMENT", 520, 551], ["antiviral agents", "TREATMENT", 556, 572], ["allograft safety", "TREATMENT", 591, 607], ["preconditioning of implanted cells", "TREATMENT", 611, 645], ["genetic transfection of transplanted cells", "TREATMENT", 649, 691], ["BMPs", "PROBLEM", 727, 731], ["insulin", "TREATMENT", 735, 742], ["growth factor", "PROBLEM", 748, 761], ["nontoxic", "PROBLEM", 765, 773], ["favorable initial biomechanical properties", "PROBLEM", 840, 882], ["low immunogenicity", "PROBLEM", 887, 905], ["allografts", "TREATMENT", 957, 967], ["recruitment of key cell types", "TREATMENT", 979, 1008], ["the clinical application", "TREATMENT", 1018, 1042], ["seeding autologous cells", "TREATMENT", 1046, 1070], ["allogeneic scaffolds", "TREATMENT", 1082, 1102], ["isolating key proteins", "TREATMENT", 1106, 1128], ["allografts", "TREATMENT", 1134, 1144], ["a chemotactic coating", "TREATMENT", 1148, 1169], ["synthetic implants", "TREATMENT", 1190, 1208], ["\u2022 modifications", "TREATMENT", 1210, 1225], ["injection", "TREATMENT", 1235, 1244], ["structural and nonstructural grafts", "TREATMENT", 1263, 1298], ["minimally invasive procedures", "TREATMENT", 1302, 1331], ["human-derived cells", "TREATMENT", 1342, 1361], ["direct injection at clinical site", "TREATMENT", 1396, 1429], ["allograft", "TREATMENT", 1465, 1474], ["pluripotent stem cells", "PROBLEM", 1491, 1513], ["personalized medicine treat", "TREATMENT", 1529, 1556], ["induce cells", "PROBLEM", 1570, 1582], ["a patient's unique condition", "PROBLEM", 1617, 1645], ["\u2022 expandable allografts", "TREATMENT", 1648, 1671], ["geometrically challenging bone void filling applications", "TREATMENT", 1676, 1732], ["improvement", "OBSERVATION", 66, 77], ["active", "OBSERVATION_MODIFIER", 98, 104], ["increased cell viability", "OBSERVATION", 177, 201], ["osteochondral grafts", "OBSERVATION", 224, 244], ["low immunogenicity", "OBSERVATION_MODIFIER", 887, 905], ["key cell", "OBSERVATION", 994, 1002], ["autologous cells", "OBSERVATION", 1054, 1070], ["chemotactic coating", "OBSERVATION_MODIFIER", 1150, 1169], ["nonstructural grafts", "OBSERVATION", 1278, 1298], ["allograft", "OBSERVATION", 1465, 1474], ["pluripotent stem cells", "OBSERVATION", 1491, 1513], ["allografts", "OBSERVATION", 1661, 1671]]], ["The use of allografts moving forward should likely not only include basic anatomic grafts but also dramatically modified human components provided as injectables, coatings, cellular therapies, and in combination with other materials.SUMMARYAllografts are widely used in orthopedic practice.", [["allografts", "ANATOMY", 11, 21], ["grafts", "ANATOMY", 83, 89], ["cellular", "ANATOMY", 173, 181], ["allografts", "TISSUE", 11, 21], ["grafts", "TISSUE", 83, 89], ["human", "ORGANISM", 121, 126], ["cellular", "CELL", 173, 181], ["human", "SPECIES", 121, 126], ["human", "SPECIES", 121, 126], ["allografts", "TREATMENT", 11, 21], ["basic anatomic grafts", "TREATMENT", 68, 89], ["dramatically modified human components", "TREATMENT", 99, 137], ["coatings", "TREATMENT", 163, 171], ["cellular therapies", "TREATMENT", 173, 191], ["allografts", "OBSERVATION", 11, 21], ["anatomic grafts", "OBSERVATION", 74, 89]]], ["Historically, tissues were typically provided as simple intact anatomical grafts, such as tendons, long bones, skin, and so forth.", [["tissues", "ANATOMY", 14, 21], ["grafts", "ANATOMY", 74, 80], ["tendons", "ANATOMY", 90, 97], ["bones", "ANATOMY", 104, 109], ["skin", "ANATOMY", 111, 115], ["tissues", "TISSUE", 14, 21], ["grafts", "TISSUE", 74, 80], ["tendons", "TISSUE", 90, 97], ["long bones", "TISSUE", 99, 109], ["skin", "ORGAN", 111, 115], ["simple intact anatomical grafts", "TREATMENT", 49, 80], ["such as tendons, long bones, skin", "PROBLEM", 82, 115], ["anatomical grafts", "OBSERVATION", 63, 80], ["tendons", "ANATOMY", 90, 97], ["bones", "ANATOMY", 104, 109], ["skin", "ANATOMY", 111, 115]]], ["As introduced in this chapter, technologies to process allografts include physical shaping, demineralization, decellularization, and preservation methodologies.", [["allografts", "ANATOMY", 55, 65], ["allografts", "TISSUE", 55, 65], ["allografts", "TREATMENT", 55, 65], ["demineralization", "PROBLEM", 92, 108], ["decellularization", "TREATMENT", 110, 127], ["allografts", "OBSERVATION", 55, 65], ["demineralization", "OBSERVATION", 92, 108]]], ["These processes, which tend to alter or deconstruct the grafts or change their physical state, are designed to yield tissues that are clinically effective while advanced disinfection and sterilization technologies assure safety.", [["grafts", "ANATOMY", 56, 62], ["tissues", "ANATOMY", 117, 124], ["grafts", "TISSUE", 56, 62], ["tissues", "TISSUE", 117, 124], ["the grafts", "TREATMENT", 52, 62], ["advanced disinfection", "TREATMENT", 161, 182], ["sterilization technologies", "TREATMENT", 187, 213], ["grafts", "OBSERVATION", 56, 62]]], ["Looking forward, human tissues should serve a very useful role still as intact structures, partially deconstructed, or altered grafts.", [["tissues", "ANATOMY", 23, 30], ["structures", "ANATOMY", 79, 89], ["grafts", "ANATOMY", 127, 133], ["human", "ORGANISM", 17, 22], ["tissues", "TISSUE", 23, 30], ["grafts", "TISSUE", 127, 133], ["human", "SPECIES", 17, 22], ["human", "SPECIES", 17, 22], ["altered grafts", "PROBLEM", 119, 133], ["altered", "OBSERVATION_MODIFIER", 119, 126], ["grafts", "OBSERVATION", 127, 133]]], ["However, advances will increasingly propel the use of tissue as reconstructed or more biologically integrative constructs using protein isolation and reconstitution methods, genetic alterations, in situ cell seeding, and other advances.", [["tissue", "ANATOMY", 54, 60], ["cell", "ANATOMY", 203, 207], ["tissue", "TISSUE", 54, 60], ["cell", "CELL", 203, 207], ["protein isolation", "TREATMENT", 128, 145], ["reconstitution methods", "TREATMENT", 150, 172], ["genetic alterations", "PROBLEM", 174, 193], ["situ cell seeding", "TREATMENT", 198, 215], ["situ cell seeding", "OBSERVATION", 198, 215]]]], "194412ed698eaea5c13e0cf9bc7a0b34d2855cc3": [["IntroductionThe first human infection from avian influenza A virus (H5N1 subtype), which resulted in 33% fatality, was reported in Hong Kong during the 1997 outbreak of bird flu in poultry [1, 2] .", [["infection", "DISEASE", 28, 37], ["avian influenza A virus", "DISEASE", 43, 66], ["bird flu", "DISEASE", 169, 177], ["human", "ORGANISM", 22, 27], ["avian influenza A virus", "ORGANISM", 43, 66], ["H5N1", "ORGANISM", 68, 72], ["human", "SPECIES", 22, 27], ["avian influenza A virus", "SPECIES", 43, 66], ["human", "SPECIES", 22, 27], ["avian influenza A virus", "SPECIES", 43, 66], ["The first human infection", "PROBLEM", 12, 37], ["avian influenza A virus (H5N1 subtype)", "PROBLEM", 43, 81], ["infection", "OBSERVATION", 28, 37]]], ["About 6 years later, an outbreak of avian flu virus (H5N1) occurred among poultry in eight other Asian countries, South Korea, China, Japan, Cambodia, Indonesia, Laos, Thailand, and Viet Nam.", [["avian flu virus", "DISEASE", 36, 51], ["H5N1", "DISEASE", 53, 57], ["avian flu virus", "ORGANISM", 36, 51], ["H5N1", "ORGANISM", 53, 57], ["avian flu virus (H5N1", "SPECIES", 36, 57], ["avian flu virus", "SPECIES", 36, 51], ["avian flu virus", "PROBLEM", 36, 51], ["H5N1", "PROBLEM", 53, 57], ["flu virus", "OBSERVATION", 42, 51]]], ["At that time, over 100 million birds died from bird flu or were killed by people in efforts to control the outbreak [3] .", [["birds", "ORGANISM", 31, 36], ["people", "ORGANISM", 74, 80], ["people", "SPECIES", 74, 80], ["bird flu", "PROBLEM", 47, 55]]], ["Among these countries, only Viet Nam and Thailand reported human infections, which resulted in 80% and 66.7% fatality rates, respectively.", [["human infections", "DISEASE", 59, 75], ["human", "ORGANISM", 59, 64], ["human", "SPECIES", 59, 64], ["human", "SPECIES", 59, 64], ["human infections", "PROBLEM", 59, 75], ["fatality rates", "TEST", 109, 123], ["infections", "OBSERVATION", 65, 75]]], ["These rates were much higher than that of the Hong Kong outbreak of 1997 [1] , but the origin of the virus responsible has not yet been identified.", [["These rates", "TEST", 0, 11], ["the virus", "PROBLEM", 97, 106], ["virus", "OBSERVATION", 101, 106]]], ["On February 2006, European Union authorities held an urgent meeting after the H5N1 avian influenza virus was found in dead swans in Italy, Greece, Slovenia, and Austria.", [["avian influenza virus", "DISEASE", 83, 104], ["H5N1", "ORGANISM", 78, 82], ["avian influenza virus", "ORGANISM", 83, 104], ["H5N1 avian influenza virus", "SPECIES", 78, 104], ["H5N1 avian influenza virus", "SPECIES", 78, 104], ["the H5N1 avian influenza virus", "PROBLEM", 74, 104], ["dead swans", "OBSERVATION", 118, 128]]], ["They agreed that Europe would be the next target for H5N1 avian flu in the near future, and the foothold for that pandemic would be Africa.", [["H5N1 avian flu", "DISEASE", 53, 67], ["H5N1", "ORGANISM", 53, 57], ["avian", "ORGANISM", 58, 63], ["H5N1 avian flu", "SPECIES", 53, 67], ["H5N1 avian flu", "SPECIES", 53, 67], ["H5N1 avian flu", "TREATMENT", 53, 67], ["Africa", "PROBLEM", 132, 138]]], ["Like other Asian countries where the human infections have occurred, the majority of chickens are kept in and around people's homes in Africa.", [["infections", "DISEASE", 43, 53], ["human", "ORGANISM", 37, 42], ["chickens", "ORGANISM", 85, 93], ["people", "ORGANISM", 117, 123], ["human", "SPECIES", 37, 42], ["chickens", "SPECIES", 85, 93], ["people", "SPECIES", 117, 123], ["human", "SPECIES", 37, 42], ["chickens", "SPECIES", 85, 93], ["the human infections", "PROBLEM", 33, 53], ["infections", "OBSERVATION", 43, 53]]], ["These environmental conditions would provide more opportunities for H5N1 influenza viruses to contact with human beings [4] .", [["influenza", "DISEASE", 73, 82], ["H5N1 influenza viruses", "ORGANISM", 68, 90], ["human", "ORGANISM", 107, 112], ["H5N1 influenza viruses", "SPECIES", 68, 90], ["human", "SPECIES", 107, 112], ["H5N1 influenza viruses", "SPECIES", 68, 90], ["human", "SPECIES", 107, 112], ["H5N1 influenza viruses", "PROBLEM", 68, 90]]], ["The recent appearance of avian flu in Europe suggests that long-distance spread of the virus is also possible via migratory birds [5] .IntroductionInfluenza viruses are classified into three groups, such as A, B, and C groups, according to the antigenicity of their internal viral nucleoproteins.", [["avian flu", "DISEASE", 25, 34], ["Influenza viruses", "DISEASE", 147, 164], ["avian flu", "ORGANISM", 25, 34], ["Influenza viruses", "ORGANISM", 147, 164], ["B", "GENE_OR_GENE_PRODUCT", 210, 211], ["internal viral nucleoproteins", "PROTEIN", 266, 295], ["avian flu", "SPECIES", 25, 34], ["avian flu", "PROBLEM", 25, 34], ["the virus", "PROBLEM", 83, 92], ["IntroductionInfluenza viruses", "PROBLEM", 135, 164], ["A, B, and C groups", "TREATMENT", 207, 225], ["avian", "OBSERVATION_MODIFIER", 25, 30], ["flu", "OBSERVATION", 31, 34], ["virus", "OBSERVATION", 87, 92]]], ["Type A viruses cause the worldwide epidemics of the respiratory disease influenza, and both type A and B viruses cause epidemics, when type C viruses cause only minor upper respiratory illness.", [["respiratory", "ANATOMY", 173, 184], ["Type A viruses", "DISEASE", 0, 14], ["respiratory disease influenza", "DISEASE", 52, 81], ["type A and B viruses", "DISEASE", 92, 112], ["respiratory illness", "DISEASE", 173, 192], ["Type A viruses", "ORGANISM", 0, 14], ["B viruses", "ORGANISM", 103, 112], ["type C viruses", "ORGANISM", 135, 149], ["Type A viruses", "SPECIES", 0, 14], ["Type A viruses", "PROBLEM", 0, 14], ["the respiratory disease influenza", "PROBLEM", 48, 81], ["type A and B viruses", "PROBLEM", 92, 112], ["epidemics", "PROBLEM", 119, 128], ["type C viruses", "PROBLEM", 135, 149], ["minor upper respiratory illness", "PROBLEM", 161, 192], ["viruses", "OBSERVATION", 7, 14], ["respiratory disease", "OBSERVATION", 52, 71], ["minor", "OBSERVATION_MODIFIER", 161, 166], ["upper", "ANATOMY_MODIFIER", 167, 172], ["respiratory", "ANATOMY", 173, 184], ["illness", "OBSERVATION", 185, 192]]], ["The primary hosts of influenza A viruses are wild aquatic birds, such as duck, terns and shore birds, and influenza B viruses mainly infect humans, with infections of non-human animals being reported only rarely [6, 7] .", [["influenza A viruses", "DISEASE", 21, 40], ["influenza B", "DISEASE", 106, 117], ["infections", "DISEASE", 153, 163], ["influenza A viruses", "ORGANISM", 21, 40], ["duck", "ORGANISM", 73, 77], ["influenza B viruses", "ORGANISM", 106, 125], ["humans", "ORGANISM", 140, 146], ["non-human", "ORGANISM", 167, 176], ["influenza A viruses", "SPECIES", 21, 40], ["duck", "SPECIES", 73, 77], ["influenza B viruses", "SPECIES", 106, 125], ["humans", "SPECIES", 140, 146], ["influenza A viruses", "SPECIES", 21, 40], ["influenza B viruses", "SPECIES", 106, 125], ["humans", "SPECIES", 140, 146], ["influenza A viruses", "PROBLEM", 21, 40], ["influenza B viruses", "PROBLEM", 106, 125], ["influenza", "OBSERVATION", 21, 30]]], ["Influenza A virus, is a member of the orthomyxoviridae family with a negative-sense single-stranded RNA.", [["Influenza A virus", "DISEASE", 0, 17], ["Influenza A virus", "ORGANISM", 0, 17], ["orthomyxoviridae", "GENE_OR_GENE_PRODUCT", 38, 54], ["orthomyxoviridae family", "PROTEIN", 38, 61], ["negative-sense single-stranded RNA", "RNA", 69, 103], ["Influenza A virus", "SPECIES", 0, 17], ["Influenza A virus", "SPECIES", 0, 17], ["Influenza A virus", "PROBLEM", 0, 17], ["stranded RNA", "OBSERVATION_MODIFIER", 91, 103]]], ["Its genome consists of eight different segments, ranging in size from 890 to 2,341 bases [8] .", [["genome", "OBSERVATION", 4, 10], ["eight", "OBSERVATION_MODIFIER", 23, 28], ["different", "OBSERVATION_MODIFIER", 29, 38], ["segments", "OBSERVATION_MODIFIER", 39, 47], ["ranging", "OBSERVATION_MODIFIER", 49, 56], ["size", "OBSERVATION_MODIFIER", 60, 64]]], ["Among the proteins encoded by these segments, two glycoproteins, such as hemagglutinin (HA; segment 4) and neuraminidase (NA; segment 6), play important roles in the immune response.", [["hemagglutinin (HA; segment 4", "GENE_OR_GENE_PRODUCT", 73, 101], ["neuraminidase (NA; segment 6", "GENE_OR_GENE_PRODUCT", 107, 135], ["glycoproteins", "PROTEIN", 50, 63], ["hemagglutinin", "PROTEIN", 73, 86], ["HA", "PROTEIN", 88, 90], ["segment 4", "PROTEIN", 92, 101], ["neuraminidase", "PROTEIN", 107, 120], ["NA", "PROTEIN", 122, 124], ["segment 6", "PROTEIN", 126, 135], ["two glycoproteins", "TREATMENT", 46, 63], ["hemagglutinin (HA", "TREATMENT", 73, 90], ["neuraminidase (NA; segment 6)", "PROBLEM", 107, 136], ["segments", "ANATOMY_MODIFIER", 36, 44]]], ["Different subtypes of HA (H1 to H15) and NA (N1 to N9) are found in avian species.", [["HA (H1 to H15", "GENE_OR_GENE_PRODUCT", 22, 35], ["HA", "PROBLEM", 22, 24], ["NA", "TEST", 41, 43], ["subtypes", "OBSERVATION_MODIFIER", 10, 18], ["HA", "OBSERVATION_MODIFIER", 22, 24], ["avian species", "OBSERVATION", 68, 81]]], ["The HAs of human viruses bind to the terminal sialic acid of glycoprotein and glycolipid receptors containing a2,6 linkages to galactose, whereas HAs of avian isolates prefer a2,3 linkages.", [["sialic acid", "CHEMICAL", 46, 57], ["galactose", "CHEMICAL", 127, 136], ["sialic acid", "CHEMICAL", 46, 57], ["galactose", "CHEMICAL", 127, 136], ["human", "ORGANISM", 11, 16], ["sialic acid", "AMINO_ACID", 46, 57], ["galactose", "SIMPLE_CHEMICAL", 127, 136], ["a2,3 linkages", "SIMPLE_CHEMICAL", 175, 188], ["glycoprotein", "PROTEIN", 61, 73], ["glycolipid receptors", "PROTEIN", 78, 98], ["human", "SPECIES", 11, 16], ["human", "SPECIES", 11, 16], ["human viruses bind", "PROBLEM", 11, 29], ["the terminal sialic acid of glycoprotein", "TREATMENT", 33, 73], ["glycolipid receptors", "TREATMENT", 78, 98], ["galactose", "TREATMENT", 127, 136], ["viruses", "OBSERVATION", 17, 24]]], ["NA is not considered to be as important an antigenic determinant as HA, but NA, like HA, is regarded as a possible restrictive factor for viral growth.", [["NA", "CHEMICAL", 0, 2], ["NA", "CHEMICAL", 76, 78], ["NA", "SIMPLE_CHEMICAL", 0, 2], ["HA", "GENE_OR_GENE_PRODUCT", 68, 70], ["NA", "SIMPLE_CHEMICAL", 76, 78], ["HA", "GENE_OR_GENE_PRODUCT", 85, 87], ["HA", "PROBLEM", 68, 70], ["NA, like HA", "PROBLEM", 76, 87], ["restrictive factor", "PROBLEM", 115, 133], ["viral growth", "PROBLEM", 138, 150], ["not considered", "UNCERTAINTY", 6, 20]]], ["The major function of NA is to remove sialic acid from the HA and NA of progeny virus particles, intercellular glycoproteins, and host cell receptors, thus facilitating virus release from infected cells and from intercellular inhibitors [9] [10] [11] .", [["intercellular", "ANATOMY", 97, 110], ["cell", "ANATOMY", 135, 139], ["cells", "ANATOMY", 197, 202], ["intercellular", "ANATOMY", 212, 225], ["NA", "CHEMICAL", 22, 24], ["sialic acid", "CHEMICAL", 38, 49], ["sialic acid", "CHEMICAL", 38, 49], ["NA", "SIMPLE_CHEMICAL", 22, 24], ["sialic acid", "SIMPLE_CHEMICAL", 38, 49], ["HA", "SIMPLE_CHEMICAL", 59, 61], ["host cell", "CELL", 130, 139], ["cells", "CELL", 197, 202], ["intercellular glycoproteins", "PROTEIN", 97, 124], ["host cell receptors", "PROTEIN", 130, 149], ["infected cells", "CELL_TYPE", 188, 202], ["sialic acid", "PROBLEM", 38, 49], ["the HA", "PROBLEM", 55, 61], ["progeny virus particles", "PROBLEM", 72, 95], ["intercellular glycoproteins", "PROBLEM", 97, 124], ["host cell receptors", "TREATMENT", 130, 149], ["facilitating virus release", "TREATMENT", 156, 182], ["infected cells", "PROBLEM", 188, 202], ["intercellular inhibitors", "TREATMENT", 212, 236], ["host cell", "OBSERVATION", 130, 139], ["infected cells", "OBSERVATION", 188, 202]]], ["In addition to HA and NA proteins, the three viral polymerase proteins, such as PB1 (polymerase basic protein1), PB2 (polymerase basic protein2), and PA (polymerase) encoded on segment 1, 2, and 3 form an enzyme complex that functions in both transcription and replication.", [["HA", "GENE_OR_GENE_PRODUCT", 15, 17], ["NA proteins", "GENE_OR_GENE_PRODUCT", 22, 33], ["PB1 (polymerase basic protein1", "GENE_OR_GENE_PRODUCT", 80, 110], ["PB2 (polymerase basic protein2", "GENE_OR_GENE_PRODUCT", 113, 143], ["PA (polymerase) encoded on segment 1", "GENE_OR_GENE_PRODUCT", 150, 186], ["2", "GENE_OR_GENE_PRODUCT", 188, 189], ["3", "GENE_OR_GENE_PRODUCT", 195, 196], ["HA", "PROTEIN", 15, 17], ["NA proteins", "PROTEIN", 22, 33], ["viral polymerase proteins", "PROTEIN", 45, 70], ["PB1", "PROTEIN", 80, 83], ["polymerase basic protein1", "PROTEIN", 85, 110], ["PB2", "PROTEIN", 113, 116], ["polymerase basic protein2", "PROTEIN", 118, 143], ["PA", "PROTEIN", 150, 152], ["polymerase", "PROTEIN", 154, 164], ["segment 1, 2, and 3", "PROTEIN", 177, 196], ["enzyme complex", "PROTEIN", 205, 219], ["HA", "PROBLEM", 15, 17], ["NA proteins", "TEST", 22, 33], ["the three viral polymerase proteins", "TEST", 35, 70], ["PB1", "TEST", 80, 83], ["polymerase basic protein1", "TEST", 85, 110], ["PB2", "TEST", 113, 116], ["polymerase basic protein2", "TEST", 118, 143], ["PA (polymerase", "TEST", 150, 164], ["an enzyme complex", "PROBLEM", 202, 219]]], ["To accomplish the replication process, virus requires that newly synthesized NP (nucleoprotein), which encoded on segment 5, to bind to either negative-strand or positive-strand RNAs that are to be used as template for full-length copying [8] .", [["NP", "GENE_OR_GENE_PRODUCT", 77, 79], ["nucleoprotein", "PROTEIN", 81, 94], ["segment 5", "DNA", 114, 123], ["negative-strand", "DNA", 143, 158], ["positive-strand RNAs", "RNA", 162, 182], ["the replication process", "PROBLEM", 14, 37], ["virus", "PROBLEM", 39, 44], ["newly synthesized NP (nucleoprotein)", "TREATMENT", 59, 95], ["strand or positive-strand RNAs", "PROBLEM", 152, 182], ["replication", "OBSERVATION", 18, 29]]], ["In this study, we analyzed the HA and NA genes which determine the host specificity, and two genes which form the enzyme complex for transcription and replication, including PA and PB2, as well as NP gene from the four subtypes of influenza A virus which has an important role in the replication process.", [["influenza A", "DISEASE", 231, 242], ["HA", "GENE_OR_GENE_PRODUCT", 31, 33], ["PA", "GENE_OR_GENE_PRODUCT", 174, 176], ["PB2", "GENE_OR_GENE_PRODUCT", 181, 184], ["NP", "GENE_OR_GENE_PRODUCT", 197, 199], ["influenza A virus", "ORGANISM", 231, 248], ["HA and NA genes", "DNA", 31, 46], ["enzyme complex", "PROTEIN", 114, 128], ["PB2", "DNA", 181, 184], ["NP gene", "DNA", 197, 204], ["influenza A virus", "SPECIES", 231, 248], ["influenza A virus", "SPECIES", 231, 248], ["this study", "TEST", 3, 13], ["the HA and NA genes", "PROBLEM", 27, 46], ["replication", "TREATMENT", 151, 162], ["PA and PB2", "TREATMENT", 174, 184], ["NP gene", "TREATMENT", 197, 204], ["influenza A virus", "PROBLEM", 231, 248], ["influenza", "OBSERVATION", 231, 240]]], ["PB1 gene was not used in this study because there were little or no full-length genomes available for four subtypes of influenza A viruses which infected human population.IntroductionAnalyses of codon usage patterns have been used by some scientists to determine the origins of species in many fields.", [["influenza A viruses", "DISEASE", 119, 138], ["PB1", "GENE_OR_GENE_PRODUCT", 0, 3], ["influenza A viruses", "ORGANISM", 119, 138], ["human", "ORGANISM", 154, 159], ["PB1 gene", "DNA", 0, 8], ["full-length genomes", "DNA", 68, 87], ["human", "SPECIES", 154, 159], ["human", "SPECIES", 154, 159], ["PB1 gene", "TREATMENT", 0, 8], ["this study", "TEST", 25, 35], ["full-length genomes", "PROBLEM", 68, 87], ["influenza A viruses", "PROBLEM", 119, 138], ["codon usage patterns", "TREATMENT", 195, 215], ["influenza", "OBSERVATION", 119, 128]]], ["Synonymous codons are usually known to encode common amino acids for protein synthesis.", [["amino acids", "CHEMICAL", 53, 64], ["amino acids", "CHEMICAL", 53, 64], ["amino acids", "AMINO_ACID", 53, 64], ["Synonymous codons", "PROBLEM", 0, 17], ["protein synthesis", "PROBLEM", 69, 86]]], ["These codons are not used randomly, but rather some codons are used more frequently than others [12] [13] [14] .", [["[12] [13] [14]", "SIMPLE_CHEMICAL", 96, 110]]], ["In prokaryotes, such as thermophilic bacteria, highly expressed genes have codon usage patterns that are shifted toward a more restricted set of ''preferred'' synonymous codons compared to the codon usage of other less highly expressed genes within a genome [15] , and codon usage patterns have a tendency to mirror the distribution of tRNA abundances [16, 17] .", [["thermophilic bacteria", "PROBLEM", 24, 45], ["codon usage patterns", "PROBLEM", 75, 95], ["synonymous codons", "PROBLEM", 159, 176], ["codon usage patterns", "TREATMENT", 269, 289]]], ["With respect to virus genomes, Gu et al. [18] reported that the relative synonymous codon usage values in Severe Acute Respiratory Syndrome (SARS) coronaviruses were virus-specific and that translational selection and gene length might have no effect on the codon usage pattern in these viruses [19] .", [["Acute Respiratory Syndrome", "DISEASE", 113, 139], ["SARS", "DISEASE", 141, 145], ["Severe Acute Respiratory", "ORGANISM", 106, 130], ["Severe Acute Respiratory Syndrome (SARS) coronaviruses", "SPECIES", 106, 160], ["virus genomes", "PROBLEM", 16, 29], ["the relative synonymous codon usage values", "PROBLEM", 60, 102], ["Severe Acute Respiratory Syndrome", "PROBLEM", 106, 139], ["SARS) coronaviruses", "PROBLEM", 141, 160], ["virus", "PROBLEM", 166, 171], ["translational selection", "TREATMENT", 190, 213], ["gene length", "PROBLEM", 218, 229], ["synonymous codon", "OBSERVATION", 73, 89], ["Severe", "OBSERVATION_MODIFIER", 106, 112], ["Acute", "OBSERVATION_MODIFIER", 113, 118], ["Respiratory Syndrome", "OBSERVATION", 119, 139]]], ["Almost all codon usage studies using the correspondence analysis method, however, were conducted in bacteria or higher species and not in virus species.IntroductionWe examined the differences in codon usage patterns among the species included in the orthomyxoviridae family first, and then, we also analyzed the differences among the H1N1, H2N2, H3N2, and H5N1 subtypes of the influenza A virus group which were isolated from human population.", [["H2N2, H3N2", "ORGANISM", 340, 350], ["H5N1 subtypes", "ORGANISM", 356, 369], ["influenza A virus", "ORGANISM", 377, 394], ["human", "ORGANISM", 426, 431], ["H5N1", "SPECIES", 356, 360], ["influenza A virus group", "SPECIES", 377, 400], ["human", "SPECIES", 426, 431], ["influenza A virus", "SPECIES", 377, 394], ["human", "SPECIES", 426, 431], ["the correspondence analysis method", "TEST", 37, 71], ["bacteria", "PROBLEM", 100, 108], ["higher species", "PROBLEM", 112, 126], ["virus species", "PROBLEM", 138, 151], ["IntroductionWe", "TREATMENT", 152, 166], ["codon usage patterns", "TREATMENT", 195, 215], ["the H1N1", "PROBLEM", 330, 338], ["H2N2", "PROBLEM", 340, 344], ["H3N2", "PROBLEM", 346, 350], ["H5N1", "PROBLEM", 356, 360], ["the influenza A virus group", "PROBLEM", 373, 400], ["higher species", "OBSERVATION", 112, 126]]], ["To investigate the codon usage patterns, the relative synonymous codon usage (RSCU) and the effective number of codons (ENC) for all species were calculated.", [["ENC", "DNA", 120, 123], ["codons (ENC)", "TREATMENT", 112, 124], ["all species", "PROBLEM", 129, 140], ["synonymous codon", "OBSERVATION", 54, 70]]], ["The correspondence analysis was used to analyze the differences statistically.Nucleotide sequencesTo investigate the overall synonymous codon usage patterns, 13,496 coding sequences (CDSs) from the orthomyxoviridae family, including influenza A virus, influenza B virus, influenza C virus, thogoto virus, and dhori virus species, were examined.", [["influenza A", "DISEASE", 233, 244], ["influenza B", "DISEASE", 252, 263], ["influenza C virus", "DISEASE", 271, 288], ["influenza A virus", "ORGANISM", 233, 250], ["influenza B virus", "ORGANISM", 252, 269], ["influenza C virus", "ORGANISM", 271, 288], ["thogoto virus", "ORGANISM", 290, 303], ["dhori virus", "ORGANISM", 309, 320], ["Nucleotide sequences", "DNA", 78, 98], ["13,496 coding sequences", "DNA", 158, 181], ["CDSs", "DNA", 183, 187], ["influenza A virus", "SPECIES", 233, 250], ["influenza B virus", "SPECIES", 252, 269], ["influenza C virus", "SPECIES", 271, 288], ["thogoto virus", "SPECIES", 290, 303], ["dhori virus", "SPECIES", 309, 320], ["influenza A virus", "SPECIES", 233, 250], ["influenza B virus", "SPECIES", 252, 269], ["influenza C virus", "SPECIES", 271, 288], ["thogoto virus", "SPECIES", 290, 303], ["The correspondence analysis", "TEST", 0, 27], ["Nucleotide sequences", "TEST", 78, 98], ["the orthomyxoviridae family", "TEST", 194, 221], ["influenza A virus", "PROBLEM", 233, 250], ["influenza B virus", "PROBLEM", 252, 269], ["influenza C virus", "PROBLEM", 271, 288], ["thogoto virus", "PROBLEM", 290, 303], ["dhori virus species", "PROBLEM", 309, 328], ["synonymous codon", "OBSERVATION", 125, 141]]], ["Using Java codes, all the complete CDSs of these five species were extracted from GenBank flat files (version 151) in NCBI ftp site (ftp://ftp.ncbi.nih.gov/genbank), and pooled by their species names.", [["CDSs", "DNA", 35, 39], ["NCBI ftp site", "DNA", 118, 131]]], ["Then, these data sets were used in the RSCU (relative synonymous codon usage) calculation and the statistical analysis for each species.Nucleotide sequencesThe full-length genes of HA (hemagglutinin), NA (neuraminidase), NP (nucleoprotein), PA (polymerase), and PB2 (polymerase basic protein 2) from the H1N1, H2N2, H3N2, and H5N1 subtypes of the influenza A virus which infected human population were also collected from \u00d4NCBI Influenza Virus Resources (http://www.ncbi.nlm.nih.gov/genomes/FLU /Database /select.cgi?go = 1)\u00d5 to analyze the differen ces among subtypes.", [["NA", "CHEMICAL", 201, 203], ["influenza A virus", "DISEASE", 347, 364], ["HA (hemagglutinin)", "GENE_OR_GENE_PRODUCT", 181, 199], ["NA (neuraminidase)", "GENE_OR_GENE_PRODUCT", 201, 219], ["NP (nucleoprotein)", "GENE_OR_GENE_PRODUCT", 221, 239], ["PA", "GENE_OR_GENE_PRODUCT", 241, 243], ["PB2 (polymerase basic protein 2", "GENE_OR_GENE_PRODUCT", 262, 293], ["H2N2, H3N2", "ORGANISM", 310, 320], ["H5N1 subtypes", "ORGANISM", 326, 339], ["influenza A virus", "ORGANISM", 347, 364], ["human", "ORGANISM", 380, 385], ["Nucleotide sequences", "DNA", 136, 156], ["full-length genes", "DNA", 160, 177], ["HA", "DNA", 181, 183], ["hemagglutinin", "PROTEIN", 185, 198], ["NA", "DNA", 201, 203], ["neuraminidase", "PROTEIN", 205, 218], ["NP", "PROTEIN", 221, 223], ["nucleoprotein", "PROTEIN", 225, 238], ["PA", "PROTEIN", 241, 243], ["polymerase", "PROTEIN", 245, 255], ["PB2", "PROTEIN", 262, 265], ["polymerase basic protein 2", "PROTEIN", 267, 293], ["H5N1", "SPECIES", 326, 330], ["influenza A virus", "SPECIES", 347, 364], ["human", "SPECIES", 380, 385], ["influenza A virus", "SPECIES", 347, 364], ["human", "SPECIES", 380, 385], ["these data sets", "TEST", 6, 21], ["relative synonymous codon usage", "TREATMENT", 45, 76], ["the statistical analysis", "TEST", 94, 118], ["Nucleotide sequences", "TEST", 136, 156], ["HA", "PROBLEM", 181, 183], ["hemagglutinin", "TEST", 185, 198], ["NA (neuraminidase", "TEST", 201, 218], ["NP (nucleoprotein)", "TEST", 221, 239], ["PA (polymerase", "TEST", 241, 255], ["PB2", "TEST", 262, 265], ["polymerase basic protein", "TEST", 267, 291], ["the H1N1", "PROBLEM", 300, 308], ["H2N2", "PROBLEM", 310, 314], ["H3N2", "PROBLEM", 316, 320], ["H5N1", "PROBLEM", 326, 330], ["the influenza A virus", "PROBLEM", 343, 364], ["infected human population", "PROBLEM", 371, 396], ["Influenza Virus Resources", "TREATMENT", 428, 453], ["H5N1", "OBSERVATION", 326, 330]]], ["Because there were little or no full-length genomes of PB1 (polymerase basic protein 1) which infected human population, we excluded PB1 gene in this study.", [["PB1 (polymerase basic protein 1", "GENE_OR_GENE_PRODUCT", 55, 86], ["human", "ORGANISM", 103, 108], ["PB1", "GENE_OR_GENE_PRODUCT", 133, 136], ["full-length genomes", "DNA", 32, 51], ["PB1", "DNA", 55, 58], ["polymerase basic protein 1", "PROTEIN", 60, 86], ["PB1 gene", "DNA", 133, 141], ["human", "SPECIES", 103, 108], ["human", "SPECIES", 103, 108], ["polymerase basic protein", "TEST", 60, 84], ["this study", "TEST", 145, 155], ["little", "OBSERVATION_MODIFIER", 19, 25]]], ["Among the sequences for each gene from four influenza subtypes, only the most recently registered and complete sequences which were isolated from Asian, European, or African countries were used (Table 1 ).", [["four influenza subtypes", "PROBLEM", 39, 62]]], ["In the case of H5N1 subtype, we collected all the possible sequences, which were registered in 2005 to compare more intensively with other subtype viruses.", [["H5N1", "ORGANISM", 15, 19], ["H5N1", "OBSERVATION", 15, 19], ["viruses", "OBSERVATION", 147, 154]]], ["Partial CDSs, complementary CDSs, and CDSs with more than one ambiguous sequence were excluded.Relative synonymous codon usage (RSCU)In a correspondence analysis, the RSCU value for each codon is usually used to prevent the amino acid composition from influencing the codon usage values for each gene [20] .", [["amino acid", "CHEMICAL", 224, 234], ["amino acid", "CHEMICAL", 224, 234], ["amino acid", "AMINO_ACID", 224, 234], ["CDSs", "DNA", 8, 12], ["complementary CDSs", "DNA", 14, 32], ["CDSs", "DNA", 38, 42], ["RSCU", "DNA", 167, 171], ["Partial CDSs", "TEST", 0, 12], ["complementary CDSs", "TEST", 14, 32], ["CDSs", "TEST", 38, 42], ["one ambiguous sequence", "TEST", 58, 80], ["a correspondence analysis", "TEST", 136, 161], ["the amino acid composition", "TREATMENT", 220, 246], ["synonymous codon", "OBSERVATION", 104, 120]]], ["The RSCU value is the number of times a particular codon is observed, relative to the number of times the codon would be observed in the absence of any codon usage bias.", [["RSCU", "DNA", 4, 8], ["The RSCU value", "TEST", 0, 14]]], ["If there were no codon usage bias, the RSCU value would be 1.00.", [["codon usage bias", "PROBLEM", 17, 33], ["the RSCU value", "TEST", 35, 49], ["no", "UNCERTAINTY", 14, 16]]], ["The RSCU was calculated asRelative synonymous codon usage (RSCU)where X ij is the frequency of occurrence of the jth codon for the ith amino acid, and n i is the number of codons for the ith amino acid.", [["amino acid", "CHEMICAL", 135, 145], ["amino acid", "CHEMICAL", 191, 201], ["amino acid", "CHEMICAL", 135, 145], ["amino acid", "CHEMICAL", 191, 201], ["amino acid", "AMINO_ACID", 135, 145], ["amino acid", "AMINO_ACID", 191, 201], ["RSCU", "DNA", 4, 8], ["X ij", "DNA", 70, 74], ["jth codon", "DNA", 113, 122], ["ij", "TREATMENT", 72, 74], ["the jth codon", "TREATMENT", 109, 122], ["the ith amino acid", "TREATMENT", 127, 145], ["codons", "TREATMENT", 172, 178], ["the ith amino acid", "TREATMENT", 183, 201], ["synonymous codon", "OBSERVATION", 35, 51]]], ["For the correspondence analysis, each gene was represented as a 59-dimensional vector excluding start and stop codons and the UGG codon, which codes tryptophan without any synonymous codons.", [["tryptophan", "CHEMICAL", 149, 159], ["tryptophan", "CHEMICAL", 149, 159], ["tryptophan", "AMINO_ACID", 149, 159], ["59-dimensional vector", "DNA", 64, 85], ["start and stop codons", "DNA", 96, 117], ["UGG codon", "DNA", 126, 135], ["the correspondence analysis", "TEST", 4, 31], ["the UGG codon", "PROBLEM", 122, 135], ["any synonymous codons", "PROBLEM", 168, 189], ["synonymous codons", "OBSERVATION", 172, 189]]], ["All 59 codons were then pooled and calculated in a contingency table according to the species genome in which they were included.", [["species genome", "DNA", 86, 100], ["species genome", "OBSERVATION", 86, 100]]], ["All the calculated RSCU values of the species from the orthomyxoviridae family, and of the H1N1, H2N2, H3N2, and H5N1 human subtypes from influenza A viruses were used to the further statistical analysis, such as correspondence analysis.Effective number of codons (ENC)In addition to the RSCU values per each amino acid, we also calculated the ENC value, which is the most common measure of codon bias [21] .", [["amino acid", "CHEMICAL", 309, 319], ["amino acid", "CHEMICAL", 309, 319], ["H2N2, H3N2", "ORGANISM", 97, 107], ["H5N1", "ORGANISM", 113, 117], ["human", "ORGANISM", 118, 123], ["influenza A viruses", "ORGANISM", 138, 157], ["amino acid", "AMINO_ACID", 309, 319], ["orthomyxoviridae family", "PROTEIN", 55, 78], ["RSCU", "DNA", 288, 292], ["ENC", "DNA", 344, 347], ["H3N2", "SPECIES", 103, 107], ["H5N1", "SPECIES", 113, 117], ["human", "SPECIES", 118, 123], ["influenza A viruses", "SPECIES", 138, 157], ["human", "SPECIES", 118, 123], ["influenza A viruses", "SPECIES", 138, 157], ["the H1N1", "PROBLEM", 87, 95], ["H2N2", "PROBLEM", 97, 101], ["H3N2", "PROBLEM", 103, 107], ["H5N1 human subtypes", "PROBLEM", 113, 132], ["influenza A viruses", "PROBLEM", 138, 157], ["the further statistical analysis", "TEST", 171, 203], ["correspondence analysis", "TEST", 213, 236], ["the ENC value", "TEST", 340, 353]]], ["ENC values range from 20, for the case in which only one codon is used for each amino acid, to 61, for the case in which all synonymous codons are used in equal frequency.", [["amino acid", "CHEMICAL", 80, 90], ["amino acid", "CHEMICAL", 80, 90], ["amino acid", "AMINO_ACID", 80, 90], ["ENC", "DNA", 0, 3], ["each amino acid", "TEST", 75, 90], ["all synonymous codons", "TREATMENT", 121, 142], ["synonymous codons", "OBSERVATION", 125, 142]]], ["ENC can be estimated asEffective number of codons (ENC)where \" F k (k = 2, 3, 4, or 6) is the average of the F k values for k-fold degenerate amino acids.", [["amino acids", "CHEMICAL", 142, 153], ["amino acids", "CHEMICAL", 142, 153], ["amino acids", "AMINO_ACID", 142, 153], ["ENC", "DNA", 0, 3], ["F k (k", "TEST", 63, 69], ["the F k values", "TEST", 105, 119], ["k-fold degenerate amino acids", "PROBLEM", 124, 153], ["amino acids", "OBSERVATION", 142, 153]]], ["F k for each of the k-fold degenerate amino acids was estimated asEffective number of codons (ENC)where n is the total number of codons for that amino acid, andEffective number of codons (ENC)where n i is the number of occurrences of the ith codon for that amino acid [14] .", [["amino acids", "CHEMICAL", 38, 49], ["amino acid", "CHEMICAL", 145, 155], ["amino acid", "CHEMICAL", 257, 267], ["amino acids", "CHEMICAL", 38, 49], ["amino acid", "CHEMICAL", 145, 155], ["amino acid", "CHEMICAL", 257, 267], ["F k", "GENE_OR_GENE_PRODUCT", 0, 3], ["amino acids", "AMINO_ACID", 38, 49], ["amino acid", "AMINO_ACID", 145, 155], ["amino acid", "AMINO_ACID", 257, 267], ["the k-fold degenerate amino acids", "PROBLEM", 16, 49], ["amino acid", "TREATMENT", 145, 155], ["codons (ENC)", "TREATMENT", 180, 192], ["the ith codon", "TREATMENT", 234, 247], ["that amino acid", "TREATMENT", 252, 267]]], ["All the calculated ENC values of the H1N1, H2N2, H3N2, and H5N1 human subtypes from influenza A viruses were divided into each gene and country group for more comparisons ( Figure 3 ).", [["H2N2, H3N2", "ORGANISM", 43, 53], ["H5N1", "ORGANISM", 59, 63], ["human", "ORGANISM", 64, 69], ["influenza A viruses", "ORGANISM", 84, 103], ["H5N1", "SPECIES", 59, 63], ["human", "SPECIES", 64, 69], ["influenza A viruses", "SPECIES", 84, 103], ["human", "SPECIES", 64, 69], ["influenza A viruses", "SPECIES", 84, 103], ["All the calculated ENC values", "TEST", 0, 29], ["the H1N1", "PROBLEM", 33, 41], ["H2N2", "PROBLEM", 43, 47], ["H3N2", "PROBLEM", 49, 53], ["H5N1 human subtypes", "TREATMENT", 59, 78], ["influenza A viruses", "TREATMENT", 84, 103], ["H1N1", "OBSERVATION", 37, 41]]], ["All calculations of codon usage numbers, RSCU, and ENC values were performed using JAVA codes that we developed in the RedHat Linux 9.0 platform.Correspondence analysisCorrespondence analysis is a type of multivariate analysis that represents associations as a table of frequencies or graphically as counts.", [["ENC", "DNA", 51, 54], ["JAVA codes", "DNA", 83, 93], ["codon usage numbers", "TEST", 20, 39], ["RSCU", "TEST", 41, 45], ["ENC values", "TEST", 51, 61], ["Correspondence analysisCorrespondence analysis", "TEST", 145, 191], ["multivariate analysis", "TEST", 205, 226]]], ["For a contingency table with I rows and J columns, the plot produced by correspondence analysis would contain two sets of points: one set of I points corresponding to the rows, and one set of J points corresponding to the columns.", [["J points", "PROTEIN", 192, 200], ["I rows and J columns", "TREATMENT", 29, 49], ["correspondence analysis", "TEST", 72, 95], ["J columns", "OBSERVATION_MODIFIER", 40, 49], ["J points", "OBSERVATION_MODIFIER", 192, 200], ["columns", "ANATOMY_MODIFIER", 222, 229]]], ["The positions of the points would reflect the associations.", [["positions", "OBSERVATION_MODIFIER", 4, 13]]], ["The RSCU values for 59 codons, as described above, were used, and the correspondence analysis process was performed using the SAS statistical program, version 9.1 [22] .", [["RSCU", "DNA", 4, 8], ["The RSCU values", "TEST", 0, 15], ["the correspondence analysis process", "TEST", 66, 101], ["version", "TEST", 151, 158]]], ["The usual output from a correspondence analysis includes the ''best'' two-dimensional representation of the data, along with the coordinates of the plotted points, and a measure (called the inertia) of the amount of information retained in each dimension [23] .", [["The usual output", "TEST", 0, 16], ["a correspondence analysis", "TEST", 22, 47], ["the data", "TEST", 104, 112], ["output", "OBSERVATION_MODIFIER", 10, 16], ["amount", "OBSERVATION_MODIFIER", 206, 212]]], ["Genes or species that are strongly associated as measured by their chi-square distances will lie in a similar direction from the origin [23, 24] .", [["Genes or species", "PROBLEM", 0, 16], ["species", "OBSERVATION", 9, 16]]], ["The chi-square distance between two coordinates with the same row or column value, called the Euclidean distance [18, 24] , has important statistical meaning, but there is no significant meaning between the row coordinate and the column coordinate.", [["no", "UNCERTAINTY", 172, 174], ["significant", "OBSERVATION_MODIFIER", 175, 186]]], ["The SigmaPlot 8.0 program was used to create the graphical correspondence analysis plots using coordinates consisting of the first and second dimensional factors that resulted from the correspondence analysis.", [["The SigmaPlot 8.0 program", "TREATMENT", 0, 25], ["the correspondence analysis", "TEST", 181, 208]]], ["The correspondence analysis was performed using both the RSCU values of the species from the orthomyxoviridae family, and of the H1N1, H2N2, H3N2, and H5N1 human subtypes from influenza A viruses (Figures 2, 4) .Other statistical analysesLinear regression analysis was also conducted to determine the correlation between the nucleotide content at the third codon position and the first axis (dim1) in the correspondence analysis results for the species from the orthomyxoviridae family.", [["influenza A viruses", "DISEASE", 176, 195], ["nucleotide", "CHEMICAL", 325, 335], ["nucleotide", "CHEMICAL", 325, 335], ["H2N2, H3N2", "ORGANISM", 135, 145], ["H5N1", "ORGANISM", 151, 155], ["human", "ORGANISM", 156, 161], ["influenza A viruses", "ORGANISM", 176, 195], ["third codon position", "DNA", 351, 371], ["dim1", "DNA", 392, 396], ["H3N2", "SPECIES", 141, 145], ["H5N1", "SPECIES", 151, 155], ["human", "SPECIES", 156, 161], ["influenza A viruses", "SPECIES", 176, 195], ["human", "SPECIES", 156, 161], ["influenza A viruses", "SPECIES", 176, 195], ["The correspondence analysis", "TEST", 0, 27], ["the H1N1", "PROBLEM", 125, 133], ["H2N2", "PROBLEM", 135, 139], ["H3N2", "PROBLEM", 141, 145], ["H5N1", "PROBLEM", 151, 155], ["influenza", "PROBLEM", 176, 185], ["Linear regression analysis", "TEST", 238, 264], ["the nucleotide content", "TEST", 321, 343], ["the correspondence analysis", "TEST", 401, 428]]], ["One-way ANOVA with Duncan's multiple range test was also used to compare the average values among the RSCU results.", [["Duncan's multiple range test", "TEST", 19, 47]]], ["All of these analyses were performed using the SAS statistical software, version 9.1 [22] .RSCU and correspondences analysis patterns of the orthomyxoviridae familyTo examine the synonymous codon usage patterns, we extracted all the complete CDSs from GenBank flat files and calculated the RSCU value for each species.", [["orthomyxoviridae family", "DNA", 141, 164], ["CDSs", "DNA", 242, 246], ["RSCU", "DNA", 290, 294], ["these analyses", "TEST", 7, 21], ["version", "TEST", 73, 80], ["correspondences analysis", "TEST", 100, 124], ["synonymous codon", "OBSERVATION", 179, 195]]], ["Not only the influenza A, B and C viruses, but also the thogoto and dhori virus in the orthomyxoviridae family were analyzed to compare the overall codon usage patterns with influenza group.", [["influenza", "DISEASE", 174, 183], ["influenza", "ORGANISM", 13, 22], ["A", "GENE_OR_GENE_PRODUCT", 23, 24], ["B and C viruses", "ORGANISM", 26, 41], ["thogoto", "ORGANISM", 56, 63], ["dhori virus", "ORGANISM", 68, 79], ["dhori virus", "SPECIES", 68, 79], ["the influenza A, B and C viruses", "PROBLEM", 9, 41], ["the thogoto and dhori virus", "PROBLEM", 52, 79], ["influenza group", "PROBLEM", 174, 189], ["influenza", "OBSERVATION", 13, 22], ["viruses", "OBSERVATION", 34, 41]]], ["The result of the RSCU patterns from five species showed that all the viruses revealed the highest value at \u00d4AGA' codon which encodes arginine (Figure 1 ).", [["arginine", "CHEMICAL", 134, 142], ["arginine", "CHEMICAL", 134, 142], ["arginine", "AMINO_ACID", 134, 142], ["\u00d4AGA' codon", "DNA", 108, 119], ["the RSCU patterns", "TEST", 14, 31], ["five species", "TEST", 37, 49], ["all the viruses", "PROBLEM", 62, 77], ["viruses", "OBSERVATION", 70, 77]]], ["The influenza B virus resulted the highest bias in \u00d4AGA' codon usage, and influenza B virus, thogoto virus, influenza A, and dhori virus were followed in descending order, and this RSCU pattern also continued in other synonymous codon groups.", [["influenza B", "DISEASE", 4, 15], ["influenza B", "DISEASE", 74, 85], ["influenza A", "DISEASE", 108, 119], ["influenza B virus", "ORGANISM", 4, 21], ["influenza B virus", "ORGANISM", 74, 91], ["thogoto virus", "ORGANISM", 93, 106], ["influenza A", "ORGANISM", 108, 119], ["dhori virus", "ORGANISM", 125, 136], ["influenza B virus", "SPECIES", 4, 21], ["influenza B virus", "SPECIES", 74, 91], ["thogoto virus", "SPECIES", 93, 106], ["dhori virus", "SPECIES", 125, 136], ["influenza B virus", "SPECIES", 4, 21], ["influenza B virus", "SPECIES", 74, 91], ["thogoto virus", "SPECIES", 93, 106], ["The influenza B virus", "PROBLEM", 0, 21], ["influenza B virus", "PROBLEM", 74, 91], ["thogoto virus", "PROBLEM", 93, 106], ["influenza A", "PROBLEM", 108, 119], ["dhori virus", "PROBLEM", 125, 136], ["this RSCU pattern", "TEST", 176, 193], ["synonymous codon", "OBSERVATION", 218, 234]]], ["If there was no synonymous codon usage bias among the codons which encodes the same amino acid, the RSCU values for those codons would be 1.00.", [["amino acid", "CHEMICAL", 84, 94], ["amino acid", "CHEMICAL", 84, 94], ["amino acid", "AMINO_ACID", 84, 94], ["synonymous codon usage bias", "PROBLEM", 16, 43], ["the same amino acid", "TEST", 75, 94], ["the RSCU values", "TEST", 96, 111], ["those codons", "TEST", 116, 128], ["no", "UNCERTAINTY", 13, 15], ["synonymous codon", "OBSERVATION", 16, 32]]], ["So, the higher RSCU values for each synonymous codon mean the higher codon usage bias in that amino acid.", [["amino acid", "CHEMICAL", 94, 104], ["amino acid", "CHEMICAL", 94, 104], ["amino acid", "AMINO_ACID", 94, 104], ["RSCU", "DNA", 15, 19], ["each synonymous codon", "PROBLEM", 31, 52], ["amino acid", "TREATMENT", 94, 104], ["higher codon", "OBSERVATION", 62, 74], ["amino acid", "OBSERVATION", 94, 104]]], ["The influenza B virus also revealed the high synonymous codon usage bias in codon groups which encoded glutamine, glycine, and threonine.", [["influenza B", "DISEASE", 4, 15], ["glutamine", "CHEMICAL", 103, 112], ["glycine", "CHEMICAL", 114, 121], ["threonine", "CHEMICAL", 127, 136], ["glutamine", "CHEMICAL", 103, 112], ["glycine", "CHEMICAL", 114, 121], ["threonine", "CHEMICAL", 127, 136], ["influenza B virus", "ORGANISM", 4, 21], ["glutamine", "AMINO_ACID", 103, 112], ["glycine", "AMINO_ACID", 114, 121], ["threonine", "AMINO_ACID", 127, 136], ["influenza B virus", "SPECIES", 4, 21], ["influenza B virus", "SPECIES", 4, 21], ["The influenza B virus", "TEST", 0, 21], ["glutamine, glycine", "TREATMENT", 103, 121], ["threonine", "TREATMENT", 127, 136], ["synonymous codon", "OBSERVATION", 45, 61]]], ["The influenza A virus, however, showed relatively the lowest codon bias among the three influenza virus group.", [["influenza", "DISEASE", 88, 97], ["influenza A virus", "ORGANISM", 4, 21], ["influenza virus", "ORGANISM", 88, 103], ["influenza A virus", "SPECIES", 4, 21], ["influenza virus group", "SPECIES", 88, 109], ["influenza A virus", "SPECIES", 4, 21], ["The influenza A virus", "PROBLEM", 0, 21], ["the lowest codon bias", "PROBLEM", 50, 71], ["the three influenza virus group", "PROBLEM", 78, 109], ["influenza virus", "OBSERVATION", 88, 103]]], ["To determine the bias for each species, we calculated the difference between the RSCU value of each species and the RSCU value of 1.00, and then averaged the differences for each virus group.", [["the RSCU value", "TEST", 112, 126]]], ["As a result, the average difference from 1.00 for the influenza A virus group was 0.300, and the average differences for the influenza B and influenza C virus groups were 0.383 and 0.510, respectively.", [["influenza A virus", "ORGANISM", 54, 71], ["influenza B", "ORGANISM", 125, 136], ["influenza C virus", "ORGANISM", 141, 158], ["influenza A virus group", "SPECIES", 54, 77], ["influenza C virus", "SPECIES", 141, 158], ["influenza A virus", "SPECIES", 54, 71], ["influenza C virus", "SPECIES", 141, 158], ["the influenza A virus group", "PROBLEM", 50, 77], ["the influenza B", "TEST", 121, 136], ["influenza C virus groups", "PROBLEM", 141, 165]]], ["The difference for the influenza A virus group was statistically smaller than that for the influenza C virus group (p < 0.05).", [["influenza A virus", "ORGANISM", 23, 40], ["influenza C virus", "ORGANISM", 91, 108], ["influenza A virus group", "SPECIES", 23, 46], ["influenza C virus group", "SPECIES", 91, 114], ["influenza A virus", "SPECIES", 23, 40], ["influenza C virus", "SPECIES", 91, 108], ["the influenza A virus group", "PROBLEM", 19, 46], ["the influenza C virus group", "PROBLEM", 87, 114]]], ["Thogoto and dhori virus showed reversal RSCU patterns codon groups for histidine and isoleucine.RSCU and correspondences analysis patterns of the orthomyxoviridae familyIn the next step, we also performed a correspondence analysis of orthomyxoviridae species using the RSCU values ( Figure 2 ).", [["Thogoto", "CHEMICAL", 0, 7], ["histidine", "CHEMICAL", 71, 80], ["isoleucine", "CHEMICAL", 85, 95], ["histidine", "CHEMICAL", 71, 80], ["isoleucine", "CHEMICAL", 85, 95], ["Thogoto", "GENE_OR_GENE_PRODUCT", 0, 7], ["dhori virus", "ORGANISM", 12, 23], ["histidine", "AMINO_ACID", 71, 80], ["isoleucine", "AMINO_ACID", 85, 95], ["orthomyxoviridae family", "DNA", 146, 169], ["dhori virus", "PROBLEM", 12, 23], ["histidine and isoleucine", "TREATMENT", 71, 95], ["correspondences analysis", "TEST", 105, 129], ["a correspondence analysis", "TEST", 205, 230], ["orthomyxoviridae species", "PROBLEM", 234, 258]]], ["The first-dimensional factor (dim1) in the correspondence analysis was significantly correlated with the base composition, especially with the GC content at the third codon position, showing the highest R 2 value (0.989; p < 0.0005) in the linear regression test (Table 2) .", [["dim1", "GENE_OR_GENE_PRODUCT", 30, 34], ["first-dimensional factor", "PROTEIN", 4, 28], ["dim1", "PROTEIN", 30, 34], ["the correspondence analysis", "TEST", 39, 66], ["the base composition", "TEST", 101, 121], ["the linear regression test", "TEST", 236, 262], ["highest", "OBSERVATION_MODIFIER", 195, 202]]], ["Among the influenza virus groups, the influenza A virus, with low synonymous codon bias, was located on the opposite side from the influenza B and influenza C virus.", [["influenza virus", "DISEASE", 10, 25], ["influenza A virus", "DISEASE", 38, 55], ["influenza B", "DISEASE", 131, 142], ["influenza C virus", "DISEASE", 147, 164], ["influenza virus", "ORGANISM", 10, 25], ["influenza A virus", "ORGANISM", 38, 55], ["influenza B", "ORGANISM", 131, 142], ["influenza C virus", "ORGANISM", 147, 164], ["influenza virus", "SPECIES", 10, 25], ["influenza A virus", "SPECIES", 38, 55], ["influenza C virus", "SPECIES", 147, 164], ["influenza virus", "SPECIES", 10, 25], ["influenza A virus", "SPECIES", 38, 55], ["influenza C virus", "SPECIES", 147, 164], ["the influenza virus groups", "PROBLEM", 6, 32], ["the influenza A virus", "PROBLEM", 34, 55], ["low synonymous codon bias", "PROBLEM", 62, 87], ["the influenza B", "PROBLEM", 127, 142], ["influenza C virus", "PROBLEM", 147, 164], ["synonymous codon bias", "OBSERVATION", 66, 87], ["influenza", "OBSERVATION", 131, 140]]], ["Thogoto and dhori viruses were also located on the same side with the influenza A virus, but they were separately located from the influenza A virus on the basis of the dim2-axis, with showing the higher synonymous codon usage bias than the influenza A viruses group.ENC patterns among influenza A virus subtypesThe nucleotide sequences of the HA, NA, NP, PA, and PB2 genes from four virus subtypes (H1N1, H2N2, H3N2, and H5N1), which were isolated from human population were used to calculate the ENC values for determining the codon usage bias (Figure 3) .", [["Thogoto", "CHEMICAL", 0, 7], ["influenza A virus", "DISEASE", 286, 303], ["nucleotide", "CHEMICAL", 316, 326], ["Thogoto", "GENE_OR_GENE_PRODUCT", 0, 7], ["dhori viruses", "ORGANISM", 12, 25], ["influenza A virus", "ORGANISM", 70, 87], ["influenza A virus", "ORGANISM", 131, 148], ["dim2", "GENE_OR_GENE_PRODUCT", 169, 173], ["influenza A viruses", "ORGANISM", 241, 260], ["influenza A virus", "ORGANISM", 286, 303], ["NP", "GENE_OR_GENE_PRODUCT", 352, 354], ["PA", "GENE_OR_GENE_PRODUCT", 356, 358], ["PB2", "GENE_OR_GENE_PRODUCT", 364, 367], ["four virus subtypes", "ORGANISM", 379, 398], ["H1N1, H2N2, H3N2", "ORGANISM", 400, 416], ["H5N1", "ORGANISM", 422, 426], ["human", "ORGANISM", 454, 459], ["dim2", "DNA", 169, 173], ["ENC", "DNA", 267, 270], ["HA, NA, NP, PA, and PB2 genes", "DNA", 344, 373], ["ENC", "DNA", 498, 501], ["influenza A virus", "SPECIES", 70, 87], ["influenza A virus", "SPECIES", 131, 148], ["influenza A virus", "SPECIES", 286, 303], ["human", "SPECIES", 454, 459], ["influenza A virus", "SPECIES", 70, 87], ["influenza A virus", "SPECIES", 131, 148], ["influenza A viruses", "SPECIES", 241, 260], ["influenza A virus", "SPECIES", 286, 303], ["human", "SPECIES", 454, 459], ["Thogoto and dhori viruses", "PROBLEM", 0, 25], ["the influenza A virus", "PROBLEM", 66, 87], ["the influenza A virus", "PROBLEM", 127, 148], ["the higher synonymous codon usage bias", "PROBLEM", 193, 231], ["the influenza A viruses group", "PROBLEM", 237, 266], ["influenza", "PROBLEM", 286, 295], ["The nucleotide sequences", "TEST", 312, 336], ["the HA", "PROBLEM", 340, 346], ["NA", "TEST", 348, 350], ["NP", "TEST", 352, 354], ["PA", "TEST", 356, 358], ["four virus subtypes", "PROBLEM", 379, 398], ["H1N1", "PROBLEM", 400, 404], ["H2N2", "PROBLEM", 406, 410], ["H3N2", "PROBLEM", 412, 416], ["H5N1", "PROBLEM", 422, 426], ["the ENC values", "TEST", 494, 508], ["dhori", "ANATOMY", 12, 17], ["viruses", "OBSERVATION", 18, 25], ["influenza", "OBSERVATION", 70, 79], ["virus", "OBSERVATION", 82, 87], ["influenza", "OBSERVATION", 131, 140], ["synonymous codon", "OBSERVATION", 204, 220]]], ["The detailed information for those sequences, including length, isolated region, year, and GenBank accession numbers for each virus subtype, are shown in Table 1 .", [["those sequences", "TEST", 29, 44], ["each virus subtype", "PROBLEM", 121, 139]]], ["In HA gene, H1N1 subtypes from both Asia and Europe showed the lowest ENC values, and H3N2 subtypes revealed the highest score.", [["HA", "GENE_OR_GENE_PRODUCT", 3, 5], ["HA gene", "DNA", 3, 10], ["ENC", "DNA", 70, 73], ["H1N1 subtypes", "PROBLEM", 12, 25], ["the lowest ENC values", "TEST", 59, 80], ["H3N2 subtypes", "PROBLEM", 86, 99], ["H1N1", "OBSERVATION", 12, 16]]], ["ENC represents the effective number of codons in each gene, ranging between 20 and 61.", [["ENC", "DNA", 0, 3]]], ["So the ENC values greater than 20 means that more than one codon is used for each amino acid, and if the ENC value is 61, then it means that all the synonymous codon are used in equal frequency.", [["amino acid", "CHEMICAL", 82, 92], ["amino acid", "CHEMICAL", 82, 92], ["amino acid", "AMINO_ACID", 82, 92], ["ENC", "DNA", 7, 10], ["the ENC values", "TEST", 3, 17], ["each amino acid", "TEST", 77, 92], ["the ENC value", "TEST", 101, 114], ["the synonymous codon", "TREATMENT", 145, 165], ["synonymous codon", "OBSERVATION", 149, 165]]], ["HA genes represented the differences among four different HA subtypes, including H1, H2, H3, and H5, but H1N1 subtype which was isolated from Switzerland in 1999 showed higher ENC value, with showing similar value with H2N2 subtype which was isolated from Germany in 1964.", [["HA", "GENE_OR_GENE_PRODUCT", 0, 2], ["H1", "GENE_OR_GENE_PRODUCT", 81, 83], ["H2", "GENE_OR_GENE_PRODUCT", 85, 87], ["H3", "GENE_OR_GENE_PRODUCT", 89, 91], ["H5", "GENE_OR_GENE_PRODUCT", 97, 99], ["but H1N1 subtype", "ORGANISM", 101, 117], ["HA genes", "DNA", 0, 8], ["ENC", "DNA", 176, 179], ["HA genes", "PROBLEM", 0, 8], ["four different HA subtypes", "PROBLEM", 43, 69], ["H1", "PROBLEM", 81, 83], ["H2", "PROBLEM", 85, 87], ["H3", "PROBLEM", 89, 91], ["H5", "PROBLEM", 97, 99], ["H1N1 subtype", "PROBLEM", 105, 117], ["higher ENC value", "PROBLEM", 169, 185], ["H2N2 subtype", "PROBLEM", 219, 231]]], ["In NA gene, the ENC values were divided into two groups by their NA subtypes, such as N1 and N2, and NA gene which was isolated from South Africa in 1997 showed the lowest ENC value.ENC patterns among influenza A virus subtypesIn NP gene, H3N2 subtypes which were isolated from Asian country (A/HK/1774/1999) showed the dramatic differences from that from European country, with showing the lowest ENC value, 47.8.", [["NA", "GENE_OR_GENE_PRODUCT", 101, 103], ["influenza A virus subtypesIn NP", "ORGANISM", 201, 232], ["H3N2 subtypes", "ORGANISM", 239, 252], ["NA gene", "DNA", 3, 10], ["ENC", "DNA", 16, 19], ["N1 and N2, and NA gene", "DNA", 86, 108], ["ENC", "DNA", 172, 175], ["ENC", "DNA", 182, 185], ["influenza A virus", "SPECIES", 201, 218], ["influenza A virus", "SPECIES", 201, 218], ["A/HK/1774/1999", "SPECIES", 293, 307], ["the ENC values", "TEST", 12, 26], ["NA gene", "TEST", 101, 108], ["influenza", "PROBLEM", 201, 210], ["H3N2 subtypes", "PROBLEM", 239, 252], ["the lowest ENC value", "TEST", 387, 407], ["dramatic", "OBSERVATION_MODIFIER", 320, 328]]], ["Moreover, there were some differences in the order of ENC values between H3N2 subtypes from Asia (A/HK/1774/1999) and from Europe (A/Switzerland/9243/1999) in PA and PB2 genes when other subtypes of Europe maintained the order of ENC values like those of Asian countries.", [["H3N2", "ORGANISM", 73, 77], ["PA", "GENE_OR_GENE_PRODUCT", 159, 161], ["ENC", "DNA", 54, 57], ["PB2 genes", "DNA", 166, 175], ["A/HK/1774/1999)", "SPECIES", 98, 113], ["ENC values", "TEST", 54, 64], ["ENC values", "TREATMENT", 230, 240]]], ["This kind of difference was also continued in the following synonymous codon usage analysis.Correspondence analysis (CA) among influenza A virus subtypesUsing the RSCU values for each gene in the four influenza A virus subtypes, we also performed a correspondence analysis to determine the codon usage patterns among the H1N1, H2N2, H3N2, and H5N1 subtypes ( Figure 4 ).", [["influenza A virus", "ORGANISM", 127, 144], ["RSCU", "CANCER", 163, 167], ["influenza A virus", "ORGANISM", 201, 218], ["H2N2, H3N2", "ORGANISM", 327, 337], ["RSCU", "DNA", 163, 167], ["influenza A virus", "SPECIES", 127, 144], ["influenza A virus", "SPECIES", 201, 218], ["influenza A virus", "SPECIES", 127, 144], ["influenza A virus", "SPECIES", 201, 218], ["Correspondence analysis", "TEST", 92, 115], ["CA) among influenza A virus", "PROBLEM", 117, 144], ["a correspondence analysis", "TEST", 247, 272], ["the H1N1", "PROBLEM", 317, 325], ["H2N2", "PROBLEM", 327, 331], ["H3N2", "PROBLEM", 333, 337]]], ["All these sequences were isolated from human population.", [["human", "ORGANISM", 39, 44], ["human", "SPECIES", 39, 44], ["human", "SPECIES", 39, 44], ["All these sequences", "TEST", 0, 19]]], ["For the HA gene, all the subtypes were distributed in the four quadrants of the correspondence plot, except for the H1N1 subtype isolated from Asia in 2002.", [["HA", "GENE_OR_GENE_PRODUCT", 8, 10], ["HA gene", "DNA", 8, 15], ["the HA gene", "PROBLEM", 4, 15], ["the H1N1 subtype", "PROBLEM", 112, 128], ["H1N1", "OBSERVATION", 116, 120]]], ["But both two H1N1 subtype genes showed the similar low values on the basis of the dim1.", [["dim1", "GENE_OR_GENE_PRODUCT", 82, 86], ["H1N1 subtype genes", "DNA", 13, 31], ["dim1", "DNA", 82, 86], ["H1N1", "OBSERVATION", 13, 17], ["similar", "OBSERVATION_MODIFIER", 43, 50], ["low values", "OBSERVATION_MODIFIER", 51, 61]]], ["This was reasonable because each subtype had different HA types, such as H1, H2, H3, and H5, respectively ( Figure 4A ).", [["H3", "GENE_OR_GENE_PRODUCT", 81, 83], ["H1", "PROTEIN", 73, 75], ["H2", "PROTEIN", 77, 79], ["H3", "PROTEIN", 81, 83], ["H5", "PROTEIN", 89, 91], ["different HA types", "PROBLEM", 45, 63], ["H1, H2, H3, and H5", "PROBLEM", 73, 91]]], ["CA result of NA gene presented that subtypes which have the same type of NA gene, such as N1 and N2, were grouped together on the basis of the dim 1 ( Figure 4B ).", [["NA", "CHEMICAL", 13, 15], ["N2", "CHEMICAL", 97, 99], ["CA", "GENE_OR_GENE_PRODUCT", 0, 2], ["NA", "GENE_OR_GENE_PRODUCT", 73, 75], ["NA gene", "DNA", 13, 20], ["NA gene", "DNA", 73, 80], ["N1", "DNA", 90, 92], ["N2", "DNA", 97, 99], ["dim 1", "DNA", 143, 148], ["CA", "TEST", 0, 2], ["NA gene", "PROBLEM", 13, 20], ["NA gene", "OBSERVATION_MODIFIER", 13, 20]]], ["Unlike the H2N2 and H3N2 subtypes, however, the H5N1 and H1N1 subtypes were located on the different quadrant along with the dim 2.", [["H3N2 subtypes", "ORGANISM", 20, 33], ["H5N1", "ORGANISM", 48, 52], ["the H2N2 and H3N2 subtypes", "PROBLEM", 7, 33], ["the H5N1 and H1N1 subtypes", "PROBLEM", 44, 70], ["H2N2", "OBSERVATION", 11, 15], ["H3N2", "OBSERVATION", 20, 24], ["H5N1", "OBSERVATION", 48, 52], ["H1N1", "OBSERVATION", 57, 61], ["different", "ANATOMY_MODIFIER", 91, 100], ["quadrant", "ANATOMY_MODIFIER", 101, 109], ["dim", "OBSERVATION", 125, 128]]], ["In both HA and NA genes, there were no significant differences among the isolated regions, including Asia, Europe and Africa.", [["HA and NA genes", "DNA", 8, 23], ["Africa", "PROBLEM", 118, 124], ["NA genes", "ANATOMY", 15, 23], ["no", "UNCERTAINTY", 36, 38], ["significant", "OBSERVATION_MODIFIER", 39, 50]]], ["In NP, PA and PB2 genes, H3N2 subtype showed different patterns between Asian and European genes, and these results were also appeared in the previous ENC analysis.", [["PA", "GENE_OR_GENE_PRODUCT", 7, 9], ["PB2", "GENE_OR_GENE_PRODUCT", 14, 17], ["NP, PA and PB2 genes", "DNA", 3, 23], ["ENC", "DNA", 151, 154], ["PA and PB2 genes", "TEST", 7, 23], ["H3N2 subtype", "PROBLEM", 25, 37], ["the previous ENC analysis", "TEST", 138, 163], ["H3N2", "OBSERVATION", 25, 29]]], ["Except for the H3N2 subtype genes isolated from Asian countries, H1N1, H2N2, and H3N2 subtypes were located on the opposite side from H5N1 subtype in NP, PA and PB2 genes (Figures 4C, D, E) .DiscussionHuge amounts of genomic data have been collected and distributed on the Web by organizations such as the U.S. National Center for Biotechnology Information (NCBI) and the European Bioinformatics Institute (EBI).", [["H3N2 subtype", "ORGANISM", 15, 27], ["H1N1, H2N2", "ORGANISM", 65, 75], ["H3N2 subtypes", "ORGANISM", 81, 94], ["PA", "GENE_OR_GENE_PRODUCT", 154, 156], ["H3N2 subtype genes", "DNA", 15, 33], ["NP, PA and PB2 genes", "DNA", 150, 170], ["the H3N2 subtype genes", "PROBLEM", 11, 33], ["H1N1", "PROBLEM", 65, 69], ["H2N2", "PROBLEM", 71, 75], ["H3N2 subtypes", "PROBLEM", 81, 94], ["H5N1 subtype in NP", "PROBLEM", 134, 152], ["PA", "TEST", 154, 156], ["Figures", "TEST", 172, 179], ["genomic data", "TEST", 217, 229], ["H5N1", "OBSERVATION", 134, 138]]], ["The NCBI regularly distributes genomic data sets as GenBank flat files via their ftp server.", [["ftp", "GENE_OR_GENE_PRODUCT", 81, 84], ["NCBI", "DNA", 4, 8], ["ftp server", "DNA", 81, 91]]], ["We collected the most recent version (version 151) of the GenBank flat files from the NCBI and extracted target sequences from the files by using Java codes.", [["the NCBI", "TEST", 82, 90]]], ["This study was designed to perform genomic analysis in two steps.", [["This study", "TEST", 0, 10], ["genomic analysis", "TEST", 35, 51]]], ["The overall RSCU patterns analysis of the five virus species in the orthomyxoviridae family was conducted first, and then, four subtypes of influenza A virus which were isolated from human population were analyzed to determine the synonymous codon usage patterns more intensively.", [["influenza A virus", "DISEASE", 140, 157], ["orthomyxoviridae", "CANCER", 68, 84], ["influenza A virus", "ORGANISM", 140, 157], ["human", "ORGANISM", 183, 188], ["influenza A virus", "SPECIES", 140, 157], ["human", "SPECIES", 183, 188], ["influenza A virus", "SPECIES", 140, 157], ["human", "SPECIES", 183, 188], ["the five virus species", "PROBLEM", 38, 60], ["influenza A virus", "PROBLEM", 140, 157], ["synonymous codon", "OBSERVATION", 231, 247]]], ["Virus species in the orthomyxoviridae family were classified very well by their synonymous codon usage patterns ( Figure 2 ).", [["Virus species", "ORGANISM", 0, 13], ["orthomyxoviridae", "GENE_OR_GENE_PRODUCT", 21, 37], ["Virus species", "PROBLEM", 0, 13]]], ["The influenza A virus group of viruses showed the lowest codon usage bias in the correspondence analysis.", [["influenza A virus", "ORGANISM", 4, 21], ["influenza A virus group", "SPECIES", 4, 27], ["influenza A virus", "SPECIES", 4, 21], ["The influenza A virus group of viruses", "PROBLEM", 0, 38], ["the correspondence analysis", "TEST", 77, 104]]], ["Pandemic diseases caused by RNA viruses, including SARS coronavirus and avian influenza A virus, have occurred worldwide during the 21st century.", [["Pandemic diseases", "DISEASE", 0, 17], ["SARS coronavirus", "DISEASE", 51, 67], ["avian influenza A virus", "DISEASE", 72, 95], ["SARS coronavirus", "ORGANISM", 51, 67], ["avian influenza A virus", "ORGANISM", 72, 95], ["SARS coronavirus", "SPECIES", 51, 67], ["avian influenza A virus", "SPECIES", 72, 95], ["SARS coronavirus", "SPECIES", 51, 67], ["avian influenza A virus", "SPECIES", 72, 95], ["Pandemic diseases", "PROBLEM", 0, 17], ["RNA viruses", "PROBLEM", 28, 39], ["SARS coronavirus", "PROBLEM", 51, 67], ["avian influenza A virus", "PROBLEM", 72, 95], ["RNA viruses", "OBSERVATION", 28, 39]]], ["These two pandemic viruses are believed to have originated through the transfer of nonhuman virus species to humans.", [["nonhuman virus species", "ORGANISM", 83, 105], ["humans", "ORGANISM", 109, 115], ["humans", "SPECIES", 109, 115], ["humans", "SPECIES", 109, 115], ["These two pandemic viruses", "PROBLEM", 0, 26], ["nonhuman virus species", "PROBLEM", 83, 105], ["pandemic", "OBSERVATION_MODIFIER", 10, 18], ["viruses", "OBSERVATION", 19, 26]]], ["According to Subbarao and Shaw [2] and Puthavathana et al. [1] , pandemic avian flu viruses appear to have crossed the species barrier, moving from avian hosts to humans.", [["flu viruses", "DISEASE", 80, 91], ["pandemic", "ORGANISM", 65, 73], ["avian flu viruses", "ORGANISM", 74, 91], ["humans", "ORGANISM", 163, 169], ["avian flu viruses", "SPECIES", 74, 91], ["humans", "SPECIES", 163, 169], ["pandemic avian flu viruses", "SPECIES", 65, 91], ["humans", "SPECIES", 163, 169], ["pandemic avian flu viruses", "PROBLEM", 65, 91]]], ["Table 1 .DiscussionAfter successfully transferring to the new host, the viruses were able to temporarily bypass the host immune response because the new host had no information about the new virus species.", [["the new virus species", "PROBLEM", 183, 204]]], ["Among the virus species in the orthomyxoviridae family, the influenza A virus group revealed the lowest synonymous codon usage bias in our result, indicating that compared to other viruses in the orthomyxoviridae family, influenza A viruses are better able to adapt to new hosts with different synonymous codon usage environments.", [["influenza A virus", "ORGANISM", 60, 77], ["orthomyxoviridae", "GENE_OR_GENE_PRODUCT", 196, 212], ["influenza A viruses", "ORGANISM", 221, 240], ["influenza A virus group", "SPECIES", 60, 83], ["influenza A virus", "SPECIES", 60, 77], ["influenza A viruses", "SPECIES", 221, 240], ["the virus species", "PROBLEM", 6, 23], ["the influenza A virus group", "TEST", 56, 83], ["influenza A viruses", "PROBLEM", 221, 240], ["different synonymous codon usage environments", "TREATMENT", 284, 329], ["virus species", "OBSERVATION", 10, 23], ["synonymous codon", "OBSERVATION", 104, 120], ["synonymous codon", "OBSERVATION", 294, 310]]], ["Many previous studies have reported that every bacteria and higher organism has its own synonymous codon usage pattern [12] [13] [14] [15] .", [["Many previous studies", "TEST", 0, 21], ["every bacteria", "PROBLEM", 41, 55], ["higher organism", "PROBLEM", 60, 75]]], ["According to a previous study, the influenza B and influenza C virus groups do not usually infect nonhuman hosts, except for swine species, and also do not exhibit antigenic shift [8] .DiscussionAmong the influenza A virus envelope proteins, the HA and NA glycoproteins evoke protective immune responses in infected persons.", [["influenza B", "DISEASE", 35, 46], ["influenza B", "ORGANISM", 35, 46], ["influenza C virus", "ORGANISM", 51, 68], ["nonhuman", "ORGANISM", 98, 106], ["influenza A virus", "ORGANISM", 205, 222], ["HA", "GENE_OR_GENE_PRODUCT", 246, 248], ["NA glycoproteins", "GENE_OR_GENE_PRODUCT", 253, 269], ["persons", "ORGANISM", 316, 323], ["influenza A virus envelope proteins", "PROTEIN", 205, 240], ["HA and NA glycoproteins", "PROTEIN", 246, 269], ["influenza C virus", "SPECIES", 51, 68], ["swine", "SPECIES", 125, 130], ["influenza A virus", "SPECIES", 205, 222], ["persons", "SPECIES", 316, 323], ["influenza C virus", "SPECIES", 51, 68], ["swine", "SPECIES", 125, 130], ["influenza A virus", "SPECIES", 205, 222], ["a previous study", "TEST", 13, 29], ["the influenza B", "PROBLEM", 31, 46], ["influenza C virus groups", "PROBLEM", 51, 75], ["swine species", "PROBLEM", 125, 138], ["the influenza A virus envelope proteins", "TREATMENT", 201, 240], ["the HA", "PROBLEM", 242, 248], ["NA glycoproteins", "TREATMENT", 253, 269]]], ["Influenza A viruses usually exhibit antigenic drift by changing their HA and NA types in a population, thereby disturbing the host immune system.", [["Influenza A viruses", "ORGANISM", 0, 19], ["Influenza A viruses", "SPECIES", 0, 19], ["Influenza A viruses", "SPECIES", 0, 19], ["Influenza A viruses", "PROBLEM", 0, 19], ["antigenic drift", "PROBLEM", 36, 51], ["antigenic drift", "OBSERVATION", 36, 51]]], ["Although the most subtypes of influenza A viruses cause minor illness in human beings, they also can lead to severe cases of pneumonia or death, as was the case in the 1918 pandemic of the Spanish flu H1N1 subtype [25] .", [["influenza A viruses", "DISEASE", 30, 49], ["pneumonia", "DISEASE", 125, 134], ["death", "DISEASE", 138, 143], ["influenza A viruses", "ORGANISM", 30, 49], ["human", "ORGANISM", 73, 78], ["human", "SPECIES", 73, 78], ["flu H1N1", "SPECIES", 197, 205], ["influenza A viruses", "SPECIES", 30, 49], ["human", "SPECIES", 73, 78], ["Spanish flu H1N1", "SPECIES", 189, 205], ["influenza", "PROBLEM", 30, 39], ["pneumonia", "PROBLEM", 125, 134], ["death", "PROBLEM", 138, 143], ["most subtypes", "OBSERVATION_MODIFIER", 13, 26], ["influenza", "OBSERVATION", 30, 39], ["pneumonia", "OBSERVATION", 125, 134]]], ["Antigenic shifts in the influenza A virus population have produced new subtypes associated with influenza epidemics or pandemics, such as those that occurred in 1918 (Spanish flu), 1957 (Asian flu), and 1968 (Hong Kong flu).", [["influenza A virus", "DISEASE", 24, 41], ["influenza epidemics", "DISEASE", 96, 115], ["influenza A virus", "ORGANISM", 24, 41], ["influenza A virus", "SPECIES", 24, 41], ["influenza A virus", "SPECIES", 24, 41], ["Asian flu)", "SPECIES", 187, 197], ["Hong Kong flu", "SPECIES", 209, 222], ["Antigenic shifts", "PROBLEM", 0, 16], ["the influenza A virus population", "PROBLEM", 20, 52], ["influenza epidemics", "PROBLEM", 96, 115], ["pandemics", "PROBLEM", 119, 128], ["influenza", "OBSERVATION", 24, 33], ["new subtypes", "OBSERVATION_MODIFIER", 67, 79], ["influenza", "OBSERVATION", 96, 105]]], ["The antigenic shift that occurred in 1957 involved changes in the structures of both HA and NA (H1N1 fi H2N2), that in 1968 involved only one (H2N2 fi H3N2) [8] .", [["NA", "CHEMICAL", 92, 94], ["H1N1 fi H2N2", "CHEMICAL", 96, 108], ["NA (H1N1 fi H2N2", "ORGANISM", 92, 108], ["H2N2 fi H3N2", "ORGANISM", 143, 155], ["H1N1 fi H2N2", "SPECIES", 96, 108], ["H2N2 fi H3N2", "SPECIES", 143, 155], ["The antigenic shift", "PROBLEM", 0, 19], ["both HA and NA (H1N1 fi H2N2", "PROBLEM", 80, 108], ["antigenic shift", "OBSERVATION", 4, 19]]], ["Therefore, we chose to compare the synonymous codon usage patterns in these four subtypes, including H1N1, H2N2, N3N2, and H5N1 subtypes, in this study.DiscussionThe ENC values on both HA and NA genes represented their HA and NA types well, and this result reveals that each influenza A virus subtype uses different in codon usage patterns as well as the amino acid compositions when it synthesizes HA and NA glycoproteins (Figure 3 ).", [["amino acid", "CHEMICAL", 355, 365], ["amino acid", "CHEMICAL", 355, 365], ["H5N1", "ORGANISM", 123, 127], ["HA", "GENE_OR_GENE_PRODUCT", 185, 187], ["influenza A virus", "ORGANISM", 275, 292], ["amino acid", "AMINO_ACID", 355, 365], ["NA glycoproteins", "GENE_OR_GENE_PRODUCT", 406, 422], ["ENC", "DNA", 166, 169], ["HA and NA genes", "DNA", 185, 200], ["HA", "PROTEIN", 399, 401], ["NA glycoproteins", "PROTEIN", 406, 422], ["influenza A virus", "SPECIES", 275, 292], ["H1N1", "PROBLEM", 101, 105], ["H2N2", "TEST", 107, 111], ["N3N2", "TEST", 113, 117], ["H5N1 subtypes", "PROBLEM", 123, 136], ["this study", "TEST", 141, 151], ["The ENC values", "TEST", 162, 176], ["each influenza A virus subtype", "PROBLEM", 270, 300], ["the amino acid compositions", "TREATMENT", 351, 378], ["synonymous codon", "OBSERVATION", 35, 51], ["four subtypes", "OBSERVATION_MODIFIER", 76, 89], ["H1N1", "OBSERVATION", 101, 105], ["H5N1 subtypes", "OBSERVATION", 123, 136]]], ["In NP, PA and PB2 genes, H3N2 subtypes which were isolated from Asia, especially Hong Kong in 1999 showed different patterns with same subtypes from Switzerland and France in 1999 and 1997, respectively.", [["PA", "GENE_OR_GENE_PRODUCT", 7, 9], ["PB2", "GENE_OR_GENE_PRODUCT", 14, 17], ["H3N2 subtypes", "ORGANISM", 25, 38], ["NP, PA and PB2 genes", "DNA", 3, 23], ["H3N2 subtypes", "PROBLEM", 25, 38], ["H3N2", "OBSERVATION", 25, 29]]], ["In HA and NA genes of H3N2 subtype from Hong Kong in 1999, however, did not showed this distinct pattern when they were compared with the H3N2 subtypes from European countries (data not shown).", [["NA", "CHEMICAL", 10, 12], ["H3N2 subtype", "ORGANISM", 22, 34], ["HA and NA genes", "DNA", 3, 18], ["HA", "PROBLEM", 3, 5], ["H3N2", "PROBLEM", 22, 26], ["the H3N2 subtypes", "PROBLEM", 134, 151], ["NA genes", "OBSERVATION_MODIFIER", 10, 18], ["H3N2", "OBSERVATION", 22, 26]]], ["According to Gregory et al. [26] who sequenced this H3N2 subtype influenza A virus first, this virus (A/ HK/1774/99) was isolated from 10-month-old girl, and it was antigenically related to early (1968) (1969) (1970) (1971) (1972) (1973) (1974) (1975) human and swine H3N2 viruses.", [["influenza A", "DISEASE", 65, 76], ["swine H3N2 viruses", "DISEASE", 262, 280], ["H3N2 subtype influenza A virus", "ORGANISM", 52, 82], ["A/ HK/1774/99", "ORGANISM", 102, 115], ["girl", "ORGANISM", 148, 152], ["human", "ORGANISM", 252, 257], ["swine H3N2 viruses", "ORGANISM", 262, 280], ["influenza A virus", "SPECIES", 65, 82], ["girl", "SPECIES", 148, 152], ["human", "SPECIES", 252, 257], ["swine H3N2 viruses", "SPECIES", 262, 280], ["influenza A virus", "SPECIES", 65, 82], ["A/ HK/1774/99", "SPECIES", 102, 115], ["human", "SPECIES", 252, 257], ["swine H3N2 viruses", "SPECIES", 262, 280], ["this H3N2 subtype influenza A virus", "PROBLEM", 47, 82], ["this virus", "TEST", 90, 100], ["A/ HK", "TEST", 102, 107], ["human and swine H3N2 viruses", "PROBLEM", 252, 280], ["H3N2 viruses", "OBSERVATION", 268, 280]]], ["But unlike other H3N2 human viruses, it was clearly distinguishable from human H3N2 viruses isolated since 1979 and avian H3 viruses, and it was closely related in its genetic characteristics to H3N2 viruses prevalent in pigs in Europe during the 1990s.", [["H3N2 viruses", "DISEASE", 79, 91], ["H3N2 viruses", "DISEASE", 195, 207], ["H3N2", "ORGANISM", 17, 21], ["human", "ORGANISM", 22, 27], ["human H3N2 viruses", "ORGANISM", 73, 91], ["avian H3 viruses", "ORGANISM", 116, 132], ["H3N2 viruses", "ORGANISM", 195, 207], ["pigs", "ORGANISM", 221, 225], ["H3N2", "SPECIES", 17, 21], ["human", "SPECIES", 22, 27], ["human", "SPECIES", 73, 78], ["pigs", "SPECIES", 221, 225], ["human", "SPECIES", 22, 27], ["human H3N2 viruses", "SPECIES", 73, 91], ["H3 viruses", "SPECIES", 122, 132], ["pigs", "SPECIES", 221, 225], ["other H3N2 human viruses", "PROBLEM", 11, 35], ["human H3N2 viruses", "PROBLEM", 73, 91], ["avian H3 viruses", "PROBLEM", 116, 132], ["H3N2 viruses", "PROBLEM", 195, 207], ["H3N2", "OBSERVATION", 17, 21], ["viruses", "OBSERVATION", 28, 35], ["H3 viruses", "OBSERVATION", 122, 132]]], ["Pigs usually have the receptors for both human and avian influenza A virus HA glycoprotein, so they may act as an intermediate host in the emergence of novel human subtypes [27] .", [["Pigs", "ORGANISM", 0, 4], ["human", "ORGANISM", 41, 46], ["avian influenza A virus", "ORGANISM", 51, 74], ["HA glycoprotein", "GENE_OR_GENE_PRODUCT", 75, 90], ["human", "ORGANISM", 158, 163], ["HA glycoprotein", "PROTEIN", 75, 90], ["Pigs", "SPECIES", 0, 4], ["human", "SPECIES", 41, 46], ["avian influenza A virus", "SPECIES", 51, 74], ["human", "SPECIES", 158, 163], ["human", "SPECIES", 41, 46], ["avian influenza A virus", "SPECIES", 51, 74], ["human", "SPECIES", 158, 163], ["the receptors", "TREATMENT", 18, 31], ["avian influenza A virus HA glycoprotein", "TREATMENT", 51, 90]]], ["These distinguishable synonymous codon usage patterns of H3N2 subtype which was isolated from Hong Kong which were resulted in our study also proved this history very well (Figures 3, 4) , and, in addition to the serological tests, this synonymous codon usage analysis might to be a useful method to identify the non-human origin of the virus in genomic levels.", [["H3N2 subtype", "ORGANISM", 57, 69], ["H3N2 subtype", "PROBLEM", 57, 69], ["our study", "TEST", 127, 136], ["the serological tests", "TEST", 209, 230], ["this synonymous codon usage analysis", "PROBLEM", 232, 268], ["the virus in genomic levels", "PROBLEM", 333, 360], ["synonymous codon", "OBSERVATION", 22, 38], ["H3N2 subtype", "OBSERVATION", 57, 69], ["virus", "OBSERVATION", 337, 342]]], ["Actually, this H3N2 virus (A/HK/1774/99) also showed very similar codon usage patterns with H5N1 subtypes which are suspected to be transmitted from non-human species, avian species on the basis of the dim1 in CA plot ( Figure 4C , D, E).DiscussionIn conclusion, influenza A virus might have an advantage in transmitting from non-human origin to the human beings because they resulted to have the lowest synonymous codon usage bias than that of other species in the orthomyxoviridae family.", [["influenza A virus", "DISEASE", 263, 280], ["H3N2 virus", "ORGANISM", 15, 25], ["A/HK/1774/99", "ORGANISM", 27, 39], ["influenza A virus", "ORGANISM", 263, 280], ["non-human", "ORGANISM", 326, 335], ["human", "ORGANISM", 350, 355], ["orthomyxoviridae", "CANCER", 466, 482], ["dim1", "DNA", 202, 206], ["orthomyxoviridae family", "PROTEIN", 466, 489], ["H3N2 virus", "SPECIES", 15, 25], ["influenza A virus", "SPECIES", 263, 280], ["human", "SPECIES", 350, 355], ["H3N2 virus", "SPECIES", 15, 25], ["A/HK/1774/99", "SPECIES", 27, 39], ["influenza A virus", "SPECIES", 263, 280], ["human", "SPECIES", 350, 355], ["this H3N2 virus", "PROBLEM", 10, 25], ["A/HK", "TEST", 27, 31], ["H5N1 subtypes", "PROBLEM", 92, 105], ["non-human species", "PROBLEM", 149, 166], ["avian species", "PROBLEM", 168, 181], ["CA plot", "TEST", 210, 217], ["influenza A virus", "PROBLEM", 263, 280], ["similar codon", "OBSERVATION", 58, 71], ["H5N1 subtypes", "OBSERVATION", 92, 105], ["synonymous codon", "OBSERVATION", 404, 420]]], ["The CA result of the four subtypes of influenza A virus group showed that the viruses which were transmitted from the non-human origin to human population use the synonymous codons in a different manner when compared to those of other humanorigin viruses, so this distinguishable synonymous codon usage patterns in non-human origin viruses might be useful in determining the origin of influenza A viruses in genomic levels as well as the serological tests.DiscussionThanks to the public genome databases, such as NCBI, EBI, and DDBJ, it became possible to analyze the genetic patterns among each country.", [["CA", "GENE_OR_GENE_PRODUCT", 4, 6], ["influenza A virus", "ORGANISM", 38, 55], ["non-human", "ORGANISM", 118, 127], ["human", "ORGANISM", 138, 143], ["humanorigin viruses", "ORGANISM", 235, 254], ["non-human", "ORGANISM", 315, 324], ["influenza A viruses", "ORGANISM", 385, 404], ["public genome databases", "DNA", 480, 503], ["NCBI, EBI, and DDBJ", "DNA", 513, 532], ["influenza A virus group", "SPECIES", 38, 61], ["human", "SPECIES", 138, 143], ["influenza A virus", "SPECIES", 38, 55], ["human", "SPECIES", 138, 143], ["influenza A viruses", "SPECIES", 385, 404], ["The CA result", "TEST", 0, 13], ["influenza A virus group", "PROBLEM", 38, 61], ["the viruses", "PROBLEM", 74, 85], ["the synonymous codons", "TREATMENT", 159, 180], ["other humanorigin viruses", "PROBLEM", 229, 254], ["non-human origin viruses", "PROBLEM", 315, 339], ["influenza A viruses in genomic levels", "PROBLEM", 385, 422], ["the serological tests", "TEST", 434, 455], ["DDBJ", "TREATMENT", 528, 532], ["influenza", "OBSERVATION", 38, 47], ["viruses", "OBSERVATION", 78, 85], ["synonymous codons", "OBSERVATION", 163, 180], ["viruses", "OBSERVATION", 247, 254], ["synonymous codon", "OBSERVATION", 280, 296], ["influenza", "OBSERVATION", 385, 394]]], ["In addition to the classical epidemiological method, genetic epidemiology using bioinformatics techniques has become more and more important these days.", [["bioinformatics techniques", "TEST", 80, 105]]], ["But most of the available data sets were mainly provided from Asia, Europe, and America except for Africa.", [["Africa", "PROBLEM", 99, 105]]], ["According to the European Union authorities, Europe will be the next target for H5N1 avian flu in a near future, and the foothold for that pandemic would be Africa [4] .", [["H5N1 avian flu", "DISEASE", 80, 94], ["H5N1 avian", "ORGANISM", 80, 90], ["H5N1 avian flu", "SPECIES", 80, 94], ["H5N1 avian flu", "SPECIES", 80, 94], ["H5N1", "PROBLEM", 80, 84]]], ["So, it will be necessary to pay more attention to these African countries for protecting Europe from the pandemic diseases, such as avian flu or SARS (severe acute respiratory syndrome), which initially occurred in Asia.", [["avian flu", "DISEASE", 132, 141], ["SARS", "DISEASE", 145, 149], ["acute respiratory syndrome", "DISEASE", 158, 184], ["avian flu", "SPECIES", 132, 141], ["the pandemic diseases", "PROBLEM", 101, 122], ["SARS (severe acute respiratory syndrome", "PROBLEM", 145, 184], ["severe", "OBSERVATION_MODIFIER", 151, 157], ["acute", "OBSERVATION_MODIFIER", 158, 163], ["respiratory syndrome", "OBSERVATION", 164, 184]]]], "c7de9f8ba837bafbb19cc1ce00ecc51aa772b873": [["IntroductionFeline infectious peritonitis (FIP) is caused by the feline infectious peritonitis virus (FIPV), a feline coronavirus (FCoV) that arises by a mutation from the feline enteric coronavirus (FECV) (Vennema et al., 1995) .", [["infectious peritonitis", "DISEASE", 19, 41], ["FIP", "DISEASE", 43, 46], ["feline infectious peritonitis", "DISEASE", 65, 94], ["feline coronavirus", "DISEASE", 111, 129], ["feline enteric coronavirus", "DISEASE", 172, 198], ["feline infectious peritonitis virus", "ORGANISM", 65, 100], ["FIPV", "ORGANISM", 102, 106], ["feline coronavirus", "ORGANISM", 111, 129], ["FCoV", "CANCER", 131, 135], ["feline enteric coronavirus", "ORGANISM", 172, 198], ["FECV", "CANCER", 200, 204], ["feline infectious peritonitis virus", "SPECIES", 65, 100], ["feline coronavirus", "SPECIES", 111, 129], ["feline enteric coronavirus", "SPECIES", 172, 198], ["feline infectious peritonitis virus", "SPECIES", 65, 100], ["FIPV", "SPECIES", 102, 106], ["feline coronavirus", "SPECIES", 111, 129], ["FCoV", "SPECIES", 131, 135], ["feline enteric coronavirus", "SPECIES", 172, 198], ["FECV", "SPECIES", 200, 204], ["IntroductionFeline infectious peritonitis", "PROBLEM", 0, 41], ["FIP", "PROBLEM", 43, 46], ["the feline infectious peritonitis virus", "PROBLEM", 61, 100], ["a feline coronavirus (FCoV", "PROBLEM", 109, 135], ["a mutation", "PROBLEM", 152, 162], ["infectious", "OBSERVATION_MODIFIER", 19, 29], ["peritonitis", "OBSERVATION", 30, 41], ["FIP", "OBSERVATION", 43, 46], ["feline", "OBSERVATION_MODIFIER", 65, 71], ["infectious", "OBSERVATION_MODIFIER", 72, 82], ["peritonitis", "OBSERVATION", 83, 94], ["enteric coronavirus", "ANATOMY", 179, 198]]], ["When FCoV is present in a cattery, it is likely to infect 90-100% of the cats and all the cats are likely to be seropositive (Addie et al., 2000) .", [["FCoV", "CHEMICAL", 5, 9], ["FCoV", "GENE_OR_GENE_PRODUCT", 5, 9], ["cats", "ORGANISM", 73, 77], ["cats", "ORGANISM", 90, 94], ["FCoV", "PROTEIN", 5, 9], ["cats", "SPECIES", 73, 77], ["cats", "SPECIES", 90, 94], ["FCoV", "OBSERVATION", 5, 9], ["likely to", "UNCERTAINTY", 41, 50]]], ["The poor specificity of serological tests often induces use of other clinico-pathological changes as diagnostic markers of FIP.", [["FIP", "DISEASE", 123, 126], ["serological tests", "TEST", 24, 41], ["FIP", "PROBLEM", 123, 126]]], ["Clinical findings are often non-specific, especially in dry forms, and the diagnosis of FIP needs to be supported by the presence of non-regenerative anaemia, neutrophilic leucocytosis, lymphopenia, hyperproteinaemia, increased total-, a 2 -and c-globulins (Pedersen, 1995) .", [["neutrophilic", "ANATOMY", 159, 171], ["FIP", "DISEASE", 88, 91], ["anaemia", "DISEASE", 150, 157], ["neutrophilic leucocytosis", "DISEASE", 159, 184], ["lymphopenia", "DISEASE", 186, 197], ["hyperproteinaemia", "DISEASE", 199, 216], ["c-globulins", "SIMPLE_CHEMICAL", 245, 256], ["FIP", "PROBLEM", 88, 91], ["non-regenerative anaemia", "PROBLEM", 133, 157], ["neutrophilic leucocytosis", "PROBLEM", 159, 184], ["lymphopenia", "PROBLEM", 186, 197], ["hyperproteinaemia", "PROBLEM", 199, 216], ["non-specific", "OBSERVATION_MODIFIER", 28, 40], ["FIP", "OBSERVATION", 88, 91], ["non-regenerative", "OBSERVATION_MODIFIER", 133, 149], ["anaemia", "OBSERVATION", 150, 157], ["neutrophilic", "OBSERVATION_MODIFIER", 159, 171], ["leucocytosis", "OBSERVATION", 172, 184], ["lymphopenia", "OBSERVATION", 186, 197], ["increased", "OBSERVATION_MODIFIER", 218, 227]]], ["Unfortunately, some of these changes can also appear in cats as a consequence of chronic inflammation, stress or crowding (Kristensen and Barsanti, 1977; Jain, 1993) : in the case of fever, neurological signs, hepatic or renal failure because of diseases other than FIP, cats with the above-mentioned laboratory alterations may be erroneously suspected to have FIP and isolated from the colony (Addie and Jarrett, 1995) or euthanasized.IntroductionIn this paper, the prevalence of haematological and electrophoretic changes in multicat environments was determined by a retrospective analysis of data obtained from blood samples collected during 1999 from cats without symptoms consistent with FIP living in catteries with different prevalence of FIP.", [["neurological", "ANATOMY", 190, 202], ["hepatic", "ANATOMY", 210, 217], ["renal", "ANATOMY", 221, 226], ["colony", "ANATOMY", 387, 393], ["haematological", "ANATOMY", 481, 495], ["blood samples", "ANATOMY", 614, 627], ["inflammation", "DISEASE", 89, 101], ["fever", "DISEASE", 183, 188], ["neurological signs", "DISEASE", 190, 208], ["hepatic or renal failure", "DISEASE", 210, 234], ["FIP", "DISEASE", 266, 269], ["FIP", "DISEASE", 361, 364], ["FIP", "DISEASE", 693, 696], ["FIP", "DISEASE", 746, 749], ["cats", "ORGANISM", 56, 60], ["hepatic", "ORGAN", 210, 217], ["renal", "ORGAN", 221, 226], ["cats", "ORGANISM", 271, 275], ["haematological", "CANCER", 481, 495], ["blood samples", "ORGANISM_SUBSTANCE", 614, 627], ["cats", "ORGANISM", 655, 659], ["cats", "SPECIES", 56, 60], ["cats", "SPECIES", 655, 659], ["chronic inflammation", "PROBLEM", 81, 101], ["stress", "PROBLEM", 103, 109], ["crowding", "PROBLEM", 113, 121], ["fever", "PROBLEM", 183, 188], ["neurological signs", "PROBLEM", 190, 208], ["hepatic or renal failure", "PROBLEM", 210, 234], ["diseases", "PROBLEM", 246, 254], ["FIP", "PROBLEM", 266, 269], ["FIP", "PROBLEM", 361, 364], ["haematological and electrophoretic changes", "PROBLEM", 481, 523], ["a retrospective analysis", "TEST", 567, 591], ["blood samples", "TEST", 614, 627], ["symptoms", "PROBLEM", 668, 676], ["FIP", "PROBLEM", 693, 696], ["FIP", "PROBLEM", 746, 749], ["chronic", "OBSERVATION_MODIFIER", 81, 88], ["inflammation", "OBSERVATION", 89, 101], ["crowding", "OBSERVATION_MODIFIER", 113, 121], ["fever", "OBSERVATION", 183, 188], ["hepatic", "ANATOMY", 210, 217], ["renal", "ANATOMY", 221, 226], ["failure", "OBSERVATION", 227, 234], ["diseases", "OBSERVATION", 246, 254], ["consistent with", "UNCERTAINTY", 677, 692], ["FIP", "OBSERVATION", 693, 696], ["FIP", "OBSERVATION", 746, 749]]], ["Based on these data, internal ranges of each parameter were calculated in all the colonies (Lumsden, 2000) in order to design the laboratory profile of each cattery and to look for any possible difference between these ranges and the reference ones.", [["colonies", "ANATOMY", 82, 90], ["these data", "TEST", 9, 19]]], ["Results from cats with symptoms suggestive of FIP recorded in the same catteries since 1997 were also examined in order to check if the use of internal ranges would affect the possibility to correctly diagnose the disease.Animals and study designThis study was performed on six catteries with different characteristics of management, health status and prevalence of FIP, according to the clinical and pathological data recorded since 1997 (Table 1 ).", [["FIP", "DISEASE", 46, 49], ["FIP", "DISEASE", 366, 369], ["cats", "ORGANISM", 13, 17], ["cats", "SPECIES", 13, 17], ["symptoms", "PROBLEM", 23, 31], ["FIP", "PROBLEM", 46, 49], ["the disease", "PROBLEM", 210, 221], ["This study", "TEST", 246, 256], ["FIP", "TREATMENT", 366, 369], ["FIP", "OBSERVATION", 46, 49], ["disease", "OBSERVATION", 214, 221]]], ["In particular, the management was considered as open, closed or mixed in case of frequent (more than once a month), rare (less than once a year) or occasional (about once every 3 or 4 months) contacts with other cats, respectively; the health status was classified as good or poor, based on the occurrence of sporadic cases or of repeated outbreaks of infectious diseases (rhinoconjunctivitis, gastroenteritis); the prevalence of FIP was considered as low or high if less or more than 10% of the cats living in the colony died because of FIP since 1997.Animals and study designIn each cattery, two groups of animals were sampled.Group AFour to seven cats without symptoms consistent with FIP were chosen in each cattery in order to sample a representative population of the whole group in terms of breed, sex and age.", [["colony", "ANATOMY", 515, 521], ["infectious diseases", "DISEASE", 352, 371], ["rhinoconjunctivitis", "DISEASE", 373, 392], ["gastroenteritis", "DISEASE", 394, 409], ["FIP", "DISEASE", 430, 433], ["FIP", "DISEASE", 538, 541], ["FIP", "DISEASE", 688, 691], ["cats", "ORGANISM", 212, 216], ["FIP", "ORGANISM", 430, 433], ["cats", "ORGANISM", 496, 500], ["animals", "ORGANISM", 608, 615], ["cats", "ORGANISM", 650, 654], ["cats", "SPECIES", 496, 500], ["cats", "SPECIES", 650, 654], ["sporadic cases", "PROBLEM", 309, 323], ["infectious diseases", "PROBLEM", 352, 371], ["rhinoconjunctivitis", "PROBLEM", 373, 392], ["gastroenteritis", "PROBLEM", 394, 409], ["FIP", "PROBLEM", 430, 433], ["FIP", "PROBLEM", 538, 541], ["symptoms", "PROBLEM", 663, 671], ["FIP", "PROBLEM", 688, 691], ["FIP", "OBSERVATION", 430, 433], ["FIP", "OBSERVATION", 538, 541]]], ["Cats with symptoms not consistent with FIP (ocular discharges, coughing, haemorragic diarrhoea, vomiting, gengivitis) were included in this group.", [["ocular", "ANATOMY", 44, 50], ["FIP", "DISEASE", 39, 42], ["ocular discharges", "DISEASE", 44, 61], ["coughing", "DISEASE", 63, 71], ["haemorragic diarrhoea", "DISEASE", 73, 94], ["vomiting", "DISEASE", 96, 104], ["gengivitis", "DISEASE", 106, 116], ["symptoms", "PROBLEM", 10, 18], ["FIP", "PROBLEM", 39, 42], ["ocular discharges", "PROBLEM", 44, 61], ["coughing", "PROBLEM", 63, 71], ["haemorragic diarrhoea", "PROBLEM", 73, 94], ["vomiting", "PROBLEM", 96, 104], ["gengivitis", "PROBLEM", 106, 116], ["not consistent with", "UNCERTAINTY", 19, 38], ["FIP", "OBSERVATION", 39, 42], ["ocular", "ANATOMY", 44, 50]]], ["From each cat, blood was drawn from the jugular vein at the beginning of the study (T0) and after 30 (T30) and 60 days (T60).", [["blood", "ANATOMY", 15, 20], ["jugular vein", "ANATOMY", 40, 52], ["cat", "ORGANISM", 10, 13], ["blood", "ORGANISM_SUBSTANCE", 15, 20], ["jugular vein", "MULTI-TISSUE_STRUCTURE", 40, 52], ["the study", "TEST", 73, 82], ["jugular vein", "ANATOMY", 40, 52]]], ["During each sampling, all the cats of the cattery were visited and the owners were asked about any change in the management (e.g. introduction of new cats, participation to cat shows, etc.), about pathopysiological (e.g. pregnancies, parturitions) or pathological changes that occurred since the previous sampling, with particular emphasis on symptoms consistent with FIP.Group BFourteen cats with symptoms consistent with FIP (fever, weakness, ocular or neurological signs, cavitary effusions), recorded by us since 1997 to date, were included in this group.", [["ocular", "ANATOMY", 445, 451], ["neurological", "ANATOMY", 455, 467], ["cavitary effusions", "ANATOMY", 475, 493], ["parturitions", "DISEASE", 234, 246], ["FIP", "DISEASE", 368, 371], ["FIP", "DISEASE", 423, 426], ["fever", "DISEASE", 428, 433], ["weakness", "DISEASE", 435, 443], ["ocular or neurological signs", "DISEASE", 445, 473], ["cavitary effusions", "DISEASE", 475, 493], ["cats", "ORGANISM", 30, 34], ["cats", "ORGANISM", 150, 154], ["cat", "ORGANISM", 173, 176], ["cats", "ORGANISM", 388, 392], ["cats", "SPECIES", 30, 34], ["cats", "SPECIES", 388, 392], ["the management", "TREATMENT", 109, 123], ["new cats", "TREATMENT", 146, 154], ["pathopysiological (e.g. pregnancies, parturitions)", "PROBLEM", 197, 247], ["pathological changes", "PROBLEM", 251, 271], ["the previous sampling", "TEST", 292, 313], ["symptoms", "PROBLEM", 343, 351], ["FIP", "PROBLEM", 368, 371], ["symptoms", "PROBLEM", 398, 406], ["FIP", "PROBLEM", 423, 426], ["fever", "PROBLEM", 428, 433], ["weakness", "PROBLEM", 435, 443], ["ocular or neurological signs", "PROBLEM", 445, 473], ["cavitary effusions", "PROBLEM", 475, 493], ["consistent with", "UNCERTAINTY", 352, 367], ["FIP", "OBSERVATION", 368, 371], ["consistent with", "UNCERTAINTY", 407, 422], ["FIP", "OBSERVATION", 423, 426], ["ocular", "ANATOMY", 445, 451], ["cavitary", "OBSERVATION_MODIFIER", 475, 483], ["effusions", "OBSERVATION", 484, 493]]], ["In all these cases, the final diagnosis was obtained by serological tests, cytology of the effusions, post-mortem examinations or by complete recovery after antibiotic therapies.HaematologyBlood collected in ethylenediaminetetraacetic acid-coated tubes was used to perform a complete cell blood count using an automatic cell counter (SEAC, Firenze, Italy), a differential leucocyte count on May-Gru\u00a8nwald Giemsa stains and a reticulocyte count on brilliant cresyl blue stained smears (Jain, 1993) .Serology and serum protein electrohporesisSerum was obtained by centrifugation (15 min, 450 \u00b7 g) of blood samples collected in tubes without anticoagulant.", [["effusions", "ANATOMY", 91, 100], ["Blood", "ANATOMY", 189, 194], ["cell blood", "ANATOMY", 284, 294], ["cell", "ANATOMY", 320, 324], ["leucocyte", "ANATOMY", 372, 381], ["reticulocyte", "ANATOMY", 425, 437], ["serum", "ANATOMY", 511, 516], ["blood samples", "ANATOMY", 598, 611], ["tubes", "ANATOMY", 625, 630], ["effusions", "DISEASE", 91, 100], ["ethylenediaminetetraacetic acid-", "CHEMICAL", 208, 240], ["cresyl blue", "CHEMICAL", 457, 468], ["ethylenediaminetetraacetic acid-", "CHEMICAL", 208, 240], ["cresyl blue", "CHEMICAL", 457, 468], ["Blood", "ORGANISM_SUBSTANCE", 189, 194], ["ethylenediaminetetraacetic acid-", "SIMPLE_CHEMICAL", 208, 240], ["cell", "CELL", 284, 288], ["blood", "ORGANISM_SUBSTANCE", 289, 294], ["cell", "CELL", 320, 324], ["leucocyte", "CELL", 372, 381], ["reticulocyte", "CELL", 425, 437], ["cresyl blue", "SIMPLE_CHEMICAL", 457, 468], ["serum", "ORGANISM_SUBSTANCE", 511, 516], ["blood samples", "ORGANISM_SUBSTANCE", 598, 611], ["tubes", "ORGANISM_SUBSTANCE", 625, 630], ["serum protein", "PROTEIN", 511, 524], ["serological tests", "TEST", 56, 73], ["cytology", "TEST", 75, 83], ["the effusions", "PROBLEM", 87, 100], ["post-mortem examinations", "TEST", 102, 126], ["antibiotic therapies", "TREATMENT", 157, 177], ["HaematologyBlood", "TEST", 178, 194], ["ethylenediaminetetraacetic acid-coated tubes", "TREATMENT", 208, 252], ["a complete cell blood count", "TEST", 273, 300], ["a differential leucocyte count", "TEST", 357, 387], ["Giemsa stains", "TEST", 405, 418], ["a reticulocyte count", "TEST", 423, 443], ["brilliant cresyl blue", "TEST", 447, 468], ["Serology", "TEST", 498, 506], ["serum protein electrohporesisSerum", "TEST", 511, 545], ["blood samples", "TEST", 598, 611], ["anticoagulant", "TREATMENT", 639, 652], ["effusions", "OBSERVATION", 91, 100]]], ["Serology for feline immunodeficiency virus (FIV) and for feline leukaemia virus (FeLV) were performed by means of an ELISA test kit (SNAP, IDEXX Lab, Westbrook, MA, USA).", [["feline immunodeficiency virus", "DISEASE", 13, 42], ["feline leukaemia virus", "DISEASE", 57, 79], ["feline immunodeficiency virus", "ORGANISM", 13, 42], ["FIV", "ORGANISM", 44, 47], ["feline leukaemia virus", "ORGANISM", 57, 79], ["FeLV", "ORGANISM", 81, 85], ["feline immunodeficiency virus", "SPECIES", 13, 42], ["feline leukaemia virus", "SPECIES", 57, 79], ["feline immunodeficiency virus", "SPECIES", 13, 42], ["FIV", "SPECIES", 44, 47], ["feline leukaemia virus", "SPECIES", 57, 79], ["FeLV", "SPECIES", 81, 85], ["Serology", "TEST", 0, 8], ["feline immunodeficiency virus", "PROBLEM", 13, 42], ["feline leukaemia virus", "PROBLEM", 57, 79], ["an ELISA test", "TEST", 114, 127]]], ["Serology for Toxoplasma gondii was assessed using a latex agglutination test (Eiken Chemical Co. Ltd., Tokyo, Japan).Serology and serum protein electrohporesisTotal proteins were measured by a discrete analyser (Abbott VP, Abbott Lab, Irving, TX, USA) by the biuret method (Abbott Lab, Abbott Park, IL, USA).", [["serum", "ANATOMY", 130, 135], ["Toxoplasma gondii", "DISEASE", 13, 30], ["Toxoplasma gondii", "ORGANISM", 13, 30], ["serum", "ORGANISM_SUBSTANCE", 130, 135], ["serum protein", "PROTEIN", 130, 143], ["Toxoplasma gondii", "SPECIES", 13, 30], ["Toxoplasma gondii", "SPECIES", 13, 30], ["Serology", "TEST", 0, 8], ["Toxoplasma gondii", "PROBLEM", 13, 30], ["a latex agglutination test", "TEST", 50, 76], ["Serology", "TEST", 117, 125], ["serum protein electrohporesis", "TEST", 130, 159], ["Total proteins", "TEST", 159, 173]]], ["Serum protein electrophoresis was performed using the semi-micro method with cellulose polyacetate strips in a barbitone and Tris buffer.", [["Serum", "ANATOMY", 0, 5], ["cellulose polyacetate", "CHEMICAL", 77, 98], ["barbitone", "CHEMICAL", 111, 120], ["Tris", "CHEMICAL", 125, 129], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["cellulose polyacetate", "SIMPLE_CHEMICAL", 77, 98], ["barbitone", "SIMPLE_CHEMICAL", 111, 120], ["Tris buffer", "SIMPLE_CHEMICAL", 125, 136], ["Serum protein electrophoresis", "TEST", 0, 29], ["the semi-micro method", "TREATMENT", 50, 71], ["cellulose polyacetate strips", "TREATMENT", 77, 105], ["a barbitone and Tris buffer", "TREATMENT", 109, 136]]], ["The strips were run (40 min, 150 V), stained for 15 min in Red Ponceau (0.5 g in 100 ml of 5% trichloroacetic acid), destained in 5% acetic acid and put in a diaphanizing solution (Helena Lab Italia Spa, Assago, MI, Italy).", [["Red Ponceau", "CHEMICAL", 59, 70], ["trichloroacetic acid", "CHEMICAL", 94, 114], ["acetic acid", "CHEMICAL", 133, 144], ["Ponceau", "CHEMICAL", 63, 70], ["trichloroacetic acid", "CHEMICAL", 94, 114], ["acetic acid", "CHEMICAL", 133, 144], ["trichloroacetic acid", "SIMPLE_CHEMICAL", 94, 114], ["acetic acid", "SIMPLE_CHEMICAL", 133, 144], ["The strips", "TREATMENT", 0, 10], ["Red Ponceau", "TREATMENT", 59, 70], ["5% trichloroacetic acid", "TREATMENT", 91, 114], ["5% acetic acid", "TREATMENT", 130, 144], ["a diaphanizing solution", "TREATMENT", 156, 179], ["MI", "PROBLEM", 212, 214]]], ["The gels were scanned in a densitometer (BT512, Biotecnica Instruments, Roma, Italy).Cytology of the effusionsAbout 50-100 ll of fluid was cytocentrifuged at 130 \u00b7 g for 10 min as previously described (Paltrinieri et al., 1999) .", [["effusions", "ANATOMY", 101, 110], ["fluid", "ANATOMY", 129, 134], ["effusions", "DISEASE", 101, 110], ["fluid", "ORGANISM_SUBSTANCE", 129, 134], ["a densitometer", "TEST", 25, 39], ["Cytology", "TEST", 85, 93], ["the effusions", "PROBLEM", 97, 110], ["effusions", "OBSERVATION", 101, 110], ["fluid", "OBSERVATION", 129, 134]]], ["The slides were stained with May Gru\u00a8nwald-Giemsa and examined by light microscopy.Post-mortem examinationsAll the animals that died with symptoms consistent with FIP were necropsied.", [["FIP", "DISEASE", 163, 166], ["animals", "ORGANISM", 115, 122], ["light microscopy", "TEST", 66, 82], ["Post-mortem examinations", "TEST", 83, 107], ["symptoms", "PROBLEM", 138, 146], ["FIP", "PROBLEM", 163, 166], ["consistent with", "UNCERTAINTY", 147, 162], ["FIP", "OBSERVATION", 163, 166]]], ["Samples (approximately 1 cm 3 ) of each affected organ were fixed in 10% iso-osmotic formalin and embedded in paraffin.", [["Samples", "ANATOMY", 0, 7], ["organ", "ANATOMY", 49, 54], ["formalin", "CHEMICAL", 85, 93], ["formalin", "CHEMICAL", 85, 93], ["paraffin", "CHEMICAL", 110, 118], ["organ", "ORGAN", 49, 54], ["formalin", "SIMPLE_CHEMICAL", 85, 93], ["Samples", "TEST", 0, 7], ["each affected organ", "PROBLEM", 35, 54], ["10% iso-osmotic formalin", "TREATMENT", 69, 93], ["organ", "ANATOMY", 49, 54]]], ["Microthomic sections (5 lm) were stained with haematoxilin and eosin and by immunohistochemistry, using a monoclonal antibody against the FCoV, kindly provided by Prof. N. C. Pedersen, Davis, USA.", [["Microthomic sections", "ANATOMY", 0, 20], ["haematoxilin", "CHEMICAL", 46, 58], ["eosin", "CHEMICAL", 63, 68], ["Microthomic sections", "MULTI-TISSUE_STRUCTURE", 0, 20], ["haematoxilin", "GENE_OR_GENE_PRODUCT", 46, 58], ["eosin", "SIMPLE_CHEMICAL", 63, 68], ["FCoV", "GENE_OR_GENE_PRODUCT", 138, 142], ["haematoxilin", "PROTEIN", 46, 58], ["monoclonal antibody", "PROTEIN", 106, 125], ["FCoV", "PROTEIN", 138, 142], ["Microthomic sections", "TEST", 0, 20], ["haematoxilin", "TREATMENT", 46, 58], ["eosin", "TEST", 63, 68], ["immunohistochemistry", "TEST", 76, 96], ["a monoclonal antibody", "TREATMENT", 104, 125]]], ["The avidin-biotin complex (ABC) method with a commercially available kit (Vectastain Elite, Vector Labs Inc, Burlingame, CA, USA) was used to detect the positive reaction, as previously described (Hsu et al., 1980) , after inhibition of the endogenous peroxidase (H 2 O 2 1% in methanol) and antigen unmasking using microwave pre-treatment (two cycles of 5 min in citrate-buffered solution, 0.01 m, pH 6.2).", [["avidin-biotin", "CHEMICAL", 4, 17], ["citrate", "CHEMICAL", 364, 371], ["biotin", "CHEMICAL", 11, 17], ["methanol", "CHEMICAL", 278, 286], ["citrate", "CHEMICAL", 364, 371], ["avidin", "GENE_OR_GENE_PRODUCT", 4, 10], ["biotin", "SIMPLE_CHEMICAL", 11, 17], ["peroxidase", "GENE_OR_GENE_PRODUCT", 252, 262], ["methanol", "SIMPLE_CHEMICAL", 278, 286], ["citrate", "SIMPLE_CHEMICAL", 364, 371], ["avidin-biotin complex", "PROTEIN", 4, 25], ["ABC", "PROTEIN", 27, 30], ["endogenous peroxidase", "PROTEIN", 241, 262], ["the positive reaction", "PROBLEM", 149, 170], ["the endogenous peroxidase", "TREATMENT", 237, 262], ["microwave pre-treatment", "TREATMENT", 316, 339], ["citrate-buffered solution", "TREATMENT", 364, 389], ["pH", "TEST", 399, 401], ["positive reaction", "OBSERVATION", 153, 170]]], ["3-Amino-9ethyl-carbazole or diaminobenzidine served as chromogen for the reaction and the slides were counterstained with Mayer's haematoxilin.", [["3-Amino-9ethyl-carbazole", "CHEMICAL", 0, 24], ["diaminobenzidine", "CHEMICAL", 28, 44], ["haematoxilin", "CHEMICAL", 130, 142], ["3-Amino-9ethyl-carbazole", "CHEMICAL", 0, 24], ["diaminobenzidine", "CHEMICAL", 28, 44], ["chromogen", "CHEMICAL", 55, 64], ["haematoxilin", "CHEMICAL", 130, 142], ["3-Amino-9ethyl-carbazole", "SIMPLE_CHEMICAL", 0, 24], ["diaminobenzidine", "SIMPLE_CHEMICAL", 28, 44], ["chromogen", "SIMPLE_CHEMICAL", 55, 64], ["haematoxilin", "SIMPLE_CHEMICAL", 130, 142], ["Amino", "TREATMENT", 2, 7], ["9ethyl-carbazole", "TREATMENT", 8, 24], ["diaminobenzidine", "TREATMENT", 28, 44], ["chromogen", "TREATMENT", 55, 64], ["the reaction", "PROBLEM", 69, 81], ["the slides", "TEST", 86, 96], ["Mayer's haematoxilin", "TREATMENT", 122, 142]]], ["Some sections of each sample were used as negative controls, with the primary antibody substituted by an equal amount of normal mouse serum (DAKO A/S, Glostrup, Denmark).", [["sections", "ANATOMY", 5, 13], ["sample", "ANATOMY", 22, 28], ["serum", "ANATOMY", 134, 139], ["mouse", "ORGANISM", 128, 133], ["serum", "ORGANISM_SUBSTANCE", 134, 139], ["Glostrup", "GENE_OR_GENE_PRODUCT", 151, 159], ["primary antibody", "PROTEIN", 70, 86], ["mouse", "SPECIES", 128, 133], ["mouse", "SPECIES", 128, 133], ["Some sections of each sample", "TEST", 0, 28], ["the primary antibody", "TEST", 66, 86]]], ["In each session of immunohistochemical test, a section of liver with a fibrinous perihepatitis from a cat with FIP was used as a positive control.Statistical analysesUsing a specific software (Statsoft Inc., Tulsa, OK, USA), mean values recorded in the six catteries at each time of sampling were compared with each other by one-way anova or, when a normality test showed that data did not have a normal distribution, by Kruskall-Wallis test.", [["liver", "ANATOMY", 58, 63], ["fibrinous perihepatitis", "ANATOMY", 71, 94], ["perihepatitis", "DISEASE", 81, 94], ["FIP", "DISEASE", 111, 114], ["liver", "ORGAN", 58, 63], ["cat", "ORGANISM", 102, 105], ["immunohistochemical test", "TEST", 19, 43], ["a fibrinous perihepatitis", "PROBLEM", 69, 94], ["FIP", "TREATMENT", 111, 114], ["a positive control", "TREATMENT", 127, 145], ["mean values", "TEST", 225, 236], ["a normality test", "TEST", 348, 364], ["liver", "ANATOMY", 58, 63], ["fibrinous", "OBSERVATION", 71, 80], ["FIP", "OBSERVATION", 111, 114], ["normal", "OBSERVATION", 397, 403]]], ["The same tests were used to compare the mean values calculated in the six catteries on the basis of the results recorded in all the samplings.", [["The same tests", "TEST", 0, 14], ["the mean values", "TEST", 36, 51]]], ["The lowest and the highest values observed both at each time of sampling and during the whole study period were used to establish internal ranges of each parameter in each cattery as suggested by Lumdsen (2000) for small groups of animals.Clinical and pathological findingsGroup A Serology for FIV, FeLV and T. gondii was negative in all the cats from this group.", [["FIV", "ORGANISM", 294, 297], ["FeLV", "ORGANISM", 299, 303], ["T. gondii", "ORGANISM", 308, 317], ["cats", "ORGANISM", 342, 346], ["T. gondii", "SPECIES", 308, 317], ["cats", "SPECIES", 342, 346], ["FIV", "SPECIES", 294, 297], ["FeLV", "SPECIES", 299, 303], ["T. gondii", "SPECIES", 308, 317], ["sampling", "TEST", 64, 72], ["the whole study", "TEST", 84, 99], ["Clinical and pathological findings", "PROBLEM", 239, 273], ["Group A Serology", "TEST", 273, 289], ["FIV", "PROBLEM", 294, 297], ["FeLV and T. gondii", "TEST", 299, 317], ["lowest", "OBSERVATION_MODIFIER", 4, 10]]], ["Moreover, none of them showed symptoms consistent with FIP and all subjects were still alive 2 years after the samplings, thus excluding that they were developing a clinical form of FIP when sampled.", [["FIP", "DISEASE", 55, 58], ["FIP", "DISEASE", 182, 185], ["symptoms", "PROBLEM", 30, 38], ["FIP", "PROBLEM", 55, 58], ["the samplings", "TEST", 107, 120], ["FIP", "PROBLEM", 182, 185], ["consistent with", "UNCERTAINTY", 39, 54], ["FIP", "OBSERVATION", 55, 58], ["FIP", "OBSERVATION", 182, 185]]], ["However, cat no. 11 received an anti-inflammatory therapy (serratio peptidase, Danzen \u00d2 , Takeda) at T0, because of a traumatic lameness.", [["traumatic lameness", "DISEASE", 118, 136], ["an anti-inflammatory therapy", "TREATMENT", 29, 57], ["serratio peptidase", "TREATMENT", 59, 77], ["a traumatic lameness", "PROBLEM", 116, 136], ["anti-inflammatory therapy", "OBSERVATION", 32, 57], ["traumatic", "OBSERVATION_MODIFIER", 118, 127], ["lameness", "OBSERVATION", 128, 136]]], ["An outbreak of rhinoconjunctivitis occurred in cattery 3 at T30, and cat nos.", [["rhinoconjunctivitis", "DISEASE", 15, 34], ["cat", "ORGANISM", 69, 72], ["rhinoconjunctivitis", "PROBLEM", 15, 34], ["outbreak", "OBSERVATION_MODIFIER", 3, 11], ["rhinoconjunctivitis", "OBSERVATION", 15, 34]]], ["In cattery 4, an outbreak of upper respiratory infection, which affected cat no. 25 at T30, and an outbreak of haemorragic diarrhoea between T0 and T30 were recorded: the latter affected cat no. 26, which was treated with fluid therapy and bacithracine (Bimixin \u00d2 , Sanofi), and caused the death of two kittens.", [["respiratory", "ANATOMY", 35, 46], ["upper respiratory infection", "DISEASE", 29, 56], ["diarrhoea", "DISEASE", 123, 132], ["bacithracine", "CHEMICAL", 240, 252], ["Bimixin \u00d2 , Sanofi", "CHEMICAL", 254, 272], ["death", "DISEASE", 290, 295], ["bacithracine", "CHEMICAL", 240, 252], ["Bimixin", "CHEMICAL", 254, 261], ["upper respiratory", "ORGANISM_SUBDIVISION", 29, 46], ["cat", "ORGANISM", 187, 190], ["bacithracine", "SIMPLE_CHEMICAL", 240, 252], ["Bimixin", "SIMPLE_CHEMICAL", 254, 261], ["upper respiratory infection", "PROBLEM", 29, 56], ["haemorragic diarrhoea", "PROBLEM", 111, 132], ["fluid therapy", "TREATMENT", 222, 235], ["bacithracine", "TREATMENT", 240, 252], ["Bimixin", "TREATMENT", 254, 261], ["Sanofi", "TREATMENT", 266, 272], ["the death of two kittens", "PROBLEM", 286, 310], ["outbreak", "OBSERVATION_MODIFIER", 17, 25], ["upper", "ANATOMY_MODIFIER", 29, 34], ["respiratory", "ANATOMY", 35, 46], ["infection", "OBSERVATION", 47, 56], ["outbreak", "OBSERVATION_MODIFIER", 99, 107]]], ["Although results from these two kittens were not included in this study, they were necropsied: a severe haemorragic gastroenteritis, with histological findings consistent with the diagnosis of parvoviral infection, was detected.Group BCat no. 24 had ataxia, repeated convulsive crisis and a high anti-T. gondii antibody titre (1:1024).", [["parvoviral", "ANATOMY", 193, 203], ["gastroenteritis", "DISEASE", 116, 131], ["parvoviral infection", "DISEASE", 193, 213], ["ataxia", "DISEASE", 250, 256], ["convulsive", "DISEASE", 267, 277], ["kittens", "ORGANISM", 32, 39], ["anti-T. gondii", "SPECIES", 296, 310], ["parvoviral", "SPECIES", 193, 203], ["anti-T. gondii", "SPECIES", 296, 310], ["this study", "TEST", 61, 71], ["a severe haemorragic gastroenteritis", "PROBLEM", 95, 131], ["histological findings", "PROBLEM", 138, 159], ["parvoviral infection", "PROBLEM", 193, 213], ["Group BCat", "TEST", 228, 238], ["ataxia", "PROBLEM", 250, 256], ["repeated convulsive crisis", "PROBLEM", 258, 284], ["a high anti-T. gondii antibody titre", "PROBLEM", 289, 325], ["severe", "OBSERVATION_MODIFIER", 97, 103], ["haemorragic", "OBSERVATION_MODIFIER", 104, 115], ["gastroenteritis", "OBSERVATION", 116, 131], ["consistent with", "UNCERTAINTY", 160, 175], ["parvoviral", "OBSERVATION_MODIFIER", 193, 203], ["infection", "OBSERVATION", 204, 213], ["convulsive crisis", "OBSERVATION", 267, 284], ["antibody titre", "OBSERVATION", 311, 325]]], ["This cat was treated with sulfamethopyrazine (Vetkefizina \u00d2 , Ceva Vetem) and had a complete recovery.", [["sulfamethopyrazine", "CHEMICAL", 26, 44], ["sulfamethopyrazine", "CHEMICAL", 26, 44], ["Vetkefizina", "CHEMICAL", 46, 57], ["cat", "ORGANISM", 5, 8], ["sulfamethopyrazine", "SIMPLE_CHEMICAL", 26, 44], ["Vetkefizina", "SIMPLE_CHEMICAL", 46, 57], ["sulfamethopyrazine", "TREATMENT", 26, 44], ["Vetkefizina", "TREATMENT", 46, 57], ["Ceva Vetem", "TREATMENT", 62, 72]]], ["Cat nos.10 and 40 had fever of unknown origin (FUO) that persisted for about 1 month in spite of different antibiotic therapies.", [["fever", "DISEASE", 22, 27], ["FUO", "DISEASE", 47, 50], ["fever", "PROBLEM", 22, 27], ["FUO", "PROBLEM", 47, 50], ["different antibiotic therapies", "TREATMENT", 97, 127], ["unknown origin", "OBSERVATION_MODIFIER", 31, 45], ["FUO", "OBSERVATION", 47, 50]]], ["Fever disappeared using Cefazoline (Cefamezin \u00d2 , Pharmacia) and Enrofloxacin (Baytril \u00d2 , Bayer), respectively.", [["Fever", "DISEASE", 0, 5], ["Cefazoline", "CHEMICAL", 24, 34], ["Cefamezin \u00d2 , Pharmacia", "CHEMICAL", 36, 59], ["Enrofloxacin", "CHEMICAL", 65, 77], ["Cefazoline", "CHEMICAL", 24, 34], ["Cefamezin", "CHEMICAL", 36, 45], ["Enrofloxacin", "CHEMICAL", 65, 77], ["Cefazoline", "SIMPLE_CHEMICAL", 24, 34], ["Cefamezin \u00d2", "SIMPLE_CHEMICAL", 36, 47], ["Pharmacia", "SIMPLE_CHEMICAL", 50, 59], ["Enrofloxacin", "SIMPLE_CHEMICAL", 65, 77], ["Fever", "PROBLEM", 0, 5], ["Cefazoline", "TREATMENT", 24, 34], ["Cefamezin", "TREATMENT", 36, 45], ["Pharmacia", "TREATMENT", 50, 59], ["Enrofloxacin", "TREATMENT", 65, 77]]], ["Both these cats were still alive after 2 years (cat no.10) and 4 years (cat no. 40) and did not show any other symptoms consistent with FIP: the observed FUO can thus be interpreted as a consequence of some bacterial infection responsive only to Cefazoline and Enrofloxacin, respectively.", [["FIP", "DISEASE", 136, 139], ["FUO", "DISEASE", 154, 157], ["infection", "DISEASE", 217, 226], ["Cefazoline", "CHEMICAL", 246, 256], ["Enrofloxacin", "CHEMICAL", 261, 273], ["Cefazoline", "CHEMICAL", 246, 256], ["Enrofloxacin", "CHEMICAL", 261, 273], ["cats", "ORGANISM", 11, 15], ["Cefazoline", "SIMPLE_CHEMICAL", 246, 256], ["Enrofloxacin", "SIMPLE_CHEMICAL", 261, 273], ["cats", "SPECIES", 11, 15], ["any other symptoms", "PROBLEM", 101, 119], ["FIP", "PROBLEM", 136, 139], ["the observed FUO", "PROBLEM", 141, 157], ["some bacterial infection", "PROBLEM", 202, 226], ["Cefazoline", "TREATMENT", 246, 256], ["Enrofloxacin", "TREATMENT", 261, 273], ["bacterial", "OBSERVATION_MODIFIER", 207, 216], ["infection", "OBSERVATION", 217, 226]]], ["Cat no. 9 had fever, jaundice and a peritoneal effusion on which neutrophils, many of which degenerated, and lymphocytes were detectable.", [["peritoneal effusion", "ANATOMY", 36, 55], ["neutrophils", "ANATOMY", 65, 76], ["lymphocytes", "ANATOMY", 109, 120], ["fever", "DISEASE", 14, 19], ["jaundice", "DISEASE", 21, 29], ["peritoneal effusion", "DISEASE", 36, 55], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 36, 46], ["neutrophils", "CELL", 65, 76], ["lymphocytes", "CELL", 109, 120], ["neutrophils", "CELL_TYPE", 65, 76], ["lymphocytes", "CELL_TYPE", 109, 120], ["fever", "PROBLEM", 14, 19], ["jaundice", "PROBLEM", 21, 29], ["a peritoneal effusion", "PROBLEM", 34, 55], ["neutrophils", "TEST", 65, 76], ["lymphocytes", "TEST", 109, 120], ["jaundice", "OBSERVATION", 21, 29], ["peritoneal", "ANATOMY", 36, 46], ["effusion", "OBSERVATION", 47, 55], ["lymphocytes", "ANATOMY", 109, 120]]], ["At the necropsy, a multifocal to coalescing severe necrotizing and suppurative hepatitis was detectable (Fig. 1) .", [["hepatitis", "DISEASE", 79, 88], ["a multifocal to coalescing severe necrotizing", "PROBLEM", 17, 62], ["suppurative hepatitis", "PROBLEM", 67, 88], ["multifocal", "OBSERVATION_MODIFIER", 19, 29], ["coalescing", "OBSERVATION_MODIFIER", 33, 43], ["severe", "OBSERVATION_MODIFIER", 44, 50], ["necrotizing", "OBSERVATION_MODIFIER", 51, 62], ["suppurative", "OBSERVATION_MODIFIER", 67, 78], ["hepatitis", "OBSERVATION", 79, 88]]], ["Cat no. 33 had fever, weakness and a progressive paralysis of the leg: large and immature myeloid cells were detectable in both peripheral blood and bone marrow (Fig. 2) suggesting the diagnosis of acute myeloid leukaemia (AML), most likely myelomonocytic.", [["leg", "ANATOMY", 66, 69], ["myeloid cells", "ANATOMY", 90, 103], ["peripheral blood", "ANATOMY", 128, 144], ["bone marrow", "ANATOMY", 149, 160], ["acute myeloid leukaemia", "ANATOMY", 198, 221], ["AML", "ANATOMY", 223, 226], ["myelomonocytic", "ANATOMY", 241, 255], ["fever", "DISEASE", 15, 20], ["weakness", "DISEASE", 22, 30], ["paralysis", "DISEASE", 49, 58], ["acute myeloid leukaemia", "DISEASE", 198, 221], ["AML", "DISEASE", 223, 226], ["myelomonocytic", "DISEASE", 241, 255], ["leg", "ORGANISM_SUBDIVISION", 66, 69], ["myeloid cells", "CELL", 90, 103], ["peripheral blood", "ORGANISM_SUBSTANCE", 128, 144], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 149, 160], ["acute myeloid leukaemia", "CANCER", 198, 221], ["AML", "CANCER", 223, 226], ["myelomonocytic", "CANCER", 241, 255], ["immature myeloid cells", "CELL_TYPE", 81, 103], ["fever", "PROBLEM", 15, 20], ["weakness", "PROBLEM", 22, 30], ["a progressive paralysis of the leg", "PROBLEM", 35, 69], ["large and immature myeloid cells", "PROBLEM", 71, 103], ["acute myeloid leukaemia", "PROBLEM", 198, 221], ["AML", "PROBLEM", 223, 226], ["myelomonocytic", "PROBLEM", 241, 255], ["weakness", "OBSERVATION", 22, 30], ["progressive", "OBSERVATION_MODIFIER", 37, 48], ["paralysis", "OBSERVATION", 49, 58], ["leg", "ANATOMY", 66, 69], ["large", "OBSERVATION_MODIFIER", 71, 76], ["immature myeloid cells", "OBSERVATION", 81, 103], ["both", "ANATOMY_MODIFIER", 123, 127], ["peripheral", "ANATOMY_MODIFIER", 128, 138], ["blood", "ANATOMY", 139, 144], ["bone marrow", "ANATOMY", 149, 160], ["suggesting the diagnosis of", "UNCERTAINTY", 170, 197], ["acute", "OBSERVATION_MODIFIER", 198, 203], ["myeloid leukaemia", "OBSERVATION", 204, 221], ["AML", "OBSERVATION", 223, 226], ["most likely", "UNCERTAINTY", 229, 240], ["myelomonocytic", "OBSERVATION", 241, 255]]], ["Histology confirmed this diagnosis (Fig. 3) .", [["Histology", "TEST", 0, 9]]], ["Cat no. 34 had a thoracic effusion on which clusters of epithelial cells with cytologic patterns consistent with the diagnosis of neoplasia were detectable ( Fig. 4) .", [["thoracic effusion", "ANATOMY", 17, 34], ["epithelial cells", "ANATOMY", 56, 72], ["neoplasia", "ANATOMY", 130, 139], ["thoracic effusion", "DISEASE", 17, 34], ["neoplasia", "DISEASE", 130, 139], ["thoracic effusion", "PATHOLOGICAL_FORMATION", 17, 34], ["epithelial cells", "CELL", 56, 72], ["neoplasia", "CANCER", 130, 139], ["epithelial cells", "CELL_TYPE", 56, 72], ["a thoracic effusion", "PROBLEM", 15, 34], ["epithelial cells", "PROBLEM", 56, 72], ["cytologic patterns", "PROBLEM", 78, 96], ["neoplasia", "PROBLEM", 130, 139], ["thoracic", "ANATOMY", 17, 25], ["effusion", "OBSERVATION", 26, 34], ["epithelial cells", "OBSERVATION", 56, 72], ["cytologic patterns", "OBSERVATION", 78, 96], ["consistent with", "UNCERTAINTY", 97, 112], ["neoplasia", "OBSERVATION", 130, 139]]], ["At the necropsy, pulmonary carcinoma was diagnosed (Fig. 5) .", [["pulmonary carcinoma", "ANATOMY", 17, 36], ["pulmonary carcinoma", "DISEASE", 17, 36], ["pulmonary carcinoma", "CANCER", 17, 36], ["pulmonary carcinoma", "PROBLEM", 17, 36], ["pulmonary", "ANATOMY", 17, 26], ["carcinoma", "OBSERVATION", 27, 36]]], ["Immunohistochemistry for FCoVs was negative in all these cats.", [["FCoVs", "GENE_OR_GENE_PRODUCT", 25, 30], ["cats", "ORGANISM", 57, 61], ["FCoVs", "PROTEIN", 25, 30], ["cats", "SPECIES", 57, 61], ["Immunohistochemistry", "TEST", 0, 20], ["FCoVs", "TEST", 25, 30]]], ["The other eight cats died with symptoms consistent with the diagnosis of effusive FIP.", [["FIP", "DISEASE", 82, 85], ["cats", "ORGANISM", 16, 20], ["cats", "SPECIES", 16, 20], ["symptoms", "PROBLEM", 31, 39], ["effusive FIP", "PROBLEM", 73, 85], ["effusive FIP", "OBSERVATION", 73, 85]]], ["This diagnosis was confirmed by both histology (Fig. 6) and immunohistochemistry (Fig. 7) .Haematological and electrophoretic findingsGroup A Data regarding the parameters commonly used to support a clinical diagnosis of FIP (Pedersen, 1995) are reported in Table 2 .Haematological and electrophoretic findingsThe mean numbers of leucocytes (WBC), neutrophils (PMNs) and lymphocytes recorded in catteries 3 and 5, and the mean a 2 -globulin concentration recorded in catteries 4-6 showed significant fluctuations among the different time samplings: total and differential leucocyte counts from cattery 4 showed evident but not significant increases at T30.", [["leucocytes", "ANATOMY", 330, 340], ["WBC", "ANATOMY", 342, 345], ["neutrophils", "ANATOMY", 348, 359], ["PMNs", "ANATOMY", 361, 365], ["lymphocytes", "ANATOMY", 371, 382], ["leucocyte", "ANATOMY", 572, 581], ["FIP", "DISEASE", 221, 224], ["2 -globulin", "CHEMICAL", 429, 440], ["leucocytes", "CELL", 330, 340], ["WBC", "CELL", 342, 345], ["neutrophils", "CELL", 348, 359], ["PMNs", "CELL", 361, 365], ["lymphocytes", "CELL", 371, 382], ["2 -globulin", "SIMPLE_CHEMICAL", 429, 440], ["leucocyte", "CELL", 572, 581], ["leucocytes", "CELL_TYPE", 330, 340], ["WBC", "CELL_TYPE", 342, 345], ["neutrophils", "CELL_TYPE", 348, 359], ["PMNs", "CELL_TYPE", 361, 365], ["lymphocytes", "CELL_TYPE", 371, 382], ["immunohistochemistry", "TEST", 60, 80], ["electrophoretic findings", "TEST", 110, 134], ["FIP", "PROBLEM", 221, 224], ["electrophoretic findings", "TEST", 286, 310], ["leucocytes", "TEST", 330, 340], ["WBC", "TEST", 342, 345], ["neutrophils", "TEST", 348, 359], ["PMNs", "TEST", 361, 365], ["lymphocytes", "TEST", 371, 382], ["catteries", "TEST", 395, 404], ["globulin concentration", "TEST", 432, 454], ["catteries", "TEST", 467, 476], ["significant fluctuations", "PROBLEM", 488, 512], ["differential leucocyte counts", "TEST", 559, 588], ["cattery", "TEST", 594, 601], ["leucocytes", "ANATOMY", 330, 340], ["lymphocytes", "ANATOMY", 371, 382], ["significant", "OBSERVATION_MODIFIER", 488, 499], ["fluctuations", "OBSERVATION", 500, 512], ["not", "UNCERTAINTY", 623, 626], ["significant", "OBSERVATION_MODIFIER", 627, 638], ["increases", "OBSERVATION_MODIFIER", 639, 648]]], ["Moreover, the mean values and the internal ranges calculated on the basis of the results recorded in the three samplings were often strongly different from the reference ranges (Kristensen and Barsanti, 1977; Jain, 1993; Kaneko, 1997 ) and significant506S.", [["the mean values", "TEST", 10, 25], ["the three samplings", "TEST", 101, 120], ["Kaneko", "TEST", 221, 227]]], ["Paltrinieri et al. 8.9 \u00b1 1.1 (7.3-10.4) 9.8 \u00b1 1.9 (7.9-12.4) 5.7 \u00b1 1.0 (4.4-6.8) 2.5 \u00b1 0.8 (1.2-3.1)5067.3 \u00b1 0.5 (6.7-8.1) 3.6 \u00b1 0.6 (3.0-4.6) 0.6 \u00b1 0.1 (0.5-0.7) 1.9 \u00b1 0.6 (1.4-2.8) T30 9.3 \u00b1 2.0 (7.3-12.6) 11.1 \u00b1 1.3 (8.9-12.5) 6.2 \u00b1 1.2 (5.1-8.0) 3.4 \u00b1 1.3 (2.0-5.4) 7.2 \u00b1 0.4 (6.8-7.7) 3.3 \u00b1 0.4 (2.8-3.8) 0.4 \u00b1 0.2 (0.2-0.6) 1.7 \u00b1 0.5 (1.3-2.6) T60 8.7 \u00b1 1.1 (7.4-9.8) 9.9 \u00b1 1.2 (8.8-11.9) 5.3 \u00b1 1.4 (3.3-7.0) 2.9 \u00b1 1.1 (1.6-4.6) 6.7 \u00b1 0.3 (6.3-7.2) 2.9 \u00b1 0.5 (2.3-3.6) 0.4 \u00b1 0.2 (0.3-0.7) 1.5 \u00b1 0.7 (0.8-2.4) Mean 8.9 \u00b1 1.4 (7.3-12.6) 10.3 \u00b1 1.5 (7.9-12.5) 5.7 \u00b1 1.2 (3.3-8.0) 2.9 \u00b1 1.1 (1.2-5.4) 7.1 \u00b1 0.5 (6.3-8.1) 3.3 \u00b1 0.5 (2.3-4.6) 0.5 \u00b1 0.2 (0.2-0.7) 1.7 \u00b1 0.6 (0.8-2.8) 2 T0 8.4 \u00b1 1.5 (6.3-9.9) 9.3 \u00b1 3.5 (4.7-14.2) 5.2 \u00b1 2.2 (2.5-8.6) 2.3 \u00b1 0.6 (1.5-3.1) 8.0 \u00b1 0.9 (6.7-9.1) 3.9 \u00b1 0.9 (2.9-5.5) 0.6 \u00b1 0.2 (0.4-1.0) 1.9 \u00b1 0.8 (1.2-3.0) T30 9.1 \u00b1 0.5 (8.5-9.8) 12.9 \u00b1 2.3 (8.7-15.3) 5.2 \u00b1 2.7 (2.7-10.7) 5.2 \u00b1 2.0 (3.1-8.1) 7.5 \u00b1 0.5 (7.1-8.1) 3.5 \u00b1 0.5 (3.0-4.4) 0.5 \u00b1 0.1 (0.4-0.6) 1.9 \u00b1 0.6 (0.9-2.8) T60 8.5 \u00b1 1.0 (7.9-10.0) 12.3 \u00b1 3.7 (6.6-18.3) 6.8 \u00b1 2.3 (4.1-9.9) 2.9 \u00b1 1.2 (1.3-4.4)5068.0 \u00b1 0.5 (7.1-8.8) 4.2 \u00b1 0.7 (3.4-5.3) 0.8 \u00b1 0.1 (0.6-1.0) 2.3 \u00b1 0.7 (1.3-3.4) Mean 8.7 \u00b1 1.1 (6.3-10.0) 12.4 \u00b1 2.9 (4.7-18.3) 5.7 \u00b1 2.4 (2.5-10.7) 3.5 \u00b1 1.9 (1.3-8.1) 7.8 \u00b1 0.7 (6.7-9.1) 3.9 \u00b1 0.7 (2.9-5.5) 0.6 \u00b1 0.2 (0.4-1.0) 2.0 \u00b1 0.7 (0.9-3.4) 3 T0 8.3 \u00b1 2.7 (4.7-11.2) 7.2 \u00b1 4.5 (2.8-13.8) 4.2 \u00b1 2.8 (1.1-8.3) 2.4 \u00b1 1.5 (1.0-4.3)5068.4 \u00b1 0.6 (7.8-9.1) 4.7 \u00b1 1.3 (3.5-6.6) 0.5 \u00b1 0.3 (0.3-1.0) 2.7 \u00b1 1.0 (1.9-4.4) T30 8.2 \u00b1 0.7 (7.4-9.2) 14.7 \u00b1 3.7 # (9.7-19.0) 9.4 \u00b1 3.4 # (6.0-13.5) 4.5 \u00b1 1.9 # (2.8-7.8) 7.5 \u00b1 0.4 (7.0-8.0) 4.1 \u00b1 0.9 (3.0-5.4) 0.5 \u00b1 0.1 (0.4-0.6) 2.5 \u00b1 0.7 (1.7-3.6) T60 7.5 \u00b1 1.1 (6.4-9.2) 5.7 \u00b1 2.7 (2.7-8.4) 3.5 \u00b1 1.5 (1.8-5.0) 1.7 \u00b1 1.1 (0.8-4.4) 7.2 \u00b1 1.5 (6.3-9.8) 4.3 \u00b1 1.6 (3.0-7.1) 0.5 \u00b1 0.2 (0.2-0.7) 2.7 \u00b1 1.6 (1.7-5.5) Mean 8.0 \u00b1 1.7 (4.7-11.2) 9.2 \u00b1 5.3 (2.8-19.0) 5.7 \u00b1 3.7 (1.1-13.5) 2.9 \u00b1 1.9 (0.8-7.8) 7.7 \u00b1 1.0 (6.3-9.8) 4.3 \u00b1 1.2 (3.0-7.1) 0.5 \u00b1 0.2 (0.2-1.0) 2.7 \u00b1 1.1 (1.7-5.5) 4 T0 8.3 \u00b1 1.4 (6.0-9.9) 17.6 \u00b1 7.3 (5.9-23.2) 11.3 \u00b1 5.5 (2.5-15.8) 5.4 \u00b1 2.1 (3.0-8.3) 7.7 \u00b1 0.9 (6.8-9.0) 4.6 \u00b1 1.3 (3.4-6.4) 0.7 \u00b1 0.2 (0.5-0.9) 2.6 \u00b1 1.2 (1.5-4.4) T30 7.9 \u00b1 2.3 (4.8-9.8) 23.0 \u00b1 12.9 (8.0-41.9) 15.5 \u00b1 9.6 (3.7-28.9) 6.2 \u00b1 3.1 (2.7-10.5) 7.0 \u00b1 0.8 (5.8-7.9) 4.3 \u00b1 0.6 (3.6-4.8) 0.7 \u00b1 0.2 (0.5-0.9) 2.5 \u00b1 0.5 (2.0-3.1) T60 6.9 \u00b1 1.7 (5.1-9.0) 15.4 \u00b1 5.4 (6.6-19.7) 10.0 \u00b1 4.5 (3.0-14.5) 4.3 \u00b1 2.4 (1.5-7.1) 7.0 \u00b1 0.4 (6.5-7.6) 4.2 \u00b1 0.6 (3.6-5.0) 0.4 \u00b1 0.1 # (0.3-0.6) 2.6 \u00b1 0.8 (2.0-3.9) Mean 7.7 \u00b1 1.8 (4.8-9.9) 18.7 \u00b1 9.0 (5.9-41.9) 12.3 \u00b1 6.9 (2.5-28.9) 5.3 \u00b1 2.5 (1.5-10.5) 7.2 \u00b1 0.8 (5.8-9.0) 4.4 \u00b1 0.8 (3.4-6.4) 0.6 \u00b1 0.2 (0.3-0.9) 2.6 \u00b1 0.8 (1.5-4.4) 5 T0 6.8 \u00b1 1.6 (5.6-9.5) 9.7 \u00b1 3.3 (6.7-15.3) 6.6 \u00b1 1.6 (4.8-9.0) 2.8 \u00b1 1.6 (1.5-5.7) 8.3 \u00b1 0.5 (7.7-9.0) 3.9 \u00b1 0.5 (3.1-4.3) 0.5 \u00b1 0.1 (0.3-0.7) 1.9 \u00b1 0.4 (1.4-2.3) T30 7.7 \u00b1 1.2 (6.1-9.0) 10.7 \u00b1 1.5 # (9.1-12.6) 7.9 \u00b1 1.3 # (6.2-9.1) 1.9 \u00b1 0.6 # (1.1-2.5) 7.3 \u00b1 0.5 (6.9-8.0) 3.8 \u00b1 0.5 (3.4-4.6) 0.7 \u00b1 0.2 # (0.5-0.9) 1.7 \u00b1 0.5 (1.3-2.3) T60 7.5 \u00b1 2.2 (5.9-11.3) 7.4 \u00b1 2.8 (3.8-10.9) 4.8 \u00b1 2.2 (1.4-7.0) 2.1 \u00b1 1.0 (1.1-3.7)5067.2 \u00b1 0.7 (6.2-8.0) 3.5 \u00b1 0.6 (2.9-4.3) 0.7 \u00b1 0.2 # (0.5-1.0) 1.8 \u00b1 0.5 (1.2-2.5) Mean 7.3 \u00b1 1.6 (5.6-11.3) 9.3 \u00b1 2.8 (3.8-15.3) 6.4 \u00b1 2.1 (1.4-9.1) 2.3 \u00b1 1.1 (1.1-5.7)5067.6 \u00b1 0.8 (6.2-9.0) 3.7 \u00b1 0.5 (2.9-4.6) 0.6 \u00b1 0.2 (0.3-1.0) 1.8 \u00b1 0.4 (1.2-2.5) 6 T0 8.5 \u00b1 2.2 (5.3-9.8) 18.6 \u00b1 3.4 (14.0-22.0) 12.4 \u00b1 1.8 (10.5-14.7) 5.0 \u00b1 1.9 (2.2-6.2) 7.6 \u00b1 0.5 (7.2-8.2) 3.5 \u00b1 0.3 (3.2-3.7) 0.5 \u00b1 0.1 (0.4-0.6) 1.7 \u00b1 0.2 (1.5-1.9) T30 7.7 \u00b1 1.7 (6.0-10.1) 13.6 \u00b1 3.5 (10.7-18.4) 9.1 \u00b1 4.7 (4.6-15.6) 3.6 \u00b1 1.3 (2.2-4.8)5067.2 \u00b1 0.8 (6.0-7.9) 3.6 \u00b1 0.5 (3.1-4.1) 0.9 \u00b1 0.3 # (0.4-1.2) 1.6 \u00b1 0.3 (1.1-1.9) T60 8.1 \u00b1 1.5 (6.4-9.8) 17.4 \u00b1 5.1 (11.2-22.2) 9.9 \u00b1 4.1 (6.2-14.6) 5.8 \u00b1 2.7 (3.1-8.2) 7.4 \u00b1 0.6 (6.6-8.0) 3.9 \u00b1 0.5 (3.4-4.6) 0.8 \u00b1 0.3 # (0.5-1.1) 1.8 \u00b1 0.6 (1.", [["Paltrinieri et al.", "TEST", 0, 18], ["T30", "TEST", 183, 186], ["T60", "TEST", 350, 353], ["Mean", "TEST", 515, 519], ["T0", "TEST", 685, 687], ["T30", "TEST", 849, 852], ["T60", "TEST", 1016, 1019], ["Mean", "TEST", 1185, 1189], ["T0", "TEST", 1356, 1358], ["T30", "TEST", 1523, 1526], ["T60", "TEST", 1696, 1699], ["Mean", "TEST", 1860, 1864], ["T0", "TEST", 2030, 2032], ["T30", "TEST", 2197, 2200], ["T60", "TEST", 2367, 2370], ["Mean", "TEST", 2537, 2541], ["T0", "TEST", 2709, 2711], ["T30", "TEST", 2873, 2876], ["T60", "TEST", 3047, 3050], ["Mean", "TEST", 3217, 3221], ["T0", "TEST", 3388, 3390], ["T30", "TEST", 3557, 3560], ["T60", "TEST", 3730, 3733]]], ["Kristensen and Barsanti (1977) .506Laboratory Diagnosis of FIP in Multicat Environments 1 507 differences among the catteries were detectable.", [["FIP", "DISEASE", 59, 62], ["FIP", "PROBLEM", 59, 62], ["FIP", "OBSERVATION", 59, 62]]], ["In particular, mean leucocyte number of cats from cattery 4 was higher than the reference range, mean total protein concentration was close to the highest reference limits in all the groups, cats from catteries 4 and 6 had the highest total and differential leucocyte counts and cats from catteries 3 and 4 had the highest total and c-globulin concentration.", [["leucocyte", "ANATOMY", 20, 29], ["leucocyte", "ANATOMY", 258, 267], ["c-globulin", "CHEMICAL", 333, 343], ["c-globulin", "CHEMICAL", 333, 343], ["leucocyte", "CELL", 20, 29], ["cats", "ORGANISM", 40, 44], ["cats", "ORGANISM", 191, 195], ["leucocyte", "CELL", 258, 267], ["c-globulin", "SIMPLE_CHEMICAL", 333, 343], ["cats", "SPECIES", 40, 44], ["cats", "SPECIES", 279, 283], ["mean leucocyte", "TEST", 15, 29], ["cattery", "TEST", 50, 57], ["mean total protein concentration", "TEST", 97, 129], ["catteries", "TEST", 201, 210], ["differential leucocyte counts", "TEST", 245, 274], ["cats", "TEST", 279, 283], ["catteries", "TEST", 289, 298], ["leucocyte counts", "OBSERVATION", 258, 274]]], ["Furthermore, in all the catteries some cat had at least one change consistent with FIP during the study period, and, except for cattery 1, cats with multiple changes were often detected (Table 3) .Group BAs shown in Table 4 , compared with reference ranges, cats with FIP had most of the changes considered highly diagnostic for this disease.", [["FIP", "DISEASE", 83, 86], ["FIP", "DISEASE", 268, 271], ["cat", "ORGANISM", 39, 42], ["cats", "ORGANISM", 139, 143], ["cats", "ORGANISM", 258, 262], ["FIP", "PROBLEM", 83, 86], ["the study", "TEST", 94, 103], ["Group BAs", "TEST", 197, 206], ["FIP", "PROBLEM", 268, 271], ["this disease", "PROBLEM", 329, 341], ["consistent with", "UNCERTAINTY", 67, 82], ["FIP", "OBSERVATION", 83, 86]]], ["Some of these changes, however, were detectable also in cats with diseases other than FIP.", [["FIP", "DISEASE", 86, 89], ["cats", "ORGANISM", 56, 60], ["cats", "SPECIES", 56, 60], ["diseases", "PROBLEM", 66, 74], ["FIP", "PROBLEM", 86, 89]]], ["In some cats with FIP, however, values that were out of the reference ranges fell into the internal ones (total proteins in cat no. 6, lymphocytes in cat no. 23, WBC in cat nos.", [["lymphocytes", "ANATOMY", 135, 146], ["WBC", "ANATOMY", 162, 165], ["FIP", "DISEASE", 18, 21], ["cats", "ORGANISM", 8, 12], ["lymphocytes", "CELL", 135, 146], ["cat", "ORGANISM", 169, 172], ["lymphocytes", "CELL_TYPE", 135, 146], ["WBC", "CELL_TYPE", 162, 165], ["FIP", "PROBLEM", 18, 21], ["total proteins", "TEST", 106, 120], ["lymphocytes", "TEST", 135, 146], ["WBC", "TEST", 162, 165], ["FIP", "OBSERVATION", 18, 21], ["internal ones", "ANATOMY", 91, 104]]], ["30 and 32, PMNs in cat nos.", [["PMNs", "ANATOMY", 11, 15], ["PMNs", "CELL", 11, 15], ["cat", "ORGANISM", 19, 22], ["PMNs", "CELL_TYPE", 11, 15]]], ["Rarely, values that were within the reference ranges fell out of the internal ones: this occurred in both cats with FIP (erythrocytes, PMNs and a 2 -globulins in cat no. 8, c-globulins in cat no. 45) and in cats not affected by FIP (cat no. 9: erythrocytes and a 2 -globulins; cat no.10: PMNs).DiscussionThe results presented here confirm that laboratory changes consistent with the diagnosis of FIP (anaemia, neutrophilic leucocytosis, lymphopenia, increased total proteins, increased total-, a 2 -and c-globulins) can be detected also in cats without Table 2 ); \u00a7 values different from the internal range (see Table 2 ).", [["erythrocytes", "ANATOMY", 121, 133], ["PMNs", "ANATOMY", 135, 139], ["erythrocytes", "ANATOMY", 244, 256], ["PMNs", "ANATOMY", 288, 292], ["neutrophilic", "ANATOMY", 410, 422], ["FIP", "DISEASE", 116, 119], ["FIP", "DISEASE", 228, 231], ["FIP", "DISEASE", 396, 399], ["anaemia", "DISEASE", 401, 408], ["neutrophilic leucocytosis", "DISEASE", 410, 435], ["lymphopenia", "DISEASE", 437, 448], ["cats", "ORGANISM", 106, 110], ["erythrocytes", "CELL", 121, 133], ["PMNs", "CELL", 135, 139], ["2 -globulins", "GENE_OR_GENE_PRODUCT", 146, 158], ["cat", "ORGANISM", 162, 165], ["c-globulins", "GENE_OR_GENE_PRODUCT", 173, 184], ["cat no. 45", "ORGANISM", 188, 198], ["cats", "ORGANISM", 207, 211], ["erythrocytes", "CELL", 244, 256], ["2 -globulins", "SIMPLE_CHEMICAL", 263, 275], ["cat", "ORGANISM", 277, 280], ["PMNs", "CELL", 288, 292], ["c-globulins", "GENE_OR_GENE_PRODUCT", 503, 514], ["erythrocytes", "CELL_TYPE", 121, 133], ["PMNs", "CELL_TYPE", 135, 139], ["c-globulins", "PROTEIN", 173, 184], ["erythrocytes", "CELL_TYPE", 244, 256], ["PMNs", "CELL_TYPE", 288, 292], ["globulins", "PROTEIN", 505, 514], ["cats", "SPECIES", 106, 110], ["cats", "SPECIES", 207, 211], ["FIP (erythrocytes", "TEST", 116, 133], ["PMNs", "TEST", 135, 139], ["c-globulins", "TEST", 173, 184], ["erythrocytes", "TEST", 244, 256], ["laboratory changes", "PROBLEM", 344, 362], ["FIP", "PROBLEM", 396, 399], ["anaemia", "PROBLEM", 401, 408], ["neutrophilic leucocytosis", "PROBLEM", 410, 435], ["lymphopenia", "PROBLEM", 437, 448], ["increased total proteins", "PROBLEM", 450, 474], ["FIP", "OBSERVATION", 116, 119], ["FIP", "OBSERVATION", 228, 231], ["erythrocytes", "ANATOMY", 244, 256], ["FIP", "OBSERVATION", 396, 399], ["neutrophilic leucocytosis", "OBSERVATION", 410, 435], ["lymphopenia", "OBSERVATION", 437, 448]]], ["NSH, necrotizing and suppurative hepatitis; FUO, fever of unknown origin (most likely because of antibiotic resistant bacteria); T, toxoplasmosis; AML, acute myeloid leukaemia (most likely myelomonocytic); PC, pulmonary carcinoma. any clinical symptom or with symptoms not consistent with FIP living in multicat environments.", [["AML", "ANATOMY", 147, 150], ["acute myeloid leukaemia", "ANATOMY", 152, 175], ["myelomonocytic", "ANATOMY", 189, 203], ["PC", "ANATOMY", 206, 208], ["pulmonary carcinoma", "ANATOMY", 210, 229], ["NSH", "DISEASE", 0, 3], ["necrotizing and suppurative hepatitis", "DISEASE", 5, 42], ["FUO", "DISEASE", 44, 47], ["fever", "DISEASE", 49, 54], ["toxoplasmosis", "DISEASE", 132, 145], ["AML", "DISEASE", 147, 150], ["acute myeloid leukaemia", "DISEASE", 152, 175], ["pulmonary carcinoma", "DISEASE", 210, 229], ["FIP", "DISEASE", 289, 292], ["AML", "CANCER", 147, 150], ["acute myeloid leukaemia", "CANCER", 152, 175], ["myelomonocytic", "CANCER", 189, 203], ["PC", "CANCER", 206, 208], ["pulmonary carcinoma", "CANCER", 210, 229], ["necrotizing", "PROBLEM", 5, 16], ["suppurative hepatitis", "PROBLEM", 21, 42], ["FUO", "PROBLEM", 44, 47], ["fever", "PROBLEM", 49, 54], ["antibiotic resistant bacteria", "PROBLEM", 97, 126], ["T, toxoplasmosis", "PROBLEM", 129, 145], ["AML", "PROBLEM", 147, 150], ["acute myeloid leukaemia", "PROBLEM", 152, 175], ["myelomonocytic)", "PROBLEM", 189, 204], ["PC", "PROBLEM", 206, 208], ["pulmonary carcinoma", "PROBLEM", 210, 229], ["any clinical symptom", "PROBLEM", 231, 251], ["symptoms", "PROBLEM", 260, 268], ["FIP", "PROBLEM", 289, 292], ["necrotizing", "OBSERVATION_MODIFIER", 5, 16], ["suppurative", "OBSERVATION_MODIFIER", 21, 32], ["hepatitis", "OBSERVATION", 33, 42], ["FUO", "OBSERVATION", 44, 47], ["fever", "OBSERVATION", 49, 54], ["most likely", "UNCERTAINTY", 74, 85], ["AML", "ANATOMY", 147, 150], ["acute", "OBSERVATION_MODIFIER", 152, 157], ["myeloid leukaemia", "OBSERVATION", 158, 175], ["most likely", "UNCERTAINTY", 177, 188], ["myelomonocytic", "OBSERVATION_MODIFIER", 189, 203], ["pulmonary", "ANATOMY", 210, 219], ["carcinoma", "OBSERVATION", 220, 229]]], ["Moreover, the analysis of repeated samplings allowed detecting significant or evident differences over the time, most frequently associated with outbreaks of infectious diseases (rinoconjunctivitis, upper respiratory infections, gastroenteritis).", [["respiratory", "ANATOMY", 205, 216], ["infectious diseases", "DISEASE", 158, 177], ["rinoconjunctivitis", "DISEASE", 179, 197], ["upper respiratory infections", "DISEASE", 199, 227], ["gastroenteritis", "DISEASE", 229, 244], ["the analysis", "TEST", 10, 22], ["repeated samplings", "TEST", 26, 44], ["infectious diseases", "PROBLEM", 158, 177], ["rinoconjunctivitis", "PROBLEM", 179, 197], ["upper respiratory infections", "PROBLEM", 199, 227], ["gastroenteritis", "PROBLEM", 229, 244], ["infectious", "OBSERVATION", 158, 168], ["upper", "ANATOMY_MODIFIER", 199, 204], ["respiratory", "ANATOMY", 205, 216], ["infections", "OBSERVATION", 217, 227], ["gastroenteritis", "OBSERVATION", 229, 244]]], ["In these cases, the most evident changes were obviously detectable in symptomatic cats (e.g. anaemia in cat no. 26 after an episode of haemorragic diarrhoea, neutrophilic leucocytosis in cat nos.", [["anaemia", "DISEASE", 93, 100], ["diarrhoea", "DISEASE", 147, 156], ["neutrophilic leucocytosis", "DISEASE", 158, 183], ["cats", "ORGANISM", 82, 86], ["cat", "ORGANISM", 187, 190], ["cats", "SPECIES", 82, 86], ["symptomatic cats", "PROBLEM", 70, 86], ["e.g. anaemia", "PROBLEM", 88, 100], ["haemorragic diarrhoea", "PROBLEM", 135, 156], ["neutrophilic leucocytosis in cat nos", "PROBLEM", 158, 194], ["diarrhoea", "OBSERVATION", 147, 156], ["neutrophilic leucocytosis", "OBSERVATION", 158, 183]]], ["21, 22 and 26, which had rhinoconjunctivitis).", [["rhinoconjunctivitis", "DISEASE", 25, 44], ["rhinoconjunctivitis", "PROBLEM", 25, 44]]], ["But also the non-symptomatic cats of the same cattery had altered parameters.", [["cats", "ORGANISM", 29, 33], ["cats", "SPECIES", 29, 33], ["altered parameters", "PROBLEM", 58, 76]]], ["As a consequence, mean values and internal ranges calculated using the lowest and the highest values observed at each sampling, as suggested by Lumdsen (2000) for small groups of animals, were strongly different not only among the catteries but also among the different samplings.", [["mean values", "TEST", 18, 29], ["internal ranges", "TEST", 34, 49], ["internal ranges", "OBSERVATION", 34, 49]]], ["In order to reduce the variability because of transient alterations, mean values and internal ranges have been calculated also based on the results recorded during the whole study period.", [["transient alterations", "PROBLEM", 46, 67], ["mean values", "TEST", 69, 80], ["the whole study", "TEST", 164, 179], ["transient", "OBSERVATION_MODIFIER", 46, 55], ["alterations", "OBSERVATION", 56, 67]]], ["Although this might not be considered statistically correct, it can be the best way to represent the real laboratory profile of cats living in small or medium catteries.", [["cats", "ORGANISM", 128, 132], ["cats", "SPECIES", 128, 132], ["small", "OBSERVATION_MODIFIER", 143, 148]]], ["The majority of breeding catteries, in fact, are composed by 5-30 animals and have \u00d4open\u00d5 or \u00d4mixed\u00d5 management, because of repeated participation in cat shows and frequent exchange of cats with other catteries.", [["cat", "ORGANISM", 150, 153], ["cats", "ORGANISM", 185, 189], ["\u00d4mixed\u00d5 management", "TREATMENT", 93, 111], ["frequent exchange of cats", "TREATMENT", 164, 189], ["other catteries", "TREATMENT", 195, 210], ["majority", "OBSERVATION_MODIFIER", 4, 12], ["breeding catteries", "OBSERVATION", 16, 34]]], ["In this situation, it is quite impossible to use a wide statistical approach and to avoid mild to moderate outbreaks of infectious diseases that can induce transient fluctuations of laboratory parameters.DiscussionThe comparison of mean values obtained in the whole study period allowed to detect that, with the exception of total protein concentration that was in all the catteries close to the highest limit of the reference range, as already reported for colony cats (Kristensen and Barsanti, 1977; Kaneko, 1997) , each cattery was characterized by a particular laboratory profile and, as a consequence, by the presence of cats with some parameter out of the reference range.", [["infectious diseases", "DISEASE", 120, 139], ["cats", "ORGANISM", 465, 469], ["cats", "ORGANISM", 626, 630], ["cats", "SPECIES", 465, 469], ["a wide statistical approach", "TREATMENT", 49, 76], ["mild to moderate outbreaks of infectious diseases", "PROBLEM", 90, 139], ["laboratory parameters", "TEST", 182, 203], ["mean values", "TEST", 232, 243], ["the whole study", "TEST", 256, 271], ["total protein concentration", "PROBLEM", 325, 352], ["moderate", "OBSERVATION_MODIFIER", 98, 106], ["infectious", "OBSERVATION", 120, 130]]], ["The presence of these changes seems to depend on the characteristic of the cattery rather than on the prevalence of FIP.", [["FIP", "DISEASE", 116, 119], ["these changes", "PROBLEM", 16, 29], ["cattery", "OBSERVATION", 75, 82], ["FIP", "OBSERVATION", 116, 119]]], ["In fact, the most evident haematological and eletrophoretic changes were detected in catteries 3 and 4, which had a high prevalence of FIP, open management and a poor health condition, while they were rare in cattery 1, which also had a high prevalence of FIP but close management practices and few cases of infectious diseases.", [["FIP", "DISEASE", 135, 138], ["FIP", "DISEASE", 256, 259], ["infectious diseases", "DISEASE", 308, 327], ["haematological", "CANCER", 26, 40], ["eletrophoretic changes", "PROBLEM", 45, 67], ["FIP", "PROBLEM", 135, 138], ["open management", "TREATMENT", 140, 155], ["a poor health condition", "PROBLEM", 160, 183], ["close management practices", "TREATMENT", 264, 290], ["infectious diseases", "PROBLEM", 308, 327], ["eletrophoretic", "OBSERVATION", 45, 59], ["high prevalence", "OBSERVATION_MODIFIER", 116, 131], ["FIP", "OBSERVATION", 135, 138], ["high prevalence", "OBSERVATION_MODIFIER", 237, 252], ["FIP", "OBSERVATION", 256, 259], ["infectious", "OBSERVATION", 308, 318]]], ["The high number of lymphocytes in cattery 6 may depend on the recent appearance of FIP, as lymphoid hyperplasia in cats living with FCoV shedders has been reported (Kipar et al., 1999) .", [["lymphocytes", "ANATOMY", 19, 30], ["lymphoid hyperplasia", "ANATOMY", 91, 111], ["FIP", "DISEASE", 83, 86], ["lymphoid hyperplasia", "DISEASE", 91, 111], ["lymphocytes", "CELL", 19, 30], ["FIP", "GENE_OR_GENE_PRODUCT", 83, 86], ["lymphoid hyperplasia", "PATHOLOGICAL_FORMATION", 91, 111], ["cats", "ORGANISM", 115, 119], ["lymphocytes", "CELL_TYPE", 19, 30], ["cats", "SPECIES", 115, 119], ["FCoV", "SPECIES", 132, 136], ["lymphocytes in cattery 6", "PROBLEM", 19, 43], ["FIP", "PROBLEM", 83, 86], ["lymphoid hyperplasia", "PROBLEM", 91, 111], ["FCoV shedders", "TREATMENT", 132, 145], ["high", "OBSERVATION_MODIFIER", 4, 8], ["number", "OBSERVATION_MODIFIER", 9, 15], ["lymphocytes", "OBSERVATION", 19, 30], ["FIP", "OBSERVATION", 83, 86], ["lymphoid hyperplasia", "OBSERVATION", 91, 111]]], ["These suggestions can be confirmed by the analysis of the number of cats per cattery that had, at least in one sampling, values different from the reference range: also in this case, the number of cats with laboratory changes was low in cattery 1 and high in catteries 3 and 4.", [["cats", "ORGANISM", 68, 72], ["cats", "ORGANISM", 197, 201], ["the analysis", "TEST", 38, 50], ["laboratory changes", "TEST", 207, 225], ["low", "OBSERVATION_MODIFIER", 230, 233], ["high", "OBSERVATION_MODIFIER", 251, 255]]], ["The high number of cats with hyperproteinaemia in catteries 2 and 5 might depend on their high percentage of old cats, which are known to have high total protein concentration (Kaneko, 1997) .", [["hyperproteinaemia", "DISEASE", 29, 46], ["cats", "ORGANISM", 19, 23], ["cats", "ORGANISM", 113, 117], ["cats", "SPECIES", 19, 23], ["cats", "SPECIES", 113, 117], ["hyperproteinaemia in catteries", "PROBLEM", 29, 59], ["high", "OBSERVATION_MODIFIER", 4, 8], ["number", "OBSERVATION_MODIFIER", 9, 15], ["cats", "OBSERVATION", 19, 23], ["hyperproteinaemia", "OBSERVATION", 29, 46]]], ["Moreover, all the cats from cattery 6 had increased a 2 -globulins and this might be further support to the hypothesis of a recent contact with the FCoV, as an increase of this electrophoretic fraction has been recorded just after experimental infection with the FCoV, most likely depending on the increase of acute phase proteins (Stoddart et al., 1988) .", [["infection", "DISEASE", 244, 253], ["cats", "ORGANISM", 18, 22], ["2 -globulins", "GENE_OR_GENE_PRODUCT", 54, 66], ["FCoV", "GENE_OR_GENE_PRODUCT", 148, 152], ["acute phase proteins", "PROTEIN", 310, 330], ["cats", "SPECIES", 18, 22], ["all the cats from cattery", "TEST", 10, 35], ["a 2 -globulins", "TREATMENT", 52, 66], ["the FCoV", "PROBLEM", 144, 152], ["this electrophoretic fraction", "PROBLEM", 172, 201], ["experimental infection", "PROBLEM", 231, 253], ["the FCoV", "PROBLEM", 259, 267], ["acute phase proteins", "PROBLEM", 310, 330], ["increase", "OBSERVATION_MODIFIER", 160, 168], ["infection", "OBSERVATION", 244, 253], ["FCoV", "OBSERVATION", 263, 267], ["most likely", "UNCERTAINTY", 269, 280], ["acute", "OBSERVATION_MODIFIER", 310, 315]]], ["For this reason, also the presence of multiple laboratory alterations, that has a high diagnostic value for FIP (Sparkes et al., 1991; Pedersen, 1995) , was evaluated.", [["FIP", "DISEASE", 108, 111], ["multiple laboratory alterations", "PROBLEM", 38, 69], ["FIP", "PROBLEM", 108, 111], ["multiple", "OBSERVATION_MODIFIER", 38, 46], ["laboratory alterations", "OBSERVATION", 47, 69]]], ["The type of change most frequently observed, however, was very variable among the catteries, most likely depending on the laboratory profile of each cattery.", [["most likely", "UNCERTAINTY", 93, 104]]], ["In fact, cats with simultaneous changes were mainly detected in catteries 3 and 4, with electrophoretic changes associated with lymphopenia in cattery 3 and neutrophilia in cattery 4.DiscussionAll these changes were obviously absent when the results are compared with internal ranges.", [["lymphopenia", "DISEASE", 128, 139], ["neutrophilia", "DISEASE", 157, 169], ["cats", "ORGANISM", 9, 13], ["cats", "SPECIES", 9, 13], ["electrophoretic changes", "PROBLEM", 88, 111], ["lymphopenia in cattery 3", "PROBLEM", 128, 152], ["neutrophilia in cattery 4", "PROBLEM", 157, 182], ["lymphopenia", "OBSERVATION", 128, 139], ["neutrophilia", "OBSERVATION", 157, 169]]], ["A possible consequence of using internal ranges would be the lack of ability to identify cats with FIP.", [["FIP", "DISEASE", 99, 102], ["cats", "ORGANISM", 89, 93], ["possible", "UNCERTAINTY", 2, 10], ["FIP", "OBSERVATION", 99, 102]]], ["The results from cats with symptoms suggestive of FIP indicate that, in the majority of the cases, the range used does not affect the possibility of detecting typical laboratory changes in cats really affected by this disease and to avoid false positive diagnoses in cats with disease other than FIP.DiscussionA more objective evaluation could be obtained by calculating sensitivity, specificity and both negative and positive predictive values for each laboratory change.", [["FIP", "DISEASE", 50, 53], ["FIP", "DISEASE", 296, 299], ["cats", "ORGANISM", 17, 21], ["cats", "ORGANISM", 189, 193], ["cats", "ORGANISM", 267, 271], ["cats", "SPECIES", 17, 21], ["cats", "SPECIES", 189, 193], ["cats", "SPECIES", 267, 271], ["symptoms", "PROBLEM", 27, 35], ["FIP", "PROBLEM", 50, 53], ["typical laboratory changes in cats", "PROBLEM", 159, 193], ["this disease", "PROBLEM", 213, 225], ["false positive diagnoses in cats", "PROBLEM", 239, 271], ["disease", "PROBLEM", 277, 284], ["FIP", "PROBLEM", 296, 299], ["objective evaluation", "TEST", 317, 337], ["FIP", "OBSERVATION", 50, 53]]], ["These parameters were not calculated in this study because they have a statistical validity only if calculated on large populations with known prevalence of infection (Jacobson, 1991) and, as previously mentioned, such a situation rarely occurs in breeding catteries.", [["infection", "DISEASE", 157, 166], ["this study", "TEST", 40, 50], ["infection", "PROBLEM", 157, 166], ["large", "OBSERVATION_MODIFIER", 114, 119], ["populations", "OBSERVATION", 120, 131], ["infection", "OBSERVATION", 157, 166]]], ["Only in catteries 1, 3 and 4 were both cats with FIP and with other diseases sampled.", [["FIP", "DISEASE", 49, 52], ["cats", "ORGANISM", 39, 43], ["other diseases", "PROBLEM", 62, 76], ["FIP", "OBSERVATION", 49, 52], ["diseases", "OBSERVATION", 68, 76]]], ["On this perspective, in some cats with FIP values out of the reference range fell into the internal ones, thus decreasing the sensitivity of these changes (hyperproteinaemia in cattery 1, lymphopenia in cattery 3, neutrophilic leucocytosis in cattery 4).", [["hyperproteinaemia", "DISEASE", 156, 173], ["lymphopenia", "DISEASE", 188, 199], ["leucocytosis", "DISEASE", 227, 239], ["cats", "ORGANISM", 29, 33], ["FIP values", "TEST", 39, 49], ["these changes (hyperproteinaemia in cattery 1", "PROBLEM", 141, 186], ["lymphopenia in cattery 3", "PROBLEM", 188, 212], ["neutrophilic leucocytosis", "PROBLEM", 214, 239], ["internal ones", "ANATOMY", 91, 104], ["decreasing", "OBSERVATION_MODIFIER", 111, 121], ["lymphopenia", "OBSERVATION", 188, 199], ["neutrophilic", "OBSERVATION_MODIFIER", 214, 226], ["leucocytosis", "OBSERVATION", 227, 239]]], ["In contrast, the number of cats without FIP with anaemia, neutrophilic leucocytosis and increased a 2 -globulins recorded in cattery 1 was higher compared with the internal ranges than compared with the reference ones.", [["FIP", "DISEASE", 40, 43], ["anaemia", "DISEASE", 49, 56], ["neutrophilic leucocytosis", "DISEASE", 58, 83], ["cats", "ORGANISM", 27, 31], ["2 -globulins", "SIMPLE_CHEMICAL", 100, 112], ["FIP", "PROBLEM", 40, 43], ["anaemia", "PROBLEM", 49, 56], ["neutrophilic leucocytosis", "PROBLEM", 58, 83], ["a 2 -globulins", "TEST", 98, 112], ["without", "UNCERTAINTY", 32, 39], ["FIP", "OBSERVATION", 40, 43], ["anaemia", "OBSERVATION", 49, 56], ["neutrophilic", "OBSERVATION_MODIFIER", 58, 70], ["leucocytosis", "OBSERVATION", 71, 83], ["increased", "OBSERVATION_MODIFIER", 88, 97], ["higher", "OBSERVATION_MODIFIER", 139, 145], ["internal ranges", "OBSERVATION_MODIFIER", 164, 179]]], ["The specificity of these changes thus decreased, but, except for c-globulin concentration, their sensitivity increased, as the number of cats with FIP that had these changes compared to internal ranges, was higher than compared to the reference ones.DiscussionIn conclusion, this study allowed to design laboratory profiles typical of each cattery and confirmed the presence of haematological and electrophoretic changes consistent with FIP in catteries characterized by poor sanitary conditions and open management.", [["FIP", "DISEASE", 147, 150], ["FIP", "DISEASE", 437, 440], ["c-globulin", "GENE_OR_GENE_PRODUCT", 65, 75], ["cats", "ORGANISM", 137, 141], ["globulin", "PROTEIN", 67, 75], ["these changes", "PROBLEM", 19, 32], ["c-globulin concentration", "TREATMENT", 65, 89], ["FIP", "PROBLEM", 147, 150], ["this study", "TEST", 275, 285], ["haematological and electrophoretic changes", "PROBLEM", 378, 420], ["FIP in catteries", "PROBLEM", 437, 453], ["poor sanitary conditions", "PROBLEM", 471, 495], ["open management", "TREATMENT", 500, 515], ["decreased", "OBSERVATION_MODIFIER", 38, 47], ["increased", "OBSERVATION_MODIFIER", 109, 118], ["higher", "OBSERVATION_MODIFIER", 207, 213], ["consistent with", "UNCERTAINTY", 421, 436], ["FIP", "OBSERVATION", 437, 440], ["poor", "OBSERVATION_MODIFIER", 471, 475], ["sanitary conditions", "OBSERVATION", 476, 495]]], ["In these colonies, the appearance of clinical signs because of diseases other than FIP might lead to wrong diagnoses of FIP.", [["colonies", "ANATOMY", 9, 17], ["FIP", "DISEASE", 83, 86], ["FIP", "DISEASE", 120, 123], ["clinical signs", "TEST", 37, 51], ["diseases", "PROBLEM", 63, 71], ["FIP", "PROBLEM", 83, 86], ["FIP", "PROBLEM", 120, 123], ["colonies", "OBSERVATION", 9, 17], ["FIP", "OBSERVATION", 120, 123]]], ["This risk might be avoided by using internal ranges, calculated on the basis of the results of repeated samplings from cats without symptoms consistent with FIP.", [["FIP", "DISEASE", 157, 160], ["cats", "ORGANISM", 119, 123], ["repeated samplings from cats", "PROBLEM", 95, 123], ["symptoms", "PROBLEM", 132, 140], ["FIP", "PROBLEM", 157, 160], ["consistent with", "UNCERTAINTY", 141, 156], ["FIP", "OBSERVATION", 157, 160]]], ["The use of these internal ranges rarely affects the possibility to correctly diagnose the disease in cats with symptoms suggestive of FIP.", [["FIP", "DISEASE", 134, 137], ["cats", "ORGANISM", 101, 105], ["the disease in cats", "PROBLEM", 86, 105], ["symptoms", "PROBLEM", 111, 119], ["FIP", "PROBLEM", 134, 137], ["disease", "OBSERVATION", 90, 97], ["suggestive of", "UNCERTAINTY", 120, 133], ["FIP", "OBSERVATION", 134, 137]]]], "PMC7524538": [["COVID-19 related antimicrobial resistance challenges and opportunitiesGlobally, the USA has recorded the highest number of COVID-19 cases and deaths,1 and still needs to simultaneously respond to another looming potential pandemic.", [["COVID-19", "CHEMICAL", 0, 8], ["deaths", "DISEASE", 142, 148], ["COVID", "TEST", 0, 5], ["antimicrobial resistance challenges", "TREATMENT", 17, 52], ["COVID", "TEST", 123, 128], ["pandemic", "PROBLEM", 222, 230], ["19 related", "OBSERVATION_MODIFIER", 6, 16], ["antimicrobial resistance", "OBSERVATION", 17, 41]]], ["The rise in multidrug-resistant bacterial infections that are undetected, undiagnosed, and increasingly untreatable threatens the health of people in the USA and globally.", [["bacterial infections", "DISEASE", 32, 52], ["people", "ORGANISM", 140, 146], ["people", "SPECIES", 140, 146], ["multidrug-resistant bacterial infections", "PROBLEM", 12, 52], ["rise", "OBSERVATION_MODIFIER", 4, 8], ["multidrug", "OBSERVATION_MODIFIER", 12, 21], ["resistant", "OBSERVATION_MODIFIER", 22, 31], ["bacterial", "OBSERVATION_MODIFIER", 32, 41], ["infections", "OBSERVATION", 42, 52], ["increasingly", "OBSERVATION_MODIFIER", 91, 103], ["untreatable", "OBSERVATION_MODIFIER", 104, 115]]], ["In 2020 and beyond, we cannot afford to ignore antimicrobial resistance (AMR).COVID-19 related antimicrobial resistance challenges and opportunitiesBacterial infections unsuccessfully treated due to AMR claim at least 700 000 lives per year worldwide and are projected to be associated with the deaths of 10 million people per year by 2050, at a cost of US$100 trillion to the global economy through loss of productivity.2 In the USA, more than 2\u00b78 million multidrug-resistant bacterial infections occur annually, causing at least 35 000 deaths and $20 billion in health-care expenditures.3", [["AMR", "DISEASE", 73, 76], ["COVID-19", "CHEMICAL", 78, 86], ["Bacterial infections", "DISEASE", 148, 168], ["AMR", "DISEASE", 199, 202], ["deaths", "DISEASE", 295, 301], ["bacterial infections", "DISEASE", 477, 497], ["deaths", "DISEASE", 538, 544], ["people", "ORGANISM", 316, 322], ["people", "SPECIES", 316, 322], ["COVID", "TEST", 78, 83], ["antimicrobial resistance challenges", "TREATMENT", 95, 130], ["Bacterial infections", "PROBLEM", 148, 168], ["resistant bacterial infections", "PROBLEM", 467, 497], ["19 related", "OBSERVATION_MODIFIER", 84, 94], ["antimicrobial resistance", "OBSERVATION", 95, 119], ["resistant", "OBSERVATION_MODIFIER", 467, 476], ["bacterial", "OBSERVATION_MODIFIER", 477, 486], ["infections", "OBSERVATION", 487, 497]]]], "f1881761df826fdcf26fc5253900bda02be098cd": [["W aste plastics are a serious and growing environmental problem.", [["W aste plastics", "TREATMENT", 0, 15]]], ["Less than 10% of plastics are recycled, with most discarded in landfills, incinerated, or simply abandoned.", [["landfills", "OBSERVATION", 63, 72]]], ["While most plastics are used and initially disposed of on land, much eventually enters aquatic ecosystems.", [["aquatic ecosystems", "OBSERVATION", 87, 105]]], ["2 Wildlife mortalities result from encounters (e.g., ingestion and entanglement) with large debris, including plastic bags.", [["large debris", "PROBLEM", 86, 98], ["plastic bags", "TREATMENT", 110, 122], ["large", "OBSERVATION_MODIFIER", 86, 91], ["debris", "OBSERVATION", 92, 98], ["plastic bags", "OBSERVATION", 110, 122]]], ["Such bags are excluded from many recycling programs, as they can entangle machinery.", [["Such bags", "TREATMENT", 0, 9]]], ["However, they can be embrittled by UV exposure and fragment into microplastics (<5 mm) and nanoplastics (<1 \u03bcm) by abrasion.", [["fragment into microplastics", "PROBLEM", 51, 78], ["nanoplastics", "TEST", 91, 103], ["abrasion", "PROBLEM", 115, 123], ["fragment", "OBSERVATION_MODIFIER", 51, 59], ["microplastics", "OBSERVATION_MODIFIER", 65, 78], ["abrasion", "OBSERVATION", 115, 123]]], ["Minute particles can be ingested by biota at all levels of the food chain.", [["particles", "OBSERVATION", 7, 16], ["food chain", "OBSERVATION", 63, 73]]], ["Associated ecosystem and human health repercussions are growing concerns.", [["human", "ORGANISM", 25, 30], ["human", "SPECIES", 25, 30], ["human", "SPECIES", 25, 30], ["ecosystem", "OBSERVATION_MODIFIER", 11, 20]]], ["2 In terms of waste minimization and sustainability, direct reuse of plastic products followed by recycling are preferred solutions.", [["waste minimization", "TREATMENT", 14, 32], ["plastic products", "TREATMENT", 69, 85], ["waste minimization", "OBSERVATION", 14, 32], ["plastic products", "OBSERVATION", 69, 85]]]], "PMC7357521": [["In regard of locally advanced esophageal cancer they suggest to apply preoperative concurrent radiochemotherapy (pRTCT), being the standard option; it should be given using the shortest fractionation scheme possible.", [["esophageal cancer", "ANATOMY", 30, 47], ["esophageal cancer", "DISEASE", 30, 47], ["esophageal cancer", "CANCER", 30, 47], ["locally advanced esophageal cancer", "PROBLEM", 13, 47], ["preoperative concurrent radiochemotherapy (pRTCT)", "TREATMENT", 70, 119], ["the standard option", "TREATMENT", 127, 146], ["the shortest fractionation scheme", "TREATMENT", 173, 206], ["locally", "OBSERVATION_MODIFIER", 13, 20], ["advanced", "OBSERVATION_MODIFIER", 21, 29], ["esophageal", "ANATOMY", 30, 40], ["cancer", "OBSERVATION", 41, 47]]], ["Finally, induction chemotherapy is mentioned as alternative to delay the initiation of daily radiotherapy, but that statement, although in view of subsequent RTCT, was controversial among authors due to still non mature supporting data.", [["induction chemotherapy", "TREATMENT", 9, 31], ["daily radiotherapy", "TREATMENT", 87, 105]]], ["We agree with Authors, since we believe RTCT is standard for esophageal cancers.", [["esophageal cancers", "ANATOMY", 61, 79], ["esophageal cancers", "DISEASE", 61, 79], ["esophageal cancers", "CANCER", 61, 79], ["esophageal cancers", "PROBLEM", 61, 79], ["esophageal", "ANATOMY", 61, 71], ["cancers", "OBSERVATION", 72, 79]]], ["Of note, esophagogastric junctional (EGJ) anatomic sub-sites as described by Siewert classification [2] belong to esophageal cancers for Siewert I and II, while type III belong to gastric primary, as by current TNM classification [3].", [["esophagogastric junctional", "ANATOMY", 9, 35], ["EGJ", "ANATOMY", 37, 40], ["esophageal cancers", "ANATOMY", 114, 132], ["gastric primary", "ANATOMY", 180, 195], ["esophageal cancers", "DISEASE", 114, 132], ["esophagogastric junctional", "MULTI-TISSUE_STRUCTURE", 9, 35], ["esophageal cancers", "CANCER", 114, 132], ["gastric primary", "CANCER", 180, 195], ["esophagogastric junctional (EGJ) anatomic sub-sites", "DNA", 9, 60], ["esophagogastric junctional (EGJ) anatomic sub-sites", "PROBLEM", 9, 60], ["esophageal cancers", "PROBLEM", 114, 132], ["esophagogastric junctional", "ANATOMY", 9, 35], ["EGJ", "ANATOMY", 37, 40], ["esophageal", "ANATOMY", 114, 124], ["cancers", "OBSERVATION", 125, 132], ["gastric", "ANATOMY", 180, 187], ["primary", "OBSERVATION", 188, 195]]], ["Actually two of the most representative international Guidelines report this indication [4], [5], [6], [7].", [["[6]", "SIMPLE_CHEMICAL", 98, 101]]], ["NCCN guidelines also include preoperative chemotherapy (pCT) as an option for esophageal cancer, but specify that pRTCT is the preferable option.", [["esophageal cancer", "ANATOMY", 78, 95], ["esophageal cancer", "DISEASE", 78, 95], ["esophageal cancer", "CANCER", 78, 95], ["NCCN guidelines", "TREATMENT", 0, 15], ["preoperative chemotherapy", "TREATMENT", 29, 54], ["pCT", "TREATMENT", 56, 59], ["esophageal cancer", "PROBLEM", 78, 95], ["esophageal", "ANATOMY", 78, 88], ["cancer", "OBSERVATION", 89, 95]]], ["In this perspective also along Covid scenario pRTCT should remain the best option.", [["Covid scenario pRTCT", "TREATMENT", 31, 51]]], ["Conversely, ESMO guidelines include pRTCT and pCT at the same priority level: in this perspective avoiding daily access to hospital for pRTCT favoring a cyclic access for pCT could be maybe preferable.", [["pRTCT", "TREATMENT", 36, 41], ["pCT", "TREATMENT", 46, 49], ["pRTCT", "TREATMENT", 136, 141], ["a cyclic access", "TREATMENT", 151, 166], ["pCT", "TREATMENT", 171, 174]]], ["Efficacy and safety of pRTCT have been unequivocally demonstrated by randomized controlled trials (RTrials) [8], [9], with long-term follow-up [10], for both squamous (SCC) and adenocarcinoma (ADK) histology [9], [10], gaining significant improvement of overall survival and local control [11].", [["squamous", "ANATOMY", 158, 166], ["SCC", "ANATOMY", 168, 171], ["adenocarcinoma", "ANATOMY", 177, 191], ["ADK", "ANATOMY", 193, 196], ["squamous (SCC) and adenocarcinoma", "DISEASE", 158, 191], ["pRTCT", "SIMPLE_CHEMICAL", 23, 28], ["squamous", "CANCER", 158, 166], ["SCC", "CANCER", 168, 171], ["adenocarcinoma", "CANCER", 177, 191], ["pRTCT", "PROTEIN", 23, 28], ["pRTCT", "TREATMENT", 23, 28], ["randomized controlled trials (RTrials)", "TREATMENT", 69, 107], ["both squamous (SCC", "PROBLEM", 153, 171], ["adenocarcinoma", "PROBLEM", 177, 191], ["histology", "TEST", 198, 207], ["squamous", "ANATOMY", 158, 166], ["adenocarcinoma", "OBSERVATION", 177, 191]]], ["Sometimes in scientific research and current clinical practice (e.g.: multidisciplinary tumor board) pCT is advocated as superior of preferable to pRTCT at least for adenocarcinoma histology and/or for Siewert type II junctional presentations.", [["tumor", "ANATOMY", 88, 93], ["adenocarcinoma", "ANATOMY", 166, 180], ["tumor", "DISEASE", 88, 93], ["adenocarcinoma", "DISEASE", 166, 180], ["tumor", "CANCER", 88, 93], ["adenocarcinoma", "CANCER", 166, 180], ["multidisciplinary tumor board", "TREATMENT", 70, 99], ["pCT", "TEST", 101, 104], ["adenocarcinoma histology", "PROBLEM", 166, 190], ["Siewert type II junctional presentations", "PROBLEM", 202, 242], ["adenocarcinoma", "OBSERVATION", 166, 180]]], ["That is usually on the basis of Guideline indications such as ESMO [5] and on the efficacy reported for ADK (often derived by RTrials on gastric primaries [12], [13] or by efficient pCT schedules as FLOT, not tested over pRTCT in RTrials [14].", [["gastric primaries", "ANATOMY", 137, 154], ["ADK", "DISEASE", 104, 107], ["gastric", "ORGAN", 137, 144], ["ADK", "PROBLEM", 104, 107], ["gastric", "ANATOMY", 137, 144]]], ["Current evidence based superiority of pRTCT over pCT also for ADK is supported by some arguments.", [["ADK", "DISEASE", 62, 65], ["pRTCT", "SIMPLE_CHEMICAL", 38, 43], ["pRTCT", "PROTEIN", 38, 43], ["pRTCT over pCT", "TREATMENT", 38, 52], ["ADK", "PROBLEM", 62, 65], ["some", "OBSERVATION_MODIFIER", 82, 86], ["arguments", "OBSERVATION", 87, 96]]], ["First: the mentioned evidences by trials specifically significant for ADK [9], [10]; then, the evidence base supporting pRTCT derive from RTrials in esophageal cancer, while that is not always the case for pCT [12].", [["esophageal cancer", "ANATOMY", 149, 166], ["esophageal cancer", "DISEASE", 149, 166], ["esophageal cancer", "CANCER", 149, 166], ["pRTCT", "PROTEIN", 120, 125], ["ADK", "TEST", 70, 73], ["esophageal cancer", "PROBLEM", 149, 166], ["pCT", "TEST", 206, 209], ["esophageal", "ANATOMY", 149, 159], ["cancer", "OBSERVATION", 160, 166]]], ["Notably, CROSS trial accrued 25% of EGJ, 57,5% of distal localization and 75% of ADK [9].", [["EGJ", "DISEASE", 36, 39], ["ADK", "DISEASE", 81, 84], ["EGJ", "CANCER", 36, 39], ["EGJ", "TEST", 36, 39], ["distal localization", "TEST", 50, 69], ["ADK", "TEST", 81, 84], ["EGJ", "ANATOMY", 36, 39], ["distal", "ANATOMY_MODIFIER", 50, 56]]], ["Sjoquist et al. in a meta-analysis on 24 studies (accounting for 4188 patients) reported survival benefit of pRTCT or pCT over surgery alone in patients with esophageal carcinoma [15].", [["esophageal carcinoma", "ANATOMY", 158, 178], ["esophageal carcinoma", "DISEASE", 158, 178], ["patients", "ORGANISM", 70, 78], ["patients", "ORGANISM", 144, 152], ["esophageal carcinoma", "CANCER", 158, 178], ["patients", "SPECIES", 70, 78], ["patients", "SPECIES", 144, 152], ["pRTCT", "TREATMENT", 109, 114], ["pCT over surgery", "TREATMENT", 118, 134], ["esophageal carcinoma", "PROBLEM", 158, 178], ["esophageal", "ANATOMY", 158, 168], ["carcinoma", "OBSERVATION", 169, 178]]], ["Although Authors didn\u2019t found clear advantage of pRTCT over pCT, they reported that the hazard ratio (HR) for all-cause mortality with pRTCT was 0.78 (95% CI 0.70\u20130.88; p<0.0001), significant for both hystologies in subgroup analyses; while HR of pCT was 0.87 (0.79\u20130.96; p=0.005), only significant for ADK.", [["pRTCT", "PROTEIN", 49, 54], ["ADK", "PROTEIN", 303, 306], ["pCT", "TEST", 60, 63], ["the hazard ratio", "TEST", 84, 100], ["HR", "TEST", 102, 104], ["pRTCT", "TEST", 135, 140], ["CI", "TEST", 155, 157], ["p", "TEST", 169, 170], ["both hystologies in subgroup analyses", "PROBLEM", 196, 233], ["HR", "TEST", 241, 243], ["pCT", "TEST", 247, 250], ["p", "TEST", 272, 273], ["ADK", "PROBLEM", 303, 306]]], ["In summary both pRTCT and pCT are significantly effective for esophageal cancer, but with much different magnitude, favoring pRTCT.", [["esophageal cancer", "ANATOMY", 62, 79], ["esophageal cancer", "DISEASE", 62, 79], ["esophageal cancer", "CANCER", 62, 79], ["pRTCT", "DNA", 16, 21], ["pRTCT", "PROTEIN", 125, 130], ["pRTCT", "TEST", 16, 21], ["pCT", "TEST", 26, 29], ["esophageal cancer", "PROBLEM", 62, 79], ["esophageal", "ANATOMY", 62, 72], ["cancer", "OBSERVATION", 73, 79]]], ["Finally Ronellenfitsch et al. published a meta-analysis on 14 studies (accounting for 2422 patients) only focused on ADK (esophageal, gastric and EGJ) [16].", [["esophageal", "ANATOMY", 122, 132], ["gastric", "ANATOMY", 134, 141], ["EGJ", "ANATOMY", 146, 149], ["esophageal, gastric and EGJ)", "DISEASE", 122, 150], ["patients", "ORGANISM", 91, 99], ["esophageal", "MULTI-TISSUE_STRUCTURE", 122, 132], ["gastric", "MULTI-TISSUE_STRUCTURE", 134, 141], ["patients", "SPECIES", 91, 99], ["14 studies", "TEST", 59, 69], ["esophageal", "ANATOMY", 122, 132], ["gastric", "ANATOMY", 134, 141], ["EGJ", "ANATOMY", 146, 149]]], ["In their analysis neoadjuvant (CT-based, including radiotherapy) approach significantly improved clinical outcomes over surgery-only.", [["CT", "TEST", 31, 33], ["radiotherapy", "TREATMENT", 51, 63], ["surgery", "TREATMENT", 120, 127]]], ["In subgroup analysis they found higher efficacy in EGJ and for pRTCT compared to pCT, but the tests for subgroup differences were not statistically significant due to the low number of patients enrolled in direct comparison trials.", [["patients", "ORGANISM", 185, 193], ["patients", "SPECIES", 185, 193], ["subgroup analysis", "TEST", 3, 20], ["higher efficacy in EGJ", "PROBLEM", 32, 54], ["pRTCT", "TEST", 63, 68], ["pCT", "TEST", 81, 84], ["the tests", "TEST", 90, 99], ["direct comparison trials", "TEST", 206, 230], ["higher", "OBSERVATION_MODIFIER", 32, 38], ["efficacy", "OBSERVATION_MODIFIER", 39, 47], ["EGJ", "ANATOMY", 51, 54]]], ["These evidences influenced the position of NCCN.", [["NCCN", "CANCER", 43, 47], ["NCCN", "PROTEIN", 43, 47], ["position", "OBSERVATION_MODIFIER", 31, 39]]], ["In conclusion we do believe that pRTCT should be preferred to pCT both in Covid era and beyond, currently being the gold standard for both SCC and ADK (including Siewert type I and II).", [["SCC", "ANATOMY", 139, 142], ["SCC", "DISEASE", 139, 142], ["ADK", "DISEASE", 147, 150], ["pRTCT", "SIMPLE_CHEMICAL", 33, 38], ["SCC", "CANCER", 139, 142], ["ADK", "CANCER", 147, 150], ["pCT", "TEST", 62, 65], ["both SCC and ADK", "PROBLEM", 134, 150]]], ["An open issue could be superiority of pCT for non-EGJ (upper, middle and lower third) presentations.", [["non-EGJ", "ANATOMY", 46, 53], ["pCT", "CANCER", 38, 41], ["upper", "ORGANISM_SUBDIVISION", 55, 60], ["pCT", "TEST", 38, 41], ["non-EGJ (upper, middle and lower third) presentations", "PROBLEM", 46, 99], ["open", "OBSERVATION", 3, 7], ["upper", "ANATOMY_MODIFIER", 55, 60], ["middle", "ANATOMY_MODIFIER", 62, 68], ["lower", "ANATOMY_MODIFIER", 73, 78]]]], "3d94191ac055bee08581038e9423511bd066b74c": [["1Most causes of sore throat are nonbacterial and neither require nor are alleviated by antibiotic therapy (Tables 1.1, 1.2, and 1.3).", [["sore throat", "ANATOMY", 16, 27], ["sore throat", "DISEASE", 16, 27], ["nonbacterial", "DISEASE", 32, 44], ["throat", "ORGANISM_SUBDIVISION", 21, 27], ["sore throat", "PROBLEM", 16, 27], ["nonbacterial", "PROBLEM", 32, 44], ["antibiotic therapy", "TREATMENT", 87, 105], ["Tables", "TEST", 107, 113], ["sore throat", "ANATOMY", 16, 27], ["nonbacterial", "OBSERVATION", 32, 44]]], ["Accurate diagnosis is essential: Acute streptococcal pharyngitis warrants diagnosis and therapy to ensure prevention of serious suppurative and nonsuppurative complications.", [["streptococcal pharyngitis", "DISEASE", 39, 64], ["Acute streptococcal pharyngitis", "PROBLEM", 33, 64], ["therapy", "TREATMENT", 88, 95], ["serious suppurative and nonsuppurative complications", "PROBLEM", 120, 172], ["Acute", "OBSERVATION_MODIFIER", 33, 38], ["streptococcal", "OBSERVATION_MODIFIER", 39, 52], ["pharyngitis", "OBSERVATION", 53, 64], ["serious", "OBSERVATION_MODIFIER", 120, 127], ["suppurative", "OBSERVATION_MODIFIER", 128, 139], ["nonsuppurative", "OBSERVATION_MODIFIER", 144, 158]]], ["Life-threatening infectious complications of oropharyngeal infections, whether streptococcal or nonstreptococcal, may manifest with mouth pain, pharyngitis, parapharyngeal space infectious extension, and/or airway obstruction (Tables 1.4 and 1.5).", [["oropharyngeal", "ANATOMY", 45, 58], ["nonstreptococcal", "ANATOMY", 96, 112], ["mouth", "ANATOMY", 132, 137], ["parapharyngeal space", "ANATOMY", 157, 177], ["airway", "ANATOMY", 207, 213], ["oropharyngeal infections", "DISEASE", 45, 69], ["streptococcal or nonstreptococcal", "DISEASE", 79, 112], ["mouth pain", "DISEASE", 132, 142], ["pharyngitis", "DISEASE", 144, 155], ["parapharyngeal space infectious extension", "DISEASE", 157, 198], ["airway obstruction", "DISEASE", 207, 225], ["oropharyngeal", "ORGANISM_SUBDIVISION", 45, 58], ["mouth", "ORGANISM_SUBDIVISION", 132, 137], ["airway", "PATHOLOGICAL_FORMATION", 207, 213], ["oropharyngeal infections", "PROBLEM", 45, 69], ["streptococcal", "PROBLEM", 79, 92], ["nonstreptococcal", "PROBLEM", 96, 112], ["mouth pain", "PROBLEM", 132, 142], ["pharyngitis", "PROBLEM", 144, 155], ["parapharyngeal space infectious extension", "PROBLEM", 157, 198], ["airway obstruction", "PROBLEM", 207, 225], ["threatening", "OBSERVATION_MODIFIER", 5, 16], ["infectious", "OBSERVATION_MODIFIER", 17, 27], ["oropharyngeal", "ANATOMY", 45, 58], ["infections", "OBSERVATION", 59, 69], ["pharyngitis", "OBSERVATION", 144, 155], ["parapharyngeal space", "ANATOMY", 157, 177], ["infectious", "OBSERVATION", 178, 188], ["airway", "ANATOMY", 207, 213], ["obstruction", "OBSERVATION", 214, 225]]], ["In many cases, the history and/or physical exam can help direct diagnosis and treatment, but the enormous number of potential causes is too large to address all of them.VIRAL PHARYNGITISMost episodes of pharyngitis are caused by viruses (see Tables 1.2 and 1.3).", [["pharyngitis", "DISEASE", 203, 214], ["physical exam", "TEST", 34, 47], ["treatment", "TREATMENT", 78, 87], ["pharyngitis", "PROBLEM", 203, 214], ["viruses", "PROBLEM", 229, 236], ["pharyngitis", "OBSERVATION", 203, 214], ["viruses", "OBSERVATION", 229, 236]]], ["It is difficult to clinically distinguish between viral and bacterial pharyngitis with a very high degree of precision, but certain clues may help the physician.", [["pharyngitis", "DISEASE", 70, 81], ["viral and bacterial pharyngitis", "PROBLEM", 50, 81], ["viral", "OBSERVATION", 50, 55], ["bacterial", "OBSERVATION_MODIFIER", 60, 69], ["pharyngitis", "OBSERVATION", 70, 81]]], ["Accompanying symptoms of conjunctivitis, rhinitis, cough, discrete ulcerations, croup, or laryngitis are common with viral infection but rare in bacterial pharyngitis.VIRAL PHARYNGITISMany viral agents can produce pharyngitis (see Tables 1.2 and 1.3) .", [["conjunctivitis", "DISEASE", 25, 39], ["rhinitis", "DISEASE", 41, 49], ["cough", "DISEASE", 51, 56], ["ulcerations", "DISEASE", 67, 78], ["croup", "DISEASE", 80, 85], ["laryngitis", "DISEASE", 90, 100], ["viral infection", "DISEASE", 117, 132], ["bacterial pharyngitis", "DISEASE", 145, 166], ["pharyngitis", "DISEASE", 214, 225], ["ulcerations", "PATHOLOGICAL_FORMATION", 67, 78], ["Accompanying symptoms", "PROBLEM", 0, 21], ["conjunctivitis", "PROBLEM", 25, 39], ["rhinitis", "PROBLEM", 41, 49], ["cough", "PROBLEM", 51, 56], ["discrete ulcerations", "PROBLEM", 58, 78], ["croup", "PROBLEM", 80, 85], ["laryngitis", "PROBLEM", 90, 100], ["viral infection", "PROBLEM", 117, 132], ["bacterial pharyngitis", "PROBLEM", 145, 166], ["VIRAL PHARYNGITISMany viral agents", "TREATMENT", 167, 201], ["pharyngitis", "PROBLEM", 214, 225], ["conjunctivitis", "OBSERVATION", 25, 39], ["rhinitis", "OBSERVATION", 41, 49], ["cough", "OBSERVATION", 51, 56], ["discrete", "OBSERVATION_MODIFIER", 58, 66], ["ulcerations", "OBSERVATION", 67, 78], ["croup", "OBSERVATION_MODIFIER", 80, 85], ["laryngitis", "OBSERVATION", 90, 100], ["viral", "OBSERVATION_MODIFIER", 117, 122], ["infection", "OBSERVATION", 123, 132], ["bacterial", "OBSERVATION_MODIFIER", 145, 154], ["pharyngitis", "OBSERVATION", 155, 166]]], ["Some cause distinct clinical syndromes that are readily diagnosed without laboratory testing (Table 1.6; see also Tables 1.1 and 1.4).", [["distinct clinical syndromes", "PROBLEM", 11, 38], ["laboratory testing", "TEST", 74, 92], ["Table", "TEST", 94, 99]]], ["In pharyngitis caused by parainfluenza and influenza viruses, rhinoviruses, coronaviruses, and respiratory syncytial virus (RSV), the symptoms of coryza and cough often overshadow sore throat, which is generally mild.", [["pharyngitis", "DISEASE", 3, 14], ["parainfluenza", "DISEASE", 25, 38], ["influenza viruses", "DISEASE", 43, 60], ["rhinoviruses, coronaviruses", "DISEASE", 62, 89], ["respiratory syncytial virus", "DISEASE", 95, 122], ["RSV", "DISEASE", 124, 127], ["coryza", "DISEASE", 146, 152], ["cough", "DISEASE", 157, 162], ["sore throat", "DISEASE", 180, 191], ["parainfluenza", "ORGANISM", 25, 38], ["influenza viruses", "ORGANISM", 43, 60], ["rhinoviruses", "ORGANISM", 62, 74], ["coronaviruses", "ORGANISM", 76, 89], ["respiratory syncytial virus", "ORGANISM", 95, 122], ["RSV", "ORGANISM", 124, 127], ["throat", "ORGANISM_SUBDIVISION", 185, 191], ["parainfluenza", "SPECIES", 25, 38], ["rhinoviruses", "SPECIES", 62, 74], ["respiratory syncytial virus", "SPECIES", 95, 122], ["respiratory syncytial virus", "SPECIES", 95, 122], ["RSV", "SPECIES", 124, 127], ["pharyngitis", "PROBLEM", 3, 14], ["parainfluenza", "PROBLEM", 25, 38], ["influenza viruses", "PROBLEM", 43, 60], ["rhinoviruses", "PROBLEM", 62, 74], ["coronaviruses", "PROBLEM", 76, 89], ["respiratory syncytial virus", "PROBLEM", 95, 122], ["the symptoms", "PROBLEM", 130, 142], ["coryza", "PROBLEM", 146, 152], ["cough", "PROBLEM", 157, 162], ["sore throat", "PROBLEM", 180, 191], ["pharyngitis", "OBSERVATION", 3, 14], ["parainfluenza", "OBSERVATION", 25, 38], ["influenza viruses", "OBSERVATION", 43, 60], ["respiratory", "ANATOMY", 95, 106], ["syncytial virus", "OBSERVATION", 107, 122], ["generally", "OBSERVATION_MODIFIER", 202, 211], ["mild", "OBSERVATION_MODIFIER", 212, 216]]], ["Influenza virus may cause high fever, cough, headache, malaise, myalgia, and cervical adenopathy in addition to pharyngitis.", [["cervical adenopathy", "ANATOMY", 77, 96], ["Influenza virus", "DISEASE", 0, 15], ["fever", "DISEASE", 31, 36], ["cough", "DISEASE", 38, 43], ["headache", "DISEASE", 45, 53], ["myalgia", "DISEASE", 64, 71], ["cervical adenopathy", "DISEASE", 77, 96], ["pharyngitis", "DISEASE", 112, 123], ["Influenza virus", "ORGANISM", 0, 15], ["cervical", "ORGAN", 77, 85], ["Influenza virus", "SPECIES", 0, 15], ["Influenza virus", "SPECIES", 0, 15], ["Influenza virus", "PROBLEM", 0, 15], ["high fever", "PROBLEM", 26, 36], ["cough", "PROBLEM", 38, 43], ["headache", "PROBLEM", 45, 53], ["malaise", "PROBLEM", 55, 62], ["myalgia", "PROBLEM", 64, 71], ["cervical adenopathy", "PROBLEM", 77, 96], ["pharyngitis", "PROBLEM", 112, 123], ["myalgia", "OBSERVATION", 64, 71], ["cervical", "ANATOMY", 77, 85], ["adenopathy", "OBSERVATION", 86, 96], ["pharyngitis", "OBSERVATION", 112, 123]]], ["In young children, croup or bronchiolitis may develop.", [["croup", "DISEASE", 19, 24], ["bronchiolitis", "DISEASE", 28, 41], ["children", "ORGANISM", 9, 17], ["children", "SPECIES", 9, 17], ["croup", "PROBLEM", 19, 24], ["bronchiolitis", "PROBLEM", 28, 41], ["bronchiolitis", "OBSERVATION", 28, 41]]], ["When influenza is suspected on clinical and epidemiologic grounds or confirmed by testing (polymerase chain reaction [PCR] is most accurate), specific antiviral therapy is available for treatment of patients and prophylaxis of family members.", [["influenza", "DISEASE", 5, 14], ["patients", "ORGANISM", 199, 207], ["patients", "SPECIES", 199, 207], ["influenza", "PROBLEM", 5, 14], ["polymerase chain reaction", "PROBLEM", 91, 116], ["PCR", "TEST", 118, 121], ["specific antiviral therapy", "TREATMENT", 142, 168], ["treatment", "TREATMENT", 186, 195]]], ["RSV is associated with bronchiolitis, pneumonia, and croup in young children.", [["RSV", "DISEASE", 0, 3], ["bronchiolitis", "DISEASE", 23, 36], ["pneumonia", "DISEASE", 38, 47], ["croup", "DISEASE", 53, 58], ["RSV", "ORGANISM", 0, 3], ["children", "ORGANISM", 68, 76], ["children", "SPECIES", 68, 76], ["RSV", "SPECIES", 0, 3], ["RSV", "PROBLEM", 0, 3], ["bronchiolitis", "PROBLEM", 23, 36], ["pneumonia", "PROBLEM", 38, 47], ["associated with", "UNCERTAINTY", 7, 22], ["bronchiolitis", "OBSERVATION", 23, 36], ["pneumonia", "OBSERVATION", 38, 47], ["croup", "OBSERVATION_MODIFIER", 53, 58]]], ["RSV infection in older children is usually indistinguishable from a simple upper respiratory tract infection.", [["upper respiratory tract", "ANATOMY", 75, 98], ["RSV infection", "DISEASE", 0, 13], ["respiratory tract infection", "DISEASE", 81, 108], ["RSV", "ORGANISM", 0, 3], ["children", "ORGANISM", 23, 31], ["upper respiratory", "ORGANISM_SUBDIVISION", 75, 92], ["tract", "ORGANISM_SUBDIVISION", 93, 98], ["children", "SPECIES", 23, 31], ["RSV", "SPECIES", 0, 3], ["RSV infection", "PROBLEM", 0, 13], ["a simple upper respiratory tract infection", "PROBLEM", 66, 108], ["infection", "OBSERVATION", 4, 13], ["simple", "OBSERVATION_MODIFIER", 68, 74], ["upper", "ANATOMY_MODIFIER", 75, 80], ["respiratory tract", "ANATOMY", 81, 98], ["infection", "OBSERVATION", 99, 108]]], ["Pharyngitis is not a prominent finding of RSV infection in any age group.", [["Pharyngitis", "DISEASE", 0, 11], ["RSV infection", "DISEASE", 42, 55], ["RSV", "ORGANISM", 42, 45], ["RSV", "SPECIES", 42, 45], ["Pharyngitis", "PROBLEM", 0, 11], ["RSV infection", "PROBLEM", 42, 55], ["not a prominent", "UNCERTAINTY", 15, 30], ["RSV", "OBSERVATION_MODIFIER", 42, 45], ["infection", "OBSERVATION", 46, 55]]], ["Parainfluenza viruses are associated with croup and bronchiolitis; minor sore throat and signs of pharyngitis are common at the outset but rapidly resolve.", [["Parainfluenza viruses", "DISEASE", 0, 21], ["croup", "DISEASE", 42, 47], ["bronchiolitis", "DISEASE", 52, 65], ["sore throat", "DISEASE", 73, 84], ["pharyngitis", "DISEASE", 98, 109], ["Parainfluenza viruses", "ORGANISM", 0, 21], ["Parainfluenza viruses", "SPECIES", 0, 21], ["Parainfluenza viruses", "PROBLEM", 0, 21], ["croup", "PROBLEM", 42, 47], ["bronchiolitis", "PROBLEM", 52, 65], ["minor sore throat", "PROBLEM", 67, 84], ["pharyngitis", "PROBLEM", 98, 109], ["viruses", "OBSERVATION", 14, 21], ["bronchiolitis", "OBSERVATION", 52, 65], ["minor", "OBSERVATION_MODIFIER", 67, 72], ["sore throat", "ANATOMY", 73, 84], ["pharyngitis", "OBSERVATION", 98, 109]]], ["Infections caused by parainfluenza, influenza, and RSV are often seen in seasonal (winter) epidemics.", [["Infections", "DISEASE", 0, 10], ["parainfluenza", "DISEASE", 21, 34], ["influenza", "DISEASE", 36, 45], ["RSV", "DISEASE", 51, 54], ["parainfluenza", "ORGANISM", 21, 34], ["RSV", "ORGANISM", 51, 54], ["parainfluenza", "SPECIES", 21, 34], ["RSV", "SPECIES", 51, 54], ["RSV", "SPECIES", 51, 54], ["Infections", "PROBLEM", 0, 10], ["parainfluenza", "PROBLEM", 21, 34], ["influenza", "PROBLEM", 36, 45], ["RSV", "PROBLEM", 51, 54], ["epidemics", "PROBLEM", 91, 100], ["parainfluenza", "OBSERVATION", 21, 34], ["influenza", "OBSERVATION", 36, 45]]], ["Many agents can be identified using multiplex or targeted PCR testing, but there is rarely reason to test outpatients and infrequent benefit to testing inpatients except to confirm and treat influenza.VIRAL PHARYNGITISAdenoviruses can cause upper and lower respiratory tract disease, ranging from ordinary colds to severe pneumonia and multisystem disease, including hepatitis, myocarditis, and myositis.", [["lower respiratory tract", "ANATOMY", 251, 274], ["influenza", "DISEASE", 191, 200], ["upper and lower respiratory tract disease", "DISEASE", 241, 282], ["colds", "DISEASE", 306, 311], ["pneumonia", "DISEASE", 322, 331], ["multisystem disease", "DISEASE", 336, 355], ["hepatitis", "DISEASE", 367, 376], ["myocarditis", "DISEASE", 378, 389], ["myositis", "DISEASE", 395, 403], ["upper", "ORGANISM_SUBDIVISION", 241, 246], ["lower", "ORGANISM_SUBDIVISION", 251, 256], ["respiratory tract", "ORGANISM_SUBDIVISION", 257, 274], ["targeted PCR testing", "TEST", 49, 69], ["testing inpatients", "TEST", 144, 162], ["influenza", "PROBLEM", 191, 200], ["VIRAL PHARYNGITISAdenoviruses", "PROBLEM", 201, 230], ["upper and lower respiratory tract disease", "PROBLEM", 241, 282], ["severe pneumonia", "PROBLEM", 315, 331], ["multisystem disease", "PROBLEM", 336, 355], ["hepatitis", "PROBLEM", 367, 376], ["myocarditis", "PROBLEM", 378, 389], ["myositis", "PROBLEM", 395, 403], ["PHARYNGITISAdenoviruses", "OBSERVATION", 207, 230], ["upper", "ANATOMY_MODIFIER", 241, 246], ["lower", "ANATOMY_MODIFIER", 251, 256], ["respiratory tract", "ANATOMY", 257, 274], ["severe", "OBSERVATION_MODIFIER", 315, 321], ["pneumonia", "OBSERVATION", 322, 331], ["multisystem disease", "OBSERVATION", 336, 355], ["hepatitis", "OBSERVATION", 367, 376], ["myocarditis", "OBSERVATION", 378, 389], ["myositis", "OBSERVATION", 395, 403]]], ["The incubation period of adenovirus infection is 2-4 days.", [["adenovirus infection", "DISEASE", 25, 45], ["adenovirus", "ORGANISM", 25, 35], ["adenovirus", "SPECIES", 25, 35], ["adenovirus infection", "PROBLEM", 25, 45], ["adenovirus", "OBSERVATION_MODIFIER", 25, 35], ["infection", "OBSERVATION", 36, 45]]], ["Upper respiratory tract infection typically produces fever, erythema of the pharynx, and follicular hyperplasia of the tonsils, together with exudate.", [["Upper respiratory tract", "ANATOMY", 0, 23], ["pharynx", "ANATOMY", 76, 83], ["follicular hyperplasia", "ANATOMY", 89, 111], ["tonsils", "ANATOMY", 119, 126], ["exudate", "ANATOMY", 142, 149], ["respiratory tract infection", "DISEASE", 6, 33], ["fever", "DISEASE", 53, 58], ["erythema of the pharynx", "DISEASE", 60, 83], ["hyperplasia of the tonsils", "DISEASE", 100, 126], ["Upper respiratory tract", "ORGANISM_SUBDIVISION", 0, 23], ["pharynx", "ORGAN", 76, 83], ["follicular hyperplasia", "PATHOLOGICAL_FORMATION", 89, 111], ["tonsils", "ORGAN", 119, 126], ["exudate", "TISSUE", 142, 149], ["Upper respiratory tract infection", "PROBLEM", 0, 33], ["fever", "PROBLEM", 53, 58], ["erythema of the pharynx", "PROBLEM", 60, 83], ["follicular hyperplasia of the tonsils", "PROBLEM", 89, 126], ["exudate", "PROBLEM", 142, 149], ["respiratory tract", "ANATOMY", 6, 23], ["infection", "OBSERVATION", 24, 33], ["fever", "OBSERVATION", 53, 58], ["erythema", "OBSERVATION", 60, 68], ["pharynx", "ANATOMY", 76, 83], ["follicular hyperplasia", "OBSERVATION", 89, 111], ["tonsils", "ANATOMY", 119, 126], ["exudate", "OBSERVATION", 142, 149]]], ["Enlargement of the cervical lymph nodes occurs frequently.", [["cervical lymph nodes", "ANATOMY", 19, 39], ["cervical lymph nodes", "MULTI-TISSUE_STRUCTURE", 19, 39], ["Enlargement of the cervical lymph nodes", "PROBLEM", 0, 39], ["cervical", "ANATOMY", 19, 27], ["lymph nodes", "OBSERVATION", 28, 39]]], ["When conjunctivitis occurs in association with adenoviral pharyngitis, the resulting syndrome is called pharyngoconjunctival fever.", [["pharyngoconjunctival", "ANATOMY", 104, 124], ["conjunctivitis", "DISEASE", 5, 19], ["adenoviral pharyngitis", "DISEASE", 47, 69], ["pharyngoconjunctival fever", "DISEASE", 104, 130], ["adenoviral", "ORGANISM", 47, 57], ["conjunctivitis", "PROBLEM", 5, 19], ["adenoviral pharyngitis", "PROBLEM", 47, 69], ["the resulting syndrome", "PROBLEM", 71, 93], ["pharyngoconjunctival fever", "PROBLEM", 104, 130], ["conjunctivitis", "OBSERVATION", 5, 19], ["pharyngitis", "OBSERVATION", 58, 69]]], ["Pharyngitis may last as long as 7 days and does not respond to antibiotics.", [["Pharyngitis", "DISEASE", 0, 11], ["Pharyngitis", "PROBLEM", 0, 11], ["antibiotics", "TREATMENT", 63, 74]]], ["There are many adenovirus serotypes; adenovirus infections may therefore develop in children more than once.", [["adenovirus infections", "DISEASE", 37, 58], ["adenovirus", "ORGANISM", 15, 25], ["adenovirus", "ORGANISM", 37, 47], ["children", "ORGANISM", 84, 92], ["children", "SPECIES", 84, 92], ["adenovirus", "SPECIES", 37, 47], ["many adenovirus serotypes", "PROBLEM", 10, 35], ["adenovirus infections", "PROBLEM", 37, 58], ["many", "OBSERVATION_MODIFIER", 10, 14], ["adenovirus serotypes", "OBSERVATION", 15, 35], ["adenovirus infections", "OBSERVATION", 37, 58]]], ["Laboratory studies may reveal a leukocytosis and an elevated erythrocyte sedimentation rate.", [["erythrocyte", "ANATOMY", 61, 72], ["leukocytosis", "DISEASE", 32, 44], ["erythrocyte", "CELL", 61, 72], ["Laboratory studies", "TEST", 0, 18], ["a leukocytosis", "PROBLEM", 30, 44], ["an elevated erythrocyte sedimentation rate", "PROBLEM", 49, 91], ["leukocytosis", "OBSERVATION", 32, 44], ["elevated erythrocyte sedimentation", "OBSERVATION", 52, 86]]], ["Adenovirus outbreaks have been associated with swimming pools and contamination in health care workers.VIRAL PHARYNGITISThe enteroviruses (coxsackievirus and echovirus) can cause sore throat, especially in the summer.", [["Adenovirus outbreaks", "DISEASE", 0, 20], ["enteroviruses (coxsackievirus and echovirus)", "DISEASE", 124, 168], ["sore throat", "DISEASE", 179, 190], ["Adenovirus", "ORGANISM", 0, 10], ["enteroviruses", "ORGANISM", 124, 137], ["coxsackievirus", "ORGANISM", 139, 153], ["Adenovirus", "SPECIES", 0, 10], ["Adenovirus outbreaks", "PROBLEM", 0, 20], ["VIRAL PHARYNGITISThe enteroviruses", "PROBLEM", 103, 137], ["coxsackievirus", "PROBLEM", 139, 153], ["echovirus", "PROBLEM", 158, 167], ["sore throat", "PROBLEM", 179, 190], ["PHARYNGITISThe enteroviruses", "OBSERVATION", 109, 137]]], ["High fever is common, and the throat is erythematous but usually not bright red; tonsillar exudate and cervical adenopathy are unusual.", [["throat", "ANATOMY", 30, 36], ["tonsillar exudate", "ANATOMY", 81, 98], ["cervical adenopathy", "ANATOMY", 103, 122], ["fever", "DISEASE", 5, 10], ["adenopathy", "DISEASE", 112, 122], ["throat", "ORGANISM_SUBDIVISION", 30, 36], ["tonsillar exudate", "MULTI-TISSUE_STRUCTURE", 81, 98], ["cervical adenopathy", "CANCER", 103, 122], ["High fever", "PROBLEM", 0, 10], ["erythematous", "PROBLEM", 40, 52], ["bright red", "PROBLEM", 69, 79], ["tonsillar exudate", "PROBLEM", 81, 98], ["cervical adenopathy", "PROBLEM", 103, 122], ["fever", "OBSERVATION", 5, 10], ["throat", "ANATOMY", 30, 36], ["erythematous", "OBSERVATION", 40, 52], ["tonsillar", "ANATOMY", 81, 90], ["exudate", "OBSERVATION", 91, 98], ["cervical", "ANATOMY", 103, 111], ["adenopathy", "OBSERVATION", 112, 122]]], ["Symptoms resolve within a few days.", [["Symptoms", "PROBLEM", 0, 8]]], ["Enteroviruses can also cause meningitis, myocarditis, rash, and two specific syndromes that involve the oropharynx.VIRAL PHARYNGITISHerpangina is characterized by distinctive discrete, painful, graywhite papulovesicular lesions distributed over the posterior oropharynx (see Table 1 .6).", [["oropharynx", "ANATOMY", 104, 114], ["graywhite papulovesicular lesions", "ANATOMY", 194, 227], ["posterior oropharynx", "ANATOMY", 249, 269], ["Enteroviruses", "DISEASE", 0, 13], ["meningitis", "DISEASE", 29, 39], ["myocarditis", "DISEASE", 41, 52], ["rash", "DISEASE", 54, 58], ["oropharynx", "ORGAN", 104, 114], ["papulovesicular lesions", "CANCER", 204, 227], ["oropharynx", "ORGAN", 259, 269], ["Enteroviruses", "PROBLEM", 0, 13], ["meningitis", "PROBLEM", 29, 39], ["myocarditis", "PROBLEM", 41, 52], ["rash", "PROBLEM", 54, 58], ["two specific syndromes", "PROBLEM", 64, 86], ["VIRAL PHARYNGITISHerpangina", "PROBLEM", 115, 142], ["distinctive discrete, painful, graywhite papulovesicular lesions", "PROBLEM", 163, 227], ["can also cause", "UNCERTAINTY", 14, 28], ["meningitis", "OBSERVATION", 29, 39], ["myocarditis", "OBSERVATION", 41, 52], ["rash", "OBSERVATION", 54, 58], ["oropharynx", "ANATOMY", 104, 114], ["PHARYNGITISHerpangina", "OBSERVATION", 121, 142], ["distinctive", "OBSERVATION_MODIFIER", 163, 174], ["discrete", "OBSERVATION_MODIFIER", 175, 183], ["painful", "OBSERVATION_MODIFIER", 185, 192], ["graywhite", "OBSERVATION_MODIFIER", 194, 203], ["papulovesicular", "OBSERVATION_MODIFIER", 204, 219], ["lesions", "OBSERVATION", 220, 227], ["posterior", "ANATOMY_MODIFIER", 249, 258], ["oropharynx", "ANATOMY", 259, 269]]], ["The vesicles are 1-2 mm in diameter and are initially surrounded by a halo of erythema before they ulcerate.", [["vesicles", "ANATOMY", 4, 12], ["erythema", "ANATOMY", 78, 86], ["erythema", "DISEASE", 78, 86], ["vesicles", "CELLULAR_COMPONENT", 4, 12], ["erythema", "PATHOLOGICAL_FORMATION", 78, 86], ["a halo of erythema", "PROBLEM", 68, 86], ["vesicles", "ANATOMY", 4, 12], ["1-2 mm", "OBSERVATION_MODIFIER", 17, 23], ["diameter", "OBSERVATION_MODIFIER", 27, 35], ["halo", "OBSERVATION_MODIFIER", 70, 74], ["erythema", "OBSERVATION", 78, 86]]], ["Fever may reach 39.5\u00b0C. The illness is due to enteroviruses and generally lasts less than 7 days, but severe pain may impair fluid intake and occasionally necessitates medical support.VIRAL PHARYNGITISHand-foot-mouth disease is caused by coxsackievirus A16.", [["fluid", "ANATOMY", 125, 130], ["Fever", "DISEASE", 0, 5], ["illness", "DISEASE", 28, 35], ["enteroviruses", "DISEASE", 46, 59], ["pain", "DISEASE", 109, 113], ["foot-mouth disease", "DISEASE", 206, 224], ["enteroviruses", "ORGANISM", 46, 59], ["fluid", "ORGANISM_SUBSTANCE", 125, 130], ["mouth", "ORGAN", 211, 216], ["coxsackievirus A16", "ORGANISM", 238, 256], ["coxsackievirus A16", "SPECIES", 238, 256], ["Fever", "PROBLEM", 0, 5], ["The illness", "PROBLEM", 24, 35], ["enteroviruses", "PROBLEM", 46, 59], ["severe pain", "PROBLEM", 102, 113], ["fluid intake", "PROBLEM", 125, 137], ["medical support", "TREATMENT", 168, 183], ["mouth disease", "PROBLEM", 211, 224], ["coxsackievirus A16", "PROBLEM", 238, 256], ["enteroviruses", "OBSERVATION", 46, 59], ["foot", "ANATOMY", 206, 210], ["mouth", "ANATOMY", 211, 216], ["disease", "OBSERVATION", 217, 224], ["coxsackievirus", "OBSERVATION", 238, 252]]], ["Painful vesicles that ulcerate can occur throughout the oropharynx.", [["vesicles", "ANATOMY", 8, 16], ["oropharynx", "ANATOMY", 56, 66], ["vesicles", "CELLULAR_COMPONENT", 8, 16], ["oropharynx", "ORGAN", 56, 66], ["Painful vesicles", "PROBLEM", 0, 16], ["ulcerate", "OBSERVATION", 22, 30], ["oropharynx", "ANATOMY", 56, 66]]], ["Vesicles also develop on the palms, soles, and, less often, on the trunk or extremities.", [["Vesicles", "ANATOMY", 0, 8], ["palms", "ANATOMY", 29, 34], ["soles", "ANATOMY", 36, 41], ["trunk", "ANATOMY", 67, 72], ["extremities", "ANATOMY", 76, 87], ["Vesicles", "ORGANISM_SUBSTANCE", 0, 8], ["palms", "ORGANISM_SUBDIVISION", 29, 34], ["soles", "ORGANISM_SUBDIVISION", 36, 41], ["trunk", "ORGANISM_SUBDIVISION", 67, 72], ["extremities", "ORGANISM_SUBDIVISION", 76, 87], ["palms", "ANATOMY", 29, 34], ["soles", "ANATOMY", 36, 41], ["less", "OBSERVATION_MODIFIER", 48, 52], ["often", "OBSERVATION_MODIFIER", 53, 58], ["trunk", "ANATOMY", 67, 72], ["extremities", "ANATOMY", 76, 87]]], ["Fever is present in most cases, but many children do not appear seriously ill.", [["Fever", "DISEASE", 0, 5], ["children", "ORGANISM", 41, 49], ["children", "SPECIES", 41, 49], ["Fever", "PROBLEM", 0, 5]]], ["This disease lasts less than 7 days.", [["This disease", "PROBLEM", 0, 12], ["disease", "OBSERVATION", 5, 12]]], ["Primary infection caused by herpes simplex virus (HSV) usually produces high fever with acute gingivostomatitis, involving vesicles (which become ulcers) throughout the anterior portion of the mouth, including the lips.", [["vesicles", "ANATOMY", 123, 131], ["ulcers", "ANATOMY", 146, 152], ["anterior portion", "ANATOMY", 169, 185], ["mouth", "ANATOMY", 193, 198], ["lips", "ANATOMY", 214, 218], ["Primary infection", "DISEASE", 0, 17], ["herpes simplex virus (HSV)", "DISEASE", 28, 54], ["fever", "DISEASE", 77, 82], ["gingivostomatitis", "DISEASE", 94, 111], ["ulcers", "DISEASE", 146, 152], ["herpes simplex virus", "ORGANISM", 28, 48], ["HSV", "ORGANISM", 50, 53], ["vesicles", "CELLULAR_COMPONENT", 123, 131], ["ulcers", "PATHOLOGICAL_FORMATION", 146, 152], ["anterior portion", "MULTI-TISSUE_STRUCTURE", 169, 185], ["mouth", "ORGAN", 193, 198], ["lips", "ORGANISM_SUBDIVISION", 214, 218], ["herpes simplex virus", "SPECIES", 28, 48], ["herpes simplex virus", "SPECIES", 28, 48], ["HSV", "SPECIES", 50, 53], ["Primary infection", "PROBLEM", 0, 17], ["herpes simplex virus", "PROBLEM", 28, 48], ["HSV", "PROBLEM", 50, 53], ["high fever", "PROBLEM", 72, 82], ["acute gingivostomatitis", "PROBLEM", 88, 111], ["vesicles", "PROBLEM", 123, 131], ["ulcers", "PROBLEM", 146, 152], ["infection", "OBSERVATION", 8, 17], ["herpes simplex virus", "OBSERVATION", 28, 48], ["high", "OBSERVATION_MODIFIER", 72, 76], ["fever", "OBSERVATION", 77, 82], ["acute", "OBSERVATION_MODIFIER", 88, 93], ["gingivostomatitis", "OBSERVATION", 94, 111], ["vesicles", "ANATOMY", 123, 131], ["ulcers", "OBSERVATION", 146, 152], ["anterior", "ANATOMY_MODIFIER", 169, 177], ["portion", "ANATOMY_MODIFIER", 178, 185], ["mouth", "ANATOMY", 193, 198], ["lips", "ANATOMY", 214, 218]]], ["There is sparing of the posterior pharynx in herpes gingivostomatitis; the infection usually occurs in young children.", [["posterior pharynx", "ANATOMY", 24, 41], ["herpes gingivostomatitis", "DISEASE", 45, 69], ["infection", "DISEASE", 75, 84], ["posterior pharynx", "ORGAN", 24, 41], ["herpes", "ORGANISM", 45, 51], ["children", "ORGANISM", 109, 117], ["children", "SPECIES", 109, 117], ["sparing of the posterior pharynx", "PROBLEM", 9, 41], ["herpes gingivostomatitis", "PROBLEM", 45, 69], ["the infection", "PROBLEM", 71, 84], ["sparing", "OBSERVATION_MODIFIER", 9, 16], ["posterior", "ANATOMY_MODIFIER", 24, 33], ["pharynx", "ANATOMY", 34, 41], ["herpes gingivostomatitis", "OBSERVATION", 45, 69], ["infection", "OBSERVATION", 75, 84]]], ["High fever is common, pain is intense, and intake of oral fluids is often impaired, which may lead to dehydration.", [["oral", "ANATOMY", 53, 57], ["fever", "DISEASE", 5, 10], ["pain", "DISEASE", 22, 26], ["dehydration", "DISEASE", 102, 113], ["oral", "ORGANISM_SUBDIVISION", 53, 57], ["High fever", "PROBLEM", 0, 10], ["pain", "PROBLEM", 22, 26], ["oral fluids", "TREATMENT", 53, 64], ["dehydration", "PROBLEM", 102, 113], ["fever", "OBSERVATION", 5, 10], ["intense", "OBSERVATION_MODIFIER", 30, 37]]], ["In addition, HSV may A common cause of a local and large lesion of unknown etiology is aphthous stomatitis (Fig. 1.1) .", [["lesion", "ANATOMY", 57, 63], ["aphthous", "ANATOMY", 87, 95], ["aphthous stomatitis", "DISEASE", 87, 106], ["HSV", "ORGANISM", 13, 16], ["lesion", "CANCER", 57, 63], ["HSV", "SPECIES", 13, 16], ["HSV", "PROBLEM", 13, 16], ["a local and large lesion", "PROBLEM", 39, 63], ["aphthous stomatitis", "PROBLEM", 87, 106], ["local", "OBSERVATION_MODIFIER", 41, 46], ["large", "OBSERVATION_MODIFIER", 51, 56], ["lesion", "OBSERVATION", 57, 63], ["unknown", "UNCERTAINTY", 67, 74], ["aphthous", "OBSERVATION_MODIFIER", 87, 95], ["stomatitis", "OBSERVATION", 96, 106]]], ["PFAPA (periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis) is an idiopathic periodic fever syndrome that occurs predictably every 2-8 weeks.", [["cervical", "ANATOMY", 61, 69], ["PFAPA", "CHEMICAL", 0, 5], ["fever", "DISEASE", 16, 21], ["aphthous stomatitis", "DISEASE", 23, 42], ["pharyngitis", "DISEASE", 44, 55], ["cervical adenitis", "DISEASE", 61, 78], ["idiopathic periodic fever syndrome", "DISEASE", 86, 120], ["PFAPA", "SIMPLE_CHEMICAL", 0, 5], ["cervical", "ORGAN", 61, 69], ["PFAPA", "PROBLEM", 0, 5], ["periodic fever", "PROBLEM", 7, 21], ["aphthous stomatitis", "PROBLEM", 23, 42], ["pharyngitis", "PROBLEM", 44, 55], ["cervical adenitis", "PROBLEM", 61, 78], ["an idiopathic periodic fever syndrome", "PROBLEM", 83, 120], ["aphthous stomatitis", "OBSERVATION_MODIFIER", 23, 42], ["pharyngitis", "OBSERVATION", 44, 55], ["cervical", "ANATOMY", 61, 69], ["adenitis", "OBSERVATION", 70, 78], ["idiopathic", "OBSERVATION_MODIFIER", 86, 96], ["periodic", "OBSERVATION_MODIFIER", 97, 105], ["fever syndrome", "OBSERVATION", 106, 120]]], ["The onset of PFAPA is usually before the age of 5 years.", [["PFAPA", "DISEASE", 13, 18], ["PFAPA", "CANCER", 13, 18], ["PFAPA", "PROBLEM", 13, 18], ["PFAPA", "OBSERVATION", 13, 18]]], ["In addition to aphthous stomatitis and pharyngitis, PFAPA is characterized by high fever lasting 4-6 days.", [["aphthous stomatitis", "DISEASE", 15, 34], ["pharyngitis", "DISEASE", 39, 50], ["PFAPA", "DISEASE", 52, 57], ["fever", "DISEASE", 83, 88], ["aphthous stomatitis", "ORGANISM", 15, 34], ["aphthous stomatitis", "PROBLEM", 15, 34], ["pharyngitis", "PROBLEM", 39, 50], ["PFAPA", "PROBLEM", 52, 57], ["high fever", "PROBLEM", 78, 88], ["aphthous", "OBSERVATION_MODIFIER", 15, 23], ["stomatitis", "OBSERVATION", 24, 34], ["pharyngitis", "OBSERVATION", 39, 50], ["high", "OBSERVATION_MODIFIER", 78, 82], ["fever", "OBSERVATION", 83, 88]]], ["Individual episodes resolve spontaneously but may respondINFECTIOUS MONONUCLEOSIS PathogenesisAcute exudative pharyngitis commonly occurs with infectious mononucleosis caused by primary infection with the Epstein-Barr virus (EBV).", [["exudative pharyngitis", "DISEASE", 100, 121], ["infectious mononucleosis", "DISEASE", 143, 167], ["primary infection", "DISEASE", 178, 195], ["Epstein-Barr virus", "ORGANISM", 205, 223], ["EBV", "ORGANISM", 225, 228], ["Epstein-Barr virus", "SPECIES", 205, 223], ["EBV", "SPECIES", 225, 228], ["Individual episodes", "PROBLEM", 0, 19], ["respondINFECTIOUS MONONUCLEOSIS PathogenesisAcute exudative pharyngitis", "PROBLEM", 50, 121], ["infectious mononucleosis", "PROBLEM", 143, 167], ["primary infection", "PROBLEM", 178, 195], ["the Epstein-Barr virus", "PROBLEM", 201, 223], ["exudative", "OBSERVATION_MODIFIER", 100, 109], ["pharyngitis", "OBSERVATION", 110, 121], ["infectious", "OBSERVATION_MODIFIER", 143, 153], ["primary", "OBSERVATION_MODIFIER", 178, 185], ["infection", "OBSERVATION", 186, 195], ["Barr virus", "OBSERVATION", 213, 223]]], ["Mononucleosis is a febrile, systemic, self-limited lymphoproliferative disorder that is usually associated with hepatosplenomegaly and generalized lymphadenopathy.", [["Mononucleosis", "DISEASE", 0, 13], ["febrile", "DISEASE", 19, 26], ["lymphoproliferative disorder", "DISEASE", 51, 79], ["hepatosplenomegaly", "DISEASE", 112, 130], ["lymphadenopathy", "DISEASE", 147, 162], ["Mononucleosis", "PROBLEM", 0, 13], ["a febrile", "PROBLEM", 17, 26], ["self-limited lymphoproliferative disorder", "PROBLEM", 38, 79], ["hepatosplenomegaly", "PROBLEM", 112, 130], ["generalized lymphadenopathy", "PROBLEM", 135, 162], ["febrile", "OBSERVATION_MODIFIER", 19, 26], ["self-limited", "OBSERVATION_MODIFIER", 38, 50], ["lymphoproliferative disorder", "OBSERVATION", 51, 79], ["usually associated with", "UNCERTAINTY", 88, 111], ["hepatosplenomegaly", "OBSERVATION", 112, 130], ["generalized", "OBSERVATION_MODIFIER", 135, 146], ["lymphadenopathy", "OBSERVATION", 147, 162]]], ["Acute pharyngitis may be mild or severe, with significant tonsillar hypertrophy (possibly producing airway obstruction), erythema, and impressive tonsillar exudates.", [["tonsillar", "ANATOMY", 58, 67], ["airway", "ANATOMY", 100, 106], ["erythema", "ANATOMY", 121, 129], ["tonsillar exudates", "ANATOMY", 146, 164], ["pharyngitis", "DISEASE", 6, 17], ["tonsillar hypertrophy", "DISEASE", 58, 79], ["airway obstruction", "DISEASE", 100, 118], ["erythema", "DISEASE", 121, 129], ["tonsillar exudates", "DISEASE", 146, 164], ["tonsillar", "ORGAN", 58, 67], ["airway obstruction", "PATHOLOGICAL_FORMATION", 100, 118], ["tonsillar exudates", "PATHOLOGICAL_FORMATION", 146, 164], ["Acute pharyngitis", "PROBLEM", 0, 17], ["significant tonsillar hypertrophy", "PROBLEM", 46, 79], ["airway obstruction)", "PROBLEM", 100, 119], ["erythema", "PROBLEM", 121, 129], ["impressive tonsillar exudates", "PROBLEM", 135, 164], ["pharyngitis", "OBSERVATION", 6, 17], ["mild", "OBSERVATION_MODIFIER", 25, 29], ["severe", "OBSERVATION_MODIFIER", 33, 39], ["significant", "OBSERVATION_MODIFIER", 46, 57], ["tonsillar", "ANATOMY", 58, 67], ["hypertrophy", "OBSERVATION", 68, 79], ["possibly producing", "UNCERTAINTY", 81, 99], ["airway", "ANATOMY", 100, 106], ["obstruction", "OBSERVATION", 107, 118], ["erythema", "OBSERVATION", 121, 129], ["impressive", "OBSERVATION_MODIFIER", 135, 145], ["tonsillar", "ANATOMY", 146, 155], ["exudates", "OBSERVATION", 156, 164]]], ["Regional lymph nodes may be particularly enlarged and slightly tender.", [["lymph nodes", "ANATOMY", 9, 20], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 9, 20], ["Regional lymph nodes", "PROBLEM", 0, 20], ["slightly tender", "PROBLEM", 54, 69], ["lymph nodes", "OBSERVATION", 9, 20], ["may be particularly", "UNCERTAINTY", 21, 40], ["enlarged", "OBSERVATION", 41, 49], ["slightly", "OBSERVATION_MODIFIER", 54, 62], ["tender", "OBSERVATION", 63, 69]]], ["Infectious mononucleosis usually occurs in adolescents and young adults; EBV infection is generally milder or subclinical in preadolescent children.", [["Infectious mononucleosis", "DISEASE", 0, 24], ["EBV infection", "DISEASE", 73, 86], ["adults", "ORGANISM", 65, 71], ["EBV", "ORGANISM", 73, 76], ["children", "ORGANISM", 139, 147], ["adolescents", "SPECIES", 43, 54], ["children", "SPECIES", 139, 147], ["EBV", "SPECIES", 73, 76], ["Infectious mononucleosis", "PROBLEM", 0, 24], ["EBV infection", "PROBLEM", 73, 86], ["infection", "OBSERVATION", 77, 86], ["subclinical", "OBSERVATION_MODIFIER", 110, 121]]], ["EBV is transmitted primarily by saliva.Clinical FeaturesAfter a 2-4 week incubation period, patients with infectious mononucleosis usually experience an abrupt onset of malaise, fatigue, fever, and headache, followed closely by pharyngitis.", [["infectious mononucleosis", "DISEASE", 106, 130], ["fatigue", "DISEASE", 178, 185], ["fever", "DISEASE", 187, 192], ["headache", "DISEASE", 198, 206], ["pharyngitis", "DISEASE", 228, 239], ["EBV", "ORGANISM", 0, 3], ["saliva", "ORGANISM_SUBSTANCE", 32, 38], ["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 92, 100], ["EBV", "SPECIES", 0, 3], ["EBV", "PROBLEM", 0, 3], ["infectious mononucleosis", "PROBLEM", 106, 130], ["malaise", "PROBLEM", 169, 176], ["fatigue", "PROBLEM", 178, 185], ["fever", "PROBLEM", 187, 192], ["headache", "PROBLEM", 198, 206], ["pharyngitis", "PROBLEM", 228, 239], ["infectious", "OBSERVATION_MODIFIER", 106, 116], ["abrupt", "OBSERVATION_MODIFIER", 153, 159], ["malaise", "OBSERVATION", 169, 176], ["pharyngitis", "OBSERVATION", 228, 239]]], ["The tonsils are enlarged with exudates and cervical adenopathy.", [["tonsils", "ANATOMY", 4, 11], ["exudates", "ANATOMY", 30, 38], ["cervical adenopathy", "ANATOMY", 43, 62], ["adenopathy", "DISEASE", 52, 62], ["tonsils", "ORGAN", 4, 11], ["cervical adenopathy", "CANCER", 43, 62], ["exudates", "PROBLEM", 30, 38], ["cervical adenopathy", "PROBLEM", 43, 62], ["tonsils", "ANATOMY", 4, 11], ["enlarged", "OBSERVATION", 16, 24], ["exudates", "OBSERVATION_MODIFIER", 30, 38], ["cervical", "ANATOMY", 43, 51], ["adenopathy", "OBSERVATION", 52, 62]]], ["More generalized adenopathy with hepatosplenomegaly often follows.", [["adenopathy", "DISEASE", 17, 27], ["hepatosplenomegaly", "DISEASE", 33, 51], ["More generalized adenopathy", "PROBLEM", 0, 27], ["hepatosplenomegaly", "PROBLEM", 33, 51], ["generalized", "OBSERVATION_MODIFIER", 5, 16], ["adenopathy", "OBSERVATION", 17, 27], ["hepatosplenomegaly", "OBSERVATION", 33, 51]]], ["Fever and pharyngitis typically last 1-3 weeks, and lymphadenopathy and hepatosplenomegaly resolve over 3-6 weeks.", [["Fever", "DISEASE", 0, 5], ["pharyngitis", "DISEASE", 10, 21], ["lymphadenopathy", "DISEASE", 52, 67], ["hepatosplenomegaly", "DISEASE", 72, 90], ["Fever", "PROBLEM", 0, 5], ["pharyngitis", "PROBLEM", 10, 21], ["lymphadenopathy", "PROBLEM", 52, 67], ["hepatosplenomegaly", "PROBLEM", 72, 90], ["pharyngitis", "OBSERVATION", 10, 21], ["lymphadenopathy", "OBSERVATION", 52, 67], ["hepatosplenomegaly", "OBSERVATION", 72, 90]]], ["Malaise and lethargy can persist for several months and can affect school or work performance.DiagnosisLaboratory studies of diagnostic value include atypical lymphocytosis; these lymphocytes are primarily EBVspecific, cytotoxic T lymphocytes that represent a reactive response to EBV-infected B lymphocytes.", [["lymphocytes", "ANATOMY", 180, 191], ["cytotoxic T lymphocytes", "ANATOMY", 219, 242], ["B lymphocytes", "ANATOMY", 294, 307], ["Malaise", "DISEASE", 0, 7], ["lethargy", "DISEASE", 12, 20], ["lymphocytosis", "DISEASE", 159, 172], ["lymphocytes", "CELL", 180, 191], ["cytotoxic T lymphocytes", "CELL", 219, 242], ["EBV", "ORGANISM", 281, 284], ["B lymphocytes", "CELL", 294, 307], ["lymphocytes", "CELL_TYPE", 180, 191], ["EBVspecific, cytotoxic T lymphocytes", "CELL_TYPE", 206, 242], ["EBV-infected B lymphocytes", "CELL_TYPE", 281, 307], ["EBV", "SPECIES", 281, 284], ["Malaise", "PROBLEM", 0, 7], ["lethargy", "PROBLEM", 12, 20], ["DiagnosisLaboratory studies", "TEST", 94, 121], ["diagnostic value", "TEST", 125, 141], ["atypical lymphocytosis", "PROBLEM", 150, 172], ["these lymphocytes", "TEST", 174, 191], ["EBVspecific", "PROBLEM", 206, 217], ["cytotoxic T lymphocytes", "PROBLEM", 219, 242], ["EBV", "TEST", 281, 284], ["infected B lymphocytes", "PROBLEM", 285, 307], ["atypical", "OBSERVATION_MODIFIER", 150, 158], ["lymphocytosis", "OBSERVATION", 159, 172], ["lymphocytes", "ANATOMY", 180, 191], ["cytotoxic T lymphocytes", "OBSERVATION", 219, 242], ["reactive response", "OBSERVATION", 260, 277], ["infected", "OBSERVATION_MODIFIER", 285, 293], ["B lymphocytes", "OBSERVATION", 294, 307]]], ["A modest elevation of serum transaminase levels, reflecting EBV hepatitis, is common.", [["serum", "ANATOMY", 22, 27], ["EBV hepatitis", "DISEASE", 60, 73], ["serum", "ORGANISM_SUBSTANCE", 22, 27], ["EBV", "ORGANISM", 60, 63], ["serum transaminase", "PROTEIN", 22, 40], ["EBV hepatitis", "SPECIES", 60, 73], ["A modest elevation of serum transaminase levels", "PROBLEM", 0, 47], ["EBV hepatitis", "PROBLEM", 60, 73], ["modest", "OBSERVATION_MODIFIER", 2, 8], ["elevation", "OBSERVATION_MODIFIER", 9, 18], ["EBV hepatitis", "OBSERVATION", 60, 73]]], ["Tests useful for diagnosis include detection of heterophile antibodies that react with bovine erythrocytes (most often detected by the monospot test) and a specific antibody against EBV viral capsid antigen (VCA), early antigen (EA), and nuclear antigen (EBNA).", [["erythrocytes", "ANATOMY", 94, 106], ["bovine", "ORGANISM", 87, 93], ["erythrocytes", "CELL", 94, 106], ["EBV", "ORGANISM", 182, 185], ["viral capsid antigen", "GENE_OR_GENE_PRODUCT", 186, 206], ["VCA", "GENE_OR_GENE_PRODUCT", 208, 211], ["early antigen", "GENE_OR_GENE_PRODUCT", 214, 227], ["EA", "GENE_OR_GENE_PRODUCT", 229, 231], ["nuclear antigen", "GENE_OR_GENE_PRODUCT", 238, 253], ["EBNA", "GENE_OR_GENE_PRODUCT", 255, 259], ["heterophile antibodies", "PROTEIN", 48, 70], ["bovine erythrocytes", "CELL_TYPE", 87, 106], ["EBV viral capsid antigen", "PROTEIN", 182, 206], ["VCA", "PROTEIN", 208, 211], ["early antigen", "PROTEIN", 214, 227], ["EA", "PROTEIN", 229, 231], ["nuclear antigen", "PROTEIN", 238, 253], ["EBNA", "PROTEIN", 255, 259], ["bovine", "SPECIES", 87, 93], ["bovine", "SPECIES", 87, 93], ["EBV", "SPECIES", 182, 185], ["Tests", "TEST", 0, 5], ["heterophile antibodies", "PROBLEM", 48, 70], ["bovine erythrocytes", "PROBLEM", 87, 106], ["the monospot test", "TEST", 131, 148], ["a specific antibody", "TEST", 154, 173], ["EBV viral capsid antigen", "TEST", 182, 206], ["heterophile antibodies", "OBSERVATION", 48, 70]]], ["Acute infectious mononucleosis is usually associated with a positive heterophile test result and antibody to VCA and EA ( Fig. 1.2) .", [["infectious mononucleosis", "DISEASE", 6, 30], ["VCA", "GENE_OR_GENE_PRODUCT", 109, 112], ["VCA", "PROTEIN", 109, 112], ["Acute infectious mononucleosis", "PROBLEM", 0, 30], ["a positive heterophile test result", "PROBLEM", 58, 92], ["antibody", "TEST", 97, 105], ["VCA", "TEST", 109, 112], ["EA", "TEST", 117, 119], ["Fig.", "TEST", 122, 126], ["infectious", "OBSERVATION", 6, 16], ["positive", "OBSERVATION_MODIFIER", 60, 68], ["heterophile", "OBSERVATION", 69, 80]]], ["The findings of acute exudative pharyngitis together with hepatomegaly, splenomegaly, and generalized lymphadenopathy suggest infectious mononucleosis.", [["pharyngitis", "DISEASE", 32, 43], ["hepatomegaly", "DISEASE", 58, 70], ["splenomegaly", "DISEASE", 72, 84], ["lymphadenopathy", "DISEASE", 102, 117], ["infectious mononucleosis", "DISEASE", 126, 150], ["acute exudative pharyngitis", "PROBLEM", 16, 43], ["hepatomegaly", "PROBLEM", 58, 70], ["splenomegaly", "PROBLEM", 72, 84], ["generalized lymphadenopathy", "PROBLEM", 90, 117], ["infectious mononucleosis", "PROBLEM", 126, 150], ["acute", "OBSERVATION_MODIFIER", 16, 21], ["exudative", "OBSERVATION_MODIFIER", 22, 31], ["pharyngitis", "OBSERVATION", 32, 43], ["hepatomegaly", "OBSERVATION", 58, 70], ["splenomegaly", "OBSERVATION", 72, 84], ["generalized", "OBSERVATION_MODIFIER", 90, 101], ["lymphadenopathy", "OBSERVATION", 102, 117], ["suggest", "UNCERTAINTY", 118, 125], ["infectious", "OBSERVATION_MODIFIER", 126, 136], ["mononucleosis", "OBSERVATION", 137, 150]]], ["Early in the disease and in cases without liver or spleen enlargement, differentiation from other causes of pharyngitis, including streptococcal pharyngitis, is difficult.", [["liver", "ANATOMY", 42, 47], ["spleen", "ANATOMY", 51, 57], ["liver or spleen enlargement", "DISEASE", 42, 69], ["pharyngitis", "DISEASE", 108, 119], ["streptococcal pharyngitis", "DISEASE", 131, 156], ["liver", "ORGAN", 42, 47], ["spleen", "ORGAN", 51, 57], ["the disease", "PROBLEM", 9, 20], ["liver or spleen enlargement", "PROBLEM", 42, 69], ["pharyngitis", "PROBLEM", 108, 119], ["streptococcal pharyngitis", "PROBLEM", 131, 156], ["disease", "OBSERVATION", 13, 20], ["without", "UNCERTAINTY", 34, 41], ["liver", "ANATOMY", 42, 47], ["spleen", "ANATOMY", 51, 57], ["enlargement", "OBSERVATION", 58, 69], ["pharyngitis", "OBSERVATION", 108, 119], ["streptococcal", "OBSERVATION_MODIFIER", 131, 144], ["pharyngitis", "OBSERVATION", 145, 156]]], ["Indeed, a small number of patients with infectious mononucleosis have a throat culture positive for group A streptococci.", [["throat", "ANATOMY", 72, 78], ["infectious mononucleosis", "DISEASE", 40, 64], ["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34], ["infectious mononucleosis", "PROBLEM", 40, 64], ["a throat culture", "TEST", 70, 86], ["group A streptococci", "PROBLEM", 100, 120], ["small", "OBSERVATION_MODIFIER", 10, 15], ["number", "OBSERVATION_MODIFIER", 16, 22], ["infectious", "OBSERVATION_MODIFIER", 40, 50], ["throat", "ANATOMY", 72, 78]]], ["(They are likely streptococcal carriers; see subsequent text.)", [["streptococcal carriers", "PROBLEM", 17, 39], ["likely", "UNCERTAINTY", 10, 16], ["streptococcal", "OBSERVATION_MODIFIER", 17, 30]]], ["An indistinguishable syndrome can occur with cytomegalovirus, but differentiation is rarely of clinical importance.", [["cytomegalovirus", "DISEASE", 45, 60], ["cytomegalovirus", "ORGANISM", 45, 60], ["An indistinguishable syndrome", "PROBLEM", 0, 29], ["cytomegalovirus", "PROBLEM", 45, 60], ["syndrome", "OBSERVATION", 21, 29], ["cytomegalovirus", "OBSERVATION", 45, 60]]], ["Serologic evidence of mononucleosis should be sought to oral prednisone or cimetidine.", [["oral", "ANATOMY", 56, 60], ["mononucleosis", "DISEASE", 22, 35], ["prednisone", "CHEMICAL", 61, 71], ["cimetidine", "CHEMICAL", 75, 85], ["prednisone", "CHEMICAL", 61, 71], ["cimetidine", "CHEMICAL", 75, 85], ["oral", "ORGANISM_SUBDIVISION", 56, 60], ["prednisone", "SIMPLE_CHEMICAL", 61, 71], ["cimetidine", "SIMPLE_CHEMICAL", 75, 85], ["mononucleosis", "PROBLEM", 22, 35], ["oral prednisone", "TREATMENT", 56, 71], ["cimetidine", "TREATMENT", 75, 85], ["mononucleosis", "OBSERVATION", 22, 35]]], ["There are reports of improvement after tonsillectomy.", [["tonsillectomy", "TREATMENT", 39, 52], ["improvement", "OBSERVATION_MODIFIER", 21, 32], ["tonsillectomy", "OBSERVATION", 39, 52]]], ["In most patients PFAPA completely resolves before puberty without sequelae.", [["PFAPA", "CHEMICAL", 17, 22], ["PFAPA", "CHEMICAL", 17, 22], ["patients", "ORGANISM", 8, 16], ["PFAPA", "SIMPLE_CHEMICAL", 17, 22], ["patients", "SPECIES", 8, 16], ["sequelae", "PROBLEM", 66, 74]]], ["The diagnosis is based on clinical criteria after excluding cyclic neutropenia, other periodic fever syndromes, infections, and malignancy.DiagnosisInfants and toddlers with measles often have prominent oral findings early in the course of the disease.", [["oral", "ANATOMY", 203, 207], ["neutropenia", "DISEASE", 67, 78], ["fever", "DISEASE", 95, 100], ["infections", "DISEASE", 112, 122], ["malignancy", "DISEASE", 128, 138], ["measles", "DISEASE", 174, 181], ["oral", "ORGANISM_SUBDIVISION", 203, 207], ["toddlers", "SPECIES", 160, 168], ["cyclic neutropenia", "PROBLEM", 60, 78], ["other periodic fever syndromes", "PROBLEM", 80, 110], ["infections", "PROBLEM", 112, 122], ["malignancy", "PROBLEM", 128, 138], ["prominent oral findings", "PROBLEM", 193, 216], ["the disease", "PROBLEM", 240, 251], ["periodic", "OBSERVATION_MODIFIER", 86, 94], ["fever syndromes", "OBSERVATION", 95, 110], ["infections", "OBSERVATION", 112, 122], ["malignancy", "OBSERVATION", 128, 138], ["prominent", "OBSERVATION_MODIFIER", 193, 202], ["disease", "OBSERVATION", 244, 251]]], ["In addition to high fever, cough,SECTION 1 Respiratory DisordersSpread of GAS in classrooms and among family members is common, especially in the presence of crowded living conditions.", [["fever", "DISEASE", 20, 25], ["cough", "DISEASE", 27, 32], ["high fever", "PROBLEM", 15, 25], ["cough", "PROBLEM", 27, 32], ["high", "OBSERVATION_MODIFIER", 15, 19], ["fever", "OBSERVATION", 20, 25], ["GAS", "OBSERVATION", 74, 77]]], ["Transmission occurs primarily by the inhalation of organisms in large droplets or by direct contact with respiratory secretions.", [["respiratory secretions", "ANATOMY", 105, 127], ["respiratory secretions", "PROBLEM", 105, 127], ["large", "OBSERVATION_MODIFIER", 64, 69], ["droplets", "OBSERVATION", 70, 78]]], ["Pets do not appear to be a frequent reservoir.", [["a frequent reservoir", "TREATMENT", 25, 45], ["frequent", "OBSERVATION_MODIFIER", 27, 35], ["reservoir", "OBSERVATION", 36, 45]]], ["Untreated streptococcal pharyngitis is particularly contagious early in the acute illness and for the first 2 weeks after the organism has been acquired, but antibiotic therapy effectively prevents disease transmission.", [["streptococcal pharyngitis", "DISEASE", 10, 35], ["Untreated streptococcal pharyngitis", "PROBLEM", 0, 35], ["the acute illness", "PROBLEM", 72, 89], ["the organism", "PROBLEM", 122, 134], ["antibiotic therapy", "TREATMENT", 158, 176], ["disease transmission", "PROBLEM", 198, 218], ["streptococcal", "OBSERVATION_MODIFIER", 10, 23], ["pharyngitis", "OBSERVATION", 24, 35], ["contagious", "OBSERVATION_MODIFIER", 52, 62], ["acute", "OBSERVATION_MODIFIER", 76, 81], ["illness", "OBSERVATION", 82, 89]]], ["Within 24 hours of institution of therapy with penicillin, it is difficult to isolate GAS from patients with acute streptococcal pharyngitis, and infected children can return to school.", [["penicillin", "CHEMICAL", 47, 57], ["streptococcal pharyngitis", "DISEASE", 115, 140], ["penicillin", "CHEMICAL", 47, 57], ["penicillin", "SIMPLE_CHEMICAL", 47, 57], ["patients", "ORGANISM", 95, 103], ["children", "ORGANISM", 155, 163], ["patients", "SPECIES", 95, 103], ["children", "SPECIES", 155, 163], ["therapy", "TREATMENT", 34, 41], ["penicillin", "TREATMENT", 47, 57], ["acute streptococcal pharyngitis", "PROBLEM", 109, 140], ["acute", "OBSERVATION_MODIFIER", 109, 114], ["streptococcal", "OBSERVATION_MODIFIER", 115, 128], ["pharyngitis", "OBSERVATION", 129, 140]]], ["Molecular epidemiology studies of streptococcal pharyngitis have shown that the prevalent M protein types vary among communities and over time.", [["streptococcal pharyngitis", "DISEASE", 34, 59], ["Molecular epidemiology studies", "TEST", 0, 30], ["streptococcal pharyngitis", "PROBLEM", 34, 59], ["the prevalent M protein types", "PROBLEM", 76, 105], ["streptococcal pharyngitis", "OBSERVATION", 34, 59]]], ["Numerous distinct strains of GAS can circulate simultaneously in a community during the peak season.", [["GAS", "GENE_OR_GENE_PRODUCT", 29, 32], ["GAS", "DNA", 29, 32], ["Numerous distinct strains of GAS", "PROBLEM", 0, 32], ["distinct", "OBSERVATION_MODIFIER", 9, 17], ["strains", "OBSERVATION", 18, 25], ["GAS", "OBSERVATION", 29, 32]]], ["GAS M proteins can be identified in research studies by using PCR to establish the specific M protein gene (emm gene); M protein identification is not available for use in clinical care.", [["GAS M proteins", "GENE_OR_GENE_PRODUCT", 0, 14], ["M protein", "GENE_OR_GENE_PRODUCT", 92, 101], ["GAS M proteins", "PROTEIN", 0, 14], ["M protein gene", "DNA", 92, 106], ["emm gene", "DNA", 108, 116], ["GAS M proteins", "TEST", 0, 14], ["research studies", "TEST", 36, 52], ["PCR", "TEST", 62, 65], ["M protein identification", "TEST", 119, 143]]], ["Children with streptococcal pharyngitis can serve as a local reservoir for strains that cause invasive disease (e.g., sepsis, streptococcal toxic shock syndrome, cellulitis, necrotizing fasciitis) in the same geographic area and season.Clinical FeaturesThe classic patient presentation of acute streptococcal pharyngitis involves a sudden onset of fever and sore throat.", [["streptococcal pharyngitis", "DISEASE", 14, 39], ["invasive disease", "DISEASE", 94, 110], ["sepsis", "DISEASE", 118, 124], ["streptococcal toxic shock syndrome", "DISEASE", 126, 160], ["cellulitis", "DISEASE", 162, 172], ["necrotizing fasciitis", "DISEASE", 174, 195], ["streptococcal pharyngitis", "DISEASE", 295, 320], ["fever", "DISEASE", 348, 353], ["sore throat", "DISEASE", 358, 369], ["Children", "ORGANISM", 0, 8], ["patient", "ORGANISM", 265, 272], ["Children", "SPECIES", 0, 8], ["patient", "SPECIES", 265, 272], ["streptococcal pharyngitis", "PROBLEM", 14, 39], ["a local reservoir", "TREATMENT", 53, 70], ["strains", "PROBLEM", 75, 82], ["invasive disease", "PROBLEM", 94, 110], ["sepsis", "PROBLEM", 118, 124], ["streptococcal toxic shock syndrome", "PROBLEM", 126, 160], ["cellulitis", "PROBLEM", 162, 172], ["necrotizing fasciitis", "PROBLEM", 174, 195], ["acute streptococcal pharyngitis", "PROBLEM", 289, 320], ["fever", "PROBLEM", 348, 353], ["sore throat", "PROBLEM", 358, 369], ["pharyngitis", "OBSERVATION", 28, 39], ["invasive", "OBSERVATION_MODIFIER", 94, 102], ["sepsis", "OBSERVATION", 118, 124], ["streptococcal", "OBSERVATION_MODIFIER", 126, 139], ["toxic shock syndrome", "OBSERVATION", 140, 160], ["cellulitis", "OBSERVATION", 162, 172], ["necrotizing", "OBSERVATION_MODIFIER", 174, 185], ["fasciitis", "OBSERVATION", 186, 195], ["acute", "OBSERVATION_MODIFIER", 289, 294], ["streptococcal", "OBSERVATION_MODIFIER", 295, 308], ["pharyngitis", "OBSERVATION", 309, 320], ["fever", "OBSERVATION", 348, 353], ["sore throat", "ANATOMY", 358, 369]]], ["Headache, malaise, abdominal pain, nausea, and vomiting occur frequently.", [["abdominal", "ANATOMY", 19, 28], ["Headache", "DISEASE", 0, 8], ["abdominal pain", "DISEASE", 19, 33], ["nausea", "DISEASE", 35, 41], ["vomiting", "DISEASE", 47, 55], ["abdominal", "ORGANISM_SUBDIVISION", 19, 28], ["Headache", "PROBLEM", 0, 8], ["malaise", "PROBLEM", 10, 17], ["abdominal pain", "PROBLEM", 19, 33], ["nausea", "PROBLEM", 35, 41], ["vomiting", "PROBLEM", 47, 55], ["malaise", "OBSERVATION", 10, 17], ["abdominal", "ANATOMY", 19, 28], ["pain", "OBSERVATION", 29, 33], ["nausea", "OBSERVATION", 35, 41]]], ["Cough, rhinorrhea, conjunctivitis, stridor, diarrhea, discrete ulcerated lesions, and hoarseness are distinctly unusual and suggest a viral etiology.Clinical FeaturesExamination of the patient reveals marked pharyngeal erythema.", [["ulcerated lesions", "ANATOMY", 63, 80], ["pharyngeal", "ANATOMY", 208, 218], ["Cough", "DISEASE", 0, 5], ["rhinorrhea", "DISEASE", 7, 17], ["conjunctivitis", "DISEASE", 19, 33], ["stridor", "DISEASE", 35, 42], ["diarrhea", "DISEASE", 44, 52], ["ulcerated lesions", "DISEASE", 63, 80], ["hoarseness", "DISEASE", 86, 96], ["pharyngeal erythema", "DISEASE", 208, 227], ["ulcerated lesions", "PATHOLOGICAL_FORMATION", 63, 80], ["patient", "ORGANISM", 185, 192], ["pharyngeal erythema", "PATHOLOGICAL_FORMATION", 208, 227], ["patient", "SPECIES", 185, 192], ["Cough", "PROBLEM", 0, 5], ["rhinorrhea", "PROBLEM", 7, 17], ["conjunctivitis", "PROBLEM", 19, 33], ["stridor", "PROBLEM", 35, 42], ["diarrhea", "PROBLEM", 44, 52], ["discrete ulcerated lesions", "PROBLEM", 54, 80], ["hoarseness", "PROBLEM", 86, 96], ["Clinical FeaturesExamination", "TEST", 149, 177], ["marked pharyngeal erythema", "PROBLEM", 201, 227], ["rhinorrhea", "OBSERVATION", 7, 17], ["conjunctivitis", "OBSERVATION", 19, 33], ["stridor", "OBSERVATION", 35, 42], ["diarrhea", "OBSERVATION", 44, 52], ["discrete", "OBSERVATION_MODIFIER", 54, 62], ["ulcerated", "OBSERVATION_MODIFIER", 63, 72], ["lesions", "OBSERVATION", 73, 80], ["hoarseness", "OBSERVATION", 86, 96], ["viral", "OBSERVATION_MODIFIER", 134, 139], ["marked", "OBSERVATION_MODIFIER", 201, 207], ["pharyngeal", "ANATOMY", 208, 218], ["erythema", "OBSERVATION", 219, 227]]], ["Petechiae may be noted on the palate, but they can also occur in viral pharyngitis, especially mononucleosis.", [["palate", "ANATOMY", 30, 36], ["viral pharyngitis", "DISEASE", 65, 82], ["mononucleosis", "DISEASE", 95, 108], ["palate", "ORGAN", 30, 36], ["Petechiae", "PROBLEM", 0, 9], ["viral pharyngitis", "PROBLEM", 65, 82], ["mononucleosis", "PROBLEM", 95, 108], ["palate", "ANATOMY", 30, 36], ["viral", "OBSERVATION_MODIFIER", 65, 70], ["pharyngitis", "OBSERVATION", 71, 82], ["mononucleosis", "OBSERVATION", 95, 108]]], ["Tonsils are enlarged, symmetric, and red, with patchy exudates on their surfaces.", [["Tonsils", "ANATOMY", 0, 7], ["exudates", "ANATOMY", 54, 62], ["Tonsils", "CANCER", 0, 7], ["patchy exudates on their surfaces", "PROBLEM", 47, 80], ["enlarged", "OBSERVATION", 12, 20], ["symmetric", "OBSERVATION_MODIFIER", 22, 31], ["red", "OBSERVATION_MODIFIER", 37, 40], ["patchy", "OBSERVATION_MODIFIER", 47, 53], ["exudates", "OBSERVATION", 54, 62], ["surfaces", "OBSERVATION_MODIFIER", 72, 80]]], ["The papillae of the when splenomegaly or other features are present or if symptoms persist longer than expected.Clinical FeaturesPrimary infection with human immunodeficiency virus (HIV) may produce a mononucleosis-like illness with sore throat, fever, lymphadenopathy, rash, myalgias, and hepatosplenomegaly.", [["papillae", "ANATOMY", 4, 12], ["splenomegaly", "ANATOMY", 25, 37], ["splenomegaly", "DISEASE", 25, 37], ["Primary infection", "DISEASE", 129, 146], ["human immunodeficiency virus (HIV)", "DISEASE", 152, 186], ["mononucleosis-like illness", "DISEASE", 201, 227], ["sore throat", "DISEASE", 233, 244], ["fever", "DISEASE", 246, 251], ["lymphadenopathy", "DISEASE", 253, 268], ["rash", "DISEASE", 270, 274], ["myalgias", "DISEASE", 276, 284], ["hepatosplenomegaly", "DISEASE", 290, 308], ["papillae", "TISSUE", 4, 12], ["human immunodeficiency virus", "ORGANISM", 152, 180], ["HIV", "ORGANISM", 182, 185], ["throat", "ORGANISM_SUBDIVISION", 238, 244], ["human immunodeficiency virus (HIV", "SPECIES", 152, 185], ["human immunodeficiency virus", "SPECIES", 152, 180], ["HIV", "SPECIES", 182, 185], ["splenomegaly", "PROBLEM", 25, 37], ["symptoms", "PROBLEM", 74, 82], ["Primary infection", "PROBLEM", 129, 146], ["human immunodeficiency virus", "PROBLEM", 152, 180], ["HIV", "PROBLEM", 182, 185], ["a mononucleosis", "PROBLEM", 199, 214], ["sore throat", "PROBLEM", 233, 244], ["fever", "PROBLEM", 246, 251], ["lymphadenopathy", "PROBLEM", 253, 268], ["rash", "PROBLEM", 270, 274], ["myalgias", "PROBLEM", 276, 284], ["hepatosplenomegaly", "PROBLEM", 290, 308], ["papillae", "OBSERVATION_MODIFIER", 4, 12], ["splenomegaly", "OBSERVATION", 25, 37], ["Primary", "OBSERVATION_MODIFIER", 129, 136], ["infection", "OBSERVATION", 137, 146], ["mononucleosis", "OBSERVATION", 201, 214], ["lymphadenopathy", "OBSERVATION", 253, 268], ["myalgias", "OBSERVATION", 276, 284], ["hepatosplenomegaly", "OBSERVATION", 290, 308]]], ["Early infection may be detected by viral RNA or DNA load because immunoglobulin (Ig)M or IgG titers may have not yet developed.GROUP A STREPTOCOCCAL INFECTIONIn the evaluation of a patient with sore throat, the primary concern in the United States is usually accurate diagnosis and treatment of pharyngitis caused by group A streptococci (GAS) or Streptococcus pyogenes, which accounts for about 15% of all episodes of pharyngitis.", [["infection", "DISEASE", 6, 15], ["sore throat", "DISEASE", 194, 205], ["pharyngitis", "DISEASE", 295, 306], ["Streptococcus pyogenes", "DISEASE", 347, 369], ["pharyngitis", "DISEASE", 419, 430], ["DNA", "CELLULAR_COMPONENT", 48, 51], ["immunoglobulin (Ig)M", "GENE_OR_GENE_PRODUCT", 65, 85], ["IgG", "GENE_OR_GENE_PRODUCT", 89, 92], ["patient", "ORGANISM", 181, 188], ["group A streptococci", "ORGANISM", 317, 337], ["GAS", "ORGANISM", 339, 342], ["Streptococcus pyogenes", "ORGANISM", 347, 369], ["viral RNA", "RNA", 35, 44], ["immunoglobulin", "PROTEIN", 65, 79], ["IgG", "PROTEIN", 89, 92], ["patient", "SPECIES", 181, 188], ["Streptococcus pyogenes", "SPECIES", 347, 369], ["Streptococcus pyogenes", "SPECIES", 347, 369], ["Early infection", "PROBLEM", 0, 15], ["viral RNA", "PROBLEM", 35, 44], ["DNA load", "PROBLEM", 48, 56], ["immunoglobulin (Ig)M", "TEST", 65, 85], ["IgG titers", "TEST", 89, 99], ["A STREPTOCOCCAL INFECTIONIn the evaluation", "TEST", 133, 175], ["sore throat", "PROBLEM", 194, 205], ["pharyngitis", "PROBLEM", 295, 306], ["group A streptococci (GAS)", "PROBLEM", 317, 343], ["Streptococcus pyogenes", "PROBLEM", 347, 369], ["pharyngitis", "PROBLEM", 419, 430], ["infection", "OBSERVATION", 6, 15], ["viral RNA", "OBSERVATION", 35, 44], ["STREPTOCOCCAL INFECTIONIn", "OBSERVATION", 135, 160], ["pharyngitis", "OBSERVATION", 295, 306], ["Streptococcus pyogenes", "OBSERVATION", 347, 369], ["pharyngitis", "OBSERVATION", 419, 430]]], ["The sequelae of GAS pharyngitis, especially acute rheumatic fever (ARF) and acute glomerulonephritis (AGN), at one time resulted in considerable morbidity and mortality in the United States and continue to do so in other parts of the world.", [["pharyngitis", "DISEASE", 20, 31], ["acute rheumatic fever", "DISEASE", 44, 65], ["ARF", "DISEASE", 67, 70], ["glomerulonephritis", "DISEASE", 82, 100], ["AGN", "DISEASE", 102, 105], ["GAS pharyngitis", "PROBLEM", 16, 31], ["acute rheumatic fever", "PROBLEM", 44, 65], ["ARF", "PROBLEM", 67, 70], ["acute glomerulonephritis", "PROBLEM", 76, 100], ["considerable morbidity", "PROBLEM", 132, 154], ["sequelae", "OBSERVATION_MODIFIER", 4, 12], ["GAS pharyngitis", "OBSERVATION", 16, 31], ["acute", "OBSERVATION_MODIFIER", 44, 49], ["rheumatic", "OBSERVATION_MODIFIER", 50, 59], ["fever", "OBSERVATION", 60, 65], ["acute", "OBSERVATION_MODIFIER", 76, 81], ["glomerulonephritis", "OBSERVATION", 82, 100], ["AGN", "OBSERVATION_MODIFIER", 102, 105], ["considerable", "OBSERVATION_MODIFIER", 132, 144], ["morbidity", "OBSERVATION", 145, 154]]], ["Prevention of ARF in particular depends on timely diagnosis of streptococcal pharyngitis and prompt antibiotic treatment.", [["ARF", "DISEASE", 14, 17], ["streptococcal pharyngitis", "DISEASE", 63, 88], ["ARF", "GENE_OR_GENE_PRODUCT", 14, 17], ["ARF", "PROBLEM", 14, 17], ["streptococcal pharyngitis", "PROBLEM", 63, 88], ["prompt antibiotic treatment", "TREATMENT", 93, 120], ["ARF", "OBSERVATION", 14, 17], ["streptococcal", "OBSERVATION_MODIFIER", 63, 76], ["pharyngitis", "OBSERVATION", 77, 88]]], ["Group A streptococci are characterized by the presence of group A carbohydrate in the cell wall, and they are further distinguished by several cell wall protein antigens (M, R, T).", [["cell wall", "ANATOMY", 86, 95], ["cell wall", "ANATOMY", 143, 152], ["carbohydrate", "CHEMICAL", 66, 78], ["Group A streptococci", "CELL", 0, 20], ["cell wall", "CELLULAR_COMPONENT", 86, 95], ["cell wall protein antigens", "GENE_OR_GENE_PRODUCT", 143, 169], ["cell wall protein antigens", "PROTEIN", 143, 169], ["R", "PROTEIN", 174, 175], ["T", "PROTEIN", 177, 178], ["Group A streptococci", "TEST", 0, 20], ["several cell wall protein antigens", "TEST", 135, 169], ["streptococci", "OBSERVATION", 8, 20], ["cell wall", "ANATOMY", 86, 95], ["several", "OBSERVATION_MODIFIER", 135, 142], ["cell", "OBSERVATION", 143, 147], ["wall", "ANATOMY_MODIFIER", 148, 152], ["protein antigens", "OBSERVATION", 153, 169]]], ["These protein antigens, especially the M protein, a virulence factor, are useful for studies of epidemiology and pathogenesis but are not used in clinical care.EpidemiologyGAS pharyngitis is endemic in the United States; epidemics occur sporadically.", [["pharyngitis", "DISEASE", 176, 187], ["M protein", "GENE_OR_GENE_PRODUCT", 39, 48], ["protein antigens", "PROTEIN", 6, 22], ["M protein", "PROTEIN", 39, 48], ["virulence factor", "PROTEIN", 52, 68], ["These protein antigens", "TEST", 0, 22], ["the M protein", "TEST", 35, 48], ["a virulence factor", "PROBLEM", 50, 68], ["pathogenesis", "PROBLEM", 113, 125], ["EpidemiologyGAS pharyngitis", "PROBLEM", 160, 187], ["epidemics", "PROBLEM", 221, 230], ["pharyngitis", "OBSERVATION", 176, 187], ["endemic", "OBSERVATION_MODIFIER", 191, 198]]], ["Episodes peak in the late winter and early spring.", [["Episodes", "PROBLEM", 0, 8], ["peak", "OBSERVATION_MODIFIER", 9, 13]]], ["Rates of GAS pharyngitis are highest among children aged 5-11 years old.", [["pharyngitis", "DISEASE", 13, 24], ["children", "ORGANISM", 43, 51], ["children", "SPECIES", 43, 51], ["GAS pharyngitis", "PROBLEM", 9, 24], ["GAS pharyngitis", "OBSERVATION", 9, 24], ["highest", "OBSERVATION_MODIFIER", 29, 36]]], ["2018) the area around the mouth often appears pale in comparison, giving the appearance of circumoral pallor.", [["mouth", "ANATOMY", 26, 31], ["circumoral pallor", "DISEASE", 91, 108], ["mouth", "ORGAN", 26, 31], ["circumoral pallor", "PROBLEM", 91, 108], ["mouth", "ANATOMY", 26, 31], ["pale", "OBSERVATION", 46, 50], ["circumoral pallor", "OBSERVATION", 91, 108]]], ["Accentuation of erythema occurs in flexor skin creases, especially in the antecubital fossae (Pastia lines).", [["flexor skin", "ANATOMY", 35, 46], ["antecubital fossae", "ANATOMY", 74, 92], ["Pastia lines", "ANATOMY", 94, 106], ["erythema", "DISEASE", 16, 24], ["erythema", "PATHOLOGICAL_FORMATION", 16, 24], ["flexor skin", "ORGAN", 35, 46], ["antecubital fossae", "MULTI-TISSUE_STRUCTURE", 74, 92], ["Pastia lines", "CELL", 94, 106], ["erythema", "PROBLEM", 16, 24], ["flexor skin creases", "PROBLEM", 35, 54], ["erythema", "OBSERVATION", 16, 24], ["flexor", "ANATOMY_MODIFIER", 35, 41], ["skin", "ANATOMY", 42, 46], ["creases", "OBSERVATION", 47, 54], ["antecubital fossae", "ANATOMY", 74, 92], ["Pastia lines", "OBSERVATION", 94, 106]]], ["The erythema begins to fade within a few days.", [["erythema", "ANATOMY", 4, 12], ["erythema", "DISEASE", 4, 12], ["The erythema", "PROBLEM", 0, 12], ["erythema", "OBSERVATION", 4, 12]]], ["Desquamation begins within a week of onset on the face and progresses downward, often resembling that seen after mild sunburn.", [["sunburn", "DISEASE", 118, 125], ["Desquamation", "PROBLEM", 0, 12], ["mild sunburn", "PROBLEM", 113, 125], ["face", "ANATOMY", 50, 54], ["mild", "OBSERVATION_MODIFIER", 113, 117], ["sunburn", "OBSERVATION", 118, 125]]], ["On occasion, sheet-like desquamation occurs around the free margins of the fingernails; this is usually coarser than the desquamation seen with Kawasaki disease.", [["fingernails", "ANATOMY", 75, 86], ["desquamation", "DISEASE", 121, 133], ["Kawasaki disease", "DISEASE", 144, 160], ["fingernails", "PATHOLOGICAL_FORMATION", 75, 86], ["desquamation", "PROBLEM", 24, 36], ["the desquamation", "PROBLEM", 117, 133], ["Kawasaki disease", "PROBLEM", 144, 160], ["desquamation", "OBSERVATION", 24, 36], ["free", "OBSERVATION_MODIFIER", 55, 59], ["margins", "OBSERVATION_MODIFIER", 60, 67], ["fingernails", "ANATOMY", 75, 86], ["coarser", "OBSERVATION_MODIFIER", 104, 111]]], ["The differential diagnosis of scarlet fever includes Kawasaki disease, measles, and staphylococcal toxic shock syndrome (Table 1 .7).DiagnosisAlthough signs and symptoms may strongly suggest acute streptococcal pharyngitis, laboratory diagnosis is strongly recommended, even for patients with scarlet fever (Fig. 1.3 ).", [["scarlet fever", "DISEASE", 30, 43], ["Kawasaki disease", "DISEASE", 53, 69], ["measles", "DISEASE", 71, 78], ["staphylococcal toxic shock syndrome", "DISEASE", 84, 119], ["streptococcal pharyngitis", "DISEASE", 197, 222], ["fever", "DISEASE", 301, 306], ["patients", "ORGANISM", 279, 287], ["patients", "SPECIES", 279, 287], ["scarlet fever", "PROBLEM", 30, 43], ["Kawasaki disease", "PROBLEM", 53, 69], ["measles", "PROBLEM", 71, 78], ["staphylococcal toxic shock syndrome", "PROBLEM", 84, 119], ["symptoms", "PROBLEM", 161, 169], ["acute streptococcal pharyngitis", "PROBLEM", 191, 222], ["laboratory diagnosis", "TEST", 224, 244], ["scarlet fever", "PROBLEM", 293, 306], ["differential diagnosis of", "UNCERTAINTY", 4, 29], ["scarlet fever", "OBSERVATION", 30, 43], ["Kawasaki disease", "OBSERVATION", 53, 69], ["staphylococcal", "OBSERVATION_MODIFIER", 84, 98], ["toxic", "OBSERVATION_MODIFIER", 99, 104], ["shock syndrome", "OBSERVATION", 105, 119], ["may strongly suggest", "UNCERTAINTY", 170, 190], ["acute", "OBSERVATION_MODIFIER", 191, 196], ["streptococcal", "OBSERVATION_MODIFIER", 197, 210], ["pharyngitis", "OBSERVATION", 211, 222]]], ["Scoring systems for diagnosing acute GAS pharyngitis on clinical grounds have not proved very satisfactory.", [["pharyngitis", "DISEASE", 41, 52], ["Scoring systems", "TEST", 0, 15], ["diagnosing acute GAS pharyngitis", "PROBLEM", 20, 52], ["pharyngitis", "OBSERVATION", 41, 52]]], ["Using clinical criteria alone, physicians overestimate the likelihood that patients have streptococcal infection.", [["streptococcal infection", "DISEASE", 89, 112], ["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 75, 83], ["streptococcal infection", "PROBLEM", 89, 112], ["streptococcal", "OBSERVATION_MODIFIER", 89, 102], ["infection", "OBSERVATION", 103, 112]]], ["The throat culture on blood agar plate has traditionally been used to diagnose streptococcal pharyngitis.", [["throat", "ANATOMY", 4, 10], ["blood", "ANATOMY", 22, 27], ["streptococcal pharyngitis", "DISEASE", 79, 104], ["blood", "ORGANISM_SUBSTANCE", 22, 27], ["The throat culture", "TEST", 0, 18], ["blood agar plate", "TEST", 22, 38], ["streptococcal pharyngitis", "PROBLEM", 79, 104], ["throat", "ANATOMY", 4, 10], ["streptococcal", "OBSERVATION_MODIFIER", 79, 92], ["pharyngitis", "OBSERVATION", 93, 104]]], ["Plating a swab of the posterior pharynx and tonsils on sheep blood agar, identifying \u03b2-hemolytic colonies, and testing them for the presence of sensitivity to a bacitracin-impregnated disk has long been the \"gold standard\" diagnostic test, but it takes 24-48 hours to obtain results.", [["swab", "ANATOMY", 10, 14], ["posterior pharynx", "ANATOMY", 22, 39], ["tonsils", "ANATOMY", 44, 51], ["blood", "ANATOMY", 61, 66], ["colonies", "ANATOMY", 97, 105], ["bacitracin", "CHEMICAL", 161, 171], ["bacitracin", "CHEMICAL", 161, 171], ["posterior pharynx", "ORGAN", 22, 39], ["tonsils", "ORGAN", 44, 51], ["sheep", "ORGANISM", 55, 60], ["blood", "ORGANISM_SUBSTANCE", 61, 66], ["bacitracin", "SIMPLE_CHEMICAL", 161, 171], ["\u03b2-hemolytic colonies", "CELL_LINE", 85, 105], ["sheep", "SPECIES", 55, 60], ["sheep", "SPECIES", 55, 60], ["sheep blood agar", "TEST", 55, 71], ["\u03b2-hemolytic colonies", "PROBLEM", 85, 105], ["testing", "TEST", 111, 118], ["sensitivity", "PROBLEM", 144, 155], ["a bacitracin-impregnated disk", "TREATMENT", 159, 188], ["diagnostic test", "TEST", 223, 238], ["swab", "OBSERVATION", 10, 14], ["posterior", "ANATOMY_MODIFIER", 22, 31], ["pharynx", "ANATOMY", 32, 39], ["tonsils", "ANATOMY", 44, 51], ["\u03b2-hemolytic colonies", "OBSERVATION", 85, 105]]], ["Rapid antigen detection tests (RADTs) that take less than 15 minutes can detect the presence of the cell wall group A carbohydrate antigen after acid extraction of organisms obtained by throat swab.", [["cell wall", "ANATOMY", 100, 109], ["throat swab", "ANATOMY", 186, 197], ["carbohydrate", "CHEMICAL", 118, 130], ["cell wall", "TISSUE", 100, 109], ["carbohydrate antigen", "GENE_OR_GENE_PRODUCT", 118, 138], ["throat", "ORGANISM_SUBDIVISION", 186, 192], ["swab", "ORGANISM_SUBSTANCE", 193, 197], ["carbohydrate antigen", "PROTEIN", 118, 138], ["Rapid antigen detection tests", "TEST", 0, 29], ["RADTs", "TEST", 31, 36], ["A carbohydrate antigen", "TEST", 116, 138], ["acid extraction", "TREATMENT", 145, 160], ["organisms", "PROBLEM", 164, 173], ["throat swab", "TEST", 186, 197]]], ["RADTs are highly specific (generally >95%) when compared to throat culture.", [["RADTs", "SIMPLE_CHEMICAL", 0, 5], ["throat culture", "TEST", 60, 74], ["highly", "OBSERVATION_MODIFIER", 10, 16], ["specific", "OBSERVATION_MODIFIER", 17, 25]]], ["In comparison to hospital or reference laboratory throat culture results, the sensitivities of these tests are generally 75-85% and can be lower.", [["reference laboratory throat culture", "TEST", 29, 64], ["the sensitivities", "TEST", 74, 91], ["these tests", "TEST", 95, 106]]], ["The low sensitivity of these tests, coupled tongue may be red and swollen, hence the designation \"strawberry tongue.\"", [["tongue", "ANATOMY", 44, 50], ["tongue", "ANATOMY", 109, 115], ["tongue", "ORGAN", 44, 50], ["tongue", "ORGAN", 109, 115], ["these tests", "TEST", 23, 34], ["coupled tongue", "PROBLEM", 36, 50], ["red", "PROBLEM", 58, 61], ["swollen", "PROBLEM", 66, 73], ["low sensitivity", "OBSERVATION_MODIFIER", 4, 19], ["tongue", "ANATOMY", 44, 50], ["may be", "UNCERTAINTY", 51, 57], ["red", "OBSERVATION", 58, 61], ["swollen", "OBSERVATION", 66, 73], ["tongue", "ANATOMY", 109, 115]]], ["Anterior cervical lymph nodes are often tender and enlarged.DiagnosisCombinations of these signs can be used to assist in diagnosis; in particular, tonsillar exudates in association with fever, palatal petechiae, and tender anterior cervical adenitis strongly suggest infection with GAS.", [["Anterior cervical lymph nodes", "ANATOMY", 0, 29], ["tonsillar exudates", "ANATOMY", 148, 166], ["palatal petechiae", "ANATOMY", 194, 211], ["cervical", "ANATOMY", 233, 241], ["fever", "DISEASE", 187, 192], ["palatal petechiae", "DISEASE", 194, 211], ["adenitis", "DISEASE", 242, 250], ["infection", "DISEASE", 268, 277], ["cervical lymph nodes", "MULTI-TISSUE_STRUCTURE", 9, 29], ["tonsillar exudates", "PATHOLOGICAL_FORMATION", 148, 166], ["cervical", "ORGAN", 233, 241], ["Anterior cervical lymph nodes", "PROBLEM", 0, 29], ["tender", "PROBLEM", 40, 46], ["enlarged", "PROBLEM", 51, 59], ["these signs", "PROBLEM", 85, 96], ["tonsillar exudates", "PROBLEM", 148, 166], ["fever", "PROBLEM", 187, 192], ["palatal petechiae", "PROBLEM", 194, 211], ["tender anterior cervical adenitis", "PROBLEM", 217, 250], ["infection with GAS", "PROBLEM", 268, 286], ["cervical", "ANATOMY", 9, 17], ["lymph nodes", "OBSERVATION", 18, 29], ["tender", "OBSERVATION_MODIFIER", 40, 46], ["enlarged", "OBSERVATION", 51, 59], ["tonsillar", "ANATOMY", 148, 157], ["exudates", "OBSERVATION", 158, 166], ["palatal", "ANATOMY", 194, 201], ["petechiae", "OBSERVATION", 202, 211], ["tender", "OBSERVATION_MODIFIER", 217, 223], ["anterior", "ANATOMY_MODIFIER", 224, 232], ["cervical", "ANATOMY", 233, 241], ["adenitis", "OBSERVATION", 242, 250], ["infection", "OBSERVATION", 268, 277], ["GAS", "OBSERVATION", 283, 286]]], ["However, other diseases can produce this constellation of findings, including infectious mononucleosis.", [["infectious mononucleosis", "DISEASE", 78, 102], ["other diseases", "PROBLEM", 9, 23], ["infectious mononucleosis", "PROBLEM", 78, 102], ["diseases", "OBSERVATION", 15, 23], ["infectious", "OBSERVATION_MODIFIER", 78, 88], ["mononucleosis", "OBSERVATION", 89, 102]]], ["Some or all of these classic characteristics may be absent in patients with streptococcal pharyngitis.", [["streptococcal pharyngitis", "DISEASE", 76, 101], ["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 62, 70], ["streptococcal pharyngitis", "PROBLEM", 76, 101], ["may be", "UNCERTAINTY", 45, 51], ["streptococcal", "OBSERVATION_MODIFIER", 76, 89], ["pharyngitis", "OBSERVATION", 90, 101]]], ["Symptoms usually resolve within 5 days even in the absence of antibiotic therapy.", [["Symptoms", "PROBLEM", 0, 8], ["antibiotic therapy", "TREATMENT", 62, 80]]], ["Younger children can have a syndrome called streptococcosis-coryza with crusting below the nares, more generalized adenopathy, and a more chronic course.", [["nares", "ANATOMY", 91, 96], ["streptococcosis-coryza", "DISEASE", 44, 66], ["adenopathy", "DISEASE", 115, 125], ["children", "ORGANISM", 8, 16], ["nares", "ORGANISM_SUBDIVISION", 91, 96], ["children", "SPECIES", 8, 16], ["a syndrome", "PROBLEM", 26, 36], ["streptococcosis", "PROBLEM", 44, 59], ["coryza", "PROBLEM", 60, 66], ["crusting below the nares", "PROBLEM", 72, 96], ["generalized adenopathy", "PROBLEM", 103, 125], ["nares", "ANATOMY", 91, 96], ["generalized", "OBSERVATION_MODIFIER", 103, 114], ["adenopathy", "OBSERVATION", 115, 125], ["more chronic", "OBSERVATION_MODIFIER", 133, 145]]], ["When rash accompanies the illness, accurate clinical diagnosis is easier.", [["rash", "DISEASE", 5, 9], ["rash", "PROBLEM", 5, 9], ["the illness", "PROBLEM", 22, 33]]], ["Scarlet fever, so-called because of the characteristic fine, diffuse red rash, is essentially pathognomonic for infection with group A streptococci.", [["fever", "DISEASE", 8, 13], ["rash", "DISEASE", 73, 77], ["infection", "DISEASE", 112, 121], ["Scarlet fever", "PROBLEM", 0, 13], ["diffuse red rash", "PROBLEM", 61, 77], ["infection", "PROBLEM", 112, 121], ["group A streptococci", "PROBLEM", 127, 147], ["fever", "OBSERVATION", 8, 13], ["diffuse", "OBSERVATION_MODIFIER", 61, 68], ["red rash", "OBSERVATION", 69, 77], ["infection", "OBSERVATION", 112, 121], ["streptococci", "OBSERVATION", 135, 147]]], ["Scarlet fever is rarely seen in children younger than 3 years old or in adults.Scarlet FeverThe rash of scarlet fever is caused by infection with a strain of GAS that contains a bacteriophage encoding for production of an erythrogenic (redness producing) toxin, usually erythrogenic (also called pyrogenic) exotoxin A (designated SPE A).", [["fever", "DISEASE", 8, 13], ["Fever", "DISEASE", 87, 92], ["rash", "DISEASE", 96, 100], ["scarlet fever", "DISEASE", 104, 117], ["infection", "DISEASE", 131, 140], ["children", "ORGANISM", 32, 40], ["pyrogenic) exotoxin A", "GENE_OR_GENE_PRODUCT", 296, 317], ["GAS", "DNA", 158, 161], ["erythrogenic (redness producing) toxin", "PROTEIN", 222, 260], ["exotoxin A", "PROTEIN", 307, 317], ["children", "SPECIES", 32, 40], ["Scarlet fever", "PROBLEM", 0, 13], ["Scarlet Fever", "PROBLEM", 79, 92], ["The rash of scarlet fever", "PROBLEM", 92, 117], ["infection", "PROBLEM", 131, 140], ["a strain of GAS", "PROBLEM", 146, 161], ["a bacteriophage", "TREATMENT", 176, 191], ["an erythrogenic (redness producing) toxin", "PROBLEM", 219, 260], ["fever", "OBSERVATION", 8, 13], ["Fever", "OBSERVATION", 87, 92], ["rash", "OBSERVATION_MODIFIER", 96, 100], ["scarlet", "OBSERVATION_MODIFIER", 104, 111], ["fever", "OBSERVATION", 112, 117], ["infection", "OBSERVATION", 131, 140], ["GAS", "OBSERVATION", 158, 161]]], ["Scarlet fever is simply GAS pharyngitis with a rash and should be explained as such to patients and their families.", [["fever", "DISEASE", 8, 13], ["pharyngitis", "DISEASE", 28, 39], ["rash", "DISEASE", 47, 51], ["patients", "ORGANISM", 87, 95], ["patients", "SPECIES", 87, 95], ["Scarlet fever", "PROBLEM", 0, 13], ["GAS pharyngitis", "PROBLEM", 24, 39], ["a rash", "PROBLEM", 45, 51], ["fever", "OBSERVATION", 8, 13], ["GAS pharyngitis", "OBSERVATION", 24, 39]]], ["Although patients with the streptococcal toxic shock syndrome are also infected with GAS that produces SPE A, most GAS pharyngeal infections are not associated with development of severe invasive or systemic disease.Scarlet FeverThe rash of scarlet fever has a texture like sandpaper and blanches with pressure.", [["pharyngeal", "ANATOMY", 119, 129], ["blanches", "ANATOMY", 288, 296], ["streptococcal toxic shock syndrome", "DISEASE", 27, 61], ["SPE A", "CHEMICAL", 103, 108], ["pharyngeal infections", "DISEASE", 119, 140], ["Fever", "DISEASE", 224, 229], ["rash", "DISEASE", 233, 237], ["fever", "DISEASE", 249, 254], ["patients", "ORGANISM", 9, 17], ["GAS", "ORGANISM", 115, 118], ["pharyngeal", "ORGAN", 119, 129], ["patients", "SPECIES", 9, 17], ["the streptococcal toxic shock syndrome", "PROBLEM", 23, 61], ["SPE A", "PROBLEM", 103, 108], ["most GAS pharyngeal infections", "PROBLEM", 110, 140], ["severe invasive or systemic disease", "PROBLEM", 180, 215], ["Scarlet Fever", "PROBLEM", 216, 229], ["The rash of scarlet fever", "PROBLEM", 229, 254], ["pressure", "TREATMENT", 302, 310], ["streptococcal", "OBSERVATION_MODIFIER", 27, 40], ["toxic shock syndrome", "OBSERVATION", 41, 61], ["pharyngeal", "ANATOMY", 119, 129], ["infections", "OBSERVATION", 130, 140], ["not associated with", "UNCERTAINTY", 145, 164], ["severe", "OBSERVATION_MODIFIER", 180, 186], ["invasive", "OBSERVATION_MODIFIER", 187, 195], ["systemic", "OBSERVATION_MODIFIER", 199, 207], ["disease", "OBSERVATION", 208, 215], ["Fever", "OBSERVATION", 224, 229], ["rash", "OBSERVATION_MODIFIER", 233, 237], ["scarlet", "OBSERVATION_MODIFIER", 241, 248], ["fever", "OBSERVATION", 249, 254], ["texture", "OBSERVATION_MODIFIER", 261, 268], ["pressure", "OBSERVATION_MODIFIER", 302, 310]]], ["It usually begins on the face, but after 24 hours, it becomes generalized.", [["generalized", "OBSERVATION_MODIFIER", 62, 73]]], ["The face is red, especially over the cheeks, and with their excellent specificity, has led to the recommendation that two throat swabs be obtained simultaneously from patients with suspected GAS pharyngitis.", [["cheeks", "ANATOMY", 37, 43], ["throat swabs", "ANATOMY", 122, 134], ["pharyngitis", "DISEASE", 195, 206], ["cheeks", "ORGANISM_SUBDIVISION", 37, 43], ["patients", "ORGANISM", 167, 175], ["patients", "SPECIES", 167, 175], ["red", "PROBLEM", 12, 15], ["two throat swabs", "TEST", 118, 134], ["GAS pharyngitis", "PROBLEM", 191, 206], ["face", "ANATOMY", 4, 8], ["red", "OBSERVATION", 12, 15], ["cheeks", "ANATOMY", 37, 43], ["GAS pharyngitis", "OBSERVATION", 191, 206]]], ["One swab is used for a rapid test.", [["swab", "ANATOMY", 4, 8], ["One swab", "TEST", 0, 8], ["a rapid test", "TEST", 21, 33]]], ["When the RADT result is positive, it is highly likely that the patient has GAS pharyngitis, and the extra swab can be discarded.", [["swab", "ANATOMY", 106, 110], ["pharyngitis", "DISEASE", 79, 90], ["patient", "ORGANISM", 63, 70], ["swab", "ORGANISM_SUBSTANCE", 106, 110], ["patient", "SPECIES", 63, 70], ["the RADT result", "TEST", 5, 20], ["GAS pharyngitis", "PROBLEM", 75, 90], ["the extra swab", "TREATMENT", 96, 110], ["positive", "OBSERVATION", 24, 32], ["highly likely", "UNCERTAINTY", 40, 53], ["GAS", "OBSERVATION_MODIFIER", 75, 78], ["pharyngitis", "OBSERVATION", 79, 90]]], ["When the RADT is negative, GAS may nonetheless be present; thus, the extra swab should be processed for culture.", [["swab", "ANATOMY", 75, 79], ["RADT", "DNA", 9, 13], ["GAS", "DNA", 27, 30], ["the RADT", "TEST", 5, 13], ["the extra swab", "TREATMENT", 65, 79], ["culture", "TEST", 104, 111], ["negative", "OBSERVATION", 17, 25]]], ["The presence of viral symptoms such as cough, rhinorrhea, conjunctivitis, laryngitis, stridor, croup, or diarrhea decreases the likelihood that the illness is due to GAS.", [["cough", "DISEASE", 39, 44], ["rhinorrhea", "DISEASE", 46, 56], ["conjunctivitis", "DISEASE", 58, 72], ["laryngitis", "DISEASE", 74, 84], ["stridor", "DISEASE", 86, 93], ["croup", "DISEASE", 95, 100], ["diarrhea", "DISEASE", 105, 113], ["illness", "DISEASE", 148, 155], ["GAS", "DNA", 166, 169], ["viral symptoms", "PROBLEM", 16, 30], ["cough", "PROBLEM", 39, 44], ["rhinorrhea", "PROBLEM", 46, 56], ["conjunctivitis", "PROBLEM", 58, 72], ["laryngitis", "PROBLEM", 74, 84], ["stridor", "PROBLEM", 86, 93], ["croup", "PROBLEM", 95, 100], ["diarrhea", "PROBLEM", 105, 113], ["the illness", "PROBLEM", 144, 155], ["GAS", "PROBLEM", 166, 169], ["viral", "OBSERVATION", 16, 21], ["conjunctivitis", "OBSERVATION", 58, 72], ["laryngitis", "OBSERVATION", 74, 84]]], ["Patients with a negative RADT result should not be treated before culture verification unless there is a particularly high suspicion of GAS infection (e.g., scarlet fever, peritonsillar abscess, or tonsillar exudates in addition to tender cervical adenopathy, palatal petechiae, fever, and recent exposure to a person with GAS pharyngitis).", [["peritonsillar abscess", "ANATOMY", 172, 193], ["tonsillar exudates", "ANATOMY", 198, 216], ["cervical", "ANATOMY", 239, 247], ["palatal petechiae", "ANATOMY", 260, 277], ["infection", "DISEASE", 140, 149], ["fever", "DISEASE", 165, 170], ["peritonsillar abscess", "DISEASE", 172, 193], ["tonsillar exudates", "DISEASE", 198, 216], ["adenopathy", "DISEASE", 248, 258], ["palatal petechiae", "DISEASE", 260, 277], ["fever", "DISEASE", 279, 284], ["pharyngitis", "DISEASE", 327, 338], ["Patients", "ORGANISM", 0, 8], ["peritonsillar abscess", "PATHOLOGICAL_FORMATION", 172, 193], ["cervical", "ORGAN", 239, 247], ["Patients", "SPECIES", 0, 8], ["person", "SPECIES", 311, 317], ["culture verification", "TEST", 66, 86], ["GAS infection", "PROBLEM", 136, 149], ["scarlet fever", "PROBLEM", 157, 170], ["peritonsillar abscess", "PROBLEM", 172, 193], ["tonsillar exudates", "PROBLEM", 198, 216], ["tender cervical adenopathy", "PROBLEM", 232, 258], ["palatal petechiae", "PROBLEM", 260, 277], ["fever", "PROBLEM", 279, 284], ["GAS pharyngitis", "PROBLEM", 323, 338], ["GAS infection", "OBSERVATION", 136, 149], ["peritonsillar", "ANATOMY", 172, 185], ["abscess", "OBSERVATION", 186, 193], ["tonsillar", "ANATOMY", 198, 207], ["exudates", "OBSERVATION", 208, 216], ["tender", "OBSERVATION_MODIFIER", 232, 238], ["cervical", "ANATOMY", 239, 247], ["adenopathy", "OBSERVATION", 248, 258], ["palatal", "ANATOMY", 260, 267], ["petechiae", "OBSERVATION", 268, 277], ["fever", "OBSERVATION", 279, 284]]], ["Molecular \"PCR-like\" tests for GAS are available for use in hospital and reference laboratories.", [["GAS", "DNA", 31, 34], ["Molecular \"PCR", "TEST", 0, 14], ["GAS", "PROBLEM", 31, 34]]], ["Some are cleared by the Food and Drug Administration (FDA) for use in physician office laboratories, particularly those offices that are certified to perform CLIA-moderate tests.", [["CLIA", "TEST", 158, 162], ["cleared", "OBSERVATION", 9, 16]]], ["These simplified molecular tests use methods that amplify the DNA of a specific GAS gene.", [["DNA", "CELLULAR_COMPONENT", 62, 65], ["GAS", "GENE_OR_GENE_PRODUCT", 80, 83], ["GAS gene", "DNA", 80, 88], ["These simplified molecular tests", "TEST", 0, 32], ["methods", "TREATMENT", 37, 44]]], ["They take less than 1 hour to perform and are reported to have both sensitivity and specificity \u226599% when compared to standard throat culture and PCR.", [["specificity", "TEST", 84, 95], ["standard throat culture", "TEST", 118, 141], ["PCR", "TEST", 146, 149]]], ["They can be used as a \"standalone\" test for GAS or as a confirmatory test when the RADT is negative.", [["a confirmatory test", "TEST", 54, 73], ["the RADT", "TEST", 79, 87], ["negative", "OBSERVATION", 91, 99]]], ["There are three concerns with these molecular tests: (1) they are so sensitive it is likely they will identify more patients who are carriers than would ordinarily be identified by RADT and/or culture; (2) unless rigorous technique is followed they may be prone to contamination with exogenous GAS DNA from other swabs, a particular concern in physician offices when performed by staff who are not trained laboratory technologists; and (3) they are much more expensive than throat culture, and their costs may not be covered by all insurance plans.Scarlet FeverTesting patients for serologic evidence of an antibody response to extracellular products of GAS is not useful for diagnosing acute pharyngitis.", [["extracellular", "ANATOMY", 628, 641], ["pharyngitis", "DISEASE", 693, 704], ["patients", "ORGANISM", 116, 124], ["DNA", "CELLULAR_COMPONENT", 298, 301], ["patients", "ORGANISM", 569, 577], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 628, 641], ["exogenous GAS DNA", "DNA", 284, 301], ["GAS", "DNA", 654, 657], ["patients", "SPECIES", 116, 124], ["patients", "SPECIES", 569, 577], ["these molecular tests", "TEST", 30, 51], ["RADT and/or culture", "TEST", 181, 200], ["rigorous technique", "TEST", 213, 231], ["exogenous GAS DNA", "PROBLEM", 284, 301], ["other swabs", "PROBLEM", 307, 318], ["throat culture", "TEST", 474, 488], ["an antibody response", "PROBLEM", 604, 624], ["extracellular products", "TREATMENT", 628, 650], ["acute pharyngitis", "PROBLEM", 687, 704], ["antibody", "OBSERVATION", 607, 615], ["acute", "OBSERVATION_MODIFIER", 687, 692], ["pharyngitis", "OBSERVATION", 693, 704]]], ["Because it generally takes several weeks for antibody levels to rise, streptococcal antibody tests are valid only for determining past infection.", [["infection", "DISEASE", 135, 144], ["streptococcal antibody", "PROTEIN", 70, 92], ["antibody levels", "TEST", 45, 60], ["streptococcal antibody tests", "TEST", 70, 98], ["past infection", "PROBLEM", 130, 144], ["infection", "OBSERVATION", 135, 144]]], ["Specific antibodies that are often measured in the appropriate clinical setting include antistreptolysin O (ASO), anti-DNase B, and antihyaluronidase (AHT).", [["ASO", "CHEMICAL", 108, 111], ["AHT", "DISEASE", 151, 154], ["antistreptolysin O", "CHEMICAL", 88, 106], ["antistreptolysin O", "SIMPLE_CHEMICAL", 88, 106], ["ASO", "SIMPLE_CHEMICAL", 108, 111], ["anti-DNase B", "GENE_OR_GENE_PRODUCT", 114, 126], ["antihyaluronidase", "SIMPLE_CHEMICAL", 132, 149], ["AHT", "SIMPLE_CHEMICAL", 151, 154], ["antibodies", "PROTEIN", 9, 19], ["DNase B", "PROTEIN", 119, 126], ["antihyaluronidase", "PROTEIN", 132, 149], ["Specific antibodies", "TEST", 0, 19], ["antistreptolysin O (ASO", "TREATMENT", 88, 111], ["anti-DNase B", "TREATMENT", 114, 126], ["antihyaluronidase (AHT", "TREATMENT", 132, 154]]], ["When antibody testing is desired in order to evaluate a possible poststreptococcal illness, more than one of these tests should be performed to improve sensitivity.TreatmentTreatment begun within 9 days of the onset of GAS pharyngitis is effective in preventing acute rheumatic fever (ARF).", [["poststreptococcal illness", "DISEASE", 65, 90], ["pharyngitis", "DISEASE", 223, 234], ["acute rheumatic fever", "DISEASE", 262, 283], ["ARF", "DISEASE", 285, 288], ["antibody testing", "TEST", 5, 21], ["poststreptococcal illness", "PROBLEM", 65, 90], ["these tests", "TEST", 109, 120], ["TreatmentTreatment", "TREATMENT", 164, 182], ["GAS pharyngitis", "PROBLEM", 219, 234], ["acute rheumatic fever", "PROBLEM", 262, 283], ["ARF", "PROBLEM", 285, 288], ["possible", "UNCERTAINTY", 56, 64], ["poststreptococcal", "OBSERVATION_MODIFIER", 65, 82], ["illness", "OBSERVATION", 83, 90], ["GAS pharyngitis", "OBSERVATION", 219, 234], ["acute", "OBSERVATION_MODIFIER", 262, 267], ["rheumatic", "OBSERVATION_MODIFIER", 268, 277], ["fever", "OBSERVATION", 278, 283]]], ["Therapy does not appear to affect the risk of acute poststreptococcal glomerulonephritis (AGN).", [["glomerulonephritis", "DISEASE", 70, 88], ["AGN", "DISEASE", 90, 93], ["AGN", "CANCER", 90, 93], ["Therapy", "TREATMENT", 0, 7], ["acute poststreptococcal glomerulonephritis", "PROBLEM", 46, 88], ["acute", "OBSERVATION_MODIFIER", 46, 51], ["poststreptococcal", "OBSERVATION_MODIFIER", 52, 69], ["glomerulonephritis", "OBSERVATION", 70, 88]]], ["Antibiotic therapy also reduces the incidence of suppurative sequelae of GAS pharyngitis, such as peritonsillar abscess and cervical adenitis.", [["peritonsillar abscess", "ANATOMY", 98, 119], ["cervical", "ANATOMY", 124, 132], ["pharyngitis", "DISEASE", 77, 88], ["peritonsillar abscess", "DISEASE", 98, 119], ["cervical adenitis", "DISEASE", 124, 141], ["peritonsillar abscess", "PATHOLOGICAL_FORMATION", 98, 119], ["cervical", "ORGAN", 124, 132], ["Antibiotic therapy", "TREATMENT", 0, 18], ["suppurative sequelae", "PROBLEM", 49, 69], ["GAS pharyngitis", "PROBLEM", 73, 88], ["peritonsillar abscess", "PROBLEM", 98, 119], ["cervical adenitis", "PROBLEM", 124, 141], ["suppurative", "OBSERVATION_MODIFIER", 49, 60], ["GAS pharyngitis", "OBSERVATION", 73, 88], ["peritonsillar", "ANATOMY", 98, 111], ["abscess", "OBSERVATION", 112, 119], ["cervical", "ANATOMY", 124, 132], ["adenitis", "OBSERVATION", 133, 141]]], ["In addition, treatment produces a more rapid resolution of signs and symptoms and terminates contagiousness within 24 hours.", [["contagiousness", "DISEASE", 93, 107], ["treatment", "TREATMENT", 13, 22], ["signs and symptoms", "PROBLEM", 59, 77], ["terminates contagiousness", "PROBLEM", 82, 107]]], ["For these reasons, antibiotics should be instituted as soon as the diagnosis is supported by laboratory studies.", [["antibiotics", "TREATMENT", 19, 30], ["laboratory studies", "TEST", 93, 111]]], ["There are numerous antibiotics available for treating streptococcal pharyngitis (Table 1 .9).", [["streptococcal pharyngitis", "DISEASE", 54, 79], ["numerous antibiotics", "TREATMENT", 10, 30], ["streptococcal pharyngitis", "PROBLEM", 54, 79], ["numerous", "OBSERVATION_MODIFIER", 10, 18], ["antibiotics", "OBSERVATION", 19, 30], ["pharyngitis", "OBSERVATION", 68, 79]]], ["The drugs of choice are penicillin and amoxicillin.", [["penicillin", "CHEMICAL", 24, 34], ["amoxicillin", "CHEMICAL", 39, 50], ["penicillin", "CHEMICAL", 24, 34], ["amoxicillin", "CHEMICAL", 39, 50], ["penicillin", "SIMPLE_CHEMICAL", 24, 34], ["amoxicillin", "SIMPLE_CHEMICAL", 39, 50], ["penicillin", "TREATMENT", 24, 34], ["amoxicillin", "TREATMENT", 39, 50]]], ["Despite the widespread use of penicillin to treat streptococcal and other infections for many decades, resistance of GAS to penicillin or any other \u03b2-lactam antibiotic has not developed.", [["penicillin", "CHEMICAL", 30, 40], ["streptococcal and other infections", "DISEASE", 50, 84], ["penicillin", "CHEMICAL", 124, 134], ["\u03b2-lactam", "CHEMICAL", 148, 156], ["penicillin", "CHEMICAL", 30, 40], ["penicillin", "CHEMICAL", 124, 134], ["\u03b2-lactam", "CHEMICAL", 148, 156], ["penicillin", "SIMPLE_CHEMICAL", 30, 40], ["GAS", "ORGANISM", 117, 120], ["penicillin", "SIMPLE_CHEMICAL", 124, 134], ["\u03b2-lactam", "SIMPLE_CHEMICAL", 148, 156], ["penicillin", "TREATMENT", 30, 40], ["streptococcal", "PROBLEM", 50, 63], ["other infections", "PROBLEM", 68, 84], ["resistance of GAS", "PROBLEM", 103, 120], ["penicillin", "TREATMENT", 124, 134], ["any other \u03b2-lactam antibiotic", "TREATMENT", 138, 167], ["infections", "OBSERVATION", 74, 84]]], ["Amoxicillin has been demonstrated to be effective in eradicating GAS when given by mouth once daily for 10 days.", [["mouth", "ANATOMY", 83, 88], ["Amoxicillin", "CHEMICAL", 0, 11], ["Amoxicillin", "CHEMICAL", 0, 11], ["Amoxicillin", "SIMPLE_CHEMICAL", 0, 11], ["GAS", "ORGANISM", 65, 68], ["mouth", "ORGANISM_SUBDIVISION", 83, 88], ["Amoxicillin", "TREATMENT", 0, 11], ["effective", "OBSERVATION_MODIFIER", 40, 49]]], ["The convenience of once-daily dosing and palatability make amoxicillin an attractive approach despite its somewhat broader spectrum of antimicrobial activity.", [["amoxicillin", "CHEMICAL", 59, 70], ["amoxicillin", "CHEMICAL", 59, 70], ["amoxicillin", "SIMPLE_CHEMICAL", 59, 70], ["palatability", "TREATMENT", 41, 53], ["amoxicillin an attractive approach", "TREATMENT", 59, 93], ["antimicrobial activity", "TREATMENT", 135, 157], ["antimicrobial activity", "OBSERVATION", 135, 157]]], ["Penicillin can be given by mouth twice daily for 10 days or intramuscularly as a single injection of benzathine penicillin.", [["mouth", "ANATOMY", 27, 32], ["Penicillin", "CHEMICAL", 0, 10], ["benzathine", "CHEMICAL", 101, 111], ["penicillin", "CHEMICAL", 112, 122], ["Penicillin", "CHEMICAL", 0, 10], ["benzathine penicillin", "CHEMICAL", 101, 122], ["Penicillin", "SIMPLE_CHEMICAL", 0, 10], ["mouth", "ORGANISM_SUBDIVISION", 27, 32], ["benzathine", "SIMPLE_CHEMICAL", 101, 111], ["penicillin", "SIMPLE_CHEMICAL", 112, 122], ["Penicillin", "TREATMENT", 0, 10], ["benzathine penicillin", "TREATMENT", 101, 122]]], ["Intramuscular benzathine penicillin alleviates concerns about patient compliance.", [["Intramuscular", "ANATOMY", 0, 13], ["benzathine", "CHEMICAL", 14, 24], ["penicillin", "CHEMICAL", 25, 35], ["benzathine penicillin", "CHEMICAL", 14, 35], ["benzathine penicillin", "SIMPLE_CHEMICAL", 14, 35], ["patient", "ORGANISM", 62, 69], ["patient", "SPECIES", 62, 69], ["Intramuscular benzathine penicillin", "TREATMENT", 0, 35]]], ["A less painful parenteral alternative is benzathine penicillin in combination with procaine penicillin.", [["benzathine", "CHEMICAL", 41, 51], ["penicillin", "CHEMICAL", 52, 62], ["procaine", "CHEMICAL", 83, 91], ["penicillin", "CHEMICAL", 92, 102], ["benzathine penicillin", "CHEMICAL", 41, 62], ["procaine penicillin", "CHEMICAL", 83, 102], ["benzathine", "SIMPLE_CHEMICAL", 41, 51], ["penicillin", "SIMPLE_CHEMICAL", 52, 62], ["procaine penicillin", "SIMPLE_CHEMICAL", 83, 102], ["A less painful parenteral alternative", "TREATMENT", 0, 37], ["benzathine penicillin", "TREATMENT", 41, 62], ["procaine penicillin", "TREATMENT", 83, 102]]], ["Intramuscular procaine penicillin alone is not effective for prevention of ARF because adequate levels of penicillin are not present in blood and tissues for a sufficient time.", [["Intramuscular", "ANATOMY", 0, 13], ["blood", "ANATOMY", 136, 141], ["tissues", "ANATOMY", 146, 153], ["procaine", "CHEMICAL", 14, 22], ["penicillin", "CHEMICAL", 23, 33], ["ARF", "DISEASE", 75, 78], ["penicillin", "CHEMICAL", 106, 116], ["procaine penicillin", "CHEMICAL", 14, 33], ["penicillin", "CHEMICAL", 106, 116], ["procaine penicillin", "SIMPLE_CHEMICAL", 14, 33], ["ARF", "GENE_OR_GENE_PRODUCT", 75, 78], ["penicillin", "SIMPLE_CHEMICAL", 106, 116], ["blood", "ORGANISM_SUBSTANCE", 136, 141], ["tissues", "TISSUE", 146, 153], ["Intramuscular procaine penicillin", "TREATMENT", 0, 33], ["ARF", "PROBLEM", 75, 78], ["penicillin", "TREATMENT", 106, 116], ["ARF", "OBSERVATION", 75, 78], ["tissues", "ANATOMY", 146, 153]]], ["Other \u03b2-lactams, including semisynthetic derivatives of penicillin and the cephalosporins, are at least as effective as penicillin for treating streptococcal pharyngitis.", [["\u03b2-lactams", "CHEMICAL", 6, 15], ["penicillin", "CHEMICAL", 56, 66], ["cephalosporins", "CHEMICAL", 75, 89], ["penicillin", "CHEMICAL", 120, 130], ["streptococcal pharyngitis", "DISEASE", 144, 169], ["\u03b2-lactams", "CHEMICAL", 6, 15], ["penicillin", "CHEMICAL", 56, 66], ["cephalosporins", "CHEMICAL", 75, 89], ["penicillin", "CHEMICAL", 120, 130], ["\u03b2-lactams", "SIMPLE_CHEMICAL", 6, 15], ["penicillin", "SIMPLE_CHEMICAL", 56, 66], ["cephalosporins", "SIMPLE_CHEMICAL", 75, 89], ["penicillin", "SIMPLE_CHEMICAL", 120, 130], ["Other \u03b2-lactams", "TREATMENT", 0, 15], ["semisynthetic derivatives", "TREATMENT", 27, 52], ["penicillin", "TREATMENT", 56, 66], ["the cephalosporins", "TREATMENT", 71, 89], ["penicillin", "TREATMENT", 120, 130], ["streptococcal pharyngitis", "PROBLEM", 144, 169], ["streptococcal", "OBSERVATION_MODIFIER", 144, 157], ["pharyngitis", "OBSERVATION", 158, 169]]], ["The broader spectrum of the cephalosporins and their higher cost relegate them to second-line status.", [["cephalosporins", "CHEMICAL", 28, 42], ["cephalosporins", "CHEMICAL", 28, 42], ["cephalosporins", "SIMPLE_CHEMICAL", 28, 42], ["the cephalosporins", "TREATMENT", 24, 42]]], ["The decreased dosing frequency of amoxicillin and some cephalosporins may improve patient adherence.TreatmentPatients who are allergic to penicillin can receive a cephalosporin if they have not had an immediate hypersensitivity reaction.", [["amoxicillin", "CHEMICAL", 34, 45], ["cephalosporins", "CHEMICAL", 55, 69], ["allergic", "DISEASE", 126, 134], ["penicillin", "CHEMICAL", 138, 148], ["cephalosporin", "CHEMICAL", 163, 176], ["hypersensitivity", "DISEASE", 211, 227], ["amoxicillin", "CHEMICAL", 34, 45], ["cephalosporins", "CHEMICAL", 55, 69], ["penicillin", "CHEMICAL", 138, 148], ["cephalosporin", "CHEMICAL", 163, 176], ["amoxicillin", "SIMPLE_CHEMICAL", 34, 45], ["cephalosporins", "SIMPLE_CHEMICAL", 55, 69], ["patient", "ORGANISM", 82, 89], ["penicillin", "SIMPLE_CHEMICAL", 138, 148], ["cephalosporin", "SIMPLE_CHEMICAL", 163, 176], ["patient", "SPECIES", 82, 89], ["amoxicillin", "TREATMENT", 34, 45], ["some cephalosporins", "TREATMENT", 50, 69], ["allergic", "PROBLEM", 126, 134], ["penicillin", "TREATMENT", 138, 148], ["a cephalosporin", "TREATMENT", 161, 176], ["an immediate hypersensitivity reaction", "PROBLEM", 198, 236], ["decreased", "OBSERVATION_MODIFIER", 4, 13], ["hypersensitivity reaction", "OBSERVATION", 211, 236]]], ["Erythromycin or another non-\u03b2-lactam antibiotic, such as clarithromycin, azithromycin, or clindamycin, can be used.", [["Erythromycin", "CHEMICAL", 0, 12], ["non-\u03b2-lactam", "CHEMICAL", 24, 36], ["clarithromycin", "CHEMICAL", 57, 71], ["azithromycin", "CHEMICAL", 73, 85], ["clindamycin", "CHEMICAL", 90, 101], ["Erythromycin", "CHEMICAL", 0, 12], ["non-\u03b2-lactam", "CHEMICAL", 24, 36], ["clarithromycin", "CHEMICAL", 57, 71], ["azithromycin", "CHEMICAL", 73, 85], ["clindamycin", "CHEMICAL", 90, 101], ["Erythromycin", "SIMPLE_CHEMICAL", 0, 12], ["non-\u03b2-lactam", "SIMPLE_CHEMICAL", 24, 36], ["clarithromycin", "SIMPLE_CHEMICAL", 57, 71], ["azithromycin", "SIMPLE_CHEMICAL", 73, 85], ["clindamycin", "SIMPLE_CHEMICAL", 90, 101], ["Erythromycin", "TREATMENT", 0, 12], ["another non-\u03b2-lactam antibiotic", "TREATMENT", 16, 47], ["clarithromycin", "TREATMENT", 57, 71], ["azithromycin", "TREATMENT", 73, 85], ["clindamycin", "TREATMENT", 90, 101]]], ["Resistance of GAS to macrolides has increased dramatically in many areas of the world where erythromycin has been widely used.", [["macrolides", "CHEMICAL", 21, 31], ["erythromycin", "CHEMICAL", 92, 104], ["macrolides", "CHEMICAL", 21, 31], ["erythromycin", "CHEMICAL", 92, 104], ["GAS", "ORGANISM", 14, 17], ["erythromycin", "SIMPLE_CHEMICAL", 92, 104], ["Resistance of GAS", "PROBLEM", 0, 17], ["macrolides", "TREATMENT", 21, 31], ["erythromycin", "TREATMENT", 92, 104], ["GAS", "OBSERVATION", 14, 17], ["macrolides", "OBSERVATION_MODIFIER", 21, 31], ["increased", "OBSERVATION_MODIFIER", 36, 45], ["dramatically", "OBSERVATION_MODIFIER", 46, 58], ["many", "OBSERVATION_MODIFIER", 62, 66], ["areas", "OBSERVATION_MODIFIER", 67, 72]]], ["Macrolide resistance also affects azithromycin and can affect clindamycin.", [["Macrolide", "CHEMICAL", 0, 9], ["azithromycin", "CHEMICAL", 34, 46], ["clindamycin", "CHEMICAL", 62, 73], ["Macrolide", "CHEMICAL", 0, 9], ["azithromycin", "CHEMICAL", 34, 46], ["clindamycin", "CHEMICAL", 62, 73], ["Macrolide", "SIMPLE_CHEMICAL", 0, 9], ["azithromycin", "SIMPLE_CHEMICAL", 34, 46], ["clindamycin", "SIMPLE_CHEMICAL", 62, 73], ["Macrolide resistance", "TREATMENT", 0, 20], ["azithromycin", "TREATMENT", 34, 46], ["clindamycin", "TREATMENT", 62, 73], ["resistance", "OBSERVATION", 10, 20]]], ["Although this resistance has not yet emerged as a major problem in the United States, where the rate of macrolide resistance among GAS is generally 5-8%, there is much local variation.", [["macrolide", "CHEMICAL", 104, 113], ["macrolide", "CHEMICAL", 104, 113], ["macrolide", "SIMPLE_CHEMICAL", 104, 113], ["macrolide resistance among GAS", "TEST", 104, 134], ["macrolide resistance", "OBSERVATION", 104, 124], ["much", "OBSERVATION_MODIFIER", 163, 167], ["local variation", "OBSERVATION", 168, 183]]], ["GAS resistance to clindamycin is in the range of 1-2%.", [["clindamycin", "CHEMICAL", 18, 29], ["clindamycin", "CHEMICAL", 18, 29], ["clindamycin", "SIMPLE_CHEMICAL", 18, 29], ["GAS resistance", "TEST", 0, 14], ["clindamycin", "TREATMENT", 18, 29]]], ["Of note, both macrolide and clindamycin resistance are more common in Canada than in the United States.", [["macrolide", "CHEMICAL", 14, 23], ["clindamycin", "CHEMICAL", 28, 39], ["macrolide", "CHEMICAL", 14, 23], ["clindamycin", "CHEMICAL", 28, 39], ["macrolide", "SIMPLE_CHEMICAL", 14, 23], ["clindamycin", "SIMPLE_CHEMICAL", 28, 39], ["macrolide", "TREATMENT", 14, 23], ["clindamycin resistance", "TREATMENT", 28, 50], ["clindamycin resistance", "OBSERVATION", 28, 50]]], ["Sulfa drugs (including sulfamethoxazole combined with trimethoprim), tetracyclines, and chloramphenicol should not be used for treatment of acute streptococcal pharyngitis because they do not eradicate GAS.Suppurative ComplicationsAntibiotic therapy has greatly reduced the likelihood of developing suppurative complications caused by spread of GAS from the pharynx or middle ear to adjacent structures.", [["pharynx", "ANATOMY", 358, 365], ["middle ear", "ANATOMY", 369, 379], ["Sulfa", "CHEMICAL", 0, 5], ["sulfamethoxazole", "CHEMICAL", 23, 39], ["trimethoprim", "CHEMICAL", 54, 66], ["tetracyclines", "CHEMICAL", 69, 82], ["chloramphenicol", "CHEMICAL", 88, 103], ["streptococcal pharyngitis", "DISEASE", 146, 171], ["Sulfa", "CHEMICAL", 0, 5], ["sulfamethoxazole", "CHEMICAL", 23, 39], ["trimethoprim", "CHEMICAL", 54, 66], ["tetracyclines", "CHEMICAL", 69, 82], ["chloramphenicol", "CHEMICAL", 88, 103], ["Sulfa drugs", "SIMPLE_CHEMICAL", 0, 11], ["sulfamethoxazole", "SIMPLE_CHEMICAL", 23, 39], ["trimethoprim", "SIMPLE_CHEMICAL", 54, 66], ["tetracyclines", "SIMPLE_CHEMICAL", 69, 82], ["chloramphenicol", "SIMPLE_CHEMICAL", 88, 103], ["pharynx", "ORGAN", 358, 365], ["ear", "ORGAN", 376, 379], ["Sulfa drugs", "TREATMENT", 0, 11], ["sulfamethoxazole", "TREATMENT", 23, 39], ["trimethoprim", "TREATMENT", 54, 66], ["tetracyclines", "TREATMENT", 69, 82], ["chloramphenicol", "TREATMENT", 88, 103], ["acute streptococcal pharyngitis", "PROBLEM", 140, 171], ["Suppurative Complications", "TREATMENT", 206, 231], ["Antibiotic therapy", "TREATMENT", 231, 249], ["developing suppurative complications", "PROBLEM", 288, 324], ["GAS from the pharynx", "PROBLEM", 345, 365], ["acute", "OBSERVATION_MODIFIER", 140, 145], ["streptococcal", "OBSERVATION_MODIFIER", 146, 159], ["pharyngitis", "OBSERVATION", 160, 171], ["reduced", "OBSERVATION_MODIFIER", 262, 269], ["suppurative", "OBSERVATION_MODIFIER", 299, 310], ["complications", "OBSERVATION", 311, 324], ["spread", "OBSERVATION_MODIFIER", 335, 341], ["GAS", "OBSERVATION", 345, 348], ["pharynx", "ANATOMY", 358, 365], ["middle ear", "ANATOMY", 369, 379]]], ["Peritonsillar abscess (\"quinsy\") manifests with fever, severe throat pain, dysphagia, \"hot potato voice,\" pain referred to the ear, and bulging of the peritonsillar area with asymmetry of the tonsils and sometimes displacement of the uvula (Fig. 1.4 ; see also Table 1 .4).", [["Peritonsillar abscess", "ANATOMY", 0, 21], ["throat", "ANATOMY", 62, 68], ["ear", "ANATOMY", 127, 130], ["peritonsillar area", "ANATOMY", 151, 169], ["tonsils", "ANATOMY", 192, 199], ["uvula", "ANATOMY", 234, 239], ["Peritonsillar abscess", "DISEASE", 0, 21], ["fever", "DISEASE", 48, 53], ["throat pain", "DISEASE", 62, 73], ["dysphagia", "DISEASE", 75, 84], ["potato voice", "DISEASE", 91, 103], ["pain", "DISEASE", 106, 110], ["peritonsillar", "DISEASE", 151, 164], ["asymmetry of the tonsils", "DISEASE", 175, 199], ["throat", "ORGANISM_SUBDIVISION", 62, 68], ["ear", "ORGAN", 127, 130], ["tonsils", "ORGAN", 192, 199], ["uvula", "ORGAN", 234, 239], ["Peritonsillar abscess", "PROBLEM", 0, 21], ["fever", "PROBLEM", 48, 53], ["severe throat pain", "PROBLEM", 55, 73], ["dysphagia", "PROBLEM", 75, 84], ["hot potato voice", "PROBLEM", 87, 103], ["\" pain", "PROBLEM", 104, 110], ["bulging of the peritonsillar area", "PROBLEM", 136, 169], ["asymmetry of the tonsils", "PROBLEM", 175, 199], ["displacement of the uvula", "PROBLEM", 214, 239], ["abscess", "OBSERVATION", 14, 21], ["fever", "OBSERVATION", 48, 53], ["severe", "OBSERVATION_MODIFIER", 55, 61], ["throat", "ANATOMY", 62, 68], ["dysphagia", "OBSERVATION", 75, 84], ["ear", "ANATOMY", 127, 130], ["bulging", "OBSERVATION", 136, 143], ["peritonsillar", "ANATOMY", 151, 164], ["area", "ANATOMY_MODIFIER", 165, 169], ["asymmetry", "OBSERVATION", 175, 184], ["tonsils", "ANATOMY", 192, 199], ["displacement", "OBSERVATION_MODIFIER", 214, 226], ["uvula", "ANATOMY", 234, 239]]], ["There can be peritonsillar cellulitis without a well-defined abscess cavity.", [["peritonsillar", "ANATOMY", 13, 26], ["abscess", "ANATOMY", 61, 68], ["cellulitis", "DISEASE", 27, 37], ["abscess", "DISEASE", 61, 68], ["abscess cavity", "PATHOLOGICAL_FORMATION", 61, 75], ["peritonsillar cellulitis", "PROBLEM", 13, 37], ["a well-defined abscess cavity", "PROBLEM", 46, 75], ["peritonsillar", "ANATOMY", 13, 26], ["cellulitis", "OBSERVATION", 27, 37], ["well-defined", "OBSERVATION_MODIFIER", 48, 60], ["abscess", "OBSERVATION", 61, 68]]], ["Trismus may be present.", [["Trismus", "PROBLEM", 0, 7], ["may be", "UNCERTAINTY", 8, 14]]], ["When an abscess is found clinically or by an imaging study such as a computed tomographic (CT) scan, surgical drainage is indicated.", [["abscess", "ANATOMY", 8, 15], ["abscess", "DISEASE", 8, 15], ["an abscess", "PROBLEM", 5, 15], ["an imaging study", "TEST", 42, 58], ["a computed tomographic (CT) scan", "TEST", 67, 99], ["surgical drainage", "TREATMENT", 101, 118], ["abscess", "OBSERVATION", 8, 15]]], ["Peritonsillar abscess occurs most commonly in older children and adolescents.", [["Peritonsillar abscess", "ANATOMY", 0, 21], ["Peritonsillar abscess", "DISEASE", 0, 21], ["Peritonsillar abscess", "PATHOLOGICAL_FORMATION", 0, 21], ["children", "ORGANISM", 52, 60], ["children", "SPECIES", 52, 60], ["adolescents", "SPECIES", 65, 76], ["Peritonsillar abscess", "PROBLEM", 0, 21], ["abscess", "OBSERVATION", 14, 21]]], ["Retropharyngeal abscess represents extension of an infection from the pharynx or peritonsillar region into the retropharyngeal (prevertebral) space, which is rich in lymphoid structures (Figs.", [["Retropharyngeal abscess", "ANATOMY", 0, 23], ["pharynx", "ANATOMY", 70, 77], ["peritonsillar region", "ANATOMY", 81, 101], ["retropharyngeal", "ANATOMY", 111, 126], ["prevertebral) space", "ANATOMY", 128, 147], ["lymphoid structures", "ANATOMY", 166, 185], ["abscess", "DISEASE", 16, 23], ["infection", "DISEASE", 51, 60], ["pharynx", "ORGAN", 70, 77], ["lymphoid structures", "TISSUE", 166, 185], ["Retropharyngeal abscess", "PROBLEM", 0, 23], ["an infection from the pharynx or peritonsillar region into the retropharyngeal (prevertebral) space", "PROBLEM", 48, 147], ["abscess", "OBSERVATION", 16, 23], ["infection", "OBSERVATION", 51, 60], ["pharynx", "ANATOMY", 70, 77], ["peritonsillar", "ANATOMY", 81, 94], ["region", "ANATOMY_MODIFIER", 95, 101], ["retropharyngeal", "ANATOMY", 111, 126], ["prevertebral", "ANATOMY", 128, 140], ["space", "ANATOMY_MODIFIER", 142, 147], ["rich", "OBSERVATION_MODIFIER", 158, 162], ["lymphoid structures", "OBSERVATION", 166, 185]]], ["Children younger than 4 years old are most often affected.", [["Children", "ORGANISM", 0, 8], ["Children", "SPECIES", 0, 8]]], ["Fever, dysphagia, drooling, stridor, extension of the neck, and a mass in the posterior pharyngeal wall may be noted.", [["neck", "ANATOMY", 54, 58], ["posterior pharyngeal wall", "ANATOMY", 78, 103], ["Fever", "DISEASE", 0, 5], ["dysphagia", "DISEASE", 7, 16], ["drooling", "DISEASE", 18, 26], ["stridor", "DISEASE", 28, 35], ["neck", "ORGAN", 54, 58], ["posterior pharyngeal wall", "MULTI-TISSUE_STRUCTURE", 78, 103], ["Fever", "PROBLEM", 0, 5], ["dysphagia", "PROBLEM", 7, 16], ["drooling", "PROBLEM", 18, 26], ["stridor", "PROBLEM", 28, 35], ["extension of the neck", "PROBLEM", 37, 58], ["a mass in the posterior pharyngeal wall", "PROBLEM", 64, 103], ["dysphagia", "OBSERVATION", 7, 16], ["drooling", "OBSERVATION", 18, 26], ["stridor", "OBSERVATION", 28, 35], ["neck", "ANATOMY", 54, 58], ["mass", "OBSERVATION", 66, 70], ["posterior", "ANATOMY_MODIFIER", 78, 87], ["pharyngeal wall", "ANATOMY", 88, 103]]], ["Surgical drainage is often required if frank suppuration has occurred.", [["suppuration", "DISEASE", 45, 56], ["Surgical drainage", "TREATMENT", 0, 17], ["frank suppuration", "PROBLEM", 39, 56], ["drainage", "OBSERVATION", 9, 17], ["suppuration", "OBSERVATION", 45, 56]]], ["Spread of GAS via pharyngeal lymphatic vessels to regional nodes can cause cervical lymphadenitis.", [["pharyngeal lymphatic vessels", "ANATOMY", 18, 46], ["regional nodes", "ANATOMY", 50, 64], ["cervical lymphadenitis", "ANATOMY", 75, 97], ["lymphadenitis", "DISEASE", 84, 97], ["GAS", "GENE_OR_GENE_PRODUCT", 10, 13], ["pharyngeal lymphatic vessels", "MULTI-TISSUE_STRUCTURE", 18, 46], ["regional nodes", "MULTI-TISSUE_STRUCTURE", 50, 64], ["cervical lymphadenitis", "PATHOLOGICAL_FORMATION", 75, 97], ["GAS", "DNA", 10, 13], ["cervical lymphadenitis", "PROBLEM", 75, 97], ["GAS", "OBSERVATION", 10, 13], ["pharyngeal", "ANATOMY_MODIFIER", 18, 28], ["lymphatic vessels", "ANATOMY", 29, 46], ["regional nodes", "OBSERVATION", 50, 64], ["cervical", "ANATOMY", 75, 83], ["lymphadenitis", "OBSERVATION", 84, 97]]], ["The markedly swollen and tender anterior cervical nodes that result can suppurate.", [["anterior cervical nodes", "ANATOMY", 32, 55], ["anterior cervical nodes", "MULTI-TISSUE_STRUCTURE", 32, 55], ["The markedly swollen and tender anterior cervical nodes", "PROBLEM", 0, 55], ["markedly", "OBSERVATION_MODIFIER", 4, 12], ["swollen", "OBSERVATION_MODIFIER", 13, 20], ["tender", "OBSERVATION_MODIFIER", 25, 31], ["anterior", "ANATOMY_MODIFIER", 32, 40], ["cervical", "ANATOMY", 41, 49], ["nodes", "OBSERVATION", 50, 55]]], ["Otitis media, mastoiditis, and sinusitis also may occur as complications of GAS pharyngitis.", [["Otitis media", "DISEASE", 0, 12], ["mastoiditis", "DISEASE", 14, 25], ["sinusitis", "DISEASE", 31, 40], ["pharyngitis", "DISEASE", 80, 91], ["Otitis media", "PROBLEM", 0, 12], ["mastoiditis", "PROBLEM", 14, 25], ["sinusitis", "PROBLEM", 31, 40], ["GAS pharyngitis", "PROBLEM", 76, 91], ["mastoiditis", "OBSERVATION", 14, 25], ["sinusitis", "OBSERVATION", 31, 40], ["GAS pharyngitis", "OBSERVATION", 76, 91]]], ["Additional parapharyngeal suppurative infections that may mimic streptococcal disease are noted in Table 1 .4.", [["parapharyngeal suppurative", "ANATOMY", 11, 37], ["suppurative infections", "DISEASE", 26, 48], ["streptococcal disease", "DISEASE", 64, 85], ["parapharyngeal suppurative", "PATHOLOGICAL_FORMATION", 11, 37], ["Additional parapharyngeal suppurative infections", "PROBLEM", 0, 48], ["streptococcal disease", "PROBLEM", 64, 85], ["parapharyngeal", "ANATOMY", 11, 25], ["suppurative", "OBSERVATION", 26, 37], ["streptococcal", "OBSERVATION_MODIFIER", 64, 77], ["disease", "OBSERVATION", 78, 85]]], ["Furthermore, any pharyngeal infectious process may produce torticollis if there is inflammation that extends to the paraspinal muscles and ligaments, producing pain, spasm, and, on occasion, rotary subluxation of the cervical spine.", [["pharyngeal", "ANATOMY", 17, 27], ["paraspinal muscles", "ANATOMY", 116, 134], ["ligaments", "ANATOMY", 139, 148], ["cervical spine", "ANATOMY", 217, 231], ["torticollis", "DISEASE", 59, 70], ["inflammation", "DISEASE", 83, 95], ["pain", "DISEASE", 160, 164], ["spasm", "DISEASE", 166, 171], ["subluxation", "DISEASE", 198, 209], ["pharyngeal", "ORGAN", 17, 27], ["paraspinal muscles", "TISSUE", 116, 134], ["ligaments", "TISSUE", 139, 148], ["cervical spine", "MULTI-TISSUE_STRUCTURE", 217, 231], ["any pharyngeal infectious process", "PROBLEM", 13, 46], ["torticollis", "PROBLEM", 59, 70], ["inflammation", "PROBLEM", 83, 95], ["pain", "PROBLEM", 160, 164], ["spasm", "PROBLEM", 166, 171], ["rotary subluxation of the cervical spine", "PROBLEM", 191, 231], ["pharyngeal", "ANATOMY", 17, 27], ["infectious", "OBSERVATION", 28, 38], ["torticollis", "OBSERVATION", 59, 70], ["inflammation", "OBSERVATION", 83, 95], ["paraspinal muscles", "ANATOMY", 116, 134], ["ligaments", "ANATOMY", 139, 148], ["pain", "OBSERVATION_MODIFIER", 160, 164], ["spasm", "OBSERVATION", 166, 171], ["rotary", "OBSERVATION_MODIFIER", 191, 197], ["subluxation", "OBSERVATION", 198, 209], ["cervical spine", "ANATOMY", 217, 231]]], ["Oropharyngeal torticollis lasts less than 2 weeks and is not associated with abnormal neurologic signs or pain over the spinous process.", [["Oropharyngeal", "ANATOMY", 0, 13], ["neurologic", "ANATOMY", 86, 96], ["Oropharyngeal torticollis", "DISEASE", 0, 25], ["abnormal neurologic signs", "DISEASE", 77, 102], ["pain", "DISEASE", 106, 110], ["Oropharyngeal torticollis", "PROBLEM", 0, 25], ["abnormal neurologic signs", "PROBLEM", 77, 102], ["pain over the spinous process", "PROBLEM", 106, 135], ["torticollis", "OBSERVATION", 14, 25], ["not associated with", "UNCERTAINTY", 57, 76], ["pain", "OBSERVATION", 106, 110], ["spinous", "ANATOMY", 120, 127]]], ["Invasive sterile site or bacteremic infection with GAS is unusual as sequelae to pharyngitis.Nonsuppurative SequelaeNonsuppurative complications include acute rheumatic fever (ARF), acute glomerulonephritis (AGN), and possibly reactive arthritis/ synovitis.", [["site", "ANATOMY", 17, 21], ["infection", "DISEASE", 36, 45], ["pharyngitis", "DISEASE", 81, 92], ["acute rheumatic fever", "DISEASE", 153, 174], ["ARF", "DISEASE", 176, 179], ["glomerulonephritis", "DISEASE", 188, 206], ["AGN", "DISEASE", 208, 211], ["reactive arthritis", "DISEASE", 227, 245], ["synovitis", "DISEASE", 247, 256], ["Invasive sterile site", "PROBLEM", 0, 21], ["bacteremic infection", "PROBLEM", 25, 45], ["pharyngitis", "PROBLEM", 81, 92], ["Nonsuppurative SequelaeNonsuppurative complications", "PROBLEM", 93, 144], ["acute rheumatic fever", "PROBLEM", 153, 174], ["ARF", "PROBLEM", 176, 179], ["acute glomerulonephritis (AGN)", "PROBLEM", 182, 212], ["reactive arthritis", "PROBLEM", 227, 245], ["synovitis", "PROBLEM", 247, 256], ["bacteremic", "OBSERVATION_MODIFIER", 25, 35], ["infection", "OBSERVATION", 36, 45], ["pharyngitis", "OBSERVATION", 81, 92], ["complications", "OBSERVATION", 131, 144], ["acute", "OBSERVATION_MODIFIER", 153, 158], ["rheumatic", "OBSERVATION_MODIFIER", 159, 168], ["fever", "OBSERVATION", 169, 174], ["ARF", "OBSERVATION", 176, 179], ["acute", "OBSERVATION_MODIFIER", 182, 187], ["glomerulonephritis", "OBSERVATION", 188, 206], ["AGN", "OBSERVATION_MODIFIER", 208, 211], ["possibly", "UNCERTAINTY", 218, 226], ["reactive", "OBSERVATION_MODIFIER", 227, 235], ["arthritis", "OBSERVATION", 236, 245], ["synovitis", "OBSERVATION", 247, 256]]], ["In addition, an association between streptococcal infection and neuropsychiatric disorders such as tic disorder, obsessivecompulsive disorder, and Tourette syndrome has been postulated.", [["streptococcal infection", "DISEASE", 36, 59], ["neuropsychiatric disorders", "DISEASE", 64, 90], ["tic disorder", "DISEASE", 99, 111], ["obsessivecompulsive disorder", "DISEASE", 113, 141], ["Tourette syndrome", "DISEASE", 147, 164], ["streptococcal infection", "PROBLEM", 36, 59], ["neuropsychiatric disorders", "PROBLEM", 64, 90], ["tic disorder", "PROBLEM", 99, 111], ["obsessivecompulsive disorder", "PROBLEM", 113, 141], ["Tourette syndrome", "PROBLEM", 147, 164], ["streptococcal", "OBSERVATION_MODIFIER", 36, 49], ["infection", "OBSERVATION", 50, 59], ["Tourette syndrome", "OBSERVATION", 147, 164]]], ["This possible association has been called PANDAS (pediatric autoimmune neuropsychiatric disorders associated with streptococci).", [["autoimmune neuropsychiatric disorders", "DISEASE", 60, 97], ["PANDAS (pediatric autoimmune neuropsychiatric disorders", "PROBLEM", 42, 97], ["streptococci", "PROBLEM", 114, 126]]], ["The terminology has been modified to \"pediatric acute-onset neuropsychiatric syndrome\" (PANS) or \"childhood acute neuropsychiatric syndrome\" (CANS), in recognition that the etiologic role of GAS and benefit from antibiotic treatment have been difficult to establish, and it is likely that infections other than GAS infection are associated with the development, recurrence, or exacerbation of neuropsychiatric symptoms.Nonsuppurative SequelaeTherapy with an appropriate antibiotic within 9 days of onset of symptoms is highly effective in preventing ARF.", [["neuropsychiatric syndrome", "DISEASE", 60, 85], ["PANS", "DISEASE", 88, 92], ["acute neuropsychiatric syndrome", "DISEASE", 108, 139], ["CANS", "DISEASE", 142, 146], ["infections", "DISEASE", 289, 299], ["infection", "DISEASE", 315, 324], ["SequelaeTherapy", "DISEASE", 434, 449], ["ARF", "DISEASE", 550, 553], ["ARF", "GENE_OR_GENE_PRODUCT", 550, 553], ["pediatric acute-onset neuropsychiatric syndrome", "PROBLEM", 38, 85], ["\"childhood acute neuropsychiatric syndrome", "PROBLEM", 97, 139], ["antibiotic treatment", "TREATMENT", 212, 232], ["infections", "PROBLEM", 289, 299], ["GAS infection", "PROBLEM", 311, 324], ["recurrence", "PROBLEM", 362, 372], ["exacerbation of neuropsychiatric symptoms", "PROBLEM", 377, 418], ["Nonsuppurative SequelaeTherapy", "TREATMENT", 419, 449], ["an appropriate antibiotic", "TREATMENT", 455, 480], ["symptoms", "PROBLEM", 507, 515], ["ARF", "PROBLEM", 550, 553], ["acute", "OBSERVATION_MODIFIER", 108, 113], ["neuropsychiatric syndrome", "OBSERVATION", 114, 139], ["is likely", "UNCERTAINTY", 274, 283], ["infections", "OBSERVATION", 289, 299], ["infection", "OBSERVATION", 315, 324], ["ARF", "OBSERVATION", 550, 553]]], ["Except in certain geographic areas (e.g., Salt Lake City) and populations (e.g., Hasidic Jewish communities) ARF is quite rare in North America.", [["ARF", "DISEASE", 109, 112], ["ARF", "GENE_OR_GENE_PRODUCT", 109, 112], ["ARF", "PROBLEM", 109, 112], ["geographic", "OBSERVATION_MODIFIER", 18, 28], ["areas", "OBSERVATION_MODIFIER", 29, 34], ["ARF", "OBSERVATION", 109, 112]]], ["The impressive reduction in ARF prevalence in the United States since the mid-1960s may be related to reductions in the prevalence of so-called \"rheumatogenic\" GAS M types.", [["ARF", "DISEASE", 28, 31], ["ARF", "GENE_OR_GENE_PRODUCT", 28, 31], ["ARF prevalence", "PROBLEM", 28, 42], ["impressive", "OBSERVATION_MODIFIER", 4, 14], ["reduction", "OBSERVATION_MODIFIER", 15, 24], ["ARF", "OBSERVATION", 28, 31], ["prevalence", "OBSERVATION_MODIFIER", 32, 42], ["may be related to", "UNCERTAINTY", 84, 101], ["reductions", "OBSERVATION_MODIFIER", 102, 112]]], ["The reason for the near disappearance of rheumatogenic types in the United States is unknown.", [["rheumatogenic types", "PROBLEM", 41, 60], ["rheumatogenic types", "OBSERVATION", 41, 60]]], ["Areas of the world with persistently high rates of ARF have different M types than the United States had in the past and has currently.", [["ARF", "DISEASE", 51, 54], ["ARF", "GENE_OR_GENE_PRODUCT", 51, 54], ["ARF", "PROBLEM", 51, 54], ["persistently", "OBSERVATION_MODIFIER", 24, 36], ["high", "OBSERVATION_MODIFIER", 37, 41], ["ARF", "OBSERVATION", 51, 54]]], ["AGN is not prevented by treatment of the antecedent streptococcal infection.", [["AGN", "DISEASE", 0, 3], ["streptococcal infection", "DISEASE", 52, 75], ["AGN", "GENE_OR_GENE_PRODUCT", 0, 3], ["the antecedent streptococcal infection", "PROBLEM", 37, 75], ["not prevented", "UNCERTAINTY", 7, 20], ["streptococcal", "OBSERVATION_MODIFIER", 52, 65], ["infection", "OBSERVATION", 66, 75]]], ["Pharyngitis caused by one of the \"nephritogenic\" strains of GAS precedes Retropharyngeal spaceNonsuppurative SequelaeRetrotracheal space spread of GAS in the community.", [["Pharyngitis", "DISEASE", 0, 11], ["Pharyngitis", "PROBLEM", 0, 11], ["the \"nephritogenic\" strains of GAS", "PROBLEM", 29, 63], ["Retropharyngeal space", "PROBLEM", 73, 94], ["GAS", "OBSERVATION_MODIFIER", 60, 63], ["Retropharyngeal", "ANATOMY", 73, 88], ["space", "ANATOMY_MODIFIER", 89, 94], ["Nonsuppurative", "OBSERVATION_MODIFIER", 94, 108], ["Sequelae", "OBSERVATION_MODIFIER", 109, 117], ["Retrotracheal", "OBSERVATION_MODIFIER", 117, 130], ["space", "OBSERVATION_MODIFIER", 131, 136], ["spread", "OBSERVATION_MODIFIER", 137, 143], ["GAS", "OBSERVATION_MODIFIER", 147, 150]]], ["There is no reason to exclude carriers from school.", [["no reason to exclude", "UNCERTAINTY", 9, 29]]], ["There is no easy way to identify chronic carriers prospectively among patients with symptoms of acute pharyngitis.", [["pharyngitis", "DISEASE", 102, 113], ["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78], ["chronic carriers", "PROBLEM", 33, 49], ["symptoms", "PROBLEM", 84, 92], ["acute pharyngitis", "PROBLEM", 96, 113], ["no", "UNCERTAINTY", 9, 11], ["acute", "OBSERVATION_MODIFIER", 96, 101], ["pharyngitis", "OBSERVATION", 102, 113]]], ["The pathophysiology of chronic carriage is unknown.", [["chronic carriage", "PROBLEM", 23, 39], ["chronic", "OBSERVATION_MODIFIER", 23, 30], ["carriage", "OBSERVATION", 31, 39]]], ["As resistance to penicillin is not a factor, many other causes have been hypothesized including non-adherence to antibiotic treatment, tolerance to antibiotics (suppression but lack of killing by antimicrobials), internalization of GAS by epithelial cells, and presence of \u03b2-lactamase-producing \"co-pathogens,\" but none has been proven.", [["epithelial cells", "ANATOMY", 239, 255], ["penicillin", "CHEMICAL", 17, 27], ["penicillin", "CHEMICAL", 17, 27], ["penicillin", "SIMPLE_CHEMICAL", 17, 27], ["GAS", "GENE_OR_GENE_PRODUCT", 232, 235], ["epithelial cells", "CELL", 239, 255], ["\u03b2-lactamase", "GENE_OR_GENE_PRODUCT", 273, 284], ["epithelial cells", "CELL_TYPE", 239, 255], ["\u03b2-lactamase", "PROTEIN", 273, 284], ["penicillin", "TREATMENT", 17, 27], ["antibiotic treatment", "TREATMENT", 113, 133], ["antibiotics", "TREATMENT", 148, 159], ["antimicrobials", "TREATMENT", 196, 210], ["epithelial cells", "PROBLEM", 239, 255], ["\u03b2-lactamase", "TEST", 273, 284], ["\"co-pathogens", "PROBLEM", 295, 308], ["epithelial cells", "OBSERVATION", 239, 255]]], ["The clinician should consider the possibility of chronic GAS carriage when a patient or a family member has multiple test-positive episodes of pharyngitis, especially when symptoms are mild or atypical.", [["pharyngitis", "DISEASE", 143, 154], ["patient", "ORGANISM", 77, 84], ["patient", "SPECIES", 77, 84], ["chronic GAS carriage", "PROBLEM", 49, 69], ["multiple test", "TEST", 108, 121], ["pharyngitis", "PROBLEM", 143, 154], ["symptoms", "PROBLEM", 172, 180], ["pharyngitis", "OBSERVATION", 143, 154], ["mild", "OBSERVATION_MODIFIER", 185, 189], ["atypical", "OBSERVATION_MODIFIER", 193, 201]]], ["A culture or other test is usually positive for GAS when the suspected carrier is symptom-free or is receiving antibiotic treatment (intramuscular benzathine penicillin is recommended in order to eliminate concerns about compliance).", [["benzathine penicillin", "CHEMICAL", 147, 168], ["benzathine penicillin", "CHEMICAL", 147, 168], ["benzathine", "SIMPLE_CHEMICAL", 147, 157], ["penicillin", "SIMPLE_CHEMICAL", 158, 168], ["A culture", "TEST", 0, 9], ["other test", "TEST", 13, 23], ["GAS", "PROBLEM", 48, 51], ["symptom", "PROBLEM", 82, 89], ["antibiotic treatment", "TREATMENT", 111, 131], ["intramuscular benzathine penicillin", "TREATMENT", 133, 168]]], ["Carriers often receive multiple unsuccessful courses of antibiotic therapy in attempts to eliminate GAS.", [["GAS", "DNA", 100, 103], ["antibiotic therapy", "TREATMENT", 56, 74], ["GAS", "TEST", 100, 103]]], ["Physician and patient anxiety is common and can develop into \"streptophobia.\"", [["anxiety", "DISEASE", 22, 29], ["streptophobia", "DISEASE", 62, 75], ["patient", "ORGANISM", 14, 21], ["patient", "SPECIES", 14, 21]]], ["Unproven and ineffective therapies include tonsillectomy, prolonged administration of antibiotics, use of \u03b2-lactamase-resistant antibiotics, and culture or treatment of pets.", [["\u03b2-lactamase", "CHEMICAL", 106, 117], ["\u03b2-lactamase", "SIMPLE_CHEMICAL", 106, 117], ["ineffective therapies", "TREATMENT", 13, 34], ["tonsillectomy", "TREATMENT", 43, 56], ["antibiotics", "TREATMENT", 86, 97], ["\u03b2-lactamase", "TREATMENT", 106, 117], ["resistant antibiotics", "TREATMENT", 118, 139], ["culture", "TEST", 145, 152], ["pets", "PROBLEM", 169, 173], ["tonsillectomy", "OBSERVATION", 43, 56]]], ["Available treatment options for the physician faced with a chronic streptococcal carrier include the following:Nonsuppurative Sequelae1.", [["a chronic streptococcal carrier", "TREATMENT", 57, 88], ["Nonsuppurative Sequelae1", "TREATMENT", 111, 135]]], ["Evaluate for GAS pharyngitis by throat swab each time the patient has pharyngitis with features that suggest streptococcal pharyngitis.", [["throat swab", "ANATOMY", 32, 43], ["pharyngitis", "DISEASE", 17, 28], ["pharyngitis", "DISEASE", 70, 81], ["streptococcal pharyngitis", "DISEASE", 109, 134], ["patient", "ORGANISM", 58, 65], ["patient", "SPECIES", 58, 65], ["GAS pharyngitis", "PROBLEM", 13, 28], ["throat swab", "TEST", 32, 43], ["pharyngitis", "PROBLEM", 70, 81], ["streptococcal pharyngitis", "PROBLEM", 109, 134], ["GAS pharyngitis", "OBSERVATION", 13, 28], ["pharyngitis", "OBSERVATION", 70, 81], ["suggest", "UNCERTAINTY", 101, 108], ["streptococcal", "OBSERVATION_MODIFIER", 109, 122], ["pharyngitis", "OBSERVATION", 123, 134]]], ["Treat as acute GAS pharyngitis with amoxicillin or penicillin (or an alternative agent) each time a test is positive; this will prevent ARF if the GAS identified has been newly acquired.", [["pharyngitis", "DISEASE", 19, 30], ["amoxicillin", "CHEMICAL", 36, 47], ["penicillin", "CHEMICAL", 51, 61], ["ARF", "DISEASE", 136, 139], ["amoxicillin", "CHEMICAL", 36, 47], ["penicillin", "CHEMICAL", 51, 61], ["amoxicillin", "SIMPLE_CHEMICAL", 36, 47], ["penicillin", "SIMPLE_CHEMICAL", 51, 61], ["ARF", "GENE_OR_GENE_PRODUCT", 136, 139], ["GAS", "DNA", 147, 150], ["acute GAS pharyngitis", "PROBLEM", 9, 30], ["amoxicillin", "TREATMENT", 36, 47], ["penicillin", "TREATMENT", 51, 61], ["an alternative agent", "TREATMENT", 66, 86], ["a test", "TEST", 98, 104], ["ARF", "PROBLEM", 136, 139], ["the GAS", "PROBLEM", 143, 150], ["acute", "OBSERVATION_MODIFIER", 9, 14], ["GAS pharyngitis", "OBSERVATION", 15, 30]]], ["Avoid testing patients who do not have signs and symptoms suggestive of acute GAS pharyngitis.Nonsuppurative Sequelaeglomerulonephritis by about 10 days.", [["pharyngitis", "DISEASE", 82, 93], ["Sequelaeglomerulonephritis", "DISEASE", 109, 135], ["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["signs and symptoms", "PROBLEM", 39, 57], ["acute GAS pharyngitis", "PROBLEM", 72, 93], ["Nonsuppurative Sequelaeglomerulonephritis", "PROBLEM", 94, 135], ["suggestive of", "UNCERTAINTY", 58, 71], ["acute", "OBSERVATION_MODIFIER", 72, 77], ["GAS pharyngitis", "OBSERVATION", 78, 93], ["Sequelaeglomerulonephritis", "OBSERVATION", 109, 135]]], ["Unlike ARF, which occurs only after GAS pharyngitis, AGN also can follow GAS skin infection.Treatment Failure and Chronic CarriageTreatment with penicillin cures GAS pharyngitis but does not eradicate GAS from the pharynx in as many as 25% of patients ( Fig. 1.7) .", [["skin", "ANATOMY", 77, 81], ["pharynx", "ANATOMY", 214, 221], ["ARF", "DISEASE", 7, 10], ["pharyngitis", "DISEASE", 40, 51], ["skin infection", "DISEASE", 77, 91], ["penicillin", "CHEMICAL", 145, 155], ["pharyngitis", "DISEASE", 166, 177], ["penicillin", "CHEMICAL", 145, 155], ["ARF", "GENE_OR_GENE_PRODUCT", 7, 10], ["skin", "ORGAN", 77, 81], ["penicillin", "SIMPLE_CHEMICAL", 145, 155], ["pharynx", "ORGAN", 214, 221], ["patients", "ORGANISM", 243, 251], ["ARF", "PROTEIN", 7, 10], ["patients", "SPECIES", 243, 251], ["ARF", "PROBLEM", 7, 10], ["GAS pharyngitis", "PROBLEM", 36, 51], ["AGN", "PROBLEM", 53, 56], ["GAS skin infection", "PROBLEM", 73, 91], ["Treatment Failure", "PROBLEM", 92, 109], ["Chronic CarriageTreatment", "PROBLEM", 114, 139], ["penicillin cures", "TREATMENT", 145, 161], ["GAS pharyngitis", "PROBLEM", 162, 177], ["ARF", "OBSERVATION", 7, 10], ["pharyngitis", "OBSERVATION", 40, 51], ["skin", "ANATOMY", 77, 81], ["infection", "OBSERVATION", 82, 91], ["Failure", "OBSERVATION", 102, 109], ["Chronic", "OBSERVATION_MODIFIER", 114, 121], ["pharyngitis", "OBSERVATION", 166, 177], ["pharynx", "ANATOMY", 214, 221]]], ["This causes considerable consternation among affected patients and their families.", [["patients", "ORGANISM", 54, 62], ["patients", "SPECIES", 54, 62]]], ["Resistance to penicillin is not the cause of treatment failure.", [["penicillin", "CHEMICAL", 14, 24], ["penicillin", "CHEMICAL", 14, 24], ["penicillin", "SIMPLE_CHEMICAL", 14, 24], ["penicillin", "TREATMENT", 14, 24], ["treatment failure", "PROBLEM", 45, 62], ["penicillin", "OBSERVATION", 14, 24], ["not the cause", "UNCERTAINTY", 28, 41], ["treatment", "OBSERVATION_MODIFIER", 45, 54], ["failure", "OBSERVATION", 55, 62]]], ["A few such patients are symptomatic and are characterized as having clinical treatment failure.", [["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19], ["symptomatic", "PROBLEM", 24, 35], ["clinical treatment failure", "PROBLEM", 68, 94], ["few", "OBSERVATION_MODIFIER", 2, 5], ["symptomatic", "OBSERVATION_MODIFIER", 24, 35]]], ["Re-infection with the same strain or a different strain is possible, as is intercurrent viral pharyngitis.", [["pharyngitis", "DISEASE", 94, 105], ["Re-infection", "PROBLEM", 0, 12], ["the same strain", "PROBLEM", 18, 33], ["a different strain", "PROBLEM", 37, 55], ["intercurrent viral pharyngitis", "PROBLEM", 75, 105], ["intercurrent", "OBSERVATION_MODIFIER", 75, 87], ["viral", "OBSERVATION_MODIFIER", 88, 93], ["pharyngitis", "OBSERVATION", 94, 105]]], ["Some of these patients may be chronic pharyngeal carriers of GAS who are suffering from a new superimposed viral infection; others may have been nonadherent to therapy.", [["pharyngeal", "ANATOMY", 38, 48], ["viral infection", "DISEASE", 107, 122], ["patients", "ORGANISM", 14, 22], ["pharyngeal", "ORGANISM_SUBDIVISION", 38, 48], ["patients", "SPECIES", 14, 22], ["chronic pharyngeal carriers of GAS", "PROBLEM", 30, 64], ["a new superimposed viral infection", "PROBLEM", 88, 122], ["therapy", "TREATMENT", 160, 167], ["may be", "UNCERTAINTY", 23, 29], ["chronic", "OBSERVATION_MODIFIER", 30, 37], ["pharyngeal", "ANATOMY", 38, 48], ["new", "OBSERVATION_MODIFIER", 90, 93], ["superimposed", "OBSERVATION_MODIFIER", 94, 106], ["viral", "OBSERVATION_MODIFIER", 107, 112], ["infection", "OBSERVATION", 113, 122], ["nonadherent", "OBSERVATION_MODIFIER", 145, 156]]], ["Many patients who continue to have positive tests for GAS despite antimicrobial treatment are asymptomatic and are identified only when follow-up throat swabs are obtained, a practice that is usually unnecessary in North America.", [["throat swabs", "ANATOMY", 146, 158], ["patients", "ORGANISM", 5, 13], ["throat", "ORGANISM", 146, 152], ["patients", "SPECIES", 5, 13], ["positive tests", "PROBLEM", 35, 49], ["GAS", "PROBLEM", 54, 57], ["antimicrobial treatment", "TREATMENT", 66, 89], ["asymptomatic", "PROBLEM", 94, 106], ["throat swabs", "TEST", 146, 158]]], ["Patients who adhered to therapy are at minimal risk for ARF.", [["ARF", "DISEASE", 56, 59], ["Patients", "ORGANISM", 0, 8], ["ARF", "GENE_OR_GENE_PRODUCT", 56, 59], ["Patients", "SPECIES", 0, 8], ["therapy", "TREATMENT", 24, 31], ["ARF", "PROBLEM", 56, 59], ["ARF", "OBSERVATION", 56, 59]]], ["One explanation for asymptomatic persistence of GAS after treatment is that these patients are chronically colonized with GAS, were initially symptomatic because of a viral pharyngitis, and did not truly have acute streptococcal pharyngitis.", [["GAS", "DISEASE", 48, 51], ["pharyngitis", "DISEASE", 173, 184], ["streptococcal pharyngitis", "DISEASE", 215, 240], ["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["treatment", "TREATMENT", 58, 67], ["symptomatic", "PROBLEM", 142, 153], ["a viral pharyngitis", "PROBLEM", 165, 184], ["acute streptococcal pharyngitis", "PROBLEM", 209, 240], ["GAS", "OBSERVATION", 48, 51], ["chronically", "OBSERVATION_MODIFIER", 95, 106], ["colonized", "OBSERVATION", 107, 116], ["viral", "OBSERVATION_MODIFIER", 167, 172], ["pharyngitis", "OBSERVATION", 173, 184], ["acute", "OBSERVATION_MODIFIER", 209, 214], ["streptococcal", "OBSERVATION_MODIFIER", 215, 228], ["pharyngitis", "OBSERVATION", 229, 240]]], ["Patients who are chronically colonized with GAS are called chronic carriers.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["chronic carriers", "PROBLEM", 59, 75], ["chronically", "OBSERVATION_MODIFIER", 17, 28], ["colonized", "OBSERVATION", 29, 38]]], ["Carriers do not appear to be at risk for ARF or for development of suppurative complications, and they are rarely sources of cause self-limited infections.", [["ARF", "DISEASE", 41, 44], ["suppurative complications", "DISEASE", 67, 92], ["infections", "DISEASE", 144, 154], ["ARF", "GENE_OR_GENE_PRODUCT", 41, 44], ["ARF", "PROBLEM", 41, 44], ["suppurative complications", "PROBLEM", 67, 92], ["self-limited infections", "PROBLEM", 131, 154], ["ARF", "OBSERVATION", 41, 44], ["suppurative", "OBSERVATION_MODIFIER", 67, 78], ["complications", "OBSERVATION", 79, 92], ["infections", "OBSERVATION", 144, 154]]], ["Acute rheumatic fever is not a sequela to these infections but acute glomerulonephritis has been documented in rare cases after epidemic group C and group G streptococcal pharyngitis.FUSOBACTERIUM NECROPHORUMFusobacterium necrophorum, an anaerobic gram-negative organism, is increasingly recognized as a cause of pharyngitis in older adolescents and adults (ages 15-30 years).", [["rheumatic fever", "DISEASE", 6, 21], ["infections", "DISEASE", 48, 58], ["glomerulonephritis", "DISEASE", 69, 87], ["streptococcal pharyngitis", "DISEASE", 157, 182], ["NECROPHORUMFusobacterium necrophorum", "DISEASE", 197, 233], ["pharyngitis", "DISEASE", 313, 324], ["NECROPHORUMFusobacterium necrophorum", "ORGANISM", 197, 233], ["adolescents", "SPECIES", 334, 345], ["NECROPHORUMFusobacterium necrophorum", "SPECIES", 197, 233], ["Acute rheumatic fever", "PROBLEM", 0, 21], ["a sequela", "PROBLEM", 29, 38], ["these infections", "PROBLEM", 42, 58], ["acute glomerulonephritis", "PROBLEM", 63, 87], ["epidemic group C", "PROBLEM", 128, 144], ["group G streptococcal pharyngitis", "PROBLEM", 149, 182], ["FUSOBACTERIUM NECROPHORUMFusobacterium necrophorum", "PROBLEM", 183, 233], ["an anaerobic gram", "TEST", 235, 252], ["negative organism", "PROBLEM", 253, 270], ["pharyngitis", "PROBLEM", 313, 324], ["rheumatic", "OBSERVATION_MODIFIER", 6, 15], ["fever", "OBSERVATION", 16, 21], ["infections", "OBSERVATION", 48, 58], ["acute", "OBSERVATION_MODIFIER", 63, 68], ["glomerulonephritis", "OBSERVATION", 69, 87], ["streptococcal", "OBSERVATION_MODIFIER", 157, 170], ["pharyngitis", "OBSERVATION", 171, 182], ["negative organism", "OBSERVATION", 253, 270], ["pharyngitis", "OBSERVATION", 313, 324]]], ["Prevalence in studies in Europe is reported to be about 10% in patients with pharyngitis not caused by GAS, but large surveillance studies have not been performed.", [["pharyngitis", "DISEASE", 77, 88], ["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71], ["pharyngitis", "PROBLEM", 77, 88], ["large surveillance studies", "TEST", 112, 138], ["pharyngitis", "OBSERVATION", 77, 88]]], ["In a U.S. study of students at a university health clinic, F. necrophorum was detected by PCR in 20.5% of patients with pharyngitis and 9.4% of an asymptomatic convenience sample; some had more than one bacterium detected by PCR of throat swabs.", [["sample", "ANATOMY", 172, 178], ["throat swabs", "ANATOMY", 232, 244], ["F. necrophorum", "DISEASE", 59, 73], ["pharyngitis", "DISEASE", 120, 131], ["F. necrophorum", "ORGANISM", 59, 73], ["patients", "ORGANISM", 106, 114], ["F. necrophorum", "SPECIES", 59, 73], ["patients", "SPECIES", 106, 114], ["F. necrophorum", "SPECIES", 59, 73], ["PCR", "TEST", 90, 93], ["pharyngitis", "PROBLEM", 120, 131], ["an asymptomatic convenience sample", "PROBLEM", 144, 178], ["one bacterium", "PROBLEM", 199, 212], ["throat swabs", "TEST", 232, 244], ["pharyngitis", "OBSERVATION", 120, 131]]], ["Many of the pharyngitis patients with F. necrophorum had signs and symptoms indistinguishable from patients with increased likelihood for GAS pharyngitis: About onethird had fever, one-third had tonsillar exudates, two-thirds had anterior cervical adenopathy, and most did not have cough.", [["tonsillar exudates", "ANATOMY", 195, 213], ["cervical", "ANATOMY", 239, 247], ["pharyngitis", "DISEASE", 12, 23], ["F. necrophorum", "DISEASE", 38, 52], ["pharyngitis", "DISEASE", 142, 153], ["fever", "DISEASE", 174, 179], ["tonsillar exudates", "DISEASE", 195, 213], ["anterior cervical adenopathy", "DISEASE", 230, 258], ["cough", "DISEASE", 282, 287], ["patients", "ORGANISM", 24, 32], ["F. necrophorum", "ORGANISM", 38, 52], ["patients", "ORGANISM", 99, 107], ["tonsillar exudates", "PATHOLOGICAL_FORMATION", 195, 213], ["cervical", "ORGAN", 239, 247], ["patients", "SPECIES", 24, 32], ["F. necrophorum", "SPECIES", 38, 52], ["patients", "SPECIES", 99, 107], ["F. necrophorum", "SPECIES", 38, 52], ["the pharyngitis", "PROBLEM", 8, 23], ["F. necrophorum", "PROBLEM", 38, 52], ["signs", "PROBLEM", 57, 62], ["symptoms", "PROBLEM", 67, 75], ["GAS pharyngitis", "PROBLEM", 138, 153], ["fever", "PROBLEM", 174, 179], ["tonsillar exudates", "PROBLEM", 195, 213], ["anterior cervical adenopathy", "PROBLEM", 230, 258], ["cough", "PROBLEM", 282, 287], ["pharyngitis", "OBSERVATION", 12, 23], ["GAS pharyngitis", "OBSERVATION", 138, 153], ["tonsillar", "ANATOMY", 195, 204], ["exudates", "OBSERVATION", 205, 213], ["anterior", "ANATOMY_MODIFIER", 230, 238], ["cervical", "ANATOMY", 239, 247], ["adenopathy", "OBSERVATION", 248, 258], ["cough", "OBSERVATION", 282, 287]]], ["The symptomatic overlap of F. necrophorum and GAS and the presence of asymptomatic carriage could complicate the clinical assessment of sore throat in adolescents but F. necrophorum is difficult to culture from the throat and neither a rapid test nor PCR is available for use in clinical care.", [["sore throat", "ANATOMY", 136, 147], ["throat", "ANATOMY", 215, 221], ["F. necrophorum", "DISEASE", 27, 41], ["sore throat", "DISEASE", 136, 147], ["F. necrophorum", "DISEASE", 167, 181], ["F. necrophorum", "ORGANISM", 27, 41], ["GAS", "ORGANISM", 46, 49], ["throat", "ORGANISM_SUBDIVISION", 141, 147], ["F. necrophorum", "ORGANISM", 167, 181], ["throat", "ORGANISM_SUBDIVISION", 215, 221], ["F. necrophorum", "SPECIES", 27, 41], ["adolescents", "SPECIES", 151, 162], ["F. necrophorum", "SPECIES", 167, 181], ["F. necrophorum", "SPECIES", 27, 41], ["F. necrophorum", "SPECIES", 167, 181], ["F. necrophorum", "PROBLEM", 27, 41], ["asymptomatic carriage", "PROBLEM", 70, 91], ["the clinical assessment", "TEST", 109, 132], ["sore throat", "PROBLEM", 136, 147], ["F. necrophorum", "PROBLEM", 167, 181], ["a rapid test nor PCR", "TEST", 234, 254], ["symptomatic", "OBSERVATION_MODIFIER", 4, 15], ["overlap", "OBSERVATION_MODIFIER", 16, 23], ["necrophorum", "OBSERVATION", 30, 41], ["asymptomatic", "OBSERVATION_MODIFIER", 70, 82], ["carriage", "OBSERVATION", 83, 91], ["throat", "ANATOMY", 215, 221]]], ["F. necrophorum pharyngitis can be associated with development of septic thrombophlebitis of the internal jugular vein, known as Lemierre syndrome ( Fig. 1.8) .", [["internal jugular vein", "ANATOMY", 96, 117], ["F. necrophorum pharyngitis", "DISEASE", 0, 26], ["septic thrombophlebitis of the internal jugular vein", "DISEASE", 65, 117], ["Lemierre syndrome", "DISEASE", 128, 145], ["F. necrophorum", "ORGANISM", 0, 14], ["internal jugular vein", "MULTI-TISSUE_STRUCTURE", 96, 117], ["F. necrophorum", "SPECIES", 0, 14], ["F. necrophorum", "SPECIES", 0, 14], ["F. necrophorum pharyngitis", "PROBLEM", 0, 26], ["septic thrombophlebitis of the internal jugular vein", "PROBLEM", 65, 117], ["Lemierre syndrome", "PROBLEM", 128, 145], ["pharyngitis", "OBSERVATION", 15, 26], ["septic", "OBSERVATION_MODIFIER", 65, 71], ["thrombophlebitis", "OBSERVATION", 72, 88], ["internal jugular vein", "ANATOMY", 96, 117], ["Lemierre syndrome", "OBSERVATION", 128, 145]]], ["Approximately 80% of cases of Lemierre syndrome are due to this bacterium, but the proportion of patients infected or colonized with F. necrophorum who develop pharyngitis and Lemierre syndrome is unknown.", [["Lemierre syndrome", "DISEASE", 30, 47], ["F. necrophorum", "DISEASE", 133, 147], ["pharyngitis", "DISEASE", 160, 171], ["Lemierre syndrome", "DISEASE", 176, 193], ["patients", "ORGANISM", 97, 105], ["F. necrophorum", "ORGANISM", 133, 147], ["patients", "SPECIES", 97, 105], ["F. necrophorum", "SPECIES", 133, 147], ["F. necrophorum", "SPECIES", 133, 147], ["Lemierre syndrome", "PROBLEM", 30, 47], ["this bacterium", "PROBLEM", 59, 73], ["pharyngitis", "PROBLEM", 160, 171], ["Lemierre syndrome", "PROBLEM", 176, 193], ["Lemierre syndrome", "OBSERVATION", 30, 47], ["infected", "OBSERVATION", 106, 114], ["pharyngitis", "OBSERVATION", 160, 171], ["Lemierre syndrome", "OBSERVATION", 176, 193]]], ["Patients present initially with fever, sore throat, exudative pharyngitis, and/or peritonsillar abscess.", [["peritonsillar abscess", "ANATOMY", 82, 103], ["fever", "DISEASE", 32, 37], ["sore throat", "DISEASE", 39, 50], ["exudative pharyngitis", "DISEASE", 52, 73], ["peritonsillar abscess", "DISEASE", 82, 103], ["Patients", "ORGANISM", 0, 8], ["peritonsillar abscess", "PATHOLOGICAL_FORMATION", 82, 103], ["Patients", "SPECIES", 0, 8], ["fever", "PROBLEM", 32, 37], ["sore throat", "PROBLEM", 39, 50], ["exudative pharyngitis", "PROBLEM", 52, 73], ["peritonsillar abscess", "PROBLEM", 82, 103], ["fever", "OBSERVATION", 32, 37], ["sore throat", "ANATOMY", 39, 50], ["exudative", "OBSERVATION_MODIFIER", 52, 61], ["pharyngitis", "OBSERVATION", 62, 73], ["peritonsillar", "ANATOMY", 82, 95], ["abscess", "OBSERVATION", 96, 103]]], ["The symptoms persist, severe neck pain and swelling develop, and the patient appears toxic.", [["neck", "ANATOMY", 29, 33], ["neck pain", "DISEASE", 29, 38], ["swelling", "DISEASE", 43, 51], ["neck", "ORGANISM_SUBDIVISION", 29, 33], ["patient", "ORGANISM", 69, 76], ["patient", "SPECIES", 69, 76], ["The symptoms", "PROBLEM", 0, 12], ["severe neck pain", "PROBLEM", 22, 38], ["swelling", "PROBLEM", 43, 51], ["toxic", "PROBLEM", 85, 90], ["severe", "OBSERVATION_MODIFIER", 22, 28], ["neck", "ANATOMY", 29, 33], ["pain", "OBSERVATION", 34, 38], ["swelling", "OBSERVATION", 43, 51], ["toxic", "OBSERVATION_MODIFIER", 85, 90]]], ["Septic shock may ensue along with metastatic complications, especially septic pulmonary emboli.", [["pulmonary", "ANATOMY", 78, 87], ["Septic shock", "DISEASE", 0, 12], ["septic pulmonary emboli", "DISEASE", 71, 94], ["pulmonary emboli", "PATHOLOGICAL_FORMATION", 78, 94], ["Septic shock", "PROBLEM", 0, 12], ["metastatic complications", "PROBLEM", 34, 58], ["septic pulmonary emboli", "PROBLEM", 71, 94], ["shock", "OBSERVATION", 7, 12], ["metastatic", "OBSERVATION_MODIFIER", 34, 44], ["septic", "OBSERVATION_MODIFIER", 71, 77], ["pulmonary", "ANATOMY", 78, 87], ["emboli", "OBSERVATION", 88, 94]]], ["Diagnosis is confirmed by computed tomography or magnetic resonance imaging of the neck and isolation of the organism on anaerobic blood culture.", [["neck", "ANATOMY", 83, 87], ["blood", "ANATOMY", 131, 136], ["neck", "ORGAN", 83, 87], ["blood", "ORGANISM_SUBSTANCE", 131, 136], ["computed tomography", "TEST", 26, 45], ["magnetic resonance imaging", "TEST", 49, 75], ["the organism", "PROBLEM", 105, 117], ["anaerobic blood culture", "TEST", 121, 144], ["neck", "ANATOMY", 83, 87]]], ["F. necrophorum is usually sensitive in vitro to penicillin, but some isolates produce \u03b2-lactamases, and treatment failure with penicillin has been reported.", [["F. necrophorum", "DISEASE", 0, 14], ["penicillin", "CHEMICAL", 48, 58], ["penicillin", "CHEMICAL", 127, 137], ["penicillin", "CHEMICAL", 48, 58], ["penicillin", "CHEMICAL", 127, 137], ["F. necrophorum", "ORGANISM", 0, 14], ["penicillin", "SIMPLE_CHEMICAL", 48, 58], ["\u03b2-lactamases", "GENE_OR_GENE_PRODUCT", 86, 98], ["penicillin", "SIMPLE_CHEMICAL", 127, 137], ["F. necrophorum", "SPECIES", 0, 14], ["F. necrophorum", "SPECIES", 0, 14], ["F. necrophorum", "PROBLEM", 0, 14], ["penicillin", "TREATMENT", 48, 58], ["some isolates produce \u03b2-lactamases", "PROBLEM", 64, 98], ["treatment failure", "PROBLEM", 104, 121], ["penicillin", "TREATMENT", 127, 137], ["necrophorum", "OBSERVATION", 3, 14], ["usually sensitive", "OBSERVATION_MODIFIER", 18, 35]]], ["Many expert clinicians use metronidazole, clindamycin, a \u03b2-lactam in combination with a \u03b2-lactamase inhibitor (such as ampicillin-sulbactam), or a carbapenem.", [["metronidazole", "CHEMICAL", 27, 40], ["clindamycin", "CHEMICAL", 42, 53], ["\u03b2-lactam", "CHEMICAL", 57, 65], ["ampicillin-sulbactam", "CHEMICAL", 119, 139], ["carbapenem", "CHEMICAL", 147, 157], ["metronidazole", "CHEMICAL", 27, 40], ["clindamycin", "CHEMICAL", 42, 53], ["\u03b2-lactam", "CHEMICAL", 57, 65], ["ampicillin", "CHEMICAL", 119, 129], ["sulbactam", "CHEMICAL", 130, 139], ["carbapenem", "CHEMICAL", 147, 157], ["metronidazole", "SIMPLE_CHEMICAL", 27, 40], ["clindamycin", "SIMPLE_CHEMICAL", 42, 53], ["\u03b2-lactam", "SIMPLE_CHEMICAL", 57, 65], ["\u03b2-lactamase", "SIMPLE_CHEMICAL", 88, 99], ["ampicillin-sulbactam", "SIMPLE_CHEMICAL", 119, 139], ["carbapenem", "SIMPLE_CHEMICAL", 147, 157], ["metronidazole", "TREATMENT", 27, 40], ["clindamycin", "TREATMENT", 42, 53], ["a \u03b2-lactam", "TREATMENT", 55, 65], ["a \u03b2-lactamase inhibitor", "TREATMENT", 86, 109], ["ampicillin", "TREATMENT", 119, 129], ["sulbactam", "TREATMENT", 130, 139], ["a carbapenem", "TREATMENT", 145, 157]]], ["The septic thrombophlebitis of Lemierre syndrome can be polymicrobial; combination antibiotic therapy may be beneficial.", [["thrombophlebitis", "DISEASE", 11, 27], ["Lemierre syndrome", "DISEASE", 31, 48], ["polymicrobial", "DISEASE", 56, 69], ["The septic thrombophlebitis", "PROBLEM", 0, 27], ["Lemierre syndrome", "PROBLEM", 31, 48], ["polymicrobial", "PROBLEM", 56, 69], ["antibiotic therapy", "TREATMENT", 83, 101], ["septic", "OBSERVATION_MODIFIER", 4, 10], ["thrombophlebitis", "OBSERVATION", 11, 27], ["Lemierre syndrome", "OBSERVATION", 31, 48], ["polymicrobial", "OBSERVATION_MODIFIER", 56, 69]]], ["Some patients require surgical debridement and/or incision and drainage.", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["surgical debridement", "TREATMENT", 22, 42], ["incision", "TREATMENT", 50, 58], ["drainage", "TREATMENT", 63, 71], ["surgical", "OBSERVATION_MODIFIER", 22, 30], ["debridement", "OBSERVATION", 31, 42], ["incision", "OBSERVATION", 50, 58], ["drainage", "OBSERVATION", 63, 71]]], ["The case-fatality rate may be as high as 4-9%.ARCANOBACTERIUM INFECTIONArcanobacterium haemolyticum is a gram-positive rod that has been reported to cause acute pharyngitis and scarlet fever-like rash, particularly in teenagers and young adults.", [["pharyngitis", "DISEASE", 161, 172], ["fever", "DISEASE", 185, 190], ["rash", "DISEASE", 196, 200], ["INFECTIONArcanobacterium haemolyticum", "ORGANISM", 62, 99], ["INFECTIONArcanobacterium haemolyticum", "SPECIES", 62, 99], ["fatality rate", "TEST", 9, 22], ["ARCANOBACTERIUM INFECTIONArcanobacterium haemolyticum", "PROBLEM", 46, 99], ["a gram-positive rod", "PROBLEM", 103, 122], ["acute pharyngitis", "PROBLEM", 155, 172], ["scarlet fever", "PROBLEM", 177, 190], ["rash", "PROBLEM", 196, 200], ["positive rod", "OBSERVATION", 110, 122], ["reported to cause", "UNCERTAINTY", 137, 154], ["acute", "OBSERVATION_MODIFIER", 155, 160], ["pharyngitis", "OBSERVATION", 161, 172], ["scarlet", "OBSERVATION_MODIFIER", 177, 184], ["fever", "OBSERVATION", 185, 190], ["rash", "OBSERVATION", 196, 200]]], ["Detecting this agent requires special methods for culture, and it has not routinely been sought in patients with scarlet fever or pharyngitis.", [["fever", "DISEASE", 121, 126], ["pharyngitis", "DISEASE", 130, 141], ["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107], ["culture", "TEST", 50, 57], ["scarlet fever", "PROBLEM", 113, 126], ["pharyngitis", "PROBLEM", 130, 141], ["pharyngitis", "OBSERVATION", 130, 141]]], ["The clinical features of A. haemolyticum are indistinguishable from GAS pharyngitis; pharyngeal erythema is present in almost all patients, patchy white to gray exudates in about 70%, cervical adenitis in about 50%, and moderate fever in 40%.", [["pharyngeal", "ANATOMY", 85, 95], ["cervical", "ANATOMY", 184, 192], ["A. haemolyticum", "DISEASE", 25, 40], ["pharyngitis", "DISEASE", 72, 83], ["pharyngeal erythema", "DISEASE", 85, 104], ["cervical adenitis", "DISEASE", 184, 201], ["fever", "DISEASE", 229, 234], ["A. haemolyticum", "ORGANISM", 25, 40], ["pharyngeal erythema", "PATHOLOGICAL_FORMATION", 85, 104], ["patients", "ORGANISM", 130, 138], ["cervical", "ORGAN", 184, 192], ["A. haemolyticum", "SPECIES", 25, 40], ["patients", "SPECIES", 130, 138], ["A. haemolyticum", "SPECIES", 25, 40], ["A. haemolyticum", "PROBLEM", 25, 40], ["GAS pharyngitis", "PROBLEM", 68, 83], ["pharyngeal erythema", "PROBLEM", 85, 104], ["patchy white to gray exudates", "PROBLEM", 140, 169], ["cervical adenitis", "PROBLEM", 184, 201], ["moderate fever", "PROBLEM", 220, 234], ["GAS pharyngitis", "OBSERVATION", 68, 83], ["pharyngeal", "ANATOMY", 85, 95], ["erythema", "OBSERVATION", 96, 104], ["patchy", "OBSERVATION_MODIFIER", 140, 146], ["white to gray", "OBSERVATION_MODIFIER", 147, 160], ["exudates", "OBSERVATION_MODIFIER", 161, 169], ["cervical", "ANATOMY", 184, 192], ["adenitis", "OBSERVATION", 193, 201], ["moderate", "OBSERVATION_MODIFIER", 220, 228], ["fever", "OBSERVATION", 229, 234]]], ["Palatal petechiae and strawberry tongue may also occur.", [["petechiae", "ANATOMY", 8, 17], ["tongue", "ANATOMY", 33, 39], ["petechiae", "DISEASE", 8, 17], ["petechiae", "PATHOLOGICAL_FORMATION", 8, 17], ["tongue", "ORGAN", 33, 39], ["Palatal petechiae and strawberry tongue", "PROBLEM", 0, 39], ["petechiae", "OBSERVATION", 8, 17], ["strawberry tongue", "ANATOMY", 22, 39]]], ["The scarlatiniform rash usually spares the face, palms, and soles.", [["scarlatiniform", "ANATOMY", 4, 18], ["face", "ANATOMY", 43, 47], ["palms", "ANATOMY", 49, 54], ["soles", "ANATOMY", 60, 65], ["rash", "DISEASE", 19, 23], ["face", "ORGANISM_SUBDIVISION", 43, 47], ["palms", "ORGANISM_SUBDIVISION", 49, 54], ["soles", "ORGANISM_SUBDIVISION", 60, 65], ["The scarlatiniform rash", "PROBLEM", 0, 23], ["scarlatiniform", "OBSERVATION_MODIFIER", 4, 18], ["rash", "OBSERVATION", 19, 23], ["face", "ANATOMY", 43, 47], ["palms", "ANATOMY", 49, 54], ["soles", "ANATOMY", 60, 65]]], ["The rash is erythematous and blanches; it may be pruritic and demonstrate minimal desquamation.", [["blanches", "ANATOMY", 29, 37], ["rash", "DISEASE", 4, 8], ["blanches", "DISEASE", 29, 37], ["pruritic", "DISEASE", 49, 57], ["The rash", "PROBLEM", 0, 8], ["erythematous", "PROBLEM", 12, 24], ["blanches", "PROBLEM", 29, 37], ["pruritic", "PROBLEM", 49, 57], ["minimal desquamation", "PROBLEM", 74, 94], ["rash", "OBSERVATION", 4, 8], ["erythematous", "OBSERVATION", 12, 24], ["may be", "UNCERTAINTY", 42, 48], ["pruritic", "OBSERVATION_MODIFIER", 49, 57], ["minimal", "OBSERVATION_MODIFIER", 74, 81], ["desquamation", "OBSERVATION", 82, 94]]], ["Erythromycin appears to be the treatment of choice.ARCANOBACTERIUM INFECTION2.", [["Erythromycin", "CHEMICAL", 0, 12], ["Erythromycin", "CHEMICAL", 0, 12], ["Erythromycin", "SIMPLE_CHEMICAL", 0, 12], ["Erythromycin", "TREATMENT", 0, 12], ["ARCANOBACTERIUM INFECTION2", "PROBLEM", 51, 77]]], ["Treating with one of the regimens effective for terminating chronic carriage.", [["the regimens", "TREATMENT", 21, 33], ["terminating chronic carriage", "PROBLEM", 48, 76], ["chronic", "OBSERVATION_MODIFIER", 60, 67], ["carriage", "OBSERVATION", 68, 76]]], ["The first option is simple, as safe as amoxicillin and penicillin, and appropriate for most patients.", [["amoxicillin", "CHEMICAL", 39, 50], ["penicillin", "CHEMICAL", 55, 65], ["amoxicillin", "CHEMICAL", 39, 50], ["penicillin", "CHEMICAL", 55, 65], ["amoxicillin", "SIMPLE_CHEMICAL", 39, 50], ["penicillin", "SIMPLE_CHEMICAL", 55, 65], ["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 92, 100], ["amoxicillin", "TREATMENT", 39, 50], ["penicillin", "TREATMENT", 55, 65]]], ["The second option should be reserved for particularly anxious patients; those with a history of ARF or living with someone who had it; or those living or working in nursing homes, chronic care facilities, and hospitals.", [["anxious", "DISEASE", 54, 61], ["ARF", "DISEASE", 96, 99], ["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 62, 70], ["The second option", "TREATMENT", 0, 17], ["ARF", "PROBLEM", 96, 99]]], ["Two antibiotic treatment regimens have been demonstrated in randomized trials to be effective for eradication of the carrier state:ARCANOBACTERIUM INFECTION\u2022 Intramuscular benzathine penicillin plus oral rifampin (10 mg/ kg/dose up to 300 mg, given twice daily for 4 days beginning on the day of the penicillin injection) \u2022 Oral clindamycin, given for 10 days (20 mg/kg/day up to 450 mg, divided into three equal doses) Clindamycin is easier to use than intramuscular penicillin plus oral rifampin and may be somewhat more effective.", [["Intramuscular", "ANATOMY", 158, 171], ["oral", "ANATOMY", 199, 203], ["Oral", "ANATOMY", 324, 328], ["intramuscular", "ANATOMY", 454, 467], ["oral", "ANATOMY", 484, 488], ["benzathine", "CHEMICAL", 172, 182], ["penicillin", "CHEMICAL", 183, 193], ["rifampin", "CHEMICAL", 204, 212], ["penicillin", "CHEMICAL", 300, 310], ["clindamycin", "CHEMICAL", 329, 340], ["Clindamycin", "CHEMICAL", 420, 431], ["penicillin", "CHEMICAL", 468, 478], ["rifampin", "CHEMICAL", 489, 497], ["benzathine penicillin", "CHEMICAL", 172, 193], ["rifampin", "CHEMICAL", 204, 212], ["penicillin", "CHEMICAL", 300, 310], ["clindamycin", "CHEMICAL", 329, 340], ["Clindamycin", "CHEMICAL", 420, 431], ["penicillin", "CHEMICAL", 468, 478], ["rifampin", "CHEMICAL", 489, 497], ["penicillin", "SIMPLE_CHEMICAL", 183, 193], ["oral", "ORGANISM_SUBDIVISION", 199, 203], ["rifampin", "SIMPLE_CHEMICAL", 204, 212], ["penicillin", "SIMPLE_CHEMICAL", 300, 310], ["clindamycin", "SIMPLE_CHEMICAL", 329, 340], ["Clindamycin", "SIMPLE_CHEMICAL", 420, 431], ["penicillin", "SIMPLE_CHEMICAL", 468, 478], ["oral", "ORGANISM_SUBDIVISION", 484, 488], ["rifampin", "SIMPLE_CHEMICAL", 489, 497], ["Two antibiotic treatment regimens", "TREATMENT", 0, 33], ["ARCANOBACTERIUM INFECTION", "PROBLEM", 131, 156], ["Intramuscular benzathine penicillin", "TREATMENT", 158, 193], ["oral rifampin", "TREATMENT", 199, 212], ["the penicillin injection", "TREATMENT", 296, 320], ["Oral clindamycin", "TREATMENT", 324, 340], ["Clindamycin", "TREATMENT", 420, 431], ["intramuscular penicillin", "TREATMENT", 454, 478], ["oral rifampin", "TREATMENT", 484, 497], ["INFECTION", "OBSERVATION", 147, 156]]], ["Amoxicillin-clavulanate (40 mg amoxicillin/kg/day up to 2000 mg amoxicillin/day divided tid for 10 days) has also been used.", [["Amoxicillin-clavulanate", "CHEMICAL", 0, 23], ["amoxicillin", "CHEMICAL", 31, 42], ["amoxicillin", "CHEMICAL", 64, 75], ["Amoxicillin-clavulanate", "CHEMICAL", 0, 23], ["amoxicillin", "CHEMICAL", 31, 42], ["amoxicillin", "CHEMICAL", 64, 75], ["Amoxicillin-clavulanate", "SIMPLE_CHEMICAL", 0, 23], ["amoxicillin", "SIMPLE_CHEMICAL", 31, 42], ["amoxicillin", "SIMPLE_CHEMICAL", 64, 75], ["Amoxicillin", "TREATMENT", 0, 11], ["clavulanate", "TREATMENT", 12, 23], ["amoxicillin", "TREATMENT", 31, 42], ["amoxicillin", "TREATMENT", 64, 75]]], ["Successful eradication of the carrier state makes evaluation of subsequent episodes of pharyngitis much easier, although chronic carriage can recur upon re-exposure to GAS.Recurrent Acute PharyngitisSome patients seem remarkably susceptible to developing GAS pharyngitis.", [["pharyngitis", "DISEASE", 87, 98], ["pharyngitis", "DISEASE", 259, 270], ["patients", "ORGANISM", 204, 212], ["GAS", "DNA", 168, 171], ["patients", "SPECIES", 204, 212], ["evaluation", "TEST", 50, 60], ["pharyngitis", "PROBLEM", 87, 98], ["chronic carriage", "PROBLEM", 121, 137], ["GAS", "TEST", 168, 171], ["Recurrent Acute PharyngitisSome patients", "PROBLEM", 172, 212], ["developing GAS pharyngitis", "PROBLEM", 244, 270], ["eradication", "OBSERVATION", 11, 22], ["pharyngitis", "OBSERVATION", 87, 98], ["chronic", "OBSERVATION_MODIFIER", 121, 128], ["Acute", "OBSERVATION_MODIFIER", 182, 187], ["PharyngitisSome", "OBSERVATION", 188, 203], ["GAS pharyngitis", "OBSERVATION", 255, 270]]], ["The reasons for frequent bona fide acute GAS pharyngitis are obscure.", [["pharyngitis", "DISEASE", 45, 56], ["frequent bona fide acute GAS pharyngitis", "PROBLEM", 16, 56], ["fide", "OBSERVATION_MODIFIER", 30, 34], ["acute", "OBSERVATION_MODIFIER", 35, 40], ["GAS pharyngitis", "OBSERVATION", 41, 56]]], ["In contrast to chronic carriers, appropriate antibiotic treatment of each episode results in eradication of the organism.Recurrent Acute PharyngitisThe role of tonsillectomy in the management of patients with multiple episodes of streptococcal pharyngitis is controversial.", [["Pharyngitis", "DISEASE", 137, 148], ["streptococcal pharyngitis", "DISEASE", 230, 255], ["patients", "ORGANISM", 195, 203], ["patients", "SPECIES", 195, 203], ["chronic carriers", "TREATMENT", 15, 31], ["appropriate antibiotic treatment", "TREATMENT", 33, 65], ["the organism", "PROBLEM", 108, 120], ["Recurrent Acute Pharyngitis", "PROBLEM", 121, 148], ["tonsillectomy", "TREATMENT", 160, 173], ["the management", "TREATMENT", 177, 191], ["streptococcal pharyngitis", "PROBLEM", 230, 255], ["chronic", "OBSERVATION_MODIFIER", 15, 22], ["Acute", "OBSERVATION_MODIFIER", 131, 136], ["Pharyngitis", "OBSERVATION", 137, 148], ["tonsillectomy", "OBSERVATION", 160, 173], ["streptococcal", "OBSERVATION_MODIFIER", 230, 243], ["pharyngitis", "OBSERVATION", 244, 255]]], ["The presence of tonsils is not necessary for GAS to infect the throat.", [["tonsils", "ANATOMY", 16, 23], ["throat", "ANATOMY", 63, 69], ["tonsils", "ORGAN", 16, 23], ["throat", "ORGANISM_SUBDIVISION", 63, 69], ["tonsils", "PROBLEM", 16, 23], ["GAS to infect the throat", "PROBLEM", 45, 69], ["tonsils", "OBSERVATION", 16, 23], ["not necessary", "UNCERTAINTY", 27, 40], ["throat", "ANATOMY", 63, 69]]], ["Fewer episodes of sore throat were reported among patients treated with tonsillectomy (in contrast to patients treated without surgery) during the first 2 years after operation.", [["sore throat", "DISEASE", 18, 29], ["patients", "ORGANISM", 50, 58], ["patients", "ORGANISM", 102, 110], ["patients", "SPECIES", 50, 58], ["patients", "SPECIES", 102, 110], ["sore throat", "PROBLEM", 18, 29], ["tonsillectomy", "TREATMENT", 72, 85], ["surgery", "TREATMENT", 127, 134], ["operation", "TREATMENT", 167, 176], ["sore throat", "ANATOMY", 18, 29], ["tonsillectomy", "OBSERVATION", 72, 85]]], ["Patients had experienced numerous episodes of pharyngitis over several years, and it appears that not all episodes were caused by GAS.", [["pharyngitis", "DISEASE", 46, 57], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["pharyngitis", "PROBLEM", 46, 57], ["numerous", "OBSERVATION_MODIFIER", 25, 33], ["episodes", "OBSERVATION_MODIFIER", 34, 42], ["pharyngitis", "OBSERVATION", 46, 57]]], ["By 2 years after tonsillectomy there was no difference between the groups in the frequency of pharyngitis.", [["pharyngitis", "DISEASE", 94, 105], ["tonsillectomy", "TREATMENT", 17, 30], ["pharyngitis", "PROBLEM", 94, 105], ["tonsillectomy", "OBSERVATION", 17, 30], ["no", "UNCERTAINTY", 41, 43], ["pharyngitis", "OBSERVATION", 94, 105]]], ["The postoperative complication rate among tonsillectomy patients was 14%.", [["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64], ["The postoperative complication rate", "PROBLEM", 0, 35], ["tonsillectomy", "TREATMENT", 42, 55], ["postoperative", "OBSERVATION_MODIFIER", 4, 17], ["complication", "OBSERVATION_MODIFIER", 18, 30], ["tonsillectomy", "OBSERVATION", 42, 55]]], ["Tonsillectomy cannot be recommended for treatment of recurrent pharyngitis except in unusual circumstances.", [["Tonsillectomy", "DISEASE", 0, 13], ["pharyngitis", "DISEASE", 63, 74], ["Tonsillectomy", "TREATMENT", 0, 13], ["treatment", "TREATMENT", 40, 49], ["recurrent pharyngitis", "PROBLEM", 53, 74], ["recurrent", "OBSERVATION_MODIFIER", 53, 62], ["pharyngitis", "OBSERVATION", 63, 74]]], ["It is preferable to treat most patients with penicillin or amoxicillin whenever symptomatic GAS pharyngitis occurs.", [["penicillin", "CHEMICAL", 45, 55], ["amoxicillin", "CHEMICAL", 59, 70], ["pharyngitis", "DISEASE", 96, 107], ["penicillin", "CHEMICAL", 45, 55], ["amoxicillin", "CHEMICAL", 59, 70], ["patients", "ORGANISM", 31, 39], ["penicillin", "SIMPLE_CHEMICAL", 45, 55], ["amoxicillin", "SIMPLE_CHEMICAL", 59, 70], ["patients", "SPECIES", 31, 39], ["penicillin", "TREATMENT", 45, 55], ["amoxicillin", "TREATMENT", 59, 70], ["symptomatic GAS pharyngitis", "PROBLEM", 80, 107], ["pharyngitis", "OBSERVATION", 96, 107]]], ["Obtaining follow-up throat specimens for culture can help distinguish recurrent pharyngitis from chronic carriage but is unnecessary in most instances.INFECTION WITH STREPTOCOCCI THAT ARE NOT GROUP A (NON-A STREPTOCOCCI)Certain \u03b2-hemolytic streptococci of serogroups other than group A cause acute pharyngitis.", [["throat specimens", "ANATOMY", 20, 36], ["pharyngitis", "DISEASE", 80, 91], ["pharyngitis", "DISEASE", 298, 309], ["follow-up throat specimens", "TEST", 10, 36], ["culture", "TEST", 41, 48], ["recurrent pharyngitis", "PROBLEM", 70, 91], ["chronic carriage", "PROBLEM", 97, 113], ["INFECTION", "PROBLEM", 151, 160], ["STREPTOCOCCI", "PROBLEM", 166, 178], ["A STREPTOCOCCI", "TEST", 205, 219], ["\u03b2-hemolytic streptococci of serogroups", "PROBLEM", 228, 266], ["acute pharyngitis", "PROBLEM", 292, 309], ["pharyngitis", "OBSERVATION", 80, 91], ["chronic", "OBSERVATION_MODIFIER", 97, 104], ["carriage", "OBSERVATION", 105, 113], ["STREPTOCOCCI", "OBSERVATION", 166, 178], ["acute", "OBSERVATION_MODIFIER", 292, 297], ["pharyngitis", "OBSERVATION", 298, 309]]], ["Well-documented epidemics of food-borne group C and group G streptococcal pharyngitis have been reported in young adults.", [["streptococcal pharyngitis", "DISEASE", 60, 85], ["food", "ORGANISM_SUBDIVISION", 29, 33], ["G streptococcal pharyngitis", "SPECIES", 58, 85], ["borne group C", "PROBLEM", 34, 47], ["group G streptococcal pharyngitis", "PROBLEM", 52, 85], ["pharyngitis", "OBSERVATION", 74, 85]]], ["In these situations, a high percentage of individuals who had ingested the contaminated food promptly developed acute pharyngitis, and throat cultures yielded virtually pure growth of the epidemiologically linked organism.", [["throat cultures", "ANATOMY", 135, 150], ["pharyngitis", "DISEASE", 118, 129], ["individuals", "ORGANISM", 42, 53], ["acute pharyngitis", "PROBLEM", 112, 129], ["throat cultures", "TEST", 135, 150], ["virtually pure growth of the epidemiologically linked organism", "PROBLEM", 159, 221], ["high", "OBSERVATION_MODIFIER", 23, 27], ["percentage", "OBSERVATION_MODIFIER", 28, 38], ["acute", "OBSERVATION_MODIFIER", 112, 117], ["pharyngitis", "OBSERVATION", 118, 129], ["throat", "ANATOMY", 135, 141]]], ["There have been outbreaks of group G streptococcal pharyngitis among children.", [["streptococcal pharyngitis", "DISEASE", 37, 62], ["children", "ORGANISM", 69, 77], ["children", "SPECIES", 69, 77], ["group G streptococcal pharyngitis", "PROBLEM", 29, 62], ["outbreaks", "OBSERVATION_MODIFIER", 16, 25], ["group G", "OBSERVATION_MODIFIER", 29, 36], ["streptococcal", "OBSERVATION_MODIFIER", 37, 50], ["pharyngitis", "OBSERVATION", 51, 62]]], ["However, the role of non-A streptococcal organisms as etiologic agents of acute pharyngitis in endemic circumstances has been difficult to establish.", [["pharyngitis", "DISEASE", 80, 91], ["non-A streptococcal", "ORGANISM", 21, 40], ["non-A streptococcal organisms", "PROBLEM", 21, 50], ["acute pharyngitis", "PROBLEM", 74, 91], ["acute", "OBSERVATION_MODIFIER", 74, 79], ["pharyngitis", "OBSERVATION", 80, 91]]], ["Group C and group G streptococci may be responsible for acute pharyngitis, particularly in adolescents.", [["pharyngitis", "DISEASE", 62, 73], ["G streptococci", "SIMPLE_CHEMICAL", 18, 32], ["adolescents", "SPECIES", 91, 102], ["Group C and group G streptococci", "PROBLEM", 0, 32], ["acute pharyngitis", "PROBLEM", 56, 73], ["may be responsible for", "UNCERTAINTY", 33, 55], ["acute", "OBSERVATION_MODIFIER", 56, 61], ["pharyngitis", "OBSERVATION", 62, 73]]], ["However, the exact role of these agents, most of which are carried asymptomatically in the pharynx of some children and young adults, remains to be fully characterized.", [["pharynx", "ANATOMY", 91, 98], ["pharynx", "ORGAN", 91, 98], ["children", "ORGANISM", 107, 115], ["children", "SPECIES", 107, 115], ["these agents", "TREATMENT", 27, 39], ["pharynx", "ANATOMY", 91, 98]]], ["When they are implicated as agents of acute pharyngitis, groups C and G organisms do not appear to necessitate treatment, inasmuch as theyEPIGLOTTITIS AND BACTERIAL TRACHEITISEpiglottitis (or supraglottitis) is a life-threatening infection of the airway proximal to the vocal cords ( Fig. 1.9 ; see also Fig. 1.6 ).", [["airway", "ANATOMY", 247, 253], ["vocal cords", "ANATOMY", 270, 281], ["pharyngitis", "DISEASE", 44, 55], ["supraglottitis", "DISEASE", 192, 206], ["infection", "DISEASE", 230, 239], ["airway", "ORGAN", 247, 253], ["vocal cords", "MULTI-TISSUE_STRUCTURE", 270, 281], ["acute pharyngitis", "PROBLEM", 38, 55], ["groups C and G organisms", "PROBLEM", 57, 81], ["treatment", "TREATMENT", 111, 120], ["theyEPIGLOTTITIS", "PROBLEM", 134, 150], ["BACTERIAL TRACHEITISEpiglottitis", "PROBLEM", 155, 187], ["supraglottitis", "PROBLEM", 192, 206], ["a life-threatening infection of the airway", "PROBLEM", 211, 253], ["Fig.", "TEST", 284, 288], ["acute", "OBSERVATION_MODIFIER", 38, 43], ["pharyngitis", "OBSERVATION", 44, 55], ["BACTERIAL TRACHEITISEpiglottitis", "OBSERVATION", 155, 187], ["infection", "OBSERVATION", 230, 239], ["airway", "ANATOMY", 247, 253], ["proximal", "ANATOMY_MODIFIER", 254, 262], ["vocal cords", "ANATOMY", 270, 281]]], ["Historically, it was an infection in 1-4 year-old children caused by Haemophilus influenzae type b.", [["infection", "DISEASE", 24, 33], ["Haemophilus influenzae type b.", "DISEASE", 69, 99], ["children", "ORGANISM", 50, 58], ["Haemophilus influenzae", "ORGANISM", 69, 91], ["children", "SPECIES", 50, 58], ["Haemophilus influenzae", "SPECIES", 69, 91], ["Haemophilus influenzae type b.", "SPECIES", 69, 99], ["an infection", "PROBLEM", 21, 33], ["Haemophilus influenzae type b.", "PROBLEM", 69, 99], ["infection", "OBSERVATION", 24, 33], ["Haemophilus influenzae", "OBSERVATION", 69, 91]]], ["It presents with acute onset of fever and severe sore throat.", [["fever", "DISEASE", 32, 37], ["sore throat", "DISEASE", 49, 60], ["fever", "PROBLEM", 32, 37], ["severe sore throat", "PROBLEM", 42, 60], ["acute", "OBSERVATION_MODIFIER", 17, 22], ["fever", "OBSERVATION", 32, 37], ["severe", "OBSERVATION_MODIFIER", 42, 48], ["sore", "OBSERVATION", 49, 53], ["throat", "ANATOMY", 54, 60]]], ["This disease progresses rapidly to airway compromise.", [["airway", "ANATOMY", 35, 41], ["airway", "MULTI-TISSUE_STRUCTURE", 35, 41], ["This disease", "PROBLEM", 0, 12], ["airway compromise", "PROBLEM", 35, 52], ["disease", "OBSERVATION", 5, 12], ["airway", "ANATOMY", 35, 41], ["compromise", "OBSERVATION", 42, 52]]], ["Patients are often drooling and leaning forward with the neck extended.", [["neck", "ANATOMY", 57, 61], ["drooling", "DISEASE", 19, 27], ["Patients", "ORGANISM", 0, 8], ["neck", "ORGANISM_SUBDIVISION", 57, 61], ["Patients", "SPECIES", 0, 8], ["often drooling", "PROBLEM", 13, 27], ["drooling", "OBSERVATION", 19, 27], ["neck", "ANATOMY", 57, 61]]], ["Some patients may have stridor, but a muffled voice is more common.", [["stridor", "DISEASE", 23, 30], ["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["stridor", "PROBLEM", 23, 30], ["stridor", "OBSERVATION", 23, 30]]], ["Management depends on establishing a secure airway by intubation and treating with antibiotics.", [["airway", "ANATOMY", 44, 50], ["airway", "MULTI-TISSUE_STRUCTURE", 44, 50], ["a secure airway", "TREATMENT", 35, 50], ["intubation", "TREATMENT", 54, 64], ["antibiotics", "TREATMENT", 83, 94], ["airway", "ANATOMY", 44, 50]]], ["When epiglottitis is suspected, the oropharynx should not be visualized or manipulated except in a controlled environment (intensive care unit or operating room) by someone with expertise in management of the airway who is prepared to immediately intubate the patient.", [["oropharynx", "ANATOMY", 36, 46], ["airway", "ANATOMY", 209, 215], ["epiglottitis", "DISEASE", 5, 17], ["oropharynx", "ORGAN", 36, 46], ["airway", "MULTI-TISSUE_STRUCTURE", 209, 215], ["patient", "ORGANISM", 260, 267], ["patient", "SPECIES", 260, 267], ["epiglottitis", "PROBLEM", 5, 17], ["epiglottitis", "OBSERVATION", 5, 17], ["oropharynx", "ANATOMY", 36, 46], ["airway", "ANATOMY", 209, 215]]], ["Vaccination against H. influenzae type b has nearly eliminated this disease in childhood; however, epiglottitis caused by GAS, Streptococcus pneumoniae, Staphyloccocus aureus, and non-type b H. influenzae occurs occasionally.EPIGLOTTITIS AND BACTERIAL TRACHEITISBacterial tracheitis (bacterial croup, bacterial laryngotracheitis) is a rare complication of viral croup.", [["laryngotracheitis", "ANATOMY", 311, 328], ["H. influenzae type b", "DISEASE", 20, 40], ["epiglottitis", "DISEASE", 99, 111], ["Streptococcus pneumoniae", "DISEASE", 127, 151], ["Staphyloccocus aureus", "DISEASE", 153, 174], ["H. influenzae", "DISEASE", 191, 204], ["croup", "DISEASE", 294, 299], ["bacterial laryngotracheitis", "DISEASE", 301, 328], ["viral croup", "DISEASE", 356, 367], ["H. influenzae type b", "ORGANISM", 20, 40], ["GAS", "ORGANISM", 122, 125], ["Streptococcus pneumoniae", "ORGANISM", 127, 151], ["Staphyloccocus aureus", "ORGANISM", 153, 174], ["non-type b H. influenzae", "ORGANISM", 180, 204], ["H. influenzae", "SPECIES", 20, 33], ["Streptococcus pneumoniae", "SPECIES", 127, 151], ["Staphyloccocus aureus", "SPECIES", 153, 174], ["H. influenzae", "SPECIES", 191, 204], ["H. influenzae", "SPECIES", 20, 33], ["Streptococcus pneumoniae", "SPECIES", 127, 151], ["Staphyloccocus aureus", "SPECIES", 153, 174], ["H. influenzae", "SPECIES", 191, 204], ["Vaccination", "TREATMENT", 0, 11], ["H. influenzae type b", "PROBLEM", 20, 40], ["this disease", "PROBLEM", 63, 75], ["epiglottitis", "PROBLEM", 99, 111], ["GAS", "TEST", 122, 125], ["Streptococcus pneumoniae", "PROBLEM", 127, 151], ["Staphyloccocus aureus", "PROBLEM", 153, 174], ["non-type b H. influenzae", "PROBLEM", 180, 204], ["EPIGLOTTITIS", "PROBLEM", 225, 237], ["BACTERIAL TRACHEITISBacterial tracheitis", "PROBLEM", 242, 282], ["bacterial croup", "PROBLEM", 284, 299], ["bacterial laryngotracheitis", "PROBLEM", 301, 328], ["viral croup", "PROBLEM", 356, 367], ["epiglottitis", "OBSERVATION", 99, 111], ["Streptococcus pneumoniae", "OBSERVATION", 127, 151], ["BACTERIAL", "OBSERVATION_MODIFIER", 242, 251], ["TRACHEITISBacterial tracheitis", "OBSERVATION", 252, 282], ["bacterial", "OBSERVATION_MODIFIER", 284, 293], ["bacterial laryngotracheitis", "OBSERVATION", 301, 328], ["viral croup", "OBSERVATION", 356, 367]]], ["S. aureus is the most common superinfecting bacteria identified.", [["S. aureus", "ORGANISM", 0, 9], ["S. aureus", "SPECIES", 0, 9], ["S. aureus", "SPECIES", 0, 9], ["S. aureus", "PROBLEM", 0, 9], ["superinfecting bacteria", "PROBLEM", 29, 52], ["aureus", "OBSERVATION", 3, 9], ["most common", "OBSERVATION_MODIFIER", 17, 28], ["superinfecting", "OBSERVATION_MODIFIER", 29, 43], ["bacteria", "OBSERVATION", 44, 52]]], ["Patients have a history of prolonged croup symptoms that become dramatically worse with fever and signs of airway obstruction.", [["airway", "ANATOMY", 107, 113], ["croup symptoms", "DISEASE", 37, 51], ["fever", "DISEASE", 88, 93], ["airway obstruction", "DISEASE", 107, 125], ["Patients", "ORGANISM", 0, 8], ["airway obstruction", "PATHOLOGICAL_FORMATION", 107, 125], ["Patients", "SPECIES", 0, 8], ["prolonged croup symptoms", "PROBLEM", 27, 51], ["fever", "PROBLEM", 88, 93], ["airway obstruction", "PROBLEM", 107, 125], ["airway", "ANATOMY", 107, 113], ["obstruction", "OBSERVATION", 114, 125]]], ["While sore throat may have been present at the onset of croup, it is not a prominent complaint once bacterial infection of the airway occurs.", [["sore throat", "ANATOMY", 6, 17], ["airway", "ANATOMY", 127, 133], ["sore throat", "DISEASE", 6, 17], ["croup", "DISEASE", 56, 61], ["infection", "DISEASE", 110, 119], ["throat", "ORGANISM_SUBDIVISION", 11, 17], ["airway", "MULTI-TISSUE_STRUCTURE", 127, 133], ["sore throat", "PROBLEM", 6, 17], ["croup", "PROBLEM", 56, 61], ["bacterial infection of the airway", "PROBLEM", 100, 133], ["bacterial", "OBSERVATION_MODIFIER", 100, 109], ["infection", "OBSERVATION", 110, 119], ["airway", "ANATOMY", 127, 133]]], ["The clinical appearance of patients with bacterial tracheitis may mimic that of patients with epiglottitis.DIPHTHERIADiphtheria is a very serious disease that is caused by pharyngeal infection by toxigenic strains of Corynebacterium diphtheriae.", [["pharyngeal", "ANATOMY", 172, 182], ["bacterial tracheitis", "DISEASE", 41, 61], ["epiglottitis", "DISEASE", 94, 106], ["pharyngeal infection", "DISEASE", 172, 192], ["Corynebacterium diphtheriae", "DISEASE", 217, 244], ["patients", "ORGANISM", 27, 35], ["patients", "ORGANISM", 80, 88], ["pharyngeal", "ORGANISM_SUBDIVISION", 172, 182], ["Corynebacterium diphtheriae", "ORGANISM", 217, 244], ["patients", "SPECIES", 27, 35], ["patients", "SPECIES", 80, 88], ["Corynebacterium diphtheriae", "SPECIES", 217, 244], ["Corynebacterium diphtheriae", "SPECIES", 217, 244], ["bacterial tracheitis", "PROBLEM", 41, 61], ["epiglottitis", "PROBLEM", 94, 106], ["a very serious disease", "PROBLEM", 131, 153], ["pharyngeal infection", "PROBLEM", 172, 192], ["toxigenic strains of Corynebacterium diphtheriae", "PROBLEM", 196, 244], ["bacterial", "OBSERVATION_MODIFIER", 41, 50], ["tracheitis", "OBSERVATION", 51, 61], ["epiglottitis", "OBSERVATION", 94, 106], ["very", "OBSERVATION_MODIFIER", 133, 137], ["serious", "OBSERVATION_MODIFIER", 138, 145], ["disease", "OBSERVATION", 146, 153], ["pharyngeal", "ANATOMY", 172, 182], ["infection", "OBSERVATION", 183, 192], ["Corynebacterium diphtheriae", "OBSERVATION", 217, 244]]], ["It has become very rare in the United States and other developed countries as a result of immunization.", [["immunization", "TREATMENT", 90, 102], ["very", "OBSERVATION_MODIFIER", 14, 18], ["rare", "OBSERVATION", 19, 23]]], ["The few diphtheria cases recognized annually in the United States usually occur in unimmunized individuals; the fatality rate is about 5%.14SECTION 1 Respiratory Disorders oral-genital contact.", [["oral", "ANATOMY", 172, 176], ["diphtheria", "DISEASE", 8, 18], ["oral", "ORGANISM_SUBDIVISION", 172, 176], ["The few diphtheria cases", "PROBLEM", 0, 24], ["the fatality rate", "TEST", 108, 125], ["Respiratory Disorders", "PROBLEM", 150, 171], ["few", "OBSERVATION_MODIFIER", 4, 7], ["diphtheria", "OBSERVATION", 8, 18], ["genital", "ANATOMY", 177, 184]]], ["In cases involving young children, sexual abuse must be suspected.", [["sexual abuse", "DISEASE", 35, 47], ["children", "ORGANISM", 25, 33], ["children", "SPECIES", 25, 33]]], ["The infection usually manifests as an ulcerative, exudative tonsillopharyngitis but may be asymptomatic and resolve spontaneously.", [["ulcerative", "ANATOMY", 38, 48], ["infection", "DISEASE", 4, 13], ["tonsillopharyngitis", "DISEASE", 60, 79], ["The infection", "PROBLEM", 0, 13], ["an ulcerative, exudative tonsillopharyngitis", "PROBLEM", 35, 79], ["asymptomatic", "PROBLEM", 91, 103], ["infection", "OBSERVATION", 4, 13], ["ulcerative", "OBSERVATION_MODIFIER", 38, 48], ["exudative", "OBSERVATION_MODIFIER", 50, 59], ["tonsillopharyngitis", "OBSERVATION", 60, 79], ["may be", "UNCERTAINTY", 84, 90], ["asymptomatic", "OBSERVATION_MODIFIER", 91, 103]]], ["Gonococcal pharyngitis occurs after fellatio in homosexual men and heterosexual women and is less readily acquired after cunnilingus.", [["pharyngitis", "DISEASE", 11, 22], ["men", "ORGANISM", 59, 62], ["women", "ORGANISM", 80, 85], ["men", "SPECIES", 59, 62], ["women", "SPECIES", 80, 85], ["Gonococcal pharyngitis", "PROBLEM", 0, 22], ["pharyngitis", "OBSERVATION", 11, 22]]], ["Gonorrhea rarely is transmitted from the pharynx to a sex partner, but pharyngitis can serve as a source for gonococcemia.", [["pharynx", "ANATOMY", 41, 48], ["Gonorrhea", "DISEASE", 0, 9], ["pharyngitis", "DISEASE", 71, 82], ["gonococcemia", "DISEASE", 109, 121], ["pharynx", "ORGAN", 41, 48], ["Gonorrhea", "PROBLEM", 0, 9], ["pharyngitis", "PROBLEM", 71, 82], ["gonococcemia", "PROBLEM", 109, 121], ["pharynx", "ANATOMY", 41, 48], ["pharyngitis", "OBSERVATION", 71, 82]]], ["Diagnosis requires culture on appropriate selective media (e.g., Thayer-Martin medium).", [["culture", "TEST", 19, 26], ["appropriate selective media", "TREATMENT", 30, 57]]], ["Nucleic acid amplification tests (NAAT) may also detect the organism from pharyngeal and other sites.", [["pharyngeal", "ANATOMY", 74, 84], ["sites", "ANATOMY", 95, 100], ["pharyngeal", "ORGAN", 74, 84], ["Nucleic acid amplification tests", "TEST", 0, 32], ["the organism from pharyngeal and other sites", "PROBLEM", 56, 100], ["pharyngeal", "ANATOMY", 74, 84]]], ["Examination and testing for other sexually transmitted infections and pregnancy are recommended.CHLAMYDIAL AND MYCOPLASMAL INFECTIONSChlamydia species and Mycoplasma pneumoniae may cause pharyngitis, although the frequency of these infections is unclear.", [["sexually transmitted infections", "DISEASE", 34, 65], ["Mycoplasma pneumoniae", "DISEASE", 155, 176], ["pharyngitis", "DISEASE", 187, 198], ["infections", "DISEASE", 232, 242], ["Mycoplasma pneumoniae", "ORGANISM", 155, 176], ["Mycoplasma pneumoniae", "SPECIES", 155, 176], ["Mycoplasma pneumoniae", "SPECIES", 155, 176], ["Examination", "TEST", 0, 11], ["testing", "TEST", 16, 23], ["other sexually transmitted infections", "PROBLEM", 28, 65], ["pregnancy", "PROBLEM", 70, 79], ["CHLAMYDIAL", "PROBLEM", 96, 106], ["MYCOPLASMAL INFECTIONSChlamydia species", "PROBLEM", 111, 150], ["Mycoplasma pneumoniae", "PROBLEM", 155, 176], ["pharyngitis", "PROBLEM", 187, 198], ["these infections", "PROBLEM", 226, 242], ["MYCOPLASMAL INFECTIONSChlamydia", "OBSERVATION", 111, 142], ["Mycoplasma pneumoniae", "OBSERVATION", 155, 176], ["may cause", "UNCERTAINTY", 177, 186], ["pharyngitis", "OBSERVATION", 187, 198], ["infections", "OBSERVATION", 232, 242]]], ["Chlamydia trachomatis has been implicated serologically as a cause of pharyngitis in as many as 20% of adults with pharyngitis, but isolation of the organism from the pharynx has proved more difficult.", [["pharynx", "ANATOMY", 167, 174], ["Chlamydia trachomatis", "DISEASE", 0, 21], ["pharyngitis", "DISEASE", 70, 81], ["pharyngitis", "DISEASE", 115, 126], ["Chlamydia trachomatis", "ORGANISM", 0, 21], ["pharynx", "ORGAN", 167, 174], ["Chlamydia trachomatis", "SPECIES", 0, 21], ["Chlamydia trachomatis", "SPECIES", 0, 21], ["Chlamydia trachomatis", "PROBLEM", 0, 21], ["pharyngitis", "PROBLEM", 70, 81], ["pharyngitis", "PROBLEM", 115, 126], ["the organism from the pharynx", "PROBLEM", 145, 174], ["pharyngitis", "OBSERVATION", 70, 81], ["pharyngitis", "OBSERVATION", 115, 126], ["pharynx", "ANATOMY", 167, 174]]], ["Chlamydia pneumoniae has also been identified as a cause of pharyngitis.", [["Chlamydia pneumoniae", "DISEASE", 0, 20], ["pharyngitis", "DISEASE", 60, 71], ["Chlamydia pneumoniae", "ORGANISM", 0, 20], ["Chlamydia pneumoniae", "SPECIES", 0, 20], ["Chlamydia pneumoniae", "SPECIES", 0, 20], ["Chlamydia pneumoniae", "PROBLEM", 0, 20], ["pharyngitis", "PROBLEM", 60, 71], ["pneumoniae", "OBSERVATION", 10, 20], ["pharyngitis", "OBSERVATION", 60, 71]]], ["Because antibodies to this organism show some cross reaction with C. trachomatis, it is possible that infections formerly attributed to C. trachomatis were really caused by C. pneumoniae.", [["C. trachomatis", "DISEASE", 66, 80], ["infections", "DISEASE", 102, 112], ["C. trachomatis", "DISEASE", 136, 150], ["C. trachomatis", "ORGANISM", 66, 80], ["C. trachomatis", "ORGANISM", 136, 150], ["C. pneumoniae", "ORGANISM", 173, 186], ["antibodies", "PROTEIN", 8, 18], ["C. trachomatis", "SPECIES", 66, 80], ["C. trachomatis", "SPECIES", 136, 150], ["C. pneumoniae", "SPECIES", 173, 186], ["C. trachomatis", "SPECIES", 66, 80], ["C. trachomatis", "SPECIES", 136, 150], ["C. pneumoniae", "SPECIES", 173, 186], ["this organism", "PROBLEM", 22, 35], ["some cross reaction", "PROBLEM", 41, 60], ["C. trachomatis", "PROBLEM", 66, 80], ["infections", "PROBLEM", 102, 112], ["C. trachomatis", "PROBLEM", 136, 150], ["C. pneumoniae", "PROBLEM", 173, 186], ["trachomatis", "OBSERVATION", 69, 80], ["infections", "OBSERVATION", 102, 112], ["trachomatis", "OBSERVATION", 139, 150], ["pneumoniae", "OBSERVATION", 176, 186]]], ["Diagnosis of chlamydial pharyngitis is difficult, whether by culture or serologically, and neither method is readily available to the clinician.", [["chlamydial pharyngitis", "DISEASE", 13, 35], ["chlamydial pharyngitis", "PROBLEM", 13, 35], ["culture", "TEST", 61, 68], ["chlamydial", "OBSERVATION_MODIFIER", 13, 23], ["pharyngitis", "OBSERVATION", 24, 35]]], ["M. pneumoniae most likely causes pharyngitis.", [["pharyngitis", "DISEASE", 33, 44], ["M. pneumoniae", "ORGANISM", 0, 13], ["M. pneumoniae", "SPECIES", 0, 13], ["M. pneumoniae", "SPECIES", 0, 13], ["M. pneumoniae", "PROBLEM", 0, 13], ["pharyngitis", "PROBLEM", 33, 44], ["pneumoniae", "OBSERVATION", 3, 13], ["most likely", "UNCERTAINTY", 14, 25], ["pharyngitis", "OBSERVATION", 33, 44]]], ["Serologic (positive mycoplasma IgM) or, less often, culture methods can be used to identify this infectious agent, which was found in 33% of college students with pharyngitis in one study.", [["pharyngitis", "DISEASE", 163, 174], ["IgM", "PROTEIN", 31, 34], ["Serologic (positive mycoplasma IgM", "TEST", 0, 34], ["culture methods", "TEST", 52, 67], ["this infectious agent", "PROBLEM", 92, 113], ["pharyngitis", "PROBLEM", 163, 174], ["one study", "TEST", 178, 187], ["pharyngitis", "OBSERVATION", 163, 174]]], ["PCR is diagnostic but there is no need to seek evidence of these organisms routinely in pharyngitis patients in the absence of ongoing research studies of nonstreptococcal pharyngitis.", [["pharyngitis", "DISEASE", 88, 99], ["pharyngitis", "DISEASE", 172, 183], ["patients", "ORGANISM", 100, 108], ["patients", "SPECIES", 100, 108], ["PCR", "TEST", 0, 3], ["these organisms", "PROBLEM", 59, 74], ["pharyngitis", "PROBLEM", 88, 99], ["nonstreptococcal pharyngitis", "PROBLEM", 155, 183], ["no need", "UNCERTAINTY", 31, 38], ["pharyngitis", "OBSERVATION", 88, 99], ["nonstreptococcal pharyngitis", "OBSERVATION", 155, 183]]], ["The efficacy of antibiotic treatment for M. pneumoniae and chlamydial pharyngitis is not known, but these illnesses appear to be self-limited.", [["M. pneumoniae", "DISEASE", 41, 54], ["chlamydial pharyngitis", "DISEASE", 59, 81], ["M. pneumoniae", "ORGANISM", 41, 54], ["M. pneumoniae", "SPECIES", 41, 54], ["M. pneumoniae", "SPECIES", 41, 54], ["antibiotic treatment", "TREATMENT", 16, 36], ["M. pneumoniae", "PROBLEM", 41, 54], ["chlamydial pharyngitis", "PROBLEM", 59, 81], ["these illnesses", "PROBLEM", 100, 115], ["chlamydial", "OBSERVATION_MODIFIER", 59, 69], ["pharyngitis", "OBSERVATION", 70, 81]]]], "aa9244cc8e319c1d2268725b7cd72c6c4d3d0d6d": [["This paper aims to answer both questions taking the design perspective on committeeselection procedure and the choice of inter-committee voting rule.IntroductionThe mainstream social-choice literature considers preferences on the set of candidates to be the primitive of the model.", [["committeeselection procedure", "TREATMENT", 74, 102]]], ["1 However, engaging in a frequent referenda may be a heavy burden for the population.", [["referenda", "DISEASE", 34, 43]]], ["This is part of the reason why historically, most of the world has moved from direct democracy to some form of representative democracy (by committees or parliaments), whereas more recently there is much interest in increased public participation via technological means [Dalton et al., 2001 , Brill, 2019 , Allen et al., 2019 .IntroductionWe follow the representative democracy approach in this paper, assuming there is a strict limit on the number of representatives that can actively vote on all issues.", [["democracy", "OBSERVATION", 126, 135]]], ["Following the standard worst-case approach in approximate mechanism design, the approximation ratio is defined as the worst-case ratio between the (expected) social cost of the elected committee and the optimal social cost.", [["the standard worst-case approach", "TREATMENT", 10, 42], ["the approximation ratio", "TEST", 76, 99]]], ["Indeed, a natural approach is to use a majority vote inside the committee but we may also consider other alternatives.IntroductionOur main goal in this paper is to understand the best approximation ratio that can be obtained by a committee, and what selection rules and/or internal voting rules are optimal.Our resultsOur main result is a characterization of the approximation ratio of k-sortition: For a committee of size k = 3 the ratio is equal to 1.316 (Example 4) and behaves as 1 + \u0398 1 \u221a k , when k increases (Theorem 2).", [["a committee of size k", "TEST", 403, 424], ["the ratio", "TEST", 429, 438], ["k", "TEST", 494, 495]]], ["As a corollary of this result, we infer that the optimal committee size k for a population of size n is of the order of n 2 3 given fixed preference-elicitation costs (Corollary 1).", [["a population of size n", "TREATMENT", 78, 100], ["size", "OBSERVATION_MODIFIER", 94, 98]]], ["However, this improvement disappears in a realistic scenario of large number of issues m, moreover, the suggested average-proximity weighing becomes harmful (Proposition 4).Our resultsWe complete the results above by showing that without further restrictions, k-sortition is the best rule among a broad family of committee-selection and inter-committee voting rules (Theorem 5).Our resultsTo summarize, in unstructured environments, k-sortition is a compelling choice for representing preferences of the electorate.Our resultsStructure of the paper The model is introduced in Section 2.", [["large", "OBSERVATION_MODIFIER", 64, 69], ["number", "OBSERVATION_MODIFIER", 70, 76]]], ["We analyze the benchmark rule, k-sortition in Section 3.", [["the benchmark rule", "TEST", 11, 29]]], ["Most of the proofs are only sketched in the main body of the paper; all the details can be found in Appendices A, B, and C.Related literatureFinding good voting rules for committee-selection and even formalizing what is \"good\" is still a big challenge for the social-choice literature, see a recent survey [Faliszewski et al., 2017] ; this literature takes a normative approach and aims to characterize voting rules by the combination of desired properties known as axioms.", [["body", "ORGANISM_SUBDIVISION", 49, 53], ["B", "CELL", 114, 115], ["main body", "ANATOMY_MODIFIER", 44, 53]]], ["This limitation does not allow to capture the objective of selecting committees that optimally represent electorate's preferences on future policies.Related literatureThe idea of selecting representatives as a small random sample from the electorate has its roots in Athenian democracy (see e.g.", [["roots", "ANATOMY", 258, 263], ["roots", "ORGAN", 258, 263], ["a small random sample", "PROBLEM", 208, 229], ["small", "OBSERVATION_MODIFIER", 210, 215], ["roots", "OBSERVATION_MODIFIER", 258, 263]]], ["Preliminary experimental data suggests that random-sample voting is suitable for political elections, see [Fishkin et al., 2018] and [Blanchard, 2019, Chapter 7] .", [["Preliminary experimental data", "TEST", 0, 29]]], ["We emphasize that in this work fairness (in the sense of representation for minorities) is not one of our goals, as the selected committee is only an intermediate step for a final decision that applies to the entire population.Related literatureOne stream of the literature on multiple referenda deals with the dependency among issues in voters' preferences (see e.g. Lang and Xia [2016] ); or with restrictions on the valid outcomes, as in judgement aggregation Pauly and Van Hees [2006] .", [["multiple referenda deals", "TREATMENT", 277, 301], ["stream", "OBSERVATION_MODIFIER", 249, 255]]], ["Indeed, in the special case of a singleton (k = 1), k-sortition boils down to the familiar random dictator voting rule, whose approximation ratio for large populations is 2.", [["a singleton (k", "TEST", 31, 45], ["k-sortition boils", "TEST", 52, 69], ["large populations", "PROBLEM", 150, 167], ["large", "OBSERVATION_MODIFIER", 150, 155], ["populations", "OBSERVATION", 156, 167]]], ["Cheng et al. [2018] also consider voting on a metric space, where candidates are uniformly sampled from the set of voters, and characterize the class of scoring rules having bounded distortion.", [["a metric space", "TREATMENT", 44, 58], ["bounded distortion", "PROBLEM", 174, 192], ["bounded distortion", "OBSERVATION", 174, 192]]], ["Our paper is different in many aspects: it analyzes the decisions of the elected committee, allows for fairly general committee-selection procedure, e.g., the sampling procedure may depend on preferences of the electorate, and achieves the approximation-ratio close to 1.Related literatureThe fact that the approximation ratio of k-sortition goes to 1 for large committee size, can be regarded as an extension of the famous Condorcet Jury theorem, which claims that if each voter receives a noisy signal about the \"right\" alternative, the majority vote of a large population reveals the ground truth.", [["selection procedure", "TREATMENT", 128, 147], ["the sampling procedure", "TREATMENT", 155, 177], ["the approximation ratio", "TEST", 303, 326], ["different", "OBSERVATION_MODIFIER", 13, 22], ["size", "OBSERVATION_MODIFIER", 372, 376], ["large", "OBSERVATION_MODIFIER", 558, 563], ["ground truth", "OBSERVATION", 587, 599]]], ["An important difference is that the jury theorem requires the population to be far enough from a tie [Paroush, 1998] , while our bounds are applicable to all preference profiles.Related literatureDelegation A compromise between the direct and representative democracies is provided by proxy voting [Alger, 2006 , Green-Armytage, 2015 , Cohensius et al., 2017 and liquid democracy , Goelz et al., 2018 : each voter has an opportunity to engage in the decision-making directly but, since he may be non-motivated enough or unavailable, there is an option to specify a representative thus delegating the vote to the proxy.", [["A compromise", "PROBLEM", 207, 219], ["compromise", "OBSERVATION", 209, 219]]], ["They demonstrate that in the limit of large electorate, the decision of the committee always matches the alternative preferred by the majority.", [["large", "OBSERVATION_MODIFIER", 38, 43], ["electorate", "OBSERVATION", 44, 54]]], ["The preference profile of the population is thus given by an n \u00d7 m-matrix X = (x i,j ) i\u2208[n],j\u2208 [m] of zeros and ones.The modelFor a pair of vectors z, z \u2032 \u2208 {0, 1} m , we define the distance d(z, z \u2032 ) between them to be the number of issues where they disagree, i.e., the Hamming distance: d(z, z \u2032 ) = j\u2208[m] |z j \u2212 z \u2032 j |.", [["zeros and ones", "PROBLEM", 103, 117], ["a pair of vectors z", "TEST", 131, 150], ["the distance d", "TEST", 179, 193], ["z", "TEST", 194, 195], ["the Hamming distance", "TEST", 270, 290], ["z", "TEST", 294, 295], ["m", "TEST", 308, 309]]], ["For a pair of voters i, k \u2208 [n], the distance between their preferences d(x i , x j ) captures the overall alignment of their tastes.The modelDefinition 1 (voting rules).", [["overall alignment", "OBSERVATION", 99, 116]]], ["A voting rule f specifies the outcome vector z \u2208 {0, 1} m for each preference profile profile X.The modelWe allow for randomization and so a voting rule maps X to a probability distribution f (X) \u2208 \u2206 {0, 1} m according to which z \u2208 {0, 1} m is then chosen.The modelHere and below \u2206(A) denotes the set of all probability measures on A.The modelClasses of committee voting rules.", [["randomization", "TREATMENT", 118, 131]]], ["We are interested in voting rules that can be represented as a two-stage procedure: first voters select a certain committee of peers C \u2282 [n] and then the committee members vote to determine the outcome for each of the issues.", [["a two-stage procedure", "TREATMENT", 61, 82]]], ["The restriction of a preference profile X to committee members C \u2282 [n] is denoted by X| C ; for definiteness, we assume that the order of rows in X| C is the same as in X, i.e., the row corresponding to a committee member with lower index comes first.The modelDefinition 2 (committee voting rules).", [["C \u2282 [n]", "SIMPLE_CHEMICAL", 63, 70], ["X| C", "GENE_OR_GENE_PRODUCT", 85, 89], ["X| C", "GENE_OR_GENE_PRODUCT", 146, 150]]], ["A committee voting rule is given by a function g that maps preference profile X to a probability distribution over pairs (C, h), where a committee C is a subset of [n] and h : {0, 1} |C|\u00d7m \u2192 {0, 1} m is a voting rule.", [["{0, 1} |C", "CHEMICAL", 176, 185], ["{0, 1} m", "SIMPLE_CHEMICAL", 191, 199], ["\u2192", "TEST", 189, 190], ["a voting rule", "TEST", 203, 216]]], ["We are interested in the opposite scenario, when the committee size k is small compared to the total number of voters, the total number of voters n.The modelWithout further restrictions, every voting rule r (even randomized) can be represented as a 1committee rule, where C contains a single arbitrary voter and h is the fixed rule h(X| C ) \u2261 r(X).The modelWe therefore consider two natural restrictions on committee rules: the selection phase can only be based on pairwise distances; and in the voting phase, the committee decides on each issue separately (formal definitions below).The modelIndeed, the idea behind committee rules is that they avoid elicitation of detailed preferences of large population and rely on a small number of committee-members instead; 2 and the decision making process of the committee itself should be simple and transparent to maintain a clear connection between representatives and the voters they represent, and to enable voting on arbitrary issues as they come along.The modelFor a preference profile X, we denote by D(X) the matrix of pairwise distances D(The model.", [["a single arbitrary voter", "TEST", 283, 307], ["large population", "PROBLEM", 691, 707], ["size", "OBSERVATION_MODIFIER", 63, 67], ["small", "OBSERVATION_MODIFIER", 73, 78], ["large", "OBSERVATION_MODIFIER", 691, 696], ["population", "OBSERVATION", 697, 707]]], ["We focus on those committee rules that base the choice of the committee and of the inter-committee rule on information encoded in D(X) only.The modelDefinition 3 (distance-based committee rules).", [["D(X)", "GENE_OR_GENE_PRODUCT", 130, 134]]], ["A committee voting rule g is distance-based if the probability distribution g(X) over pairs (C, f ) of a committee and an inter-committee voting rule depends only on matrix of pairwise distances D(X).", [["matrix", "CELLULAR_COMPONENT", 166, 172]]], ["It picks a committee C that minimizes the total distance to all the voters i\u2208[n] min i \u2032 \u2208C d(x i , x i \u2032 ) (if there are several such committees, it randomizes over them uniformly) and the inter-committee rule h is the weighted majority vote on every issue, where the weight of a member c is given byThe modelSo for issue j, the outcome z j = 1 whenever c\u2208C: xc,j =1 w c > 1 2 c\u2208C w c ; in case of opposite strict inequality, z j = 0 and z j \u2208 {0, 1} is picked at random in case of a tie.The modelDefinition 4 (issue-wise voting rule).", [["c\u2208C", "TEST", 355, 358], ["xc", "TEST", 360, 362], ["inequality", "TEST", 415, 425], ["z j \u2208", "TEST", 439, 444]]], ["A voting rule f is issue-wise if it treats all issues separately i.e., for any pair of preference profiles X, X \u2032 that coincide on issue j and the corresponding outcome vectors z \u223c f (X) and z \u2032 \u223c f (X \u2032 ), we have P(z j = 1) = P(z \u2032 j = 1).", [["z j", "TEST", 217, 220], ["z \u2032 j", "TEST", 230, 235]]], ["The latter property is also known as independence of irrelevant alternatives (IIA) (see e.g.", [["IIA", "PROTEIN", 78, 81]]], ["A committee rule g is has issue-wise inter-committee vote if for any preference profile X the probability distribution g(X) is supported on pairs (C, h) such that the inter-committee voting rule h is issue-wise.The modelAll the committee rules we consider will be distance-based with issue-wise inter-committee vote.", [["any preference profile", "PROBLEM", 65, 87]]], ["An example of a committee voting rule that violates the definition, is when h approves the three issues with the largest support in X| C and rejects all others.The modelInefficiency of voting rules.", [["X| C", "GENE_OR_GENE_PRODUCT", 132, 136], ["X| C", "CELL_LINE", 132, 136], ["largest", "OBSERVATION_MODIFIER", 113, 120], ["Inefficiency", "OBSERVATION_MODIFIER", 169, 181]]], ["To quantify this inefficiency, we employ the utilitarian approach.", [["this inefficiency", "PROBLEM", 12, 29]]], ["We define the disutility of a voter i for an outcome-vector z \u2208 {0, 1} m as the total number of issues, where i's preferences and z disagree, i.e., this disutility equals to the distance d(x i , z).The modelThe utilitarian social cost of an outcome vector z is given by the sum of disutilities, and the social cost of a voting rule f on a preference profile X is defined as the expected social cost of its outcome:The modelDenote by z opt = z opt (X) the socially-optimal outcome, i.e., the one with the minimal costThe modelDefinition 6.", [["an outcome vector z", "TREATMENT", 238, 257]]], ["The approximation ratio of a voting rule f is the worst-case ratio of the expected social cost of its outcome z and the optimal social costThe modelThe maximum is over all preference profiles X with fixed numbers n, m of voters and issues.", [["maximum", "OBSERVATION_MODIFIER", 152, 159]]], ["If the denominator is zero (this happens for unanimous preference profiles), the following agreement is used: 0 0 = 1 and C 0 = +\u221e for C > 0.", [["C", "TEST", 135, 136]]], ["When we drop some of the subscripts n and/or m, this means considering their worst-case values, i.e., AR n = sup m\u2208N AR n,m , AR m = sup n\u2208N AR n,m , and AR = sup n,m\u2208N AR n,m , Example 2 (The simple majority rule MAJ).", [["AR", "PROTEIN", 102, 104], ["AR", "PROTEIN", 126, 128], ["AR", "PROTEIN", 141, 143], ["AR", "PROTEIN", 154, 156], ["MAJ", "PROTEIN", 214, 217], ["case values", "TEST", 83, 94], ["AR", "TEST", 102, 104], ["AR m", "TEST", 126, 130], ["m", "TEST", 146, 147], ["AR", "TEST", 154, 156], ["sup n", "TEST", 159, 164], ["m", "TEST", 165, 166], ["\u2208", "TEST", 166, 167], ["AR n", "TEST", 169, 173], ["m", "TEST", 174, 175], ["Example", "TEST", 178, 185], ["The simple", "TEST", 189, 199]]], ["The outcome z j for each issue j is determined on the wholepopulation referendum: z j = 0 if i\u2208 [n] x i,j < n 2 ; for the opposite strict inequality, z j equals 1; and z j is 0 or 1 equally likely in case of a tie.", [["the wholepopulation referendum", "TEST", 50, 80], ["i\u2208", "TEST", 93, 95], ["the opposite strict inequality", "TEST", 118, 148], ["z j equals", "TEST", 150, 160], ["z j is", "TEST", 168, 174]]], ["The resulting majority rule denoted by MAJ has the approximation ratio AR n,m (MAJ) = 1, i.e., it always select the socially-optimal outcome.", [["MAJ", "PROTEIN", 39, 42]]], ["Indeed, minimization of the social cost of SC(z) splits into a family of issue-wise minimization problems min zj i\u2208[n] |x i,j \u2212 z j | for each j \u2208 [m] and the minimum is achieved if z j matches the majority of (x i,j ) i\u2208 [n] .", [["zj", "TEST", 110, 112], ["j", "TEST", 143, 144], ["the minimum", "TEST", 155, 166]]], ["Optimality of MAJ comes at the cost of huge burden imposed on the population: to compute the outcome we may need the preferences of the whole population on all the issues.", [["huge burden", "PROBLEM", 39, 50], ["huge", "OBSERVATION_MODIFIER", 39, 43], ["burden", "OBSERVATION", 44, 50]]], ["In our setting it works as follows: a voter i \u2208 [n] is selected uniformly at random and i's preference dictates the outcome of each referendum, i.e., z = x i .", [["\u2208 [n]", "SIMPLE_CHEMICAL", 46, 51]]], ["However this does not improve the approximation ratio.The modelLet us compute the approximation ratio for the one-issue case.", [["modelLet", "DNA", 58, 66], ["the approximation ratio", "TEST", 30, 53]]], ["Without loss of generality, we can restrict our attention to profiles X such that the majority prefers the alternative 0 but not unanimously (for unanimity SC(z opt ) = SC(RD(X)) = 1).", [["loss of generality", "PROBLEM", 8, 26]]], ["Therefore, SC(RD(X)) SC(z opt ) = n1 n \u00b7 (n \u2212 n 1 ) + 1 \u2212 n1 n \u00b7 n 1 n 1 = 2 \u2212 2n 1 n .The modelThe maximal value AR n,1 (RD) = 2 \u2212 2 n is achieved at n 1 = 1.", [["n", "TEST", 65, 66], ["The model", "TEST", 87, 96], ["The maximal value AR", "TEST", 96, 116]]], ["A simple argument (Lemma 1 below) implies that AR n,m (RD) does not depend on m and thus AR n,m (RD) = 2 \u2212 2 n for any number of issues.Random committees with simple majority rule do good jobAt the end of the last section, we considered the two examples.", [["AR", "PROTEIN", 89, 91], ["A simple argument (Lemma", "TREATMENT", 0, 24], ["AR", "PROBLEM", 47, 49], ["simple", "OBSERVATION_MODIFIER", 2, 8], ["argument", "OBSERVATION", 9, 17]]], ["Our goal in this section is to find the middle ground between these two extremes.", [["this section", "TREATMENT", 12, 24], ["middle", "ANATOMY_MODIFIER", 40, 46]]], ["The preferences of the committee members are aggregated using the simple majority rule h = MAJ (see Example 2).Random committees with simple majority rule do good jobNote that for a population of n voters, n-SORT coincides with the simple majority rule MAJ, while 1-SORT coincides with RD.Random committees with simple majority rule do good jobExample 4 (The approximation ratio for 3-SORT and one issue).", [["1-SORT", "GENE_OR_GENE_PRODUCT", 264, 270], ["n-SORT", "PROTEIN", 206, 212], ["SORT", "PROTEIN", 266, 270], ["The approximation ratio", "TEST", 355, 378]]], ["We denote by p = n1 n \u2208 0, 1 2 the probability that a random voter supports 1.Random committees with simple majority rule do good jobLet A be the event that the committee with 3 members selects the suboptimal alternative 1; A occurs if and only if two or three members support 1.", [["a random voter supports", "TREATMENT", 52, 75]]], ["The probability of this event equals toRandom committees with simple majority rule do good jobThe probability P(A) tends to p 2 (3 \u2212 2p) for fixed p and large n.", [["fixed p and large n.", "PROBLEM", 141, 161]]], ["For p \u2264 1 2 and any n, this limiting value provides an upper bound: P(A) \u2264 p 2 (3 \u2212 2p).Random committees with simple majority rule do good jobTaking into account that SC(0) = n 1 and SC(1) = n \u2212 n 1 , we obtainRandom committees with simple majority rule do good jobTaking supremum over p \u2208 0, 1 2 results in an upper bound on the approximation ratio AR n,1 3-SORT \u2264 1 + supRandom committees with simple majority rule do good jobThe maximum is attained at p * = 4\u2212 \u221a 7 6 \u2248 0.226.", [["SC", "TEST", 168, 170], ["an upper bound", "PROBLEM", 309, 323], ["upper", "ANATOMY_MODIFIER", 312, 317], ["maximum", "OBSERVATION_MODIFIER", 433, 440]]], ["Thus AR m=1 3-SORT = 1 + 7 \u221a 7 \u2212 10 27 \u2248 1.316.Random committees with simple majority rule do good jobThe next simple lemma implies that the approximation ratios computed for RD and 3-SORT in the one-issue case remain the same for any number of issues.Random committees with simple majority rule do good jobLemma 1.", [["1 3-SORT", "CHEMICAL", 10, 18], ["3-SORT", "CHEMICAL", 182, 188], ["3-SORT", "GENE_OR_GENE_PRODUCT", 182, 188], ["AR m", "TEST", 5, 9], ["SORT", "TEST", 14, 18], ["the approximation ratios", "TEST", 137, 161], ["jobLemma", "OBSERVATION", 304, 312]]], ["For any number of voters n and any committee size k \u2264 n, the approximation ratio of k-SORT does not depend on the number of issues m: AR n,m k-SORT = AR n,1 k-SORTRandom committees with simple majority rule do good jobThe lemma is proved in Appendix A; here we present a sketch.Random committees with simple majority rule do good jobProof sketch of Lemma 1.", [["k-SORT", "PROTEIN", 84, 90], ["AR", "PROBLEM", 134, 136], ["k-SORTRandom committees", "TREATMENT", 157, 180], ["lemma", "OBSERVATION", 222, 227], ["Appendix", "ANATOMY", 241, 249]]], ["The left-hand side of (3) is bounded by the right-hand side since any worstcase profile with one issue can be cloned m times.", [["left-hand", "ANATOMY", 4, 13], ["right-hand", "ANATOMY", 44, 54], ["left", "ANATOMY_MODIFIER", 4, 8], ["hand side", "ANATOMY_MODIFIER", 9, 18], ["right", "ANATOMY_MODIFIER", 44, 49], ["hand", "ANATOMY", 50, 54]]], ["To prove the opposite inequality, we observe that the worst-case profile with m issues cannot be worse than its restriction to the worst issue.Random committees with simple majority rule do good jobCorollary 1.", [["m issues", "PROBLEM", 78, 86]]], ["For a random committee of size k = 3, the approximation ratio AR m 3-SORT \u2248 1.316 for any number of issues m.Random committees with simple majority rule do good jobWe see that passing from a random dictator to a random 3-committee significantly improves the approximation ratio.", [["size k", "TEST", 26, 32], ["the approximation ratio AR m", "TEST", 38, 66], ["the approximation ratio", "TEST", 254, 277]]], ["The following theorem covers the case of committees of arbitrary size k and demonstrates that the approximation ratio converges to 1 fast with the growth of k.Random committees with simple majority rule do good jobTheorem 2.", [["the approximation ratio", "TEST", 94, 117]]], ["For any number of voters n, committee size k \u2264 n, and number of issues m, the approximation ratio of k-SORT enjoys the following upper boundRandom committees with simple majority rule do good jobThis upper bound has the right order of magnitude as a function of k.", [["upper", "ORGANISM_SUBDIVISION", 200, 205], ["This upper bound", "PROBLEM", 195, 211], ["right", "ANATOMY_MODIFIER", 220, 225]]], ["The lower bound isRandom committees with simple majority rule do good jobdy is the standard Gaussian cumulative distribution function.Random committees with simple majority rule do good jobThe proof is rather long because of technicalities and is postponed to Appendix A; here we sketch the main ideas.Random committees with simple majority rule do good jobProof sketch of Theorem 2.", [["lower", "ANATOMY_MODIFIER", 4, 9]]], ["This bound and optimization over p leads to upper bound (4).", [["This bound", "PROBLEM", 0, 10], ["upper", "ANATOMY_MODIFIER", 44, 49]]], ["Note that the worst-case p = 1 2 \u2212 \u0398 1 \u221a k ; however, it takes additional work to exclude small p because the denominator in the approximation ratio (1) vanishes as p \u2192 0.Random committees with simple majority rule do good jobFor the lower bound, we approximate the hypergeometric distribution by the sum of i.i.d.", [["small p", "PROBLEM", 90, 97], ["the lower bound", "PROBLEM", 230, 245]]], ["Bernoulli random variables and apply the Central Limit Theorem to this sum (we use the so-called Berry-Esseen version of the CLT, which provides an upper bound on the error term).", [["Bernoulli random variables", "PROBLEM", 0, 26], ["the CLT", "TREATMENT", 121, 128]]], ["As a result, we get a statement even stronger than the lower bound (5): this lower bound holds for AR n,m k-SORT if that n is big enough compared to k, namely, 2(k + 1) 2 \u2264 n.Random committees with simple majority rule do good jobCorollary 2 (Asymptotic behavior).", [["AR", "PROTEIN", 99, 101], ["k", "TEST", 149, 150]]], ["Combining upper and lower bound we see that AR m k-SORT = 1 + \u0398 1 \u221a k .", [["upper", "ORGANISM_SUBDIVISION", 10, 15], ["AR", "PROTEIN", 44, 46], ["Combining upper and lower bound", "PROBLEM", 0, 31], ["SORT", "TEST", 51, 55], ["upper", "ANATOMY_MODIFIER", 10, 15], ["lower", "ANATOMY_MODIFIER", 20, 25]]], ["Proof of the theorem demonstrates that worst-case preference profiles for large k are those, where both alternatives have approximately equal support with the imbalance created by \u0398 1 \u221a k -fraction of voters.Random committees with simple majority rule do good jobCorollary 3 (Deterministic committees).", [["large k", "PROBLEM", 74, 81]]], ["Assume that eliciting preference of one voter on one issue has some fixed cost c measured in the same units as social costs of a voting outcome.", [["some fixed cost c", "PROBLEM", 63, 80]]], ["Let's determine the optimal committee size that minimizes the worst-case regret for large number of voters n.", [["Let", "GENE_OR_GENE_PRODUCT", 0, 3], ["size", "OBSERVATION_MODIFIER", 38, 42]]], ["Regret is defined as the difference between the total cost of k-SORT (including the elicitation cost) and the social cost of the optimal outcomeRandom committees with simple majority rule do good jobRegret(X) = SC k-SORT(X) + c \u00b7 k \u00b7 m \u2212 SC(z opt (X)).Random committees with simple majority rule do good jobBy Corollary 2,Random committees with simple majority rule do good jobMinimizing the worst-case regret over k is, therefore, equivalent to minimizing \u0398 1 \u221a k + c n \u00b7 k.", [["k-SORT", "TREATMENT", 62, 68], ["k", "TEST", 230, 231]]], ["The optimal committee size is k = \u0398 n c 2 3Random committees with simple majority rule do good job.Delegation is good with few issues but harmful with manyIn the previous section, we saw that the k-sortition achieves an approximation ratio close to 1.", [["k", "TEST", 30, 31], ["an approximation ratio", "TEST", 217, 239], ["size", "OBSERVATION_MODIFIER", 22, 26], ["good", "OBSERVATION_MODIFIER", 113, 117]]], ["We first show that the approximation ratios from the previous section can be significantly improved if the number of issues m is small.", [["the approximation ratios", "TEST", 19, 43], ["significantly", "OBSERVATION_MODIFIER", 77, 90], ["improved", "OBSERVATION_MODIFIER", 91, 99], ["small", "OBSERVATION_MODIFIER", 129, 134]]], ["For this purpose, we use weighted majority voting to aggregate preferences of the committee members, where the weight of a member is determined by the fraction of voters to which this member is the \"closest\" representative Alger [2006] , Cohensius et al. [2017] .Delegation is good with few issues but harmful with manySimilar approach to weighing representatives is studied in the field of proxy voting (see Section 1).", [["good", "OBSERVATION_MODIFIER", 277, 281]]], ["The common wisdom suggested by that strain of literature is that usually the quality of opinion-aggregation can be significantly improved by finding a clever way of transforming proximity to weights.", [["aggregation", "PROBLEM", 96, 107]]], ["It turns out, that in case of large number of issues, this is not the case.Delegation is good with few issues but harmful with manyWhile for small number of issues, weighing makes the approximation ratio exponentially close to 1 in the committee size k (compare with 1 + O(1/ \u221a k) from Theorem 2), we show that for large number m of issues, delegation is harmful and the approximation ratio is bounded from below by 9 8 for any size of the committee k.Delegation is good with few issues but harmful with manyFor a committee C \u2282 [n] and a voter i \u2208 [n], denote by C i the subset of committee members closest to i, his best representatives.", [["the approximation ratio", "TEST", 367, 390], ["large", "OBSERVATION_MODIFIER", 30, 35], ["number", "OBSERVATION_MODIFIER", 36, 42], ["good", "OBSERVATION_MODIFIER", 89, 93], ["small", "OBSERVATION_MODIFIER", 141, 146], ["number", "OBSERVATION_MODIFIER", 147, 153], ["good", "OBSERVATION_MODIFIER", 466, 470]]], ["So the weight w c of a committee member c \u2208 C is given by w c = i\u2208[n]: c\u2208Ci 1 |Ci| .Delegation is good with few issues but harmful with manyDefinition 8 (k-wSORT: weighted k-sortition).", [["manyDefinition", "TEST", 136, 150], ["good", "OBSERVATION_MODIFIER", 98, 102]]], ["A committee C \u2282 [n] of size |C| = k is selected uniformly at random.Delegation is good with few issues but harmful with manyThe committee decides on each issue j \u2208 [m] using weighted majority vote with weights w c : if c\u2208C x c,j \u00b7 w c > 1 2 c\u2208C w c , then the outcome is z j = 1; in case of the the opposite strict inequality, z j = 0; in case of a tie, z j \u2208 {0, 1} is taken equally likely.Delegation is good with few issues but harmful with manyThe following simple example shows that the approximation ratio is exponentially close to 1 in the one-issue case.Delegation is good with few issues but harmful with manyExample 5 (k-wSORT for 1 issue).", [["weights", "TEST", 202, 209], ["C", "PROBLEM", 221, 222], ["the outcome", "TEST", 256, 267], ["inequality", "TEST", 315, 325], ["a tie", "TEST", 347, 352], ["Example", "TEST", 617, 624], ["good", "OBSERVATION_MODIFIER", 82, 86], ["good", "OBSERVATION_MODIFIER", 405, 409], ["good", "OBSERVATION_MODIFIER", 575, 579]]], ["Without loss of generality, 0 < p < 1 2 , i.e., the majority of voters prefers the alternative 0 that has the social cost of p \u00b7 n.Delegation is good with few issues but harmful with manyIf the preferences of all the committee members coincide with those of majority (x c,1 = 0, \u2200c \u2208 C), then, the committee selects the optimal alternative 0.", [["loss of generality", "PROBLEM", 8, 26]]], ["Similarly, if x c,1 = 1 for all c \u2208 C, the sub-optimal alternative 1 with the social cost (1 \u2212 p) \u00b7 n is selected.Delegation is good with few issues but harmful with manyConsider the remaining case: both views 0 and 1 are presented in C. We check that, in this case, the decision is socially optimal for any proportion of supporters of each of the alternatives (compare with at least k+1 2 members needed without weighing!).", [["c \u2208 C", "SIMPLE_CHEMICAL", 32, 37], ["all c \u2208 C", "PROBLEM", 28, 37], ["the social cost (1 \u2212 p) \u00b7 n", "TREATMENT", 74, 101], ["good", "OBSERVATION_MODIFIER", 128, 132]]], ["Therefore, the approximation ratio admits the following upper boundDelegation is good with few issues but harmful with manyTo find the worst-case, we take the logarithmic derivative and get k\u22121 p = 1 1 2 \u2212p ; hence, p * = 1 2 k\u22121 k = 1 2 \u2212 1 2k .", [["the logarithmic derivative", "TREATMENT", 155, 181], ["k", "TEST", 230, 231]]], ["We get AR n,1 k-wSORT \u2264 1 + 1 k \u00b7 2 k\u22121 1 \u2212 1 k k\u22121 .", [["k-wSORT", "TEST", 14, 21], ["k\u2212", "TEST", 36, 38], ["k k\u2212", "TEST", 46, 50]]], ["This follows from Lemma 1 (for m) and from the fact that the worst instances are those where the minority fraction p is far from 0.Delegation is good with few issues but harmful with manyBy taking a sequence of preference profiles with growing number n of voters and \u230ap \u00b7 n\u230b supporters of the alternative 1, we see that the upper bound is achieved in the limit.", [["good", "OBSERVATION_MODIFIER", 145, 149], ["upper", "ANATOMY_MODIFIER", 324, 329]]], ["ThusDelegation is good with few issues but harmful with manyWe see that weighing drastically improves the approximation ratio:Delegation is good with few issues but harmful with manyIf there are several issues, weights of the committee members depend on all of them.", [["several issues", "PROBLEM", 195, 209], ["good", "OBSERVATION_MODIFIER", 18, 22], ["several", "OBSERVATION_MODIFIER", 195, 202], ["issues", "OBSERVATION", 203, 209]]], ["In particular, for k-wSORT, the approximation ratio depends on the number of issues.", [["k-wSORT", "PROTEIN", 19, 26]]], ["Now we demonstrate that for small number of issues, delegation leads to exponential improvement as in Example 5.", [["small number of issues", "PROBLEM", 28, 50], ["small", "OBSERVATION_MODIFIER", 28, 33], ["number", "OBSERVATION_MODIFIER", 34, 40], ["exponential", "OBSERVATION_MODIFIER", 72, 83], ["improvement", "OBSERVATION_MODIFIER", 84, 95]]], ["To simplify the analysis we focus on preference-profiles with i.i.d. issues.Delegation is good with few issues but harmful with manyWe say that the profile X = (x i,j ) i\u2208[n],j\u2208 [m] has i.i.d. issues if, when we sample a voter i \u2208 [n] uniformly at random, the random variables (x i,j ) j\u2208m are independent and identically distributed.", [["the analysis", "TEST", 12, 24], ["the random variables", "TEST", 256, 276], ["good", "OBSERVATION_MODIFIER", 90, 94], ["independent", "OBSERVATION", 294, 305]]], ["Informally this property means that issues are similar but unrelated: there are no logical dependencies between them or other correlations in preferences.Delegation is good with few issues but harmful with manyWe define approximation ratio for i.i.d. issues by restricting the maximization in (1) to profiles with i.i.d. conditionDelegation is good with few issues but harmful with manyNote that AR i.i.d. n,m is always below AR n,m .Delegation is good with few issues but harmful with manyProposition 3.", [["AR", "PROTEIN", 396, 398], ["AR", "PROTEIN", 426, 428], ["logical dependencies", "PROBLEM", 83, 103], ["good", "OBSERVATION_MODIFIER", 168, 172], ["good", "OBSERVATION_MODIFIER", 344, 348], ["good", "OBSERVATION_MODIFIER", 448, 452]]], ["The approximation ratio of k-wSORT satisfies the following upper bound for profiles with m i.i.d. issuesDelegation is good with few issues but harmful with manyWe see that for small number m of issues the approximation ratio converges to 1 exponentially fast in the size of the committee.", [["k-wSORT", "PROTEIN", 27, 34], ["good", "OBSERVATION_MODIFIER", 118, 122], ["size", "OBSERVATION_MODIFIER", 266, 270]]], ["Thus, as in Example 5, the delegation improves the asymptotic behavior compared to k-SORT (note that AR i.i.d.Delegation is good with few issues but harmful with manyn,m and AR n,m coincide for k-SORT; the argument is similar to Lemma 1 and is omitted).", [["AR", "PROTEIN", 101, 103], ["AR", "PROTEIN", 174, 176], ["k-SORT", "PROTEIN", 194, 200], ["k-SORT", "TREATMENT", 194, 200]]], ["However, the rate of exponential convergence drops drastically with the growth of the number of issues m.", [["exponential convergence drops", "PROBLEM", 21, 50], ["exponential", "OBSERVATION_MODIFIER", 21, 32], ["convergence drops", "OBSERVATION", 33, 50], ["growth", "OBSERVATION_MODIFIER", 72, 78]]], ["Below we will see that this is not a coincidence.Delegation is good with few issues but harmful with manyProposition 3 is proved in Appendix B and the proof is sketched here.Delegation is good with few issues but harmful with manyProof sketch of Proposition 3.", [["good", "OBSERVATION_MODIFIER", 63, 67], ["good", "OBSERVATION_MODIFIER", 188, 192]]], ["If p is very small (p < 1 2m ), then by the union bound, more than half of the population prefers 0 for all issues.", [["very", "OBSERVATION_MODIFIER", 8, 12], ["small", "OBSERVATION_MODIFIER", 13, 18]]], ["Since such voters are likely to be among the committee members (the probability is at least 1 \u2212 (pm) k ), the social cost of k-wSORT at X is exponentially close to optimal.Delegation is good with few issues but harmful with manyFor p \u2265 1 2m , the argument for the low social cost is different.", [["k-wSORT", "PROTEIN", 125, 132], ["good", "OBSERVATION_MODIFIER", 186, 190]]], ["Using the union bound we show that, with high probability, for each sequence z \u2208 {0, 1} m there is a committee member with such preferences.", [["each sequence z \u2208", "TEST", 63, 80]]], ["Details of the computation can be found in Appendix B.Delegation is good with few issues but harmful with manyThe next result complements Proposition 3 and shows that for unbounded number of issues, delegation is harmful and the approximation ratio is separated from 1 even for big committees.Delegation is good with few issues but harmful with manyProposition 4.", [["the approximation ratio", "TEST", 225, 248], ["manyProposition", "TREATMENT", 345, 360], ["Appendix", "ANATOMY", 43, 51], ["good", "OBSERVATION_MODIFIER", 307, 311]]], ["For unbounded number of issues, the approximation ratio of k-wSORT admits the following lower bound AR k-wSORT \u2265 9 8 for any committee size k.Delegation is good with few issues but harmful with manyCorollary 5.", [["k-wSORT", "PROTEIN", 59, 66], ["AR", "PROTEIN", 100, 102], ["good", "OBSERVATION_MODIFIER", 156, 160]]], ["Comparing this result with Theorem 2, we see that 1000-SORT outperforms k-wSORT for any committee size k.", [["1000-SORT", "DNA", 50, 59], ["k-wSORT", "DNA", 72, 79]]], ["Committees of size 1000 are also recommended by Mueller et al. [1972] .Delegation is good with few issues but harmful with manyThe fact that delegation in multi-issue setting may lead to inferior outcomes compared to majority vote is mentioned in [Cohensius et al., 2017, Section 5 ] for a similar model but without the worst-case analysis.", [["size", "OBSERVATION_MODIFIER", 14, 18], ["good", "OBSERVATION_MODIFIER", 85, 89]]], ["Their insight is that for some preference profiles delegation leads to the most extreme voters attracting almost all weight, thus wasting the information about others' preferences.", [["wasting", "DISEASE", 130, 137]]], ["We build upon this insight.Delegation is good with few issues but harmful with manyProof sketch (for details, see Appendix B).", [["good", "OBSERVATION_MODIFIER", 41, 45]]], ["The idea is to construct a preference profile X with two groups of voters P and Q. All voters from Q have identical preferences and all voters from P are equidistant and the distance between any two distinct voters from P is bigger than the distance between a voter from P and a voter from Q.Delegation is good with few issues but harmful with manyGiven such a metric structure, if any voters from Q enter the committee, they receive the weight both from Q and P and thus the committee decision becomes dictatorial and coincides with preferences of a voter from Q. In particular, the social cost of the outcome coincides with the social cost of the unanimous preferences of Q.Delegation is good with few issues but harmful with manyIn the appendix, we show existence of such a preference profile X, where the social cost of Q's preferences is 9 8 of the optimum.", [["appendix", "ORGAN", 739, 747], ["P", "DNA", 148, 149], ["P", "DNA", 220, 221], ["appendix", "ANATOMY", 739, 747]]], ["Bernoulli random variables with success probability q < p.", [["Bernoulli random variables", "PROBLEM", 0, 26]]], ["Therefore, for large number of issues m, the distance between any two voters from P is approximately 2p(1 \u2212 p)m \u00b7 (1 + o(1)), while the distance between a voter from P and a voter from Q is (p(1 \u2212 q) + q(1 \u2212 p))m \u00b7 (1 + o(1)).", [["P", "DNA", 82, 83], ["P", "PROTEIN", 166, 167]]], ["Optimization over p, q, and sizes of P and Q leads to the desired lower bound.Optimality of SortitionIn Section 4, we considered weighing of the committee members, where a voter delegates one unit of weight to the closest representative.", [["P and Q leads", "TREATMENT", 37, 50]]], ["This method proved to be much better than the simple majority rule for a few i.i.d. issues, however it gives no advantage and may even harm if the number of issues is big.Optimality of SortitionOne may think that poor guarantees for large number of issues is a feature of this particular delegation method.", [["a few i.i.d. issues", "PROBLEM", 71, 90]]], ["Indeed, it is easy to come up with alternative proposals that seem to be better: a voter may \"smoothly\" distribute the weight among the committee members in a way that members that are closer to him get more weight.", [["alternative proposals", "TREATMENT", 35, 56]]], ["For any distance-based k-committee rule g with issue-wise inter-committee vote and any number of voters n, we have sup m\u2208N AR n,m g \u2265 AR n,1 k-SORT .Optimality of SortitionIn other words, a uniformly-random committee with the simple majority rule is worst-case optimal within this family of committee rules.Optimality of SortitionWe prove a stronger result: instead of supremum over m on the left-hand side, one can take m = n! issues.Optimality of SortitionThe proof is based on two lemmas.", [["left-hand", "ANATOMY", 392, 401], ["AR", "PROTEIN", 134, 136], ["SORT", "PROTEIN", 143, 147], ["AR", "PROBLEM", 123, 125], ["left", "ANATOMY_MODIFIER", 392, 396], ["hand", "ANATOMY", 397, 401]]], ["The first one shows that it is enough to prove the theorem for anonymous committee rules, i.e., symmetric with respect to permutation of voters.Optimality of SortitionFor a preference profile X with n voters and a permutation \u03c0 of [n], we denote by \u03c0(X) the preference profile with permuted voters: \u03c0(X) i,j = X \u03c0(i),j .Optimality of SortitionDefinition 9 (anonymous voting rules).", [["SortitionDefinition 9", "CHEMICAL", 334, 355], ["[n]", "SIMPLE_CHEMICAL", 231, 234], ["anonymous committee rules", "TEST", 63, 88]]], ["For example, k-wSORT rule is anonymous.Optimality of SortitionFor a rule h, denote by h anym its anonymization: for any preference profile XOptimality of Sortitionwhere n is the number of voters and S n is the set of all permutations of [n].Optimality of SortitionLemma 6.", [["k-wSORT rule", "DNA", 13, 25], ["SortitionLemma", "OBSERVATION", 255, 269]]], ["For any numbers of voters and issues and any voting rule h AR n,m h anym \u2264 AR n,m h .Optimality of SortitionThe proof is elementary and can be found in Appendix C. The combination of anonymity and the distant-based property becomes very restrictive if distances between pairs of voters are all the same.", [["AR", "PROTEIN", 59, 61], ["AR", "PROTEIN", 75, 77], ["Appendix", "ANATOMY", 152, 160], ["restrictive", "OBSERVATION", 237, 248]]], ["The following lemma demonstrates that the set of such preference profiles is rich enough.Optimality of SortitionLemma 7.", [["SortitionLemma", "OBSERVATION", 103, 117]]], ["For any number of voters n and n 1 \u2264 n, there exists a preference profile with n voters and m = n! issues such that for each issue j \u2208 [m] exactly n 1 voters support the alternative 1 and for each pair of distinct votersOptimality of SortitionSketch of the proof (see Appendix C for the formal argument): The idea is similar to the one used in Proposition 4: if preferences of each voter are given by a vector of i.i.d.", [["Appendix", "ANATOMY", 268, 276]]], ["Bernoulli random variables with success probability p = n1 n , then, in expectation, n 1 voters prefer alternative 1 for each j \u2208 [m], and the distance between any pair of voters concentrates around 2p(1 \u2212 p)m for large m by the law of large numbers.Optimality of SortitionTo prove Lemma 7 we use a derandomization of this construction.", [["Bernoulli random variables", "PROBLEM", 0, 26], ["this construction", "TREATMENT", 318, 335], ["large", "OBSERVATION_MODIFIER", 236, 241], ["numbers", "OBSERVATION", 242, 249]]], ["By Lemma 6, we can assume that g is anonymous without loss of generality.Optimality of SortitionUsing Lemma 7, we pick a profile X such that all the voters are equidistant.", [["loss of generality", "PROBLEM", 54, 72], ["SortitionUsing Lemma", "OBSERVATION", 87, 107]]], ["On such a profile, the metric information encoded in the distance matrix becomes useless and the only anonymous way to select a committee is uniformly at random.", [["matrix", "CELLULAR_COMPONENT", 66, 72]]], ["The next step is to show that among the family of all committee rules with uniformly random committee and ble inter-committee vote, no rule can outperform k-SORT both on the profile X and on the complement profileX, where preference of all the voters are flipped.", [["k-SORT", "PROTEIN", 155, 161], ["complement profileX", "PROTEIN", 195, 214]]], ["This boils down to solving an explicit optimization problem; the details can be found in Appendix C.Optimality of SortitionLemma 7 provides enough flexibility to make X (and, hence,X), the worst-case profile for k-SORT.", [["k-SORT", "PROTEIN", 212, 218], ["an explicit optimization problem", "TREATMENT", 27, 59], ["Appendix", "ANATOMY", 89, 97]]], ["Since g is worse off on one of these profiles, it has higher approximation ratio.DiscussionThe main takeaway message from our work is that at least when the preferences of the individuals in the society are separable, the simple and well known k-sortition rule is a reasonable choice that guarantees low approximation ratio.DiscussionWhile for a low number of issues we saw that there are more representative rules than the k-sortition rule, the latter also has other benefits.", [["worse", "OBSERVATION_MODIFIER", 11, 16], ["higher", "OBSERVATION_MODIFIER", 54, 60]]], ["In contrast, under the proxy-weighted variant, voters may have an incentive to lie in order to affect the weights of committee members.DiscussionThe main direction we are currently investigating is a better understanding of the effects of delegation, in particular when there are few issues and/or our restrictions on the structure of preferences.DiscussionIn the long run, we are interested in how sortition and/or delegation-based voting rule can guarantee low distortion and good approximation in other domains, including ranked preferences and interdependent issues.A Proofs for Section 3Proof of Lemma 1.", [["low distortion", "PROBLEM", 459, 473], ["good", "OBSERVATION_MODIFIER", 478, 482]]], ["In order to show that AR n,m k-SORT \u2264 AR n,1 k-SORT , consider a worst-case profile X * \u2208 {0, 1} n\u00d71 for one issue.", [["AR", "PROTEIN", 22, 24], ["SORT", "PROTEIN", 31, 35], ["AR", "PROTEIN", 38, 40]]], ["Since different issues contribute to the Hamming distance in an additive way and k-SORT operates on each issue separately,A Proofs for Section 3To prove the opposite inequality, pick a worst-case profile Y * \u2208 {0, 1} n\u00d7m with m issues and denote by Y j a one-issue profile obtained by the restriction of Y to issue j, i.e., y j i = y * i,j .", [["k-SORT", "DNA", 81, 87], ["j", "ANATOMY", 338, 339]]], ["The following computation shows that the worst-case profile with m issues is not worse than its restriction to the worst issueA Proofs for Section 3Combining inequalities (6) and (7), we obtain the desired equality of approximation ratios.A Proofs for Section 3Proof of Theorem 2.", [["The following computation", "TEST", 0, 25], ["m issues", "PROBLEM", 65, 73]]], ["By Lemma 1, it is enough to consider a one-issue profile X. Without loss of generality, we assume that the majority supports the alternative 0: 1 \u2264 n 1 \u2264 n 2 voters prefer the alternative 1, and the rest prefer 0.", [["loss of generality", "PROBLEM", 68, 86]]], ["Let \u03be be the number of committee members supporting the alternative 1.", [["Let \u03be", "GENE_OR_GENE_PRODUCT", 0, 5]]], ["Recall that the hypergeometric distribution describes the number of red balls among k draws without replacement from an urn with n 1 red and n \u2212 n 1 white balls.", [["red balls", "TEST", 68, 77], ["replacement", "TREATMENT", 100, 111]]], ["If we represent supporters of 0 as white balls and supporters of 1 as red and take into account that sampling without replacement is equivalent to picking a uniformly random subset, it becomes obvious that \u03be is hypergeometric.A Proofs for Section 3If \u03be < k 2 , then the committee selects the socially-optimal alternative 0 with the social cost p \u00b7 n; for \u03be = k 2 (can happen only if k is even), there is a tie and the committee picks any of the two alternatives equally likely; for \u03be > k 2 , the committee selects the sub-optimal alternative 1 with the social cost (1\u2212p)\u00b7n.", [["replacement", "TREATMENT", 118, 129], ["hypergeometric", "PROBLEM", 211, 225], ["hypergeometric", "OBSERVATION", 211, 225]]], ["Therefore, the ratio of social costs in (1) can be represented as SC k-SORT(X) SC z opt = P \u03be < k 2 \u00b7 p \u00b7 n + P \u03be = k 2 \u00b7 n 2 + P \u03be > k 2 (1 \u2212 p) \u00b7 n p \u00b7 n \u2264 (8)A Proofs for Section 3We will consider the two cases of p close to zero and p close to 1 2 separately.", [["opt", "TEST", 84, 87], ["k", "TEST", 96, 97], ["p", "TEST", 102, 103], ["n", "TEST", 106, 107], ["\u03be", "TEST", 112, 113], ["k", "TEST", 116, 117], ["\u03be", "TEST", 130, 131], ["k", "TEST", 134, 135], ["p", "TEST", 143, 144], ["\u00b7", "TEST", 146, 147], ["p", "TEST", 150, 151], ["\u2264", "TEST", 156, 157], ["A Proofs", "TEST", 161, 169], ["Section", "TEST", 174, 181]]], ["For small p, we use a rough bound on P(\u03be \u2265 k 2 ) based on the Chebyshev inequality.", [["P(\u03be \u2265 k 2", "TREATMENT", 37, 46]]], ["By the Chebyshev inequality,A Proofs for Section 3Thus by (8),A Proofs for Section 3Since 1 2m \u2264 p, the right-hand side does not exceedA Proofs for Section 3where in the last inequality we used that (1 \u2212 t) 1 t \u2264 1 e for any t \u2208 (0, 1).", [["right-hand", "ANATOMY", 104, 114], ["right", "ANATOMY_MODIFIER", 104, 109]]], ["Note that for any m, k \u2265 1, this upper bound exceeds the one obtained for p < 1 2m and thusA Proofs for Section 3Proof of Proposition 4.", [["this upper bound", "PROBLEM", 28, 44]]], ["There are two groups of voters P and Q with sizes \u03b1 \u00b7 n and (1 \u2212 \u03b1) \u00b7 n, respectively.", [["(1 \u2212 \u03b1", "SIMPLE_CHEMICAL", 60, 66], ["sizes", "TEST", 44, 49], ["two", "OBSERVATION_MODIFIER", 10, 13], ["groups", "OBSERVATION_MODIFIER", 14, 20]]], ["All the voters i \u2208 Q are unanimous: their preferences x i coincide with a vector \u03be = (\u03be j ) j\u2208[m] with components given by i.i.d.", [["a vector \u03be", "TREATMENT", 72, 82]]], ["Bernoulli random variables with success probability q < 1 2 .", [["Bernoulli random variables", "PROBLEM", 0, 26]]], ["In contrast, preferences of voters in P are not aligned: (x i,j ) i\u2208P,j\u2208[m] is a matrix with i.i.d.", [["matrix", "CELLULAR_COMPONENT", 81, 87], ["P", "DNA", 38, 39]]], ["The expected distance between two distinct voters iA Proofs for Section 3] is equal to pm for i \u2208 P and qm for i \u2208 Q.A Proofs for Section 3By the law of large numbers, for any \u03b5 > 0 we can find m = m(\u03b5, n, p, q) such that all the distances are within a factor 1 \u00b1 \u03b5 from their expected values with positive probability:A Proofs for Section 3Abusing the notation, we denote by X the realization of the random profile satisfying these inequalities.A Proofs for Section 3Assuming that \u03b5 is small, we see that the distance between any two voters from P exceeds the distance between voters from P and voters from Q (it is enough to assume thatA Proofs for Section 3Consider a random committee C of size k.", [["P", "DNA", 547, 548], ["P", "DNA", 590, 591], ["small", "OBSERVATION_MODIFIER", 487, 492]]], ["If C contains some voters from Q, all voters from [n] \u00a0C delegate their weight to them.", [["[n] \u00a0C", "CHEMICAL", 50, 56], ["[n] \u00a0C", "SIMPLE_CHEMICAL", 50, 56], ["C", "PROBLEM", 3, 4]]], ["Therefore, if n \u2212 k > k 2 (i.e., n is large enough compared to k), voters from C \u2229 Q get more than half of the total weight and, therefore, their unanimous preferences \u03be coincide with the outcome of the committee vote.A Proofs for Section 3The chance that C \u2229 Q is nonempty equals 1 \u2212 \u03b1n k n k \u2265 1 \u2212 \u03b1 k .", [["k", "TEST", 18, 19], ["k", "TEST", 288, 289], ["k \u2265", "TEST", 292, 295]]], ["Putting all the pieces together, we obtain the following lower bound on the approximation ratioA Proofs for Section 3Taking into account that SC(z opt ) \u2264 SC(0) and using the lower bound on the minimal distance, we getA Proofs for Section 3Letting \u03b5 \u2192 +0 and q \u2192 p \u2212 0, we get rid of \u03b5 and simplify the expressionA Proofs for Section 3Now, letting p go to 0, we see thatA Proofs for Section 3For k = 1, the maximum of the right-hand side is achieved at \u03b1 = 3 4 .", [["right-hand", "ANATOMY", 422, 432], ["\u03b5", "PROTEIN", 284, 285], ["SC(z opt )", "TREATMENT", 142, 152], ["right", "ANATOMY_MODIFIER", 422, 427]]], ["Substituting this value for any k, we obtain AR k-wSORT \u2265 3 2 \u2212 1 2 3 4 k \u2265 9 8 .C Proofs for Section 5Proof for Lemma 6.", [["AR", "PROTEIN", 45, 47], ["any k", "TEST", 28, 33], ["AR k-wSORT", "TEST", 45, 55]]], ["Therefore,C Proofs for Section 5By maximizing the left-hand side over X, we obtain the desired inequality.C Proofs for Section 5Proof of Lemma 7.", [["left-hand", "ANATOMY", 50, 59], ["left", "ANATOMY_MODIFIER", 50, 54]]], ["In other words, preference of a voter i on an issue \u03c0 is given by x i,\u03c0 = 1, \u03c0(i) \u2208 A 0, \u03c0(i) / \u2208 A.C Proofs for Section 5By the construction, exactly n 1 voter prefers 1 for each issue.", [["Section", "TEST", 113, 120]]], ["Consider the distance d(x i , x i \u2032 ) = \u03c0\u2208Sn |x i,\u03c0 \u2212 x i \u2032 ,\u03c0 | between two distinct voters i, i \u2032 \u2208 [n].", [["Sn", "CHEMICAL", 42, 44], ["\u03c0", "CHEMICAL", 50, 51], ["i \u2032 \u2208 [n]", "SIMPLE_CHEMICAL", 96, 105], ["the distance d(x i", "TEST", 9, 27], ["Sn", "TEST", 42, 44], ["\u2032", "TEST", 58, 59]]], ["Let \u03c4 be the permutation such that \u03c4 (i) = 1 and \u03c4 (i \u2032 ) = 2.", [["Let \u03c4", "GENE_OR_GENE_PRODUCT", 0, 5]]], ["Taking into account that \u03c0 \u2192 \u03c0 \u2022 \u03c4 defines an automorphism of S n and that x i,\u03c0\u2022\u03c4 = x \u03c4 (i),\u03c0 , we getC Proofs for Section 5Therefore, all the distances between distinct voters are equal to common constant d = d(x 1 , x 2 ).", [["\u03c0", "PROTEIN", 25, 26], ["\u03c0", "PROTEIN", 29, 30], ["\u03c4", "PROTEIN", 33, 34], ["\u03c0", "PROTEIN", 93, 94], ["getC", "PROTEIN", 100, 104]]], ["Thus n 2 \u2212 n n 2 \u00b7 d = n 1 (n \u2212 n 1 ) + (n \u2212 n 1 )n 1 n 2 =\u21d2 d = 2p (1 \u2212 p) 1 \u2212 1 n .C Proofs for Section 5Proof of Theorem 5.", [["d", "TEST", 61, 62], ["p", "TEST", 73, 74], ["Proofs", "TEST", 87, 93], ["Section", "TEST", 98, 105], ["Theorem", "TEST", 116, 123]]], ["Consider the anonymized rule g anym and check that for m = n! we have AR n,m g anym \u2265 AR n,m k-SORT .C Proofs for Section 5By Lemma 6, this implies the same lower bound for g.", [["AR", "PROTEIN", 70, 72]]], ["Both X and X \u2032 are worst profiles for k-SORT (see Lemma 1) and have the same socially-optimal cost SC(z opt (X)) = SC(z opt (X \u2032 )).", [["X \u2032", "GENE_OR_GENE_PRODUCT", 11, 14], ["X and X \u2032", "DNA", 5, 14], ["k-SORT", "PROTEIN", 38, 44], ["optimal cost SC(z opt (X)", "TREATMENT", 86, 111]]], ["Therefore, AR n,m k-SORT = 1 2 SC k-SORT(X) + SC k-SORT(X \u2032 ) SC(z opt (X)) .C Proofs for Section 5Our goal is to show that SC k-SORT(X) + SC k-SORT(X \u2032 ) \u2264 SC g anym (X) + SC g anym (X \u2032 ) .C Proofs for Section 5Together with (14) this inequality would imply (13) since AR n,m g anym \u2265 SC g anym (Y ) SC z opt (Y )C Proofs for Section 5for any profile Y .C Proofs for Section 5Consider the distributions g anym (X) and g anym (X \u2032 ) on pairs (C, h) of a committee with k members and the inter-committee rule.", [["X \u2032", "SIMPLE_CHEMICAL", 149, 152], ["X \u2032", "SIMPLE_CHEMICAL", 184, 187], ["AR", "PROTEIN", 11, 13], ["SORT", "TEST", 20, 24], ["SORT", "TEST", 36, 40], ["k", "TEST", 49, 50], ["SORT", "TEST", 129, 133], ["SORT", "TEST", 144, 148], ["\u2032", "TEST", 151, 152], ["anym", "TEST", 422, 426]]], ["The two distributions coincide because g anym is distance-based and matrices of distances for X andX are the same; for definiteness, let's focus on X.C Proofs for Section 5Since all pairs of voters in X are equidistant, the only anonymous way to select a committee C of size k is to take it uniformly at random among subsets C \u2282 [n] with |C| = k.", [["X andX", "GENE_OR_GENE_PRODUCT", 94, 100], ["X andX", "DNA", 94, 100], ["X.C Proofs", "DNA", 148, 158], ["definiteness", "PROBLEM", 119, 131]]], ["Indeed if two such subsets C and C \u2032 differ in probability, this contradicts anonymity because C = \u03c0(C \u2032 ) for some permutation \u03c0 of [n] and no permutation changes the matrix of distances.C Proofs for Section 5Consider the probability P(z j = 1 | C) that the outcome of g anym (X) for issue j is 1 conditional on the selected committee C. This probability can only depend on (x i,j ) i\u2208C because h is issue-wise.", [["C", "CHEMICAL", 101, 102], ["C \u2032", "SIMPLE_CHEMICAL", 33, 36], ["C = \u03c0", "SIMPLE_CHEMICAL", 95, 100], ["[n]", "SIMPLE_CHEMICAL", 133, 136], ["C", "TEST", 95, 96], ["no", "UNCERTAINTY", 141, 143]]], ["Since g anym is distance-based and anonymous, and any permutation of voters (in particular, those in C) leaves the matrix of distances unchanged, we see that the probability can only depend on q = i\u2208C x i,j , i.e., the total number of supporters of the alternative 1 for issue j.", [["anym", "GENE_OR_GENE_PRODUCT", 8, 12]]], ["Hence, P(z j = 1 | C) = h q,j = h q,j (C).C Proofs for Section 5For any alternative j, the chance that the uniformly random committee C contains exactly q supporters of the alternative 1 is equal to n 1 q \u00b7 n \u2212 n 1 k \u2212 q n k for the profile X and n \u2212 n 1 q \u00b7 n k \u2212 q n k for X \u2032 .", [["X \u2032", "PROTEIN", 275, 278], ["Hence", "TEST", 0, 5], ["P", "TEST", 7, 8], ["(z j", "TEST", 8, 12], ["j", "TEST", 28, 29], ["C", "TEST", 39, 40], ["Section", "TEST", 55, 62], ["k", "TEST", 215, 216], ["the profile", "TEST", 229, 240], ["n", "TEST", 247, 248], ["\u2212", "TEST", 249, 250], ["n", "TEST", 251, 252], ["k", "TEST", 261, 262], ["\u2032", "TEST", 277, 278]]], ["This allows to rewrite the right-hand side of (15):C Proofs for Section 5SC g anym (X) + SC g anym (X \u2032 ) = = j\u2208[m] k q=0 n 1 q \u00b7 n \u2212 n 1 k \u2212 q n k (n \u2212 n 1 )h q,j + n 1 (1 \u2212 h q,j ) + + n \u2212 n 1 q \u00b7 n 1 k \u2212 q n k n 1 h q,j + (n \u2212 n 1 )(1 \u2212 h q,j ) .C Proofs for Section 5To minimize this expression over h q,j \u2208 [0, 1], one should minimize the contribution of the first summand whenever n 1 q \u00b7 n \u2212 n 1 k \u2212 q n k > n \u2212 n 1 q \u00b7 n k \u2212 q n k which leads to h q,j = 0; similarly, for the opposite strict inequality, it is optimal to minimize the second summand, which gives h q,j = 1.", [["right-hand", "ANATOMY", 27, 37], ["(15):C", "CHEMICAL", 46, 52], ["n", "TEST", 134, 135], ["k", "TEST", 138, 139], ["k", "TEST", 146, 147], ["j", "TEST", 162, 163], ["j", "TEST", 179, 180], ["j", "TEST", 221, 222], ["\u2212", "TEST", 397, 398], ["n", "TEST", 399, 400], ["k", "TEST", 403, 404], ["\u2212", "TEST", 405, 406], ["k", "TEST", 411, 412], ["\u2212", "TEST", 417, 418], ["n", "TEST", 419, 420], ["\u00b7", "TEST", 425, 426], ["k", "TEST", 429, 430], ["\u2212", "TEST", 431, 432], ["k", "TEST", 437, 438], ["leads", "TEST", 445, 450], ["j", "TEST", 458, 459], ["the opposite strict inequality", "PROBLEM", 480, 510], ["right", "ANATOMY_MODIFIER", 27, 32]]], ["Therefore, the optimal h q,j equals 0 if q < k 2 and 1 if q > k 2 .", [["j equals", "TEST", 27, 35]]], ["Therefore, SC g anym (X) + SC g anym (X \u2032 ) \u2265 SC k-SORT(X) + SC k-SORT(X \u2032 ) , which completes the proof.", [["SC", "TEST", 11, 13]]]], "PMC7310941": [["CLINICAL PICTUREThe respiratory tract can be divided into upper and lower parts, with the boundary at the lower end of the larynx.", [["respiratory tract", "ANATOMY", 20, 37], ["upper", "ANATOMY", 58, 63], ["lower parts", "ANATOMY", 68, 79], ["larynx", "ANATOMY", 123, 129], ["respiratory tract", "ORGAN", 20, 37], ["upper", "ORGANISM_SUBDIVISION", 58, 63], ["larynx", "ORGAN", 123, 129], ["CLINICAL PICTUREThe respiratory tract", "TREATMENT", 0, 37], ["respiratory tract", "OBSERVATION", 20, 37], ["upper", "ANATOMY_MODIFIER", 58, 63], ["lower parts", "ANATOMY_MODIFIER", 68, 79], ["lower end", "ANATOMY_MODIFIER", 106, 115], ["larynx", "ANATOMY", 123, 129]]], ["Viral infections confined to the upper part (upper respiratory tract infection, URTI) are rarely life-threatening, with the exception of croup.", [["upper part", "ANATOMY", 33, 43], ["upper respiratory tract", "ANATOMY", 45, 68], ["Viral infections", "DISEASE", 0, 16], ["respiratory tract infection", "DISEASE", 51, 78], ["URTI", "DISEASE", 80, 84], ["croup", "DISEASE", 137, 142], ["upper part", "ORGANISM_SUBDIVISION", 33, 43], ["upper respiratory", "ORGANISM_SUBDIVISION", 45, 62], ["tract", "ORGANISM_SUBDIVISION", 63, 68], ["Viral infections", "PROBLEM", 0, 16], ["upper respiratory tract infection", "PROBLEM", 45, 78], ["croup", "PROBLEM", 137, 142], ["infections", "OBSERVATION", 6, 16], ["upper part", "ANATOMY_MODIFIER", 33, 43], ["upper", "ANATOMY_MODIFIER", 45, 50], ["respiratory tract", "ANATOMY", 51, 68], ["infection", "OBSERVATION", 69, 78], ["croup", "OBSERVATION", 137, 142]]], ["These infections do not automatically spread to the lower respiratory tract, but where the lower respiratory tract is involved the process is extensive and rarely confined to one lobe or even one lung.", [["lower respiratory tract", "ANATOMY", 52, 75], ["lower respiratory tract", "ANATOMY", 91, 114], ["lobe", "ANATOMY", 179, 183], ["lung", "ANATOMY", 196, 200], ["infections", "DISEASE", 6, 16], ["lower", "ORGANISM_SUBDIVISION", 52, 57], ["respiratory tract", "ORGANISM_SUBDIVISION", 58, 75], ["lower", "ORGANISM_SUBDIVISION", 91, 96], ["respiratory tract", "ORGANISM_SUBDIVISION", 97, 114], ["lobe", "CANCER", 179, 183], ["lung", "ORGAN", 196, 200], ["These infections", "PROBLEM", 0, 16], ["the lower respiratory tract", "PROBLEM", 87, 114], ["infections", "OBSERVATION", 6, 16], ["lower", "ANATOMY_MODIFIER", 52, 57], ["respiratory tract", "ANATOMY", 58, 75], ["lower", "ANATOMY_MODIFIER", 91, 96], ["respiratory tract", "ANATOMY", 97, 114], ["extensive", "OBSERVATION_MODIFIER", 142, 151], ["lobe", "ANATOMY_MODIFIER", 179, 183], ["lung", "ANATOMY", 196, 200]]], ["This contrasts with pneumococcal pneumonia, which is typically confined to one lobe of one lung (see also Chapter 11).CLINICAL PICTUREAlthough widespread, the clinical consequences of viral infection are usually less severe than those seen in bacterial pneumonia; otherwise, such infections would be much more lethal.", [["lobe", "ANATOMY", 79, 83], ["lung", "ANATOMY", 91, 95], ["pneumonia", "DISEASE", 33, 42], ["viral infection", "DISEASE", 184, 199], ["pneumonia", "DISEASE", 253, 262], ["infections", "DISEASE", 280, 290], ["lobe", "ORGAN", 79, 83], ["lung", "ORGAN", 91, 95], ["pneumococcal", "SPECIES", 20, 32], ["pneumococcal pneumonia", "PROBLEM", 20, 42], ["viral infection", "PROBLEM", 184, 199], ["bacterial pneumonia", "PROBLEM", 243, 262], ["such infections", "PROBLEM", 275, 290], ["pneumococcal", "OBSERVATION_MODIFIER", 20, 32], ["pneumonia", "OBSERVATION", 33, 42], ["lobe", "ANATOMY_MODIFIER", 79, 83], ["one", "ANATOMY_MODIFIER", 87, 90], ["lung", "ANATOMY", 91, 95], ["widespread", "OBSERVATION_MODIFIER", 143, 153], ["viral", "OBSERVATION_MODIFIER", 184, 189], ["infection", "OBSERVATION", 190, 199], ["less severe", "OBSERVATION_MODIFIER", 212, 223], ["bacterial", "OBSERVATION_MODIFIER", 243, 252], ["pneumonia", "OBSERVATION", 253, 262]]], ["Severe Acute Respiratory Syndrome (SARS) and disease due to avian influenza subtype H5N1 are notable exceptions, where disease severity and mortality from a virus infection is particularly high.", [["Acute Respiratory Syndrome", "DISEASE", 7, 33], ["SARS", "DISEASE", 35, 39], ["avian influenza subtype H5N1", "DISEASE", 60, 88], ["infection", "DISEASE", 163, 172], ["avian influenza subtype H5N1", "ORGANISM", 60, 88], ["avian influenza subtype H5N1", "SPECIES", 60, 88], ["Severe Acute Respiratory Syndrome", "PROBLEM", 0, 33], ["SARS)", "PROBLEM", 35, 40], ["disease", "PROBLEM", 45, 52], ["avian influenza subtype H5N1", "PROBLEM", 60, 88], ["disease severity", "PROBLEM", 119, 135], ["a virus infection", "PROBLEM", 155, 172], ["Acute", "OBSERVATION_MODIFIER", 7, 12], ["Respiratory Syndrome", "OBSERVATION", 13, 33], ["virus infection", "OBSERVATION", 157, 172], ["high", "OBSERVATION_MODIFIER", 189, 193]]], ["The most common manifestations of a lower respiratory tract infection (LRTI) are bronchiolitis (in infants) or an atypical pneumonia.", [["lower respiratory tract", "ANATOMY", 36, 59], ["lower respiratory tract infection", "DISEASE", 36, 69], ["LRTI", "DISEASE", 71, 75], ["bronchiolitis", "DISEASE", 81, 94], ["pneumonia", "DISEASE", 123, 132], ["lower", "ORGANISM_SUBDIVISION", 36, 41], ["respiratory tract", "ORGANISM_SUBDIVISION", 42, 59], ["infants", "ORGANISM", 99, 106], ["infants", "SPECIES", 99, 106], ["a lower respiratory tract infection", "PROBLEM", 34, 69], ["bronchiolitis", "PROBLEM", 81, 94], ["an atypical pneumonia", "PROBLEM", 111, 132], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["lower", "ANATOMY_MODIFIER", 36, 41], ["respiratory tract", "ANATOMY", 42, 59], ["infection", "OBSERVATION", 60, 69], ["LRTI", "OBSERVATION_MODIFIER", 71, 75], ["bronchiolitis", "OBSERVATION", 81, 94], ["atypical", "OBSERVATION_MODIFIER", 114, 122], ["pneumonia", "OBSERVATION", 123, 132]]], ["Even when an LRTI occurs, the upper tract is also usually involved and the causative virus can usually be recovered from it.CLINICAL PICTUREThere are no clear-cut differences between the clinical presentation(s) of any viruses in the respiratory tract.", [["upper tract", "ANATOMY", 30, 41], ["respiratory tract", "ANATOMY", 234, 251], ["LRTI", "DISEASE", 13, 17], ["upper tract", "ORGANISM_SUBDIVISION", 30, 41], ["respiratory tract", "ORGANISM_SUBDIVISION", 234, 251], ["an LRTI", "PROBLEM", 10, 17], ["the causative virus", "PROBLEM", 71, 90], ["any viruses in the respiratory tract", "PROBLEM", 215, 251], ["LRTI", "OBSERVATION", 13, 17], ["upper tract", "ANATOMY", 30, 41], ["no", "UNCERTAINTY", 150, 152], ["clear", "OBSERVATION_MODIFIER", 153, 158], ["viruses", "OBSERVATION", 219, 226], ["respiratory tract", "ANATOMY", 234, 251]]], ["For example, although respiratory syncytial virus (RSV) is the most common cause of bronchiolitis worldwide, this clinical condition may also be caused by parainfluenza viruses, influenza viruses, adenoviruses or rhinoviruses.", [["respiratory syncytial virus (RSV)", "DISEASE", 22, 55], ["bronchiolitis", "DISEASE", 84, 97], ["parainfluenza viruses", "DISEASE", 155, 176], ["influenza viruses", "DISEASE", 178, 195], ["rhinoviruses", "DISEASE", 213, 225], ["respiratory syncytial virus", "ORGANISM", 22, 49], ["RSV", "ORGANISM", 51, 54], ["parainfluenza viruses", "ORGANISM", 155, 176], ["influenza viruses", "ORGANISM", 178, 195], ["adenoviruses", "ORGANISM", 197, 209], ["rhinoviruses", "ORGANISM", 213, 225], ["respiratory syncytial virus (RSV", "SPECIES", 22, 54], ["parainfluenza", "SPECIES", 155, 168], ["respiratory syncytial virus", "SPECIES", 22, 49], ["RSV", "SPECIES", 51, 54], ["respiratory syncytial virus (RSV", "PROBLEM", 22, 54], ["bronchiolitis", "PROBLEM", 84, 97], ["this clinical condition", "PROBLEM", 109, 132], ["parainfluenza viruses", "PROBLEM", 155, 176], ["influenza viruses", "PROBLEM", 178, 195], ["adenoviruses", "PROBLEM", 197, 209], ["rhinoviruses", "PROBLEM", 213, 225], ["respiratory", "OBSERVATION", 22, 33], ["syncytial virus", "OBSERVATION", 34, 49], ["most common", "OBSERVATION_MODIFIER", 63, 74], ["bronchiolitis", "OBSERVATION", 84, 97], ["may also be caused", "UNCERTAINTY", 133, 151], ["parainfluenza viruses", "OBSERVATION", 155, 176]]], ["Consequently, it must not be assumed that two patients with similar clinical illnesses will have been infected by the same virus.", [["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54], ["similar clinical illnesses", "PROBLEM", 60, 86]]], ["This is particularly so in babies and young children.", [["babies", "ORGANISM", 27, 33], ["children", "ORGANISM", 44, 52], ["children", "SPECIES", 44, 52]]], ["Conversely, the same virus may cause a range of clinical manifestations in different patients.3", [["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["the same virus", "PROBLEM", 12, 26]]]], "36312af549474228d178e8d7d0da35b531b413f1": [["The coronavirus disease 2019 (COVID-19) has rapidly been spreading worldwide, and Italy has been hit hard, forcing the Italian Healthcare System to change and adapt to these extreme conditions.", [["coronavirus disease", "DISEASE", 4, 23], ["COVID-19", "CHEMICAL", 30, 38], ["coronavirus", "ORGANISM", 4, 15], ["coronavirus disease 2019 (COVID-19", "SPECIES", 4, 38], ["The coronavirus disease", "PROBLEM", 0, 23], ["COVID", "TEST", 30, 35], ["coronavirus disease", "OBSERVATION", 4, 23], ["spreading", "OBSERVATION_MODIFIER", 57, 66], ["worldwide", "OBSERVATION_MODIFIER", 67, 76]]], ["The daily activities of the Urology Department have been drastically reduced and limited only to non-deferrable procedures, and the entire organogram reorganised following a rigorous flowchart [1] .", [["the entire organogram", "TEST", 128, 149]]]]}